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int-LV integrating lentiviral vector 
int-LV-eGFP integrating lentiviral vector expressing/gene transfer of 
eGFP 
int-LV-Nogo-B integrating lentiviral vector expressing/gene transfer of 
Nogo-B 
int-LV-full-length 
Nogo-B 
integrating lentiviral vector expressing/gene transfer of 
full-length Nogo-B 
int-LV-mutant Nogo-
B 
integrating lentiviral vector expressing/gene transfer of 
mutant (soluble) Nogo-B 
int-LV-SFFV SFFV-driven integrating lentiviral vector 
int-LV-UCOE UCOE-driven integrating lentiviral vector 
IRE1 inositol-requiring kinase 1 
ISR in-stent restenosis 
iu/ml infectious unit of LV per ml 
JAK3 janus  kinase 3 
JNK c-JUN NH2-terminal kinase 
kan kanamycin 
KAT Kuopio angiogenesis trial 
kbp kilo base pairs 
kDa kilo Dalton 
l litre 
lacZ lacZ gene encoding for β-galactosidase 
LAM-PCR linear amplification-mediated PCR 
LB Luria-Bertani 
LMO2 LIM-domain only 2 proto-oncogene 
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LV lentiviral vector 
M molar (moles per litre) 
mAmp milliamp 
MAPK mitogen-activated protein kinase 
MCS multiple cloning site 
MDS1-EVI1 myelodysplasia syndrome 1-ecotropic viral integration site 
1 gene 
MEM minimum essential media 
mg/l  milligram per litre 
MI myocardial infarction 
min minute 
miR microRNA 
ml millilitre 
MLV murine leukaemia virus 
MLV-A murine leukaemia virus-amphotropic 
MLV-E  murine leukaemia virus-ecotropic 
mM millimolar (millimoles per litre) 
MMP matrix metallo-proteinase 
MOI multiplicity of infection 
mRNA messenger RNA 
MTT 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide 
N-terminal amino-acid terminal domain 
Nef negative replication factor 
ng nanogram 
ng/µl nanogram per microlitre 
Ng-BR Nogo-B receptor 
NIF neointima formation 
NILV non-integrating lentiviral vector 
NILV-eGFP non-integrating lentiviral vector expressing/gene transfer 
of eGFP 
NILV-Nogo-B non-integrating lentiviral vector expressing/gene transfer 
of Nogo-B 
nm nanometre 
nM nanomolar (nanomoles per litre) 
NO nitric oxide 
Nogo neurite outgrowth inhibitor 
Nogo-66 neurite outgrowth inhibitor -66 loop 
Nogo-B neurite outgrowth inhibitor isoform B 
OD optical density 
ODU units of optical density 
p53 tumour suppressor protein 53 
p56 tumour suppressor protein 56 
PAGE polyacrylamide gel electrophoresis 
p-Akt phosphorylated-Akt 
PB primer binding site 
PBS phosphate buffered saline 
PCI percutaneous coronary interventions 
PCR polymerase chain reaction 
PDGF platelet derived growth factor 
PDGFR platelet derived growth factor receptor 
PDI protein disulphide isomerase 
PEI polyethylenimine 
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p-ERK phosphorylated-extracellular signal-regulated kinase 
PERK  protein kinase-like ER kinase 
PFA paraformaldehyde 
PGK phosphoglycerate kinase 1 
PI3K phosphatidylinositol-3-kinase 
PIC pre-integration complex 
PMA phorbol 12-myristate 13-acetate 
pmol/µl picomole per microlitre 
PNS peripheral nervous system 
PPT polypurine tract 
PRDM16 PR domain containing 16 gene 
PREVENT project of ex vivo vein graft engineering via transfection 
qPCR quantitative PCR 
R repeat region 
Rac Ras-related C3 botulinum toxin substrate (Rho kinase 
family monomeric G-proteins) 
Rb retinoblastoma protein 
Rev regulatory viral protein 
RFU relative fluorescent unit 
RHD reticulon homology domain 
Rho Ras homolog gene family protein (Rho kinase family 
monomeric G-proteins) 
RhoA Ras homolog gene family protein, member A (Rho kinase 
family monomeric G-proteins) 
RLU relative luminescence unit 
RNA ribonucleic acid 
RPE65 retinal pigment epithelium-specific 65 kDa protein 
rpm revolutions per minute 
RRE rev response element 
RRM ready reaction mix 
RRV ross river virus 
RT room temperature 
RTK receptor tyrosine kinase 
RTN  reticulon protein 
SAP shrimp alkaline phosphatase 
SDS sodium dodecyl sulphate 
sec seconds 
S.E.M standard error of the mean 
SETBP1 SET binding protein 1 gene 
SFFV spleen focus forming virus 
SIN self-inactivating 
SM smooth muscle 
SM-actin smooth muscle-actin 
SMC smooth muscle cell 
SM-MHC SM-myosin heavy chain 
SOC super optimal broth with catabolite repression 
SOD  superoxide dismutase 
SPRI solid phase reversible immobilization 
SV-40 simian virus-40 
SVG saphenous vein graft 
TAMRA tetramethylrhodamine 
Tat  transactivator of transcription 
TBE tris/borate 
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TBS-T  tris buffered saline-tween 
TEMED tetramethylethylenediamine 
Th2 T-lymphocyte helper 2 
Tie2 tyrosine kinase 2 
TIMP tissue inhibitors of matrix metalloproteinases 
Tm melting temperature 
TM transmembrane 
TNF-α  tumour necrosis factor-alpha 
TUNEL terminal deoxynucleotidyl transferase dUTP nick end 
labelling 
U unit of restriction enzyme activity 
U3 unique 3’ region 
U5 unique 5’ region 
UCOE  ubiquitously acting chromatin opening element 
UPR unfolded protein response 
UTR untranslated region 
UV ultraviolet light 
V voltage 
v/v volume per volume 
VEC  vascular endothelial cell 
VEGF vascular endothelial growth factor 
Vif viral infectivity factor 
Vpr viral protein R 
Vpu viral protein U 
VSMC vascular smooth muscle cell 
VSV-g vesicular stomatitis virus glycoprotein 
w week 
w/v  weight per volume 
WAS Wiskott-Aldrich syndrome 
WPRE woodchuck post-transcriptional regulatory element 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
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Summary 
Vascular smooth muscle cell (VSMC) migration and proliferation are important 
hallmarks in the development of the neointima formation (NIF) following acute 
vascular injury, contributing significantly to the pathogenesis of post-angioplasty 
restenosis, in-stent restenosis (ISR) and low lumen patency of coronary artery 
bypass grafting. At present there are a finite number of pharmacological 
treatments in use for the prevention of the NIF, such as drug-eluting stents (DES) 
for ISR and more are under development. Vascular gene delivery strategies have 
been extensively explored. There is a requirement to identify and provide a safe 
and effective gene transfer strategy for therapeutic gene delivery to attenuate 
NIF in the clinical setting.  Lentiviral vector (LV)s are efficient in transducing 
vascular cells and have been considered as useful vectors for delivering 
therapeutic interventions to reduce the NIF following acute vascular injury in 
vivo. Non-integrating LV (NILV)s offer additional potential for LVs in vascular 
gene therapy. Nogo-B is a member of the reticulon 4 family of transmembrane 
proteins, and is expressed in vascular endothelial cell (VEC)s and VSMCs. Nogo-B 
is a regulator in vascular maintenance and remodelling. Nogo-B has a favourable 
profile for the prevention of the NIF, because this protein acts as a positive and 
negative regulator of VECs and VSMCs, respectively. This effect is facilitated by 
Nogo-B mediated chemo-attraction of VECs, and the antagonism of migration 
and proliferation of VSMCs in response to platelet derived growth factor (PDGF) 
and/or serum. Nogo-B is down-regulated following vascular injury, which 
correlates with the development of NIF. Previously, it was demonstrated that 
adenoviral-mediated Nogo-B gene transfer facilitated over-expression of Nogo-B, 
and rescued the injury-induced NIF in two distinct and appropriate in vivo 
models of acute vascular injury (the murine wire-injury model and the porcine 
vein grafting model).  
The aim of this thesis was to assess the potential of NILVs for application to 
vascular gene therapy, by over-expression of Nogo-B. First, second generation 
self-inactivating (SIN) LVs were optimised (in terms of promoter alternatives, 
pseudotyping and integration-deficiency) for transgene expression in human 
vascular cells. Second, the effects of Nogo-B over-expression on human VSMC 
migration and proliferation, mediated by NILVs were assessed in vitro and 
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compared to its integrating counterparts. Third, the mechanism of action of 
Nogo-B on human primary VSMCs was explored in vitro. 
LVs were evaluated for efficiency and/or longevity in vascular cell gene transfer 
in vitro with regards to alternative internal heterologous promoters, 
pseudotyping and integration-proficiency versus integration-deficiency. 
Undoubtedly, both promoters, spleen focus forming virus (SFFV) and enhancer-
less ubiquitously chromatin opening element (UCOE) evoked efficient and 
longevity of [vesicular stomatitis virus glycoprotein (VSV-g) pseudotyped] 
integrating-LV (int-LV)-mediated eGFP transgene expression in VECs and VSMCs. 
However in contrast to the UCOE promoter, the SFFV promoter was significantly 
higher in terms of transgene expression in VECs and VSMCs, and thereby was 
used in subsequent experiments. Interestingly, int-LVs pseudotyped with Rabies, 
Baculovirus glycoprotein 64 or Ebola Zaire glycoprotein envelope, demonstrated 
their potential usefulness in efficient VEC transduction and subsequent eGFP 
transgene expression. Importantly, VSV-g pseudotyped NILVs were efficient in 
mediating the expression of eGFP in VECs and VSMCs. Thereafter, these selected 
VSV-g pseudotyped NILVs under the control of the SFFV promoter were used for 
therapeutic gene transfer analysis in VSMCs in vitro.  
A new gene delivery vector, NILV expressing Nogo-B (NILV-Nogo-B) was 
constructed and analysed in vitro for its therapeutic potential in the prevention 
of NIF associated with acute vascular injury. The Nogo-B cDNA was cloned into a 
LV construct plasmid (consisting of the SFFV promoter) for the generation of int-
LV expressing Nogo-B (int-LV-Nogo-B) and NILV-Nogo-B. Indeed, in contrast to 
their LV expressing eGFP (LV-eGFP) control vector and un-infected VSMCs 
(endogenous Nogo-B level), NILV-Nogo-B mediated efficient Nogo-B over-
expression in human VSMCs, which led to significant phenotypic effects on 
migration and proliferation with similar effects to int-LV-Nogo-B. NILV-Nogo-B-
mediated gene transfer was as effective as its integrating counterparts in 
reducing VSMC migration. Interestingly, NILV-Nogo-B was at least as good as int-
LV-Nogo-B in inhibiting VSMC proliferation.  
The mechanism of action of Nogo-B associated with phenotypic effects on VSMC 
migration and proliferation was evaluated in vitro. Previous reports have 
implicated Nogo-B as being a pro-apoptotic protein, and therefore the effect of 
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LV-mediated gene transfer of Nogo-B on VSMC apoptosis was assessed. Evidently, 
neither int-LV-Nogo-B nor NILV-Nogo-B significantly induced VSMC apoptosis. 
Over-expression of Nogo-B mediated by int-LV was observed co-localised with 
the endoplasmic reticulum (ER) in VSMCs. A published report indicated that the 
over-expression of Nogo-B induced ER-stress mediated apoptosis. Results 
suggested that Nogo-B over-expression did not significantly induce ER-stress 
signalling in VSMCs. Interestingly, Nogo-B over-expression significantly reduced 
ERK 1 & 2 activation in VSMCs, but not Akt signalling transduction pathway, and 
therefore this could have possible implications in phenotypic effects on VSMC 
migration and proliferation. 
Taken together, this thesis demonstrated that SFFV-driven VSV-g pseudotyped 
NILVs are efficient for vascular cell gene transfer at least in vitro. Additionally, 
this thesis supports the use of NILV-Nogo-B as a candidate for therapeutic 
application for the prevention of NIF associated with acute vascular injury during 
revascularisation in vivo. In conclusion, this study addresses important 
implications for the use of NILVs as a potential therapeutic vector in vascular 
cell gene delivery studies.   
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1 Introduction 
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1.1 General introduction 
Revascularisation procedures are initially effective methods in relieving the 
symptoms of angina and prolonging survival. Despite this, the development of 
the neointima formation (NIF) following acute vascular injury is a major 
contributory factor in post-angioplasty restenosis, in-stent restenosis and 
coronary artery bypass vascular graft failure. Furthermore, the increasing 
numbers of revascularisation techniques in the foreseeable future inevitably 
means that the magnitude of this clinical problem will continue to rise unless 
novel solutions are explored. There is always on-going need for research, 
development and target validation of new and far more effective therapies in 
cardiovascular medicine. At present, there are limited numbers of effective 
pharmacological treatments for the prevention of the NIF. Vascular gene therapy 
is one such strategy which has been extensively explored over the years. 
However, there still remains a need to identify and provide a safe and effective 
delivery strategy for therapeutic genes to prevent the NIF during acute vascular 
injury in this clinical setting. Lentiviral vectors (LVs) and their integration-
deficient counterparts are potentially suitable gene transfer systems for vascular 
gene therapy.  
1.2 Cardiovascular diseases  
Cardiovascular diseases (CVDs) refers to a group of disorders affecting the heart 
and circulatory system and these include: hypertension, coronary heart disease 
(CHD) [associated with myocardial infarction (MI)], cerebrovascular disease 
(associated with stroke), peripheral vascular disease and many more diseases 
that are associated with the cardiovascular system. Although there have been 
many significant advances in therapeutic interventions for CVDs which have 
helped to control symptoms and reduce the risk of further health problems, 
CVDs are still the most common cause of premature death in both men and 
women worldwide. An estimated 17.1 million people die worldwide from CVDs 
per year, which represents 29 % of all global deaths (http://www.who.int, 
2009). It is estimated that CVDs cause approximately 38 % of all deaths in the 
UK, accounting for approximately 200,000 deaths each year 
(http://www.bhf.org.uk, 2008, http://www.heartstats.org, 2009a). It is 
estimated by 2030 almost 23.6 million people worldwide will die from CVDs, but 
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mainly from CHD and stroke (http://www.who.int, 2009). CHD by itself is the 
UK’s most common cause of death before the age of 75. Current figures for the 
UK indicate that around 2.5 million people are living with CHD, which accounts 
for approximately 94,000 deaths every year. CHD still has the highest mortality 
rate compared to any other human disease such as cancer within the developed 
world (http://www.bhf.org.uk, 2008, http://www.heartstats.org, 2010b). 
Moreover, CHD mortality is higher in Scotland than any other part of the UK, 
with the highest in the west of Scotland (http://www.heartstats.org, 2010a). 
These current statistics are surprising considering the significant improvements 
to the management of associated risk factors and medical interventions. With 
respect to these current issues, there remains a need for research and 
development of new and more effective therapies in cardiovascular medicine for 
the prevention and treatment of CVDs. This is why cardiovascular gene therapy 
is continually under intensive investigation and more so in recent years.  
1.2.1 Structure of a blood vessel 
The structure of a normal blood vessel wall consists of three morphologically 
distinct layers: the tunica intima (inner layer), the tunica media (middle layer) 
and the tunica adventitia (external layer) (Figure 1.1). The intima consists of a 
continuous endothelial monolayer (relatively quiescent) that forms a protective 
barrier between the vessel wall and the blood, and overlies the following: a thin 
layer of basement membrane, an extracellular proteoglycan rich matrix and an 
internal elastic lamina. Basement membranes contain type IV collagen, heparan 
sulphate proteoglycans such as perlecan and syndecans, and laminin. Altogether, 
these components help maintain VSMCs contractile phenotype state (relatively 
quiescent). The media layer is mainly composed of vascular smooth muscle cells 
(VSMCs), surrounded by their own basement membrane, and densely packed into 
an extracellular matrix (ECM). The ECM consists of types I and III collagen, 
fibronectin, and chondroitin/dermatan sulphate proteoglycans (such as verican). 
Medial VSMC dilate or contract the vessel, following responses to intimal cues. 
The media layer is seated on external elastic lamina. The adventitial layer 
consists of fibroblasts and VSMCs in a loose interstitial matrix, which also 
contains small blood vessels and lipids. All layers support the structural integrity 
of a blood vessel (Figure 1.1) (Newby and Zaltsman, 2000). 
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Figure 1.1. The structure of a normal blood vessel.  
This schematic diagram highlights the three morphologically distinct layers of a normal blood 
vessel. The intima consists of a continuous endothelial monolayer, which overlies the following: 
a basement membrane, an extracellular proteoglycan rich matrix and internal elastic laminae. 
The media layer mainly consists of VSMCs surrounded by basement membrane and densely 
packed into an ECM. The media layer overlies on external elastic laminae. The Adventitia layer 
consists of VFs and VSMCs in a loose ECM. Adapted from Newby and Zaltsman (2000). 
1.2.2 Atherosclerosis 
Atherosclerosis is one of the known underlying causes of CHD. Atherosclerosis 
(origin is from the Greek words ‘athero’ meaning gruel or paste and ‘sclerosis’ 
meaning hardness) is a progressive disease which involves the formation of an 
atherosclerotic plaque within the vasculature and has a very complex aetiology. 
Atherogenesis (fatty streak lesions) occurs naturally with increasing age and 
mainly within large and medium-sized blood vessels such as the aorta, iliac, 
coronary, femoral and cerebral arteries. Fatty streak lesions are precursors of 
more complex advanced lesions within the vasculature. Only a small fraction of 
individuals will experience advanced atheroma plaque developments (complex 
advanced lesions) associated with modifiable risk factors (for example obesity, 
hypertension or hyperglycaemia in diabetes mellitus) and/or un-modifiable risk 
factors (for example age, gender or genetic determinants/family history of CVD, 
can predispose individuals). These complex advanced lesions cause mechanical 
obstruction within the lumen of the blood vessel and mediate tissue ischaemia 
such as myocardial ischaemia (angina) or cerebral ischaemia. These 
complications predispose individuals to have a MI or stroke, respectively (Ross, 
1999, Lusis, 2000, Glass and Witztum, 2001, Libby and Theroux, 2005, Libby et 
al., 2011).   
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1.2.3 Revascularisation 
Angina is caused by occlusive advanced atherosclerotic lesions in the coronary 
arteries (CHD), which requires revascularisation strategies to re-establish the 
blood flow. These surgical interventions include coronary artery bypass grafting 
surgery (CABG) and percutaneous coronary interventions (PCIs) such as balloon 
catheter angioplasty or stent placement (http://www.bhf.org.uk, 2010b, 
http://www.bhf.org.uk, 2010a). CABG involves an autologous blood vessel from 
the chest (i.e. internal mammary artery), leg (i.e. saphenous vein) or arm (i.e. 
radial artery), which is used to bypass a blockage within the coronary artery. 
This blood vessel is attached from the aorta and past the point of blockage 
within the coronary artery, which gives rise to improved blood supply to the 
heart (http://www.bhf.org.uk, 2010b). During a balloon catheter angioplasty 
procedure, a cardiac catheter with a tightly folded balloon around it, is inserted 
and inflated in the narrow area of the coronary artery. This expansion diminishes 
the impeding blockage, hence widening the artery. Balloon-angioplasty may be 
followed by intravascular implantation of a short tube of expandable bare metal 
mesh (known as a stent) to prevent elastic re-coil of the artery 
(http://www.bhf.org.uk, 2010a).  
Successful revascularisation therapy can provide great clinical benefit in CHD by 
treating angina and preventing MI, heart failure, and even death, and therefore 
increasing life expectancy (http://www.bhf.org.uk, 2010a, 
http://www.bhf.org.uk, 2010b). However, the long-term clinical effectiveness 
of a revascularisation procedure (PCI or CABG treated patients) can be (in some 
cases) greatly compromised due to an abnormal vascular remodelling process 
associated with a response to acute vascular injury, and this subsequently results 
in neointima formation (NIF) at the site of therapeutic intervention. The NIF 
contributes to the pathogenesis of post-angioplasty restenosis, in-stent 
restenosis (ISR) and vascular conduit bypass graft failure.  The long-term clinical 
success of a revascularisation procedure is therefore limited by the occurrence 
of the NIF, which results in recurrent symptoms, such as angina, and possible 
clinical complications including MI and heart failure. As a consequence, a 
repeated revascularisation procedure is required, which can impose a major 
burden on healthcare resources (Mehta et al., 1997, Tsui and Dashwood, 2002, 
Weintraub, 2007, http://www.bhf.org.uk, 2010a). Restenosis is characterised by 
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the re-occurrence of stenosis (re-occlusion) after a successful PCI. Restenosis 
occurs in 10-30 % of intravascular stent placements and in 30-50 % of patients 
receiving balloon-angioplasty interventions, both within 6 months to 1 year post-
surgery (Weintraub, 2007). Vascular conduit graft failure is a significant clinical 
problem in CABG treated patients, with a 15-30 % failure rate within one year 
post-surgery (Mehta et al., 1997, Buxton and Fuller, 2004, Cho et al., 2006). This 
increases to approximately 50 % after 10 years (Mehta et al., 1997, Buxton and 
Fuller, 2004) and a further 15 years results in a failure rate of up to 80 % (Shah 
et al., 2003, Buxton and Fuller, 2004). 
1.2.3.1 Pathogenesis of the neointima formation 
In a normal blood vessel (under normal conditions), the vascular endothelium 
plays an essential role in vessel wall structural integrity and functions as a 
protective barrier (VECs are tightly packed in a continuous monolayer) between 
the vessel wall and the blood flow. Fully differentiated medial VSMCs are 
quiescent and exhibit very low levels of proliferative and apoptotic activities, 
and as a result are rarely induced to migrate and proliferate to re-establish 
vascular structural integrity (Newby and Zaltsman, 2000).  
The major hallmarks that contribute to the NIF following acute vascular injury 
involve damage to the endothelial monolayer (depletion of VECs), an increase in 
VSMC migration and proliferation and ECM deposition (Ross et al., 1977, Ross, 
1993, Ross, 1995, Ross, 1999, Newby and Zaltsman, 2000). Acute vascular injury 
mediates a combination of changes in the vasculature, these include vascular 
structural integrity, stretch forces, shear stress and flow stress, and as a 
consequence contributes to the NIF associated with an interplay of vascular 
remodelling events (Newby and Zaltsman, 2000, Mitra et al., 2006, Muto et al., 
2010). Briefly, vascular injury induces endothelial dysfunction (injury) and/or 
medial damage, which mediates the exposure of sub-endothelial connective 
tissue, and this subsequently disturbs blood flow causing platelet adherence, 
aggregation and release of platelet-derived growth factor (PDGF) (also released 
from dedifferentiated VSMCs). As a consequence, PDGF acts has a chemo-
attractant mediating phenotypically modified medial VSMCs (from differentiated 
to dedifferentiated state) to migrate into the intimal layer where they 
proliferate and produce ECM proteins (Figure 1.2). Moreover, the alteration in 
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the regulation of ECM also contributes to the NIF. The up-regulation and 
activation of matrix metalloproteinases (MMPs) contributes to the remodelling of 
the ECM following acute vascular injury. Subsequently, this up-regulates the 
degradation of the ECM, and increases medial VSMC migration and proliferation 
in the intimal layer. In addition, the down-regulation of basement membrane 
components (type IV collagen, heparin sulphate proteoglycans and laminin) 
surrounding VSMCs, facilitates the migration of medial VSMCs into the intimal 
layer following acute vascular injury. Furthermore, VSMCs increase their 
production of ECM components such as type I collagen, elastin and fibronectin, 
and PDGF greatly stimulates further collagen and proteoglycan synthesis; all of 
which contributes to more ECM deposits within the NIF (Figure 1.2) (Newby and 
Zaltsman, 2000, Raines, 2004b, Mitra et al., 2006, Newby, 2006). There are 
many growth factors involved in the NIF following response to acute vascular 
injury (Newby and Zaltsman, 2000, Berk, 2001, Mitra et al., 2006). In terms of 
CABG, the NIF acts as a precursor for the development of 
superimposed/accelerated atherosclerosis in vascular bypass graft failure (Figure 
1.3) (Bryan and Angelini, 1994, Newby and Zaltsman, 2000, Muto et al., 2010). 
VSMCs are not terminally differentiated and are able to modulate their 
phenotype in response to changing environmental cues. During vascular injury 
(also occurs with atherosclerosis), VSMCs switch from a contractile 
(differentiated) to a synthetic (de-differentiated) phenotype, commonly 
referred to as phenotypic switching (Newby and Zaltsman, 2000, Mitra et al., 
2006). Expression of a repertoire of contractile factors (a complex interplay of 
multiple molecular and cellular regulatory components) contributes to the up-
regulation of SMC-specific/-selective marker genes, for example smooth muscle 
(SM) alpha (α) -actin, SM-myosin heavy chain (MHC) and SM22-α, which are 
required for VSMC specialised contractile function, and exhibit low rate of 
proliferation and low synthetic activity. Indeed, molecular and cellular 
regulation of VSMC differentiation is modified during vascular injury, which 
results in the down-regulation of SMC-specific marker genes, bringing about the 
phenotypic switching into the synthetic state associated with induced migration 
and proliferation phenotypic effects (Owens, 1995, Yoshida and Owens, 2005). 
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Figure 1.2 Pathogenesis of the neointima formation (NIF).  
This schematic diagram highlights the events in NIF after acute vascular injury. Vascular injury 
induces endothelial dysfunction (injury) and/or medial damage, which results in the exposure of 
sub-endothelial connective tissue. The disruption of blood flow causes platelet adherence, 
aggregation and release of PDGF. PDGF acts as a chemo-attractant promoting phenotypically 
modified medial VSMCs to migrate into the intimal layer, where these VSMCs proliferate and 
produce ECM protein. The up-regulation and activation of MMPs contributes to the remodelling of 
the ECM following vascular injury and up-regulates the degradation of the ECM, which facilitates 
medial VSMC migration and proliferation in the intimal layer. The down-regulation of basement 
membrane components surrounding VSMCs promotes the migration of medial VSMCs. Adapted 
from Newby and Zaltsman (2000) (Raines, 2004b, Newby, 2006). 
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Figure 1.3. Pathogenesis of vascular bypass graft failure.  
Surgical injury, wall stretch and shear stress facilitates endothelial injury/damage, which 
subsequently mediates the neointima formation (NIF). NIF encourages a response to 
inflammation, involving infiltration and interaction of inflammatory cells, macrophage-foam cell 
formation and accumulation, and ECM production and deposition. Over time, these foam cells 
die and contribute their lipid-filled contents to necrotic core of the lesion. Thus, the NIF 
associated with vascular bypass graft failure, forms a template for the development of 
superimposed/accelerated atherosclerosis. Adapted from George et al., (2006) (Bryan and 
Angelini, 1994, Newby and Zaltsman, 2000, Muto et al., 2010).  
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Animal models of vascular injury and human autopsy specimens have been used 
to define mechanisms/components which contribute to the NIF and to assist with 
the development of therapeutic strategies to prevent human NIF (Angelini et al., 
1992, Lindner et al., 1993, Groves et al., 1995, Kumar and Lindner, 1997, De 
Scheerder et al., 1999, Schwartz and Henry, 2002, Schwartz et al., 2004, Popov 
et al., 2008). In a murine wire-injury model, it is well-established that NIF is 
evident at 2 weeks post-injury. This involves the proliferation of medial VSMCs 
within days, migration of VSMCs to the intima by 1 week and expansion of the 
NIF by 3-4 weeks post-injury (Lindner et al., 1993).  After approximately 4 weeks 
post-injury, the repair of the endothelium is complete and VSMCs return to a 
normal differentiated state with a very low cell turnover (Lindner et al., 1993). 
In a porcine vein graft model using a saphenous vein as a conduit, NIF is evident 
between 1-4 weeks post-injury (consisting of migration and proliferation, and a 
large amount of extracellular matrix) and a slower NIF occurs 4-39 weeks after 
grafting (Angelini et al., 1992). Both models share key elements and stages 
associated with the NIF (Angelini et al., 1992, Lindner et al., 1993). In addition, 
the response to acute vascular injury in humans with regards to precise times of 
each stage during the vascular remodelling process remains unclear (Weintraub, 
2007). 
Despite the occurrence of the NIF, revascularisation procedures are still the 
ideal choice for treatment and prevention of CHD, with improved clinical 
outcomes outweighing the risks (Hueb et al., 2007, Hueb et al., 2010, Yamaji et 
al., 2010). The total number of these surgical interventions carried out to treat 
CHD increases every year. It was reported by the British Cardiovascular 
Intervention Society in 2008, that 80331 PCIs and  22846 CABG operations were 
performed in the UK alone (http://www.heartstats.org, 2009b). PCIs are 
considered as the surgical intervention of choice because these procedures are 
less invasive (http://www.heartstats.org, 2010c). The increasing use of 
revascularisation procedures in the foreseeable future undoubtedly means that 
this clinical problem (NIF following acute vascular injury) will continue to 
increase unless novel therapeutic strategies to limit restenosis and increase 
patency rates are explored and developed (George et al., 2006). 
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1.3 Therapeutic interventions for acute vascular injury   
1.3.1 Drug-eluting stents 
Drug-eluting stents (DESs) have significantly reduced the incidence of ISR 
compared to bare metal bare stents since their introduction in 2002. DESs have 
become popular in the management of CHD because of the relief of symptoms in 
most patients and improved survival in those with the most severe disease 
(Lange and Hillis, 2010). After the DES is inserted, the anti-proliferative agent is 
gradually released into the blood vessel wall by contact transfer and takes effect 
over the time course of hours to months, and as a result provides a sustained 
reduction of the NIF during the acute vascular injury response. This effect is 
mediated by the cell-cycle inhibition of injured/phenotypically modified 
vascular cells, especially medial VSMCs (Lange and Hillis, 2010).  
The first generation of DESs released sirolimus (Morice et al., 2002, Schofer et 
al., 2003) or paclitaxel (Stone et al., 2004b, Stone et al., 2004a). These were 
designed to arrest medial VSMC proliferation, and as a consequence reduce the 
NIF, the incidence of restenosis and the need for re-intervention; improving 
clinical outcome (Costa and Simon, 2005). However, data demonstrated that 
these anti-proliferative compounds were very potent and had long-term effects 
on other cell types, especially VECs. Paclitaxel inhibited VEC migration, and 
both paclitaxel and sirolimus inhibited VEC proliferation (Parry et al., 2005). 
Most importantly giving rise to delayed healing characterised by persistent fibrin 
deposition and incomplete/delayed re-endothelialisation, which resulted in a 
risk of late-stent thrombosis (occurs 30 days or more after DES implantation) 
(Joner et al., 2006, Finn et al., 2007). In spite of the risk, DESs improve clinical 
outcome in terms of restenosis and therefore the risk does not outweigh the 
benefits (Jensen et al., 2007). Due to the delayed re-endothelialisation, a dual 
anti-platelet therapy with aspirin and clopidogrel (for inhibition of platelet 
aggregation and thrombus formation) is required by at least several months 
during the perceived endothelial regeneration period (King et al., 2008, Kushner 
et al., 2009), thereby increasing clinical outcome and improving the therapeutic 
index of DESs. The second generation of DESs such as the everolimus-eluting 
stents are more effective in inhibiting ISR and reducing the incidence of late-
stent thrombosis, when comparing them to the first generation such as 
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paclitaxel-eluting stents (Stone et al., 2010). These second generation DESs are 
currently used in clinical practice and have been since 2006 in the UK (Lange and 
Hillis, 2010). 
Currently there still remains a need to develop innovative new therapies, which 
combine the beneficial effects of stenting with agents that mediate only the 
desired effect on vascular cell pathobiology, and therefore, dramatically reduce 
the incidence of ISR and thrombosis, and greatly improve clinical outcome. 
Research and development of molecular or gene delivery systems for the 
prevention of the NIF during acute vascular injury associated with the stent 
implantation procedure, represents a novel and compelling alternative, which is 
worthy of investigation.  
1.3.2 Molecular interventions  
Cell-cycle progression is controlled by a repertoire of cell-cycle regulatory genes 
for example c-myc, c-myb, cdc2 and many others. Therefore, these cell-cycle 
regulatory genes have roles in cell proliferation. In quiescent cells, the 
elongation 2 transcriptional factor (E2F) is bound in a protein complex [includes 
retinoblastoma (Rb) protein] which prevents its binding to its consensus E2F-
binding sequence in the promoter regions of cell-cycle regulatory genes. This 
prevents the stimulation of these cell-cycle regulatory genes/proteins involved 
in cell-cycle progression (Ehsan and Mann, 2000, Mann and Dzau, 2000). In 
proliferating cells (cell-cycle progression), E2F is released from its protein 
complex (by phosphorylation), and as a result activates cell-cycle regulatory 
gene expression (Ehsan and Mann, 2000, Mann and Dzau, 2000).  
A strategy to block the function of the transcription factor E2F, involved a 
double-stranded E2F “decoy” oligonucleotide that consisted of the consensus 
E2F-binding site. As a consequence, this prevented the interaction of the E2F 
with the E2F-binding sequence in the promoter regions of cell-cycle regulatory 
genes, thereby inhibiting their activation and blocking VSMC proliferation and 
the NIF following acute vascular injury (Morishita et al., 1995). An ex vivo study 
in a rabbit vein graft model demonstrated that vein grafts treated 
intraoperatively with E2F “decoy” (also known as edifoligide), substantially 
inhibited the NIF and subsequently inhibited accelerated/ superimposed 
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atherosclerosis (Ehsan et al., 2001). Based on these promising experimental 
results, the project of ex vivo vein graft engineering via transfection (PREVENT) 
clinical trials (I to IV) were undertaken (Mann et al., 1999, SoRelle, 2001, 
Alexander et al., 2005a, Alexander et al., 2005b, Conte et al., 2005, Conte et 
al., 2006) and to date have provided the most extensive investigations within the 
molecular therapy approach in the prevention of vascular bypass graft failure. 
Despite these promising preliminary clinical results from single-centre phases I 
and II (PREVENT I and II) in peripheral limb vein grafts and CABG respectively 
(Mann et al., 1999, SoRelle, 2001), this E2F “decoy” therapy was ineffective in 
preventing lower extremity vein graft and CABG failure in two large phase III 
multicentre clinical phases (PREVENT III and IV, respectively) (Alexander et al., 
2005b, Conte et al., 2006). These results demonstrated that the edifoligide 
regime was not efficient in the reduction of the NIF.  
1.4 Gene therapy 
Gene therapy is defined as the insertion/delivery of a gene into an individual’s 
cell or tissue to the correct inherited or acquired pathology by gene 
replacement, gene over-expression or gene silencing, and therefore to 
ultimately achieve beneficial/therapeutic effects 
(http://www.dh.gov.uk/ab/GTAC/Genetherapy/, 2011). Gene therapy was 
originally conceived for the treatment of inherited monogenic disorders such as 
Duchene’s muscular dystrophy, cystic fibrosis, sickle cell anaemia, severe 
combined immunodeficiency (SCID) and haemophilia A or B, where gene 
replacement (replacement of the non-functional gene with the “wild-
type”/functional gene) “should” restore a normal phenotype. Gene therapy 
approaches are also applied to the treatment of acquired diseases including 
cardiovascular diseases (CVDs) and cancer, and have enormous potential to 
provide novel and alternative therapeutic interventions for diseases which are 
currently lacking in suitable therapies. However, the success of gene therapy is 
restricted by the limited number of suitable vectors for each application and 
limitations in delivery to the target site, and therefore will depend on further 
research into optimisation (Edelstein et al., 2004, Edelstein et al., 2007). 
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1.5 Gene therapy clinical trials 
Since 1989 to 2010, 1703 gene therapy clinical trials have been approved 
worldwide (http://www.wiley.com/legacy/wileychi/genmed/clinical/, 2011b). 
Approximately 68.7 % of gene therapy clinical trials have used viral vectors as 
their vector of choice, whereas approximately 25.1 % have been approved and 
conducted with the use of non-viral vectors 
(http://www.wiley.com/legacy/wileychi/genmed/clinical/, 2011c). There have 
been many successful gene therapy clinical phase I/II trials, for example for the 
treatment of X-linked SCID which is a monogenic disorder of the immune system 
that occurs exclusively in males. This occurs due to a mutation in the gene that 
encodes for the common gamma chain (γc) within the receptors (of early 
lymphoid progenitor cells) for interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15 and IL-21, 
which gives rise to the absence of janus kinase 3 (JAK3) signal transduction.  
Thus, the early lymphoid progenitor cells in patients with X-linked SCID are 
defective in cytokine signalling, resulting in the absence of T-lymphocytes and 
natural killer (NK) cells, dysfunctional B-lymphocytes and 
hypogammaglobulinemia. This condition is also commonly known among the 
general public as “bubble boy” syndrome. Patients with X-linked SCID suffer 
from recurrent infections, failure to thrive and may die within the first year of 
life due to an impaired adaptive immune response. In the absence of an 
effective treatment, allogenic bone marrow transplantation (BMT) has become 
the therapeutic intervention. However, BMT can be associated with incomplete 
reconstitution of B-lymphocyte function and/or severe complications such as 
graft-versus-host disease (Santilli et al., 2008). In addition, gene therapy is 
another therapeutic intervention that has been explored since 1996 for its 
possible clinical application. Gene therapy clinical trials were initiated after 
successful preclinical data of retroviral mediated gene transfer of the functional 
γc gene in lymphoid cells (with a mutated γc gene), which resulted in restored 
receptor expression and function (Candotti et al., 1996, Cavazzana-Calvo et al., 
1996, Hacein-Bey et al., 1996, Taylor et al., 1996, Hacein-Bey et al., 1998, 
Whitwam et al., 1998, Lo et al., 1999, Soudais et al., 2000). Ex vivo retroviral 
gene transfer of the correct γc gene in CD34 positive cells [haematopoietic stem 
cells (HSC)] in X-linked SCID patients, have shown long-term benefits with 
developed and functional T and B-lymphocytes and NK cells in the normal ranges 
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of a normal healthy patient (Cavazzana-Calvo et al., 2000, Hacein-Bey-Abina et 
al., 2002, Gaspar et al., 2004, Hacein-Bey-Abina et al., 2010). Unfortunately, 
there have been a few cases of adverse events with the onset of leukaemia in 
these X-linked SCID treated patients, caused by insertional mutagenesis 
mediated retroviral vectors, which resulted in the expression of endogenous 
proto-oncogenes (Hacein-Bey-Abina et al., 2003a, Hacein-Bey-Abina et al., 
2003b, Hacein-Bey-Abina et al., 2008, Howe et al., 2008). However, these risks 
are counterbalanced by outstanding results demonstrated in these clinical gene 
therapy trials, because of the benefits observed and disease-free remission many 
years after gene delivery in the majority of these patients.   
1.6 Gene therapy for CVD 
Gene therapy for CVD became a new and exciting discipline for the prevention 
and treatment of a multitude of CVDs, ignited by the earliest successful 
evidence of in vivo vascular gene transfer and expression in VECs by Nabel et al. 
in 1989 (Nabel et al., 1989, Nabel et al., 1990, Nabel et al., 1991). Since that 
time, intensive investigations (preclinical and clinical trials) have explored viral 
and non-viral gene delivery vectors for many CVD applications, and these 
include: complex polygenic traits such as hypertension; acute vascular injury 
including restenosis and vascular graft bypass failure; ischaemic disease 
including myocardial or peripheral ischaemia, as well as monogenic disorders 
(familial hypercholesterolaemia) (Gaffney et al., 2007, Rissanen and Yla-
Herttuala, 2007).  
1.7 Cardiovascular gene therapy clinical trials 
In terms of gene therapy clinical trials for CVDs, 144 out of 1703 (8.5 %) have 
been carried out so far worldwide and this is the second most frequently studied 
target (http://www.wiley.com/legacy/wileychi/genmed/clinical/, 2011a). Pro-
angiogenic gene therapy clinical trials for the coronary artery and peripheral 
vascular disease are the most explored area of cardiovascular gene therapy with 
several completed clinical trials. This pro-angiogenic gene therapy approach 
involves the stimulation of neovascularisation (also known as therapeutic 
angiogenesis). This strategy involves enhancing the development of blood vessels 
to bypass occluded arteries. Angiogenic growth factors such as vascular 
Introduction  41 
    
endothelial growth factor (VEGF) are associated with VEC proliferation and 
migration, which subsequently results in accelerated endothelial repair and tube 
formation (Gaffney et al., 2007, Rissanen and Yla-Herttuala, 2007). 
To date, clinical investigations carried out in Finland by Seppo Ylä-herttuala et 
al., have explored VEGF gene transfer mediated by either viral (for example 
adenovirus) or non-viral vectors in phase I/II trials in patients with severe 
vascular diseases for pro-angiogenesis and/or anti-restenosis (Laitinen et al., 
2000, Makinen et al., 2002, Hedman et al., 2003, Hedman et al., 2009). These 
studies have demonstrated that these vector delivery systems are well 
tolerated, safe and feasible for gene transfer (Laitinen et al., 2000, Makinen et 
al., 2002, Hedman et al., 2003, Hedman et al., 2009). In terms of anti-
restenosis, VEGF gene transfer induced nitric oxide (NO) production from the 
endothelium, which subsequently reduced VSMC proliferation and migration and 
platelet aggregation, and therefore inhibited the NIF in a preclinical model of 
vascular disease (Laitinen et al., 1997). However, disappointing results were 
found in the clinical setting for the prevention of restenosis (Laitinen et al., 
2000, Hedman et al., 2003). The clinical importance of this study demonstrates 
that the most appropriate and efficient gene delivery vector system and 
therapeutic transgene is critical in design and utility to target restenosis in 
vascular gene therapy. As a consequence, this may explain why previous work 
has failed for example transient transgene expression, gene transfer vectors of 
either non-viral or non-integrating viral systems and better choice of therapeutic 
gene (Hedman et al., 2011). Therefore, this is an area of interest for this study 
in terms of vascular gene transfer for the inhibition of NIF following acute 
vascular injury with an aim to improve or provide an altenative gene delivery 
vector system coupled with a better choice of therapeutic gene which will be 
discussed further in this thesis. Nevertheless, in the Kuopio Angiogenesis Trial 
(KAT) (phase II), a significant improvement in myocardial perfusion was observed 
in patients treated with adenoviral-mediated VEGF gene transfer in ischaemic 
hearts (Hedman et al., 2003). Furthermore, another study (phase II) 
demonstrated that patients with peripheral arterial occlusive disease who 
received either adenoviral- or plasmid DNA- mediated VEGF gene transfer had 
improved vascularity (Makinen et al., 2002).  
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There have been many positive preclinical and phase I/II pro-angiogenic gene 
therapy trials worldwide. In addition, a number of clinical phase II/III trials have 
been undertaken, but no advancement to clinical practice due to low gene 
transfer efficiency (Rissanen and Yla-Herttuala, 2007, Karvinen and Yla-
Herttuala, 2010, Hedman et al., 2011). However, overall, many investigations 
have indicated that pro-angiogenic growth factor gene therapy has the potential 
to be useful in the clinical setting for CHD and peripheral vascular disease in the 
foreseeable future.  
1.8 Requirements of a gene transfer vector to the 
vasculature 
There are many different types of gene transfer vector systems that have the 
potential for being useful in vascular gene therapy. Overall, viral vectors have 
the ability to mediate efficient gene transfer and transgene expression in the 
vasculature, compared to non-viral vectors which elicit relatively low-levels of 
gene transfer efficiency and transgene expression (Baker, 2004, Gaffney et al., 
2007, Rissanen and Yla-Herttuala, 2007, Karvinen and Yla-Herttuala, 2010). 
However, safety risks (immunogenicity and toxicity profiles) arise with viral 
vectors, compared to non-viral vectors (Baker, 2004, Rissanen and Yla-Herttuala, 
2007). Another important quality to be considered is the cloning capacity 
available in the vector genome for the insertion of the transgene cassette. Non-
viral vectors have a large cloning capacity, whereas for viral vectors this is 
determined by the amount of genome that can be excised whilst preserving 
vector infectivity status (Thomas et al., 2003). 
The choice of the most appropriate gene transfer vector for delivery and 
efficient transgene expression is a critical component in the design and utility 
for many gene therapy applications. The following are important vector 
features/characteristics to be considered for vascular gene therapy (for an ideal 
vector): 
• Highly efficient transduction (viral) or transfection (non-viral) for vascular 
cells with limited gene transfer to non-target cells.  
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• Ability to mediate gene transfer and transgene expression in dividing and 
non-dividing cells. 
• Ability to mediate sustained transgene expression during the acute vascular 
injury. 
• The level of gene delivery clearly must be sufficient to achieve therapeutic 
benefit in absence of toxicity, eliciting host immune response (lack of 
immunogenicity is desirable) and any other potentially deleterious side 
effects.  
• The ease in high vector titre productions at clinical grade.  
• Episomal (non-integration) or integration maintenance of transgene without 
deleterious side effects (such as insertional mutagenesis can occur after 
integration into the host’s genome). 
• The vector should have a sufficient cloning capacity. 
Table 1.1 illustrates characteristics of each gene transfer vector for the 
vasculature (Thomas et al., 2003, Baker et al., 2005, Baker et al., 2006, George 
et al., 2006, Gaffney et al., 2007, Rissanen and Yla-Herttuala, 2007, Waehler et 
al., 2007, White et al., 2007, Karvinen and Yla-Herttuala, 2010). To date, none 
of the current vectors fulfil all these qualities required for use in vascular gene 
therapy (Rissanen and Yla-Herttuala, 2007, Karvinen and Yla-Herttuala, 2010). In 
addition, viral and non-viral vectors have the ability to be modified to increase 
their selectivity and efficiency to the vascular tissue, which includes methods of 
“tropism alternation” such as modifications of the capsid (targeted peptides) or 
pseudotyping (with different serotype capsids/envelopes) and peptide-targeted 
liposome/plasmid DNA complexes, respectively (Baker, 2004, Baker et al., 2005, 
White et al., 2007, White et al., 2008). There is a requirement to identify and 
provide a safe and effective gene transfer strategy for therapeutic gene delivery 
to attenuate the NIF following acute vascular injury. Thus, this current study will 
address an alternative vector system, NILVs, which is an area of interest. 
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Vector Cloning 
capacity
Immunogencity Vector 
genome forms
Advantages Disadvantages
•Safe (limited toxicity) •Low transfection efficiency 
•Ease of production •Non-specific transfection
•Ability to transfect dividing and non-dividing cells •Poor nuclear trafficking
•Transient transgene expression
•Efficient vascular transduction •Transient transgene expression
•High titre production at clinical grade •High degree of hepatic tropism following systemic 
delivery
•Ability to transduce dividing and non-dividing cells •Viral gene products induce inflammatory and 
immunogenic responses
•Well characterised in vivo 
•Relatively easy to produce high titres for clinical 
application 
•Relatively a low level of vascular transduction 
efficiency 
•Improved vascular transduction efficiency mediated 
by AAV pseudotyping/targeting peptides 
•Partially integrative, with minimal risk of insertional 
mutagenesis
•Good safety profile •Limited cloning capacity 
•Ability to transduce dividing and non-dividing cells •After systemic delivery majority of transduction 
found in the liver
•Wild-type virus is non-pathogenic in humans 
•Sustained transgene expression
Plasmid 
DNA
Unlimited size Low Episomal
Adenoviral 
vector 
(serotype 
5)
Approximately 
8 kbp
High Episomal
Adeno-
associated 
virus (AAV) 
(serotype 
2)
Approximately 
4.5 kbp
Low Episomal or 
integrative 
maintenance
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Vector Cloning 
capacity
Immunogencity Vector 
genome forms
Advantages Disadvantages
•Persistent transgene expression •Inability to transduce non-dividing cells 
•Efficient vascular transduction •Relatively low-titre productions 
•Integration may mediate the risk of insertional 
mutagenesis and oncogenesis
•Ability to transduce dividing and non-dividing cells •Difficult to produce high-titres for clinical grade 
•Easy to pseudotype with heterologous envelope 
glycoproteins 
•Integrative- therefore raises safety issues with 
insertional mutagenesis and oncogenesis 
•Long-term transgene expression 
•Efficient vascular transduction 
Retroviral 
vector
Approximately
8 kbp
Low Integrative
Lentiviral 
vector
Approximately 
8 kbp
Low Integrative
 
Table 1.1 Summary of characteristics of each gene delivery vector for the vasculature.  
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1.9 Viral vectors 
To date, adenoviral vectors [typically serotype 5(Ad5)] are widely used in gene 
therapy applications [approximately 23.8% of the total gene therapy clinical 
trials approved have used adenoviral vectors 
(http://www.wiley.com/legacy/wileychi/genmed/clinical/, 2011c)]. In 
addition, for cardiovascular gene therapy these vectors hold promise for their 
use in gene transfer of pro-angiogenic factors (previously mentioned in section 
1.7). In terms of vascular gene therapy for the prevention of the NIF, adenoviral 
vectors are the most commonly used vectors for gene transfer in preclinical 
studies and clinical trials, and are so far the most promising vectors for the 
potential use in this clinical setting (Gaffney et al., 2007, Rissanen and Yla-
Herttuala, 2007, Karvinen and Yla-Herttuala, 2010). However, Ad5 vector 
mediates a high degree of hepatic tropism following systemic delivery, which is 
an undesirable characteristic for many clinical applications in gene therapy. This 
has led to the successful use of adenoviral vectors in ex vivo transduction prior 
to vein grafting (George et al., 2000, Baker et al., 2006, Kritz et al., 2008) and 
in vivo stent-based delivery (gene-eluting stent) (Johnson et al., 2005, Sharif et 
al., 2008) in preclinical studies. In addition, recent developments in other 
vectors have highlighted their potential utility in vascular gene therapy, for 
example lentiviral vectors (LVs).   
1.10 Lentiviral vectors 
1.10.1 Retroviruses  
The retroviridae family consists of many genera of retroviruses, these include: 
alpharetroviruses, betaretroviruses, gammaretroviruses, deltaretroviruses, 
epsilonretroviruses (for all the above, the term oncoretroviruses are still 
commonly used), spumaviruses and lentiviruses (Federico, 2003, Cann, 2005, 
Bartholomae et al., 2010), all of which are under development for use in many 
applications in gene therapy (Bartholomae et al., 2010, Mátrai et al., 2010). All 
retroviruses have evolved to use their host as a continuous reservoir of viral 
replication because of their permanent integration into the host genome. 
Oncoretrovirus infections cause diseases such as cancer, which are mostly 
benign. Lentiviruses (lenti is the latin word for “slow”) infections are 
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characterized by relatively long incubations periods, followed by severe and 
usually fatal disease such as cancer (Federico, 2003).   
As previously mentioned, the first gene delivery system to be used successfully 
for in vivo gene transfer into the vasculature was a retroviral vector, namely an 
amphotrophic murine gamma-retroviral vector (Nabel et al., 1989, Nabel et al., 
1990, Nabel et al., 1991). To date, approximately 20.5 % and 1.7 % of the 
world’s gene therapy clinical trials (since 1989 to present) have used retroviral 
vectors and LVs as their platform vector, respectively 
(http://www.wiley.com/legacy/wileychi/genmed/clinical/, 2011c). 
Retroviruses are small envelope RNA viruses. All retroviruses are composed of 
two single-stranded positive-sense RNAs (except spumaviruses), with a genome 
that does not serve directly as messenger RNA (mRNA) immediately after 
infection. Each RNA strand comprises of three basic essential genes: gag 
(encodes structural proteins), pol (encodes enzymes such as reverse 
transcriptase, integrase and protease) and env (encodes the viral envelope 
glycoprotein). The genomic RNA is capped at the 5’ region and polyadenylated at 
the 3’ region as expected for a RNA molecule that is expressed by cellular 
transcription machinery (retroviron production) (Figure 1.4). The retrovirus 
particle is comprised of the diploid RNA genome complexed with nucleocapsid 
proteins (encoded by the gag gene), reverse transcriptase, integrase and 
protease (required for gag-pol cleavage and maturation of viral particles), which 
are encapsulated into a retrovirus capsid (encoded by the gag gene), followed by 
matrix proteins (encoded by the gag gene) which assist with the formation of the 
envelope comprised of viral envelope glycoproteins (encoded by the env gene) 
and host cell-membrane. A glycoprotein comprises of a transmembrane domain 
and a surface domain (Buchschacher and Wong-Staal, 2000, Palu et al., 2000, 
Bartholomae et al., 2010).  
The replication cycle of the retroviridae is shown in Figure 1.5. The virus 
genome is converted into double stranded DNA molecule by reverse transcriptase 
in the cytoplasm of the host cell and transported into the cell nucleus in 
association with matrix proteins and integrase, and this known as the pre-
integration complex (PIC). The double stranded DNA molecule is then 
incorporated into the host’s genome by the integrase enzyme. Thereafter, 
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retroviruses replicate via an integrated DNA intermediate, known as a provirus 
DNA, as part of the host cell’s genome by cellular transcriptional machinery. A 
provirus DNA is longer than a RNA template due to duplication of direct repeat 
sequences at the 5 prime end (5’) and 3 prime end (3’) of the sequence; these 
elements are known as the long terminal repeats (LTRs) (Figure 1.4). These LTRs 
are necessary for integration into the host genome, expression of viral genes, 
and defines the 5’ and 3’ ends of the provirus DNA (Buchschacher and Wong-
Staal, 2000, Palu et al., 2000, Bartholomae et al., 2010).  
The retrovirus genome contains essential viral sequences, such as the direct 
repeat sequences with elements required for reverse transcription, integration 
and gene expression. The RNA genome comprises the following direct repeat 
sequences: 5’ end (in this order) begins with a repeat region (R) followed by a 
unique 5’ region (U5), and 3’ end of the RNA genome terminates with the unique 
3’ region (U3) followed by a 3’ R element (Figure 1.4). During reverse 
transcription the U3 and U5 regions are duplicated in the proviral DNA and are 
known as the LTRs. Both LTRs are comprised of the proviral U3, R and U5 regions 
(in this order) and the arrangements of these regions are required for viral gene 
expression (Figure 1.4). Attachment (att) sites in the 5’ and 3’ LTRs are essential 
for proviral DNA integration (Figure 1.4). The U3 region at the 5’ LTR contains a 
viral enhancer-promoter region which facilitates the initiation of transcription at 
the U3/R junction (Figure 1.4). The proviral genome contains a transcription 
termination signal at the 3’ LTR. In addition, there are other elements within 
the retroviral RNA genome which are required for reverse transcription, 
integration and gene expression. The primer binding site (PB) in the 5’ end of 
the RNA genome is essential for reverse transcription for the initiation of the 
negative-strand DNA synthesis mediated by host’s cell derived tRNA primer 
(Figure 1.4). The polypurine tract (PPT) within the 3’ end of the RNA genome is 
copied to generate a PPT primer site, which is essential to initiate the synthesis 
of the positive-strand DNA (Figure 1.4). Moreover, another important element 
within the viral genome is the packaging sequence/signal, which aids the viral 
RNA to be distinguished from other RNAs generated by the host cell and for RNA 
encapsidation (Buchschacher and Wong-Staal, 2000, Palu et al., 2000, 
Buchschacher, 2001). Simple gammaretroviruses for example murine leukaemia 
viruses (MLV) are the most commonly used retroviruses as delivery vector 
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systems (Bartholomae et al., 2010). For the rest of this thesis gammaretroviruses 
will be referred to as retroviruses/retroviral vectors unless otherwise stated.  
 
Figure 1.4. Basic features of genomes of retroviruses.  
Positive sense strands of viral RNA genome is comprised of the gag, pol and env genes, with 
direct repeat sequences at the 5’ and 3’ regions: 5’ R U5 and 3’ U3 R. Primer binding site (PB) is 
essential for reverse transcription and the polypurine tract (PPT) is necessary for positive-strand 
DNA synthesis (PPT primer site on negative-strand DNA). This genomic viral RNA is capped (cap) 
at the 5’ and polyadenylated (AAAAAA) at the 3’ (by cellular transcription machinery during 
retrovirion production). During reverse transcription the U3 and U5 are duplicated in the proviral 
DNA and give rise to two identical long terminal repeats (LTRs, U3 R U5 region) at the 5’ and 3’ 
regions. Attachment (att) sites are required for integration. Enhancer-promoter region and the 
U3/R junction are required for transcription. Ψ packaging signal/sequence. R, repeat region; U3, 
unique 3’ region; U5, unique 5’ region (Palu et al., 2000, Buchschacher, 2001).  
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Figure 1.5. Retroviral replication cycle.  
Infection begins when a retroviron enters its target (host) cell through interactions between the 
envelope glycoprotein and the cellular receptor. Viral-cell membrane fusion virion 
internalisation mediates release of viral core into cell cytoplasm. Viral RNA is reverse transcribed 
into double-stranded DNA by reverse transcriptase and then transported to the cell nucleus 
mediated by the pre-integration complex (PIC). Viral DNA is permanently integrated into the 
host’s genome by integrase, and thereafter retroviruses replicate via an integrated DNA 
intermediate (known as a proviral DNA) as part of the host cell’s genome by cellular 
transcriptional machinery. Proviral DNA is transcribed into viral RNA and translated to produce 
viral structural proteins and enzymes. These all assemble to form the new virion core (viral RNA 
encapsidation) and obtain the viral glycoprotein envelope as they bud from the host cell-
membrane (Buchschacher and Wong-Staal, 2000, Palu et al., 2000, Bartholomae et al., 2010). 
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1.10.2 Lentiviruses to lentiviral vectors  
Lentiviruses are a subclass of retroviruses and these include human 
immunodeficiency virus type-1 (HIV-1), simian immunodeficiency virus (SIV), 
feline immunodeficiency virus (FIV) and equine infectious anaemia virus (EIAV). 
HIV-1 glycoprotein (gp120 and gp41) envelope targets immune cells, primarily 
CD4+ expressing T lymphocytes, macrophage and dendritic cells by utilising CD4 
(cluster of differentiation 4 glycoprotein) and chemokine co-receptors CCR5 (C-C 
chemokine receptor type 5) or CXCR4 (CXC chemokine receptor type 4) (Waki 
and Freed, 2010). The lentivirus HIV-1 genome is very similar to the basic 
genome organisation of all retroviruses and integrates into the host’s genome 
(see section 1.10.1). In addition, lentiviruses encode two regulatory proteins Tat 
and Rev essential for viral replication, and four accessory proteins Vif, Vpr, Vpu 
and Nef necessary for viral replication and/or pathogenesis. The majority of 
these regulate replication of HIV-1 during its latent period of infection [pre-
acquired immune deficiency syndrome (AIDS)] and active AIDS (Federico, 2003, 
Seelamgari et al., 2004). The genome structure of wild-type HIV-1 lentivirus 
proviral DNA is shown in Figure 1.6. For the rest of this thesis HIV-1-derived LV is 
referred to as LV, unless otherwise stated.  
 
Figure 1.6. The genome (proviral DNA) structure of a wild-type HIV-1 lentivirus.  
The gag, pol and env genes encode: structural proteins; integrase, protease and reverse 
transcriptase, and envelope glycoprotein, respectively. Tat (transactivator of transcription) and 
rev (regulatory viral protein) genes encode regulatory proteins essential for viral replication. Vif 
(viral infectivity factor), vpr (viral protein R), vpu (viral protein U) and nef (negative replication 
factor) genes encode accessory proteins essential for viral replication and/or pathogenesis. Ψ, 
packaging sequence. LTR, long terminal repeats (Buchschacher and Wong-Staal, 2000, Federico, 
2003, Sinn et al., 2005b). 
Lentiviruses have the ability to transduce dividing and non-dividing cells, and 
therefore offer one greater advantage over (gamma)retroviruses as gene transfer 
vector systems. Retroviruses possess low transduction efficiency for non-dividing 
cells in comparison to dividing cells. This is because the translocation of the 
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retrovirus PIC into the nucleus requires the dissolution of the nuclear membrane 
during mitosis. Unlike retroviruses, lentiviruses mediate gene transfer through 
the nuclear envelope and into the nucleus of non-dividing cells, which is 
facilitated by the PIC associated with integrase, matrix protein, Vpr and central 
polypurine tract (cPPT) (Heinzinger et al., 1994, Naldini et al., 1996b, 
VandenDriessche et al., 2002). This major attribute led to the development of 
LVs for their use in gene therapy.  These LVs have been genetically engineered 
to express a therapeutic/marker gene and are devoid of their virulent 
endogenous viral proteins. Like that of retroviral vectors, the designs of LVs are 
based on the separation of cis- and trans- acting elements, and therefore are 
replication-defective. Similar to retroviral vectors, LV gene transfer provides 
long-term transgene expression because it integrates the gene into the host’s 
genome and will subsequently replicate as part of the target cell’s DNA (Naldini 
et al., 1996b).  
Briefly, for retroviral vectors and LVs, their viral vector constructs are generated 
by deleting their viral genes (gag, pol and env) and replacing them with a 
transgene of interest under the control of a chosen alternative internal 
heterologous promoter element. Essential viral sequences known as cis-acting 
elements remain within the construct (transfer plasmid) because they are 
essential for vector production, reverse transcription, integration and transgene 
expression such as the two LTRs, PB, PPT, packaging sequence and sequences 
involved with integration of the proviral DNA (att sites). Other viral genes are 
required for vector production and function (such as the envelope, reverse 
transcriptase, integrase, matrix proteins and other structural proteins) and these 
are inserted into separate plasmids or stably integrated into the DNA of a 
packaging cell line to provide helper functions in trans. These viral genes exist in 
trans to improve safety of these vectors, by significantly reducing the possibility 
of recombination events, which may give rise to replication-component 
recombinant retroviral vectors or LVs. These vectors are generated by the 
introduction of the construct/transfer plasmid into either a packaging cell line 
or a transient co-transfection method with helper plasmids, both providing a 
single cycle of vector propagation (Buchschacher and Wong-Staal, 2000, Sinn et 
al., 2005b, Bartholomae et al., 2010, Matrai et al., 2010, Mátrai et al., 2010). 
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1.10.2.1 Biosafety and improved lentiviral vector performance 
Most replication defective LVs are produced by transient co-transfection of three 
plasmids in human embryonic kidney (HEK) 293T cells mediated by 
polyethylenimine (PEI). This involves the following plasmids: a packaging 
plasmid, a construct/transfer plasmid (containing the internal heterologous 
promoter and the gene of interest) and an envelope plasmid (described in Figure 
1.7) (Sinn et al., 2005b, Cockrell and Kafri, 2007, Escors and Breckpot, 2010, 
Matrai et al., 2010). LVs are most commonly pseudotyped with the vesicular 
stomatitis virus (Rhabdoviridae) glycoprotein (VSV-g) envelope. This is because 
of its broad tropism and stability of vector particles and high-titre stocks during 
production (Cockrell and Kafri, 2007, Escors and Breckpot, 2010, Matrai et al., 
2010). LVs have been developed over the years for biosafety to prevent the 
emergence of replication-competent wild-type human HIV-1 recombinants and 
are referred to as ‘generations’ with association to the modified packaging 
plasmid (trans-acting element modifications) (Cockrell and Kafri, 2007, Escors 
and Breckpot, 2010, Matrai et al., 2010). The first generation comprised of gag 
and pol genes, viral regulatory genes tat and rev and accessory genes vif, vpr, 
vpu and nef in the packaging plasmid (Naldini et al., 1996a). In contrast, the 
second generation of LVs were engineered to be multiple attenuated. This 
second generation packaging system involved the deletion of four accessory 
genes vif, vpr, vpu and nef, which had no effect of vector titres and 
transduction efficiency. Furthermore, this packaging system improved safety 
because if any recombination events occurred, these replication-competent LVs 
would be devoid of virulence factors (Zufferey et al., 1997). The Tat and Rev 
proteins regulate transgene expression (Dull et al., 1998, Buchschacher and 
Wong-Staal, 2000). Figure 1.8 illustrates the basic cis- and trans-acting elements 
within the plasmids used for the production of the second generation LVs 
(elements mentioned in this figure are discussed later in this section). It was this 
generation system that was used in this research thesis. The third generation is 
the latest LVs. The packaging system no longer has the tat gene, and the rev 
gene is encoded not in the packaging plasmid, but in a fourth plasmid. This 
enhances the unlikely possibility of wild-type replication-competent 
recombinants generation (Dull et al., 1998, Zufferey et al., 1998).  
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Figure 1.7. A schematic representation of lentiviral vector production.  
Replication defective lentiviral vectors are produced by a transient co-transfection of three 
plasmids in human embryonic kidney (HEK) 293T cells mediated by polyethylenimine (PEI). This 
includes the following three plasmids: a packaging plasmid, a construct/transfer plasmid 
(comprising of the promoter and the gene of interest) and an envelope plasmid. These plasmids 
are incorporated into the nucleus. It is here where the transgene is transcribed from the transfer 
plasmid to make lentiviral vector RNA. Plus, the envelope glycoprotein and viral proteins 
(including integrase and reverse transcriptase) are transcribed and translated from their 
corresponding plasmids. Subsequently, this produces functional proteins which are either 
packaged into the vector particle or are used during the production of these vectors. Lentiviral 
vectors are packaged by the HEK 293T cells (packaging signal involved in this process,Ψ), which 
is shed from the cell membrane into the cell’s supernatant. The important components of these 
vectors are the vector RNA genome, the lentiviral enzymes integrase and reverse transcriptase. 
Lentiviral vectors can be harvested from the supernatant and used to infect target cells to 
mediate gene transfer. Viral genes in trans-acting are not carried along with the vector because 
they lack the cis-acting sequences required for propagation, thus rendering these vectors 
replication-defective. Adapted from Verma and Somia (1997) (Zufferey et al., 1997, 
Buchschacher and Wong-Staal, 2000). 
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Figure 1.8. A schematic representation of the plasmids used in the second generation 
lentiviral vector production.   
This second generation packaging system of these self-activating (SIN) lentiviral vectors involves 
the basic cis- and trans- acting elements within three different plasmids. The transfer/construct 
plasmid comprises of the following and its cis–acting elements: an expression cassette with the 
gene of interest under the control of an internal heterologous promoter element; Rev responsive 
element (RRE); Woodchuck post-transcriptional regulatory element (WPRE) and cis-acting factors 
[packaging sequence (Ψ), primer binding site (not shown), polypurine tract (not shown),  central 
polypurine tract (cPPT), attachment (att) sites (not shown) and long terminal repeats (LTRs)], 
which are necessary for lentiviral vector production and/or transgene expression. SIN lentiviral 
vectors were generated by partial deletion in the U3 region, which involved removing the 
sequence encoding the viral enhancer-promoter (∆U3). The packaging plasmid contains trans-
acting elements (minus four accessory genes vif, vpr, vpu and nef) required for one round of 
packaging during the lentiviral vector production and/or transgene expression and this includes: 
the gag gene for structural proteins; the pol gene for lentiviral enzymes integrase and reverse 
transcriptase; genes tat and rev for viral production and transgene expression (all under the 
control of an internal heterologous viral promoter). Moreover, this plasmid contains a deletion in 
the packaging sequence (∆Ψ). The Rev protein binds to the RRE to enhance RNA nuclear export. 
The envelope plasmid (trans-acting) consists of the glycoprotein envelope gene under the control 
of an internal heterologous promoter sequence. pA, polyadenylation signal (Cochrane et al., 
1990, Zufferey et al., 1997, Dull et al., 1998, Zufferey et al., 1998, Zufferey et al., 1999, Sirven 
et al., 2000, Vigna and Naldini, 2000, Demaison et al., 2002, VandenDriessche et al., 2002, Logan 
et al., 2004, Cockrell and Kafri, 2007). 
The transfer plasmid consists of an expression cassette with the gene of interest 
under the control of an internal heterologous promoter element, plus cis-acting 
factors which are essential for packaging; reverse transcription and integration 
(see section 1.10.2). This transfer plasmid has undergone further modifications 
to improve biosafety (rendering them more replication-defective) and LV 
performance (Escors and Breckpot, 2010, Matrai et al., 2010). Self-inactivating 
(SIN) LVs have been engineered by deleting transcriptional regulatory sequences 
(homogenous viral enhancer-promoter unit), which abolishes the risk of 
replication-competent recombinants, vector mobilization and host gene 
transactivation (enhancer-mediated mutagenesis). During reverse transcription, 
the U3 regions in the 3’ and 5’ LTRs of the integrated provirus DNA are 
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generated from the U3 region in the 3’ end of the viral RNA genome. The U3 
region is important in the 5’ LTR of proviral DNA because it contains the LV 
enhancer-promoter sequence.  A modification in the U3 region within the 3’ end 
of the viral RNA genome was introduced [incorporated in the transfer plasmid 
(Figure 1.8)], which involved a deletion in the enhancer-promoter sequences. 
During reverse transcription, this deletion was transferred to the 5’ LTR of the 
proviral DNA, hence no viral enhancer-promoter sequences. As a result, this 
mediates transcriptional inactivation of the 5’ LTR, which prevents the 
production of full-length vector RNA within the target cells/tissue. This modified 
element minimises the production risk of replication-competent recombinants 
LVs in transduced target cells/tissue. It is the internal heterogeneous promoter 
that controls the expression of the transgene. Efficient self-inactivation does not 
influence vector titre or impair transgene expression. This deletion spares but 
weakens the 3’-polyadenylation region which is essential for transgene 
expression (Zufferey et al., 1998). These SIN LVs have enhanced biosafety and 
have increased the utility of LVs in gene therapy studies over the years (Matrai 
et al., 2010). For the rest of this thesis, SIN LVs are referred to as LVs unless 
otherwise stated. 
There have been several cis-acting element additions to the transfer plasmid, 
which have demonstrated improvements in LV performance, these include the 
following:  woodchuck hepatitis virus post-transcriptional regulatory element 
(WPRE); Rev-responsive element (RRE) and central polypurine tract or central 
flap (cPPT) element. The WPRE mediates the enhancement of viral genomic 
transcript packaging and thus increases LV titres. Furthermore, this element 
increases expression of transgenes by regulating the polyadenylation (increased 
mRNA stability), RNA export (enhanced nuclear export) and translation (Zufferey 
et al., 1999, Demaison et al., 2002, Sinn et al., 2005b). The RRE remains in or is 
reintroduced into the LVs because it facilitates Rev-mediated export of RNA 
from the nucleus into the cytoplasm.  Therefore, this element enhances LV titres 
and increases transgene expression. Furthermore this element is also present on 
the packaging (trans-acting) plasmid (Cochrane et al., 1990, Dull et al., 1998, 
Buchschacher and Wong-Staal, 2000, Sinn et al., 2005b). The cPPT is normally 
deleted from the transfer plasmid because it is present in the middle of the HIV 
genome embedded in the pol gene. However, this element is important and thus 
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reinserted. This cPPT element increases LV titres, enhances the nuclear 
translocation of the vector genome (PIC), increases total amount of vector 
genome integrated into the host chromosome and improves gene transfer 
performance of the vector (Sirven et al., 2000, Demaison et al., 2002, 
VandenDriessche et al., 2002, Logan et al., 2004, Sinn et al., 2005b). LVs have 
been indicated to be highly efficient in transduction and mediate enhanced 
transgene expression in human HSCs with these incorporated elements into the 
LV transfer plasmid (Demaison et al., 2002). These additional cis-acting 
elements in the SIN second generation LVs will be used in the context of vascular 
gene delivery within this thesis. 
1.10.3 Lentiviral gene therapy applications 
Many advantageous characteristics enable LVs to be ideal vectors for gene 
transfer. LVs resemble retroviral vectors in their ability to provide long-term 
transgene expression mediated by integration into the target host cell genome. 
In addition, LVs have the ability to transduce non-dividing cells as well as 
dividing cells, because these vectors do not depend on the dissolution of the 
nuclear membrane during mitosis (Naldini et al., 1996b). LVs mediate a 
relatively low inflammatory response and lessened immunogenicity, thus offer 
an excellent opportunity for in vivo gene transfer with efficient and sustained 
transgene expression over a long duration (Abordo-Adesida et al., 2005). It is 
relatively easy to pseudotype LVs with a heterologous viral envelope protein, 
such as the VSV-g protein which broadens the viral vector tropism and enables 
this LV to be robust (can be easily concentrated by centrifugation) (Matrai et al., 
2010). LVs have a large cloning capacity of approximately 8-10 kbp (Kumar et 
al., 2001, Matrai et al., 2010). However, LVs are integrative in a semi-random 
manner, harbouring common integration sites (CIS) within proto-oncogenes 
(Modlich et al., 2009, Cavazzana-Calvo et al., 2010) with similarities to retroviral 
vectors (Hacein-Bey-Abina et al., 2003b, Ott et al., 2006, Deichmann et al., 
2007, Schwarzwaelder et al., 2007, Hacein-Bey-Abina et al., 2008, Modlich et 
al., 2009). Therefore, LVs raise safety issues with insertional mutagenesis and 
oncogenesis (Modlich et al., 2009, Cavazzana-Calvo et al., 2010, Matrai et al., 
2010), but with lower frequencies [LV hotspots reflect a benign integration bias 
rather than oncogenic selection (Biffi et al., 2011)] compared to other retroviral 
vectors (Montini et al., 2006, Matrai et al., 2010, Biffi et al., 2011). As a 
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consequence, it is important for integration site analysis to be carried out for 
monitioring of CIS (Schmidt et al., 2007, Gabriel et al., 2009, Schmidt et al., 
2009). LV titres are relatively low compared to other viral vectors (Matrai et al., 
2010). In addition, a recent report presented a simple and inexpensive LV 
production method using caffeine to increase titres of LVs for clinical grade (Ellis 
et al., 2011). Furthermore, LVs can be engineered to express one or more 
transgenes and thus aids its appeal has a gene delivery vector (Sinn et al., 
2005b). Figure 1.9 illustrates LV-mediated gene transfer, reverse transcription, 
integration and transgene expression within a target cell of either dividing or 
non-dividing. 
LVs have the potential to achieve permanent therapeutic benefit in the clinic for 
the following diseases/disorders/applications: neurological (Naldini et al., 
1996a, Naldini et al., 1996b, Rahim et al., 2009), haematological (Cavazzana-
Calvo et al., 2010, Ward et al., 2011), immunodeficiencies (Mortellaro et al., 
2006, Charrier et al., 2007, Marangoni et al., 2009, Zhou et al., 2010), stem cell 
manipulation (Gropp et al., 2003, Lombardo et al., 2007), somatic cell 
reprogramming (Chang et al., 2009), liver (Matrai et al., 2011), muscular 
(Apolonia et al., 2007, Talbot et al., 2010), lung (Buckley et al., 2008), ocular 
(Yanez-Munoz et al., 2006) and CVD (Dishart et al., 2003a, Cefai et al., 2005, 
Qian et al., 2006, Yang et al., 2010), and other applications to cells/tissues 
which are otherwise difficult to transduce (Matrai et al., 2010). Several clinical 
trials have been approved and are ongoing or being prepared with LV as the 
vehicle of choice for many gene therapy applications, for example β-thalassemia 
(Cavazzana-Calvo et al., 2010), adrenoleukodystrophy (ALD) (Cartier et al., 
2009), Parkinson’s disease (EIAV-LV) (http://www.oxfordbiomedica.co.uk/, 
2011, Stewart et al., 2011) and Wiskott-Aldrich syndrome (WAS) (Galy et al., 
2008). 
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Figure 1.9. A schematic representation of lentiviral vector infection/transduction within a 
target cell of either dividing or non-dividing status.  
A lentiviral vector infects the target cell, which allows the RNA vector genome to enter. The 
lentiviral enzyme reverse transcriptase converts the RNA vector genome into a RNA-DNA hybrid, 
then into the linear double-stranded DNA molecule, during reverse transcription. The lentiviral 
vector DNA associated with the pre-integration complex (PIC) is then translocated into the 
nucleus. The lentiviral vector DNA is then integrated into the host’s cell genome, facilitated by 
the lentiviral enzyme integrase. Finally, the transgene is expressed by the host-cell machinery. 
Adapted from Verma and Somia (1997). 
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1.10.4 Lentiviral-mediated gene transfer to the vasculature 
LVs offer an alternative yet promising option for therapeutic vascular gene 
transfer into the vasculature (George et al., 2006, Gaffney et al., 2007, White et 
al., 2007), because it is largely comprised of relatively slow dividing vascular 
cells in a disease state (Gordon et al., 1990) and even during the acute vascular 
injury response (Westerband et al., 1997, Hilker et al., 2002). LVs have 
demonstrated to be highly efficient in transduction of VSMCs and VECs (Dishart 
et al., 2003a, Cefai et al., 2005, Qian et al., 2006, Yang et al., 2010). The VSV-g 
pseudotyped LV at a short exposure time of 30 minutes in vitro demonstrated 
comparable transduction efficiencies in human VECs and VSMCs to adenoviral 
vectors (Dishart et al., 2003a, Cefai et al., 2005). Dishart et al., indicated that 
LVs mediated significantly higher transgene expression in VSMCs compared to 
adenoviral vectors. However, in terms of VECs, the transduction efficiency was 
vice versa (Dishart et al., 2003a). In addition, Cefai et al., demonstrated that 
LVs transduced VECs and VSMCs with greater efficiency compared to adenoviral 
vectors (Cefai et al., 2005). Taken together, these two investigations evidently 
show that LVs are efficient in transducing human VSMCs (Dishart et al., 2003a, 
Cefai et al., 2005). VSV-g pseudotyped LV gene transfer of TIMP-3 mediated 
efficient transduction and over-expression in human VSMCs, which reduced 
migration and induced apoptosis of these cells in vitro and this was comparable 
to adenoviral vector gene transfer (Dishart et al., 2003a). VSV-g pseudotyped LV-
mediated VEGF gene transfer promoted human VEC proliferation and sprouting 
in vitro (Cefai et al., 2005).  
LVs have demonstrated their usefulness in delivering therapeutic genes into the 
vasculature in vivo and thus reducing the NIF (Qian et al., 2006, Yang et al., 
2010). Hanta pseudotyped LV-mediated gene delivery of the therapeutic gene 
human extracellular superoxide dismutase (EC-SOD) mediated over-expression 
and prevented NIF in a rabbit model of acute vascular injury. These results 
indicated LVs are efficient in transduction of the vasculature via a catheter-
mediated delivery of this vector and had no significant effect on inflammation 
and toxicity (Qian et al., 2006). LV-mediated gene transfer of small interfering 
RNA of CREB binding protein (CBP) via a catheter-mediated delivery was 
investigated in a rat model of acute vascular injury. Results indicated a 
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reduction in the NIF and the promotion of re-endothelialisation (Yang et al., 
2010). LV-mediated gene transfer of broad spectrum CC-CK binding protein 35k 
[also known as Vaccina virus strain Lister 35 kilo Dalton (kDa) protein (35k)] 
demonstrated a reduction in atherosclerosis progression in vivo and the potential 
benefits of long-term LV transduction (Bursill et al., 2009). 
A low titre production of LVs remains problematic for clinical application for 
example vascular gene therapy (Matrai et al., 2010). Regardless, LVs are 
attractive for vascular gene therapy because these vectors could potentially 
mediate efficient and sustained transgene expression in the vasculature (Dishart 
et al., 2003b, Baker et al., 2006, George et al., 2006, Gaffney et al., 2007, 
White et al., 2007). LVs mediate semi-random integration into the host’s 
chromosome and thus may potentially induce the risk of insertional mutagenesis, 
which could lead to oncogenesis in the vasculature (see section 1.10.3). LVs have 
the potential to mediate gene transfer of a therapeutic gene into the 
vasculature within a short time exposure, which is required in this clinical 
setting (Dishart et al., 2003a, Cefai et al., 2005, George et al., 2006, White et 
al., 2007). LV gene transfer demonstrated relatively low inflammation in the 
vasculature (Cefai et al., 2005). NILVs aid LVs appeal for many gene therapy 
applications (see section 1.11.3 for more detail), especially in the vasculature 
(George et al., 2006, White et al., 2007). To date, a number of studies have 
used LVs for gene transfer into the vasculature, and in addition none have used 
NILVs which is an area of interest for this study. 
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1.11 Optimisation of lentiviral vectors 
LVs are relatively versatile in optimising for various gene therapy applications, 
by improving vector performance and safety. These include envelope alternation 
(pseudotyping), promoter alternation (to drive transgene expression) and non-
integration or integration (packaging plasmid) (Figure 1.10). Optimisation of LVs 
can greatly improve efficiency and long-term transgene expression in target cells 
and tissue. Promoter alternation, pseudotyping and non-integration will be 
discussed further in this section. 
 
Figure 1.10. A schematic representation of the optimisation of lentiviral vectors.  
Lentiviral vectors are relatively versatile in optimising for application, by improving vector 
performance and safety. Lentiviral vectors can be modified by the interchange of the packaging 
plasmid for integration or mutated-integration genes, alternation of the viral envelope plasmid 
(pseudotyping) and transfer/construct plasmid for the chosen internal heterologous promoter to 
drive the expression of the transgene of interest. Circle or square for packaging plasmid = 
integration-proficient or integration-deficient. Orange or green = glycoprotein envelope. Pink or 
blue = lentiviral vector genome. 
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1.11.1 Promoter alternation 
The control of transgene expression after LV gene transfer is mediated by an 
internal heterologous promoter. Many studies continue to validate and refine 
ideal promoters to improve safety and performance of LVs as gene transfer 
vehicles for particular disease applications. These promoters can be ubiquitous 
or cell-type specific. Cell- and tissue- specific promoters are advantageous 
because they have the ability to confine expression to targeted cells or tissues, 
while maintaining sufficient levels of transgene expression to achieve a desired 
effect. Moreover, they are less prone to promoter inactivation, and thus provide 
stability and longevity of transgene expression (Sinn et al., 2005b, Escors and 
Breckpot, 2010). Regulatory promoters are favourable since they have the 
potential to regulate transgene expression, which is appealing for many gene 
therapy applications such as monogenic disorders (Sinn et al., 2005b, Zhang et 
al., 2007, Escors and Breckpot, 2010). Another example includes regulated gene 
expression levels and relatively rapid onset of transgene transcription mediated 
by LVs, which would be desirable for acute vascular injury.     
LVs have been shown to be efficient delivery vehicles for gene transfer to the 
vasculature. Past studies have demonstrated LV-mediated transgene expression 
in the vasculature facilitated by various internal heterologous promoters, and 
these include the following:  cytomegalovirus (CMV), CMV immediate early 
enhancer/chicken beta-actin (CAG) promoter, phosphoglycerate kinase 1 (PGK) 
(housekeeper-derived) promoter, tyrosine kinase 2 (Tie2, angiopoietin receptor) 
promoter and elongation factor-1α (EF1α) (housekeeper-derived) promoter. As 
mentioned previously (section 1.11.2), HNTV-pseudotyped LVs mediated 
efficient gene transfer and the over-expression of human EC-SOD in the 
vasculature facilitated by the PGK promoter, following acute vascular injury 
(Qian et al., 2006). A study by Dishart et al., demonstrated that the CMV 
promoter facilitated stronger LV-mediated transgene expression in VECs and 
VSMCs, compared with the CAG and PGK promoter (Dishart et al., 2003a). In 
addition to these findings, another study indicated that the CMV promoter 
elicited greater LV-mediated transgene expression in comparison to EF1α 
promoter in VECs and VSMCs (Cefai et al., 2005). Moreover, the PGK promoter 
facilitated relatively lower transcriptional activity compared to CMV and EF1α 
promoters in vascular cells. This study also observed that the endothelium-
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specific Tie2 promoter facilitated significant cell-specific LV-mediated transgene 
expression in VECs, although a reduced level was achieved compared to the CMV 
promoter (Cefai et al., 2005). In addition, an investigation reported that 
adenoviral-mediated gene transfer of an anti-proliferative hybrid transgene and 
its expression under the control of a cell-specific human SM α-actin promoter 
inhibited VSMC proliferation and the NIF (Wills et al., 2001). However, smooth 
muscle cell specific promoters such as the human SM α-actin promoter have not 
been explored in the context of LV-mediated transgene expression in the 
vasculature.  
It was reported that an internal spleen focus forming virus (SFFV) promoter 
(enhancer region of the SFFV, U3-LTR) elicited a higher level and long-term 
transgene expression in human haematopoietic cells in vivo mediated by LVs, 
compared to the CMV promoter (Demaison et al., 2002). In the context of the 
vasculature, LV mediated transgene expression facilitated by the SFFV promoter 
has not yet been tested, and this may have the potential to improve the level of 
transgene expression.  
All enhancer elements associated with internal regulatory elements have the 
potential to enhance insertional mutagenesis associated with LV-mediated gene 
transfer (Hacein-Bey-Abina et al., 2003b, Ott et al., 2006, Zhang et al., 2007, 
Howe et al., 2008). Ubiquitously acting chromatin opening element (UCOE) is an 
enhancer-less regulatory element, which consists of a methylation-free CpG 
island associated with closely spaced dual divergently transcribed promoters of 
house-keeping genes [derived from the human HNRPA2B1-CBX3 (heterogeneous 
nuclear ribonucleoprotein A2/B1-chromobox homolog 3) house-keeping gene 
locus] and maintains a chromatin-opening function, and thus is resistant to 
transcriptional silencing (irrespective of tissue/cell-type and integration site 
position effects) (Williams et al., 2005, Zhang et al., 2007). As a result, UCOEs 
allow closely-associated promoters of transgene expression to function with 
increased efficiency, stability, consistency and longevity (Williams et al., 2005). 
In comparison to viral SFFV promoter (an enhancer-associated viral promoter, 
prone to insertion-site position effects and transcriptional silencing), UCOE 
facilitated higher, consistent and stable transgene expression in haematopoietic 
cells (mediated by LV gene transfer) and was resistant to transcriptional 
silencing, while the minimal, enhancer-less re-composite house-keeping gene 
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promoters were less likely to induce LV-mediated insertional mutagenesis (Zhang 
et al., 2007). Unlike the SFFV promoter element, the stability of transgene 
expression from the UCOE element in a LV system is mediated by resistance to 
DNA methylation induced silencing (Zhang et al., 2010). Altogether, LV-mediated 
transgene expression via the enhancer-less UCOE regulatory element is 
favourable since it has the potential to regulate transgene expression, resist 
transcriptional silencing and overcome integration-site position effects such as 
insertional mutagenesis (may aid a better safety profile). Therefore, this 
regulatory element is desirable for many gene therapy applications, especially 
for acute vascular injury and has not been tested in the vasculature. In 
summary, there is a continuous need to validate and refine ideal promoter 
elements to improve safety and performance of LVs as gene transfer vehicles 
and indeed for acute vascular injury.  
1.11.2 Pseudotyping 
A LV can be pseudotyped with an envelope protein derived from a virus other 
than the parent vector genome (heterologous glycoprotein envelope). 
Pseudotyping the LV can broaden or narrow the tropism of these vectors to 
different cells or tissue types. Each envelope glycoprotein preferentially 
interacts with specific cell/tissue types and their receptors, and therefore may 
potentially narrow or broaden transduction. Rhabdovirus VSV-g (as mentioned 
previously) is the most commonly used viral envelope protein for pseudotyping 
LVs because it aids in high titre productions, typically broadens the tropism 
(cellular membrane mediated endocytosis) and enhances transduction to a 
variety of cells. However one major drawback is the induction of cytotoxicity 
which may limit this pseudotyped LV and its potential use in the clinic. The 
challenge is finding an envelope glycoprotein in pseudotyping the LV successfully 
for enhancing transduction and/or cell/tissue-specific targeting (Cronin et al., 
2005, Sinn et al., 2005b, Cockrell and Kafri, 2007, Escors and Breckpot, 2010, 
Matrai et al., 2010). Various other viral envelopes have been used to pseudotype 
LVs and have demonstrated their potential in transduction efficiency in targeted 
cell/tissue types with limited cytotoxicity, for example rabies, Ross River virus, 
Ebola-Zaire, baculovirus gp64, murine leukaemia virus (MLV) –amphotropic and –
ecotropic  and Hantavirus (Cronin et al., 2005, Sinn et al., 2005b, Escors and 
Breckpot, 2010, Matrai et al., 2010).  
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Rabies virus belongs to the Lyssavirus genus and predominantly infects the 
central nervous system (CNS) and causes inflammation of the brain and 
eventually death. A few animal model studies have demonstrated the use of 
rabies (glycoprotein envelope) pseudotyped LVs for efficient transduction and 
sustained transgene expression within cells of the central nervous system (CNS) 
(Mazarakis et al., 2001, Kato et al., 2007, Rahim et al., 2009). Two of these 
studies observed that rabies pseudotyped LVs successfully mediated gene 
transfer in neurones in vivo due to retrograde axonal transport, whereas this 
function did not occur with VSV-g pseudotyped LVs (Mazarakis et al., 2001, Kato 
et al., 2007). In addition, a recent study demonstrated rabies pseudotyped NILV-
mediated gene delivery efficiently transduced neurones in adult rats in vivo 
(Rahim et al., 2009). These preclinical studies support the use of rabies 
pseudotyped LVs as effective vectors for gene therapy applications, especially 
for the treatment of inherited and acquired neurological disorders.   
Ross River virus (RRV) belongs to the virus genus Alphaviruses and causes 
polyarthritis. RRV glycoprotein envelope has a broad tropism for various species 
and many cell types (Jakobsson et al., 2006). This viral envelope protein has 
been implicated to have potential utility for various cell types, for example LV 
pseudotyped with RRV envelope demonstrated higher transduction efficiency in 
murine hepatocytes, kupffer cells, astrocytes and oligodendrocytes and induced 
less cytotoxicity, compared with VSV-g pseudotyped LV in vivo  (Kang et al., 
2002). RRV pseudotyped LVs have demonstrated efficient transduction of 
neurons and glial cells when injected into different structures in the rat brain, 
plus these vectors had the ability to transduce human neuronal progenitor cells 
in vitro (Jakobsson et al., 2006).   
Ebola Zaire (EbolaZ) virus belongs to the family of filoviruses and is transmitted 
through bodily fluids causing lethal haemorrhagic fever. One of the main targets 
is endothelial cells (Sanders, 2004). The examination of in vivo tropism of EbolaZ 
pseudotyped LVs compared to VSV-g pseudotyped LVs, indicated these vectors 
were more efficient in transduction of myocytes and equally the same for 
cardiomyocytes (MacKenzie et al., 2002). EbolaZ pseudotyped LVs were injected 
into murine muscle in utero and these vectors were found to transduce muscle 
satellite/stem cells. Subsequently, regenerated muscle after injury 
demonstrated transgene expression had originated from transduced satellite 
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cells (MacKenzie et al., 2005). EbolaZ pseudotyped LVs have demonstrated their 
effectiveness in efficient transduction of the airway epithelia in in vitro and in 
vivo models (Kobinger et al., 2001, Sinn et al., 2003). Altogether, these 
investigations indicate that EbolaZ pseudotyped LV-mediated gene transfer may 
hold promise for the treatment of respiratory diseases (i.e. cystitic fibrosis), 
muscular diseases and CVDs. 
Baculovirus glycoprotein 64 (GP64) belongs to the Baculovirus family and have 
species-specific tropisms among many invertebrates. LVs pseudotyped with GP64 
glycoprotein envelope have shown narrower tropism, lack of cytotoxicity and 
higher vector titre productions with greater stability (Kumar et al., 2003, 
Schauber et al., 2004, Cronin et al., 2005). GP64 pseudotyped LVs in comparison 
to VSV-g pseudotyped LVs, have been proven to efficiently transduce a variety of 
cell lines but with a slightly more restricted tropism and a poor ability to 
transduce haematopoietic cell types. Moreover, the GP64 pseudotyped LV was 
demonstrated to be an attractive alternative to the VSV-g pseudotyped LV with 
comparable transduction efficiency in mouse liver tissue in vivo (Schauber et al., 
2004). In addition, GP64 pseudotyped LV-mediated gene transfer indicated 
greater transduction efficiency of mouse nasal epithelia than observed with VSV-
g pseudotyped LV (Sinn et al., 2005a). Furthermore, a study concluded that LVs 
pseudotyped with GP64 provided efficient cell-specific, high-level transgene 
expression in fetal and neonatal airway epithelial cells in the murine lung, 
compared to LVs pseudotyped with VSV-g. GP64 pseudotyped LV mediated long-
term transgene expression in the mouse lung after neonatal administration 
(Buckley et al., 2008). In addition, GP64 pseudotyped LVs mediated efficient 
transduction levels in cells of the astrocytic lineage in adult rats (Rahim et al., 
2009)  In summary, these studies suggest that GP64 pseudotyped LVs have the 
potential to provide modality for treatment in liver and lung diseases. 
Murine leukaemia virus (MLV) are oncoretroviruses (part of the gammaretrovirus 
genus) and have the ability to infect and cause cancer in mice. MLV-amphotropic 
envelope (MLV-A) has a broad host range compared to MLV-ecotropic envelope 
(MLV-E). MLV-A pseudotyped LVs infected human skin tissues (epidermal and 
dermal layers) with higher efficiency compared to VSV-g pseudotyped LVs, at 
low virus titres (Kunicher et al., 2008). These particular pseudotyped LVs were 
highly efficient in gene transfer to specific cells of the CNS such as the striatum 
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and thalamus, compared to VSV-g pseudotyped LVs, following injection into 
separate brain regions of adult mice (Watson et al., 2002). LVs pseudotyped with 
the MLV-A envelope protein were more efficient in transducing human adult cord 
blood CD34+ cells and superior in establishing human haematopoiesis in 
immunodeficient mice, compared to VSV-g pseudotyped LVs (Hanawa et al., 
2002). Altogether, these investigations propose that MLV-A pseudotyped LVs may 
be effective in gene therapy applications for skin diseases, neurological 
disorders and immunodeficiencies.  
LVs pseudotyped with MLV-E glycoprotein envelope effectively transduce 
pluripotent human embryonic stem cells (Koch et al., 2006). Thus, this particular 
pseudotyped LV has the potential to provide an alternative to the VSV-g 
pseudotyped LV-mediated gene transfer in stem cell manipulation. 
Hantavirus (HNTV) is collectively a family of viruses which cause fatal respiratory 
disease and haemorrhagic fever with renal syndrome in humans (Bahr et al., 
2004, Muranyi et al., 2004). A study investigated the transduction of VECs with 
LVs pseudotyped different strains of Hantavirus (Qian et al., 2006). In vitro data 
from this study indicated that the Hantaan strain mediated higher transduction 
efficiency for VECs (bovine aortic VECs and human umbilical vein VECs), 
compared to VSV-g pseudotyped LVs. In vivo locally delivered HNTV pseudotyped 
LVs were highly efficient in transduction of vascular cells in a rabbit model of 
acute vascular injury and greatly targeted the site of vascular injury. 
Furthermore, in vivo results demonstrated that transduction efficiency of this 
pseudotyped LV was evidently superior compared to VSV-g pseudotyped LV and 
adenoviral vector, following local delivery. In addition, HNTV pseudotyped LV 
gene transfer of human EC-SOD mediated over-expression and reduced the NIF in 
a rabbit acute vascular injury model 6 weeks after delivery.  These findings 
suggest the potential use of this particular HNTV pseudotyped LV for therapeutic 
gene transfer into the vasculature for the prevention of the NIF (Qian et al., 
2006). 
In summary, all these preclinical investigations have demonstrated that cell 
targeting can be enhanced/modified with pseudotyped LVs (plus possibly with 
limited cytotoxicity), in comparison to VSV-g. All pseudotyped-LVs mentioned 
have yet to be tested in the context of acute vascular injury (with an exception 
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to HNTV glycoprotein envelope) and offer additional potential for these vectors 
in vascular gene therapy. 
1.11.3 Integration-deficient lentiviral vectors 
As previously mentioned, LVs mediate integration and long-term transgene 
expression and have the potential to be very useful for diseases/disorders, in 
which permanent cell correction is required by gene therapy, for example 
monogenic disorders  including WAS (Charrier et al., 2007, Galy et al., 2008, 
Marangoni et al., 2009), adenosine deaminase-deficient (ADA)-SCID (Mortellaro 
et al., 2006) and X-linked SCID (Zhang et al., 2007, Zhou et al., 2010, Almarza et 
al., 2011). Despite this, one of the major limitations of using integrating LV (int-
LV) gene transfer is the occurrence of semi-random integration, which can 
potentially lead to oncogenesis associated with insertional mutagenesis as 
observed in a clinical trial (Hacein-Bey-Abina et al., 2003b, Hacein-Bey-Abina et 
al., 2008) and previously described in section 1.5. Importantly, disease 
applications involving non-dividing (post-mitotic or quiescent) cells for LV-
mediated gene transfers do not require integration and these include the retina, 
brain, liver and skeletal muscle. These shortcomings led to a major 
advancement in LVs, the development of non-integrating LVs (NILVs). These 
NILVs mediate gene transfer with minimal host genome integration, whilst 
retaining similar transduction efficiency of their integrating counterparts (still 
harness lentiviral-mediated gene transfer to non-dividing and dividing cells) and 
provide stable transgene expression. NILVs offer enormous potential for the 
utility of LVs in clinical gene therapy (Vargas et al., 2004, Nightingale et al., 
2006, Philippe et al., 2006, Yanez-Munoz et al., 2006, Apolonia et al., 2007, 
Philpott and Thrasher, 2007, Rahim et al., 2009).  
1.11.3.1 Integrase proteins 
After reverse transcription in the cytoplasm, the lentiviral double-stranded DNA 
is associated with the PIC, which facilitates nuclear entry (see section 1.10.2.1). 
The integrase protein (approximately 32-45 kDa in size and encoded in the pol 
gene) is a major component of the PIC and catalyses the proviral double-
stranded DNA integration into the host chromosome (Philpott and Thrasher, 
2007, Wanisch and Yanez-Munoz, 2009, Banasik and McCray, 2010). Moreover, it 
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is known that there are two different circular non-integrated lentiviral double-
stranded DNA molecules (episomes) present naturally in a cell after lentivirus 
infection. Extrachromosomal lentiviral DNA exists and accumulates in the 
nucleus in the following three forms: double-stranded linear DNA (precursor to 
the integrated provirus); intramolecular homologous recombination between 
LTRs forming an episome with a single LTR (1-LTR circle) and intramolecular 
non-homologous end joining of the LTRs forming an episome with two adjacent 
LTRs (2-LTR circle). The levels of 1-LTR episomes are greater than the 2-LTR 
episomes. Both episomes are stable and have the ability to facilitate transgene 
expression, but lack replication signals i.e. origin of replication, and thus dilute 
during cell division and do not persist in dividing cells (Butler et al., 2002, 
Pierson et al., 2002, Philpott and Thrasher, 2007, Wanisch and Yanez-Munoz, 
2009, Banasik and McCray, 2010). The integration process of proviral DNA is 
slightly inefficient and as a result these episomes normally persist in cells 
infected by retroviruses, retroviral vectors, lentiviruses and LVs, but at a 
relatively low level (Wanisch and Yanez-Munoz, 2009).  
A representation of the integration process is shown in Figure 1.11. The 
integrase protein has 3 functional domains: the N-terminal zinc finger domain, 
the core catalytic domain and the C-terminal DNA-binding domain (Figure 1.12). 
The core catalytic amino-acid triad motif consists of amino-acids D64, D116 and 
E152 (DDE motif, known as the catalytic triad) in lentiviruses and retroviruses 
and is absolutely necessary for integration. The process of integration begins 
with viral DNA binding via the C-terminal domain of the integrase protein. 
Integrase binds to the U3 and U5 att sites within the LTRs of the double-stranded 
linear lentiviral DNA. The integrase protein facilitates the 3’ process, which 
involves the cleavage of the 3’ terminal dinucleotides within both LTRs. As a 
result, this generates a 3’ hydroxyl group (OH) at each end of the viral DNA, 
which are absolutely essential for the catalytic process mediated by the 
catalytic domain (important positions are D64, D116 and E152). Integrase then 
binds and brings together the genomic DNA and the viral DNA, thereby initiating 
integration. The integration reaction occurs when these 3’ hydroxyl groups 
attack the phosphodiester bonds on the opposite strands of the target DNA. As a 
consequence, this process mediates transfer and the joining of the double-
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stranded viral DNA into the host’s DNA (Philpott and Thrasher, 2007, Banasik and 
McCray, 2010).  
 
Figure 1.11. A schematic diagram of the integration process.  
Integrase binds to the double-stranded linear lentiviral DNA via U3 and U5 att sites within the 
LTRs. Integrase facilitates the cleavage of 3’ terminal dinucleotides within both LTRs and as a 
result generates a 3’ hydroxyl group (OH) at each end of the viral DNA which are necessary for 
the catalytic process. Integrase then binds and brings together the host’s DNA and the viral DNA. 
The integration reaction occurs when 3’ hydroxyl groups attack phosphodiester bonds on the 
opposite strands of the host’s DNA, and thereby mediating transfer and joining of the viral DNA 
into the genomic DNA (Philpott and Thrasher, 2007, Banasik and McCray, 2010). 
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Figure 1.12. Structure of the lentiviral integrase protein.  
A schematic representation of the three functional domains of integrase which comprise of the 
following: the zinc-binding N-terminal domain, the catalytic core domain and the DNA-binding C-
terminal domain. Arrows illustrate the amino acids that give rise to class I integrase mutations, 
thereby rendering lentiviral vectors, non-integrating. Residues D64, D116 and E152 (in bold red 
and underlined), generates the DDE catalytic triad which is absolutely essential for integration. A 
point mutation in any of these residues affects the catalytic triad and thus blocks integration. A 
point mutation in anyone of these residues: N120, W235, RRK (262-264) and K273 (in black and 
underlined), affects the binding of integrase to the genomic DNA, thereby inhibiting integration 
(Philpott and Thrasher, 2007, Banasik and McCray, 2010).   
1.11.3.2 Development of non-integrating lentiviral vectors 
In general, NILVs are integration-deficient due to mutations in the integrase 
gene. The integrase protein has pleiotropic effects in PIC nuclear translocation 
and integration, thus many mutants to this protein will have an effect on several 
viral functions as well as integration. Integration-deficient LVs and retroviral 
vectors are created, by introduction of specific point mutations in the gene 
which encodes for the integrase protein via the packaging plasmid. Integrase 
mutations can be divided into two classes. Class I integrase mutations result in 
normal DNA synthesis, integration failure and accumulation in the cell nucleus as 
double-stranded DNA episomes. However, class II integrase mutations (in the N-
terminal domain) have pleiotropic effects (defects in assembly, reverse 
transcription and a lack of integration) and cause limited transgene expression. 
Thus, class II mutations are not considered for NILV-mediated transgene 
expression, whereas class I mutations are more appropriate (Philpott and 
Thrasher, 2007, Wanisch and Yanez-Munoz, 2009, Banasik and McCray, 2010). 
There are a large number of class I integrase point mutations, which affect 
different steps of the integration process, thereby giving rise to NILV-mediated 
gene transfer and transgene expression (Figure 1.12 & Figure 1.13). The most 
common class I integrase mutations used in NILVs are point mutations in the 
catalytic triad. A point mutation in any of these residues (D64, D116 and E152, 
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the DDE catalytic triad) inactivates the catalytic function of integrase and 
prevents integrase function, thus rendering integration deficiency (Figure 1.12). 
In addition, other integrase residues can bear a point mutation rendering the 
integrase protein ineffective, thereby inhibiting integration (Figure 1.12), these 
include the following:  
• Position Q148 in the core domain: blocks vector DNA binding via the att site 
and strand transfer (class I).  
• Residues N120, K156 & K159 in the core domain: impairs the binding of the 
integrase to the genomic DNA (class I). 
• The W235 residue and the RRK (262-264) motif in the DNA-binding C-terminal 
domain: inhibits integrase binding to the target host genomic DNA (class I). 
• The K264/K266/K273 triad in the DNA-binding C-terminal domain: impairs 
target DNA binding and strand transfer (class I). 
• The H12 residue in the zinc-binding N-terminal domain: blocks integrase 
multimerization function (class II). 
(Apolonia et al., 2007, Philpott and Thrasher, 2007, Wanisch and Yanez-Munoz, 
2009, Banasik and McCray, 2010). The most common mutant residue used in 
studies to date, which facilitates the inactivation of integrase, is the D64 residue 
known as the D64V mutant [a single amino acid change, aspartic acid to valine at 
position D64 in the HIV-1 integrase protein sequence (Naldini et al., 1996a)] 
(Nightingale et al., 2006, Yanez-Munoz et al., 2006, Apolonia et al., 2007, Rahim 
et al., 2009).  
A CA dinucleotide in the 3’ strand of the att site of the viral DNA is required for 
3’ cleavage mediated by integrase during the integration process (Philpott and 
Thrasher, 2007, Wanisch and Yanez-Munoz, 2009, Banasik and McCray, 2010).   
Instead of the mutational inactivation of the integrase protein, NILVs can also be 
developed by mutating (for example replacing conserved CA with TG 
dinucleotides) these att sites at the U3 and U5 ends of the viral genome via the 
transfer/construct plasmid and thereby blocking integration (Nightingale et al., 
2006, Apolonia et al., 2007).  
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These class I integrase and/or att site mutants prevent the integration process 
of the double stranded viral DNA molecule. Instead two circular forms of non-
integrated double-stranded viral DNA are generated from the linear form, giving 
rise to 1-LTR and 2-LTR episomes. These episomes accumulate in the nucleus. 
These viral DNA circular forms are transcriptionally active and facilitate 
transgene expression (Figure 1.13) (Philpott and Thrasher, 2007, Wanisch and 
Yanez-Munoz, 2009, Banasik and McCray, 2010).  
In post-mitotic cells these episomal forms are stably maintained. However, these 
episomes lack replication signals and as a consequence dilute during cell division 
and do not persist in dividing cells. NILVs retain the high transduction efficiency 
of their integrating counterparts, with reduced host genome integration and 
risks associated with insertional mutagenesis. NILV-mediated transgene 
expression is as efficient as their integrating counterparts in non-dividing cells 
and at the initial infection of dividing cells (Nightingale et al., 2006, Philippe et 
al., 2006, Yanez-Munoz et al., 2006, Apolonia et al., 2007, Philpott and 
Thrasher, 2007, Rahim et al., 2009, Wanisch and Yanez-Munoz, 2009).  
NILVs increases bio-safety not only in terms of having the ability to be 
integration-deficient, but also less likely to generate replication-competent-
recombinants. Ideally NILVs require both integrase and att site mutations for 
clinical application in order to: minimise integration if vector mobilization 
occurs; enhance the reduction in the risk of replication-competent-recombinant 
generation, and limit the emergence of residual integration frequency  (Philippe 
et al., 2006, Wanisch and Yanez-Munoz, 2009, Matrai et al., 2010). 
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Figure 1.13. Representation of the non-integration process.  
Class I integrase and/or att site mutants prevent the integration process of the linear double 
stranded viral DNA molecule. Instead two circular forms of non-integrated double-stranded viral 
DNA are formed from the linear form and accumulate in the nucleus. These episomes are 
generated either by intramolecular homologous recombination between LTRs forming an episome 
with a single LTR (1-LTR circle) and intramolecular non-homologous end joining of the LTRs 
forming an episome with two adjacent LTRs (2-LTR circle). These circular forms of viral DNA are 
transcriptionally active and facilitate transgene expression. However, these episomes lack 
replication signals and as a consequence dilute during cell division. Adapted from Philpott and 
Thrasher (2007) (Wanisch and Yanez-Munoz, 2009, Banasik and McCray, 2010). 
 
NILVs are by definition relatively integration-defective, but this is not absolute 
because of residual integration, which is suggested to occur by background 
cellular recombination events (mediated through DNA nicks located anywhere in 
the vector episome) and not by integrase. Consequently, all NILVs mutations 
possess residual integration efficiencies (Philpott and Thrasher, 2007, Wanisch 
and Yanez-Munoz, 2009). In contrast to their integrating counterparts, the most 
commonly used D64V mutant possesses approximately a 103-fold reduction in 
integration efficiency as well as N120L and W235E mutants. Mutants K264R, 
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Q148A and K264, 266, 273R gave rise to residual integration rates of 3-, 13- and 
14-fold lower than integrating LVs (int-LV). The residual integration rate of the 
att site mutant was approximately 200-fold lower than the wild-type vector 
(Apolonia et al., 2007). The D64V mutant has also been demonstrated to 
decrease integration by 104-fold lower than the wild-type HIV-1 vector (Leavitt 
et al., 1996). In addition, residual integration frequencies were also evident in 
NILV combination mutants (mutations in the att site and integrase gene) with no 
further reduction compared to integrase mutants alone (for example D64V 
mutant) (Nightingale et al., 2006, Apolonia et al., 2007).  
A number of studies have demonstrated the potential use of NILVs for gene 
transfer (Vargas et al., 2004, Nightingale et al., 2006, Philippe et al., 2006, 
Yanez-Munoz et al., 2006, Apolonia et al., 2007, Rahim et al., 2009). Vargas et 
al., demonstrated that NILVs (D116N mutant) with the incorporation of the 
simian virus-40 (SV-40) origin of replication in their genome, have the ability to 
retain transgene expression in 293T cells (dividing cells) that contain the SV-40 
large T antigen. Thus, this study implied the potential application of NILVs for 
gene transfer in dividing cells (Vargas et al., 2004). Mutations in the att sites 
and the integrase protein (D64V mutation) mediated a high and stable 
transduction efficiency, but transgene expression was transient in dividing 
haematopoietic cells after one month post-transduction, due to the dilution of 
lentiviral episomes (1-LTR and 2-LTR) during cell division (Nightingale et al., 
2006). Class I integrase mutation in the RRK motif generated NILVs with efficient 
transduction for dividing and non-dividing cells in vitro, but provided transient 
transgene expression in dividing cells. In contrast, these vectors mediated long-
term and stable transgene expression in non-dividing cells (neural cells) in vitro 
and (murine brain tissue) in vivo, which were as efficient as int-LVs (Philippe et 
al., 2006). The D64V mutant NILV exhibited highly efficient gene transfer and 
sustained transgene expression in vivo in the retina and brain tissue of mice, 
which was as efficient as the int-LV-mediated gene transfer. In addition, NILV-
mediated gene transfer of rpe65 (retinal pigment epithelium-specific 65 kDa 
protein) facilitated functional rescue of congenital blindness in a murine model 
of autosomal recessive retinitis pigmentosa (due to mutations in the rpe65 gene) 
(Yanez-Munoz et al., 2006). In addition, it is known that D64V mutant NILVs have 
similar transduction efficiencies as int-LVs (Yanez-Munoz et al., 2006), whereas 
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RRK motif mutant NILVs exhibit lower transduction efficiencies compared to 
their integrating versions (Philippe et al., 2006). NILVs with class I point 
mutations in the integrase or mutations in the integrase att sites on the vector 
DNA genome or in combination, demonstrated efficient transduction and 
integration deficiency in vitro. In additions, these NILVs exhibited transient 
transgene expression in dividing cells, whereas non-dividing cells retained 
transgene expression overtime. Evidently, four different NILVs [the D64V 
mutant, the mutant which comprised of a deletion in the att site (∆att site), 
D64V∆att mutant, and the D64VN120LW235E∆att mutant] retained high 
transduction efficiency and longevity of transgene expression in murine muscle 
tissue in vivo, similar to their integrating counterparts (Apolonia et al., 2007). 
Recently, Rahim et al., reported NILVs (D64V mutants) mediated efficient 
transduction and long-term transgene expression in tissues of the central 
nervous system (CNS) in rodents in vivo. Moreover, NILVs were as effective as 
their integrating versions in vivo, suggesting implications for these vectors in 
clinical gene therapy applications for neurological disorders (Rahim et al., 2009).  
Permanent transgene expression is not necessarily important during acute 
vascular injury. Many studies have reported that transient transgene expression 
mediated by adenoviral vectors can provide sufficient therapeutic benefits 
(George et al., 2000, Wan et al., 2004, Johnson et al., 2005, Kritz et al., 2008). 
An alternative to int-LV-mediated transgene expression is NILVs. NILVs exhibited 
by the D64V mutant [high transduction efficiency and lower residual integration 
efficiency (Leavitt et al., 1996, Apolonia et al., 2007)] have yet to be tested for 
their therapeutic use in the context of the acute vascular injury response and 
offer additional potential for these vectors in vascular gene therapy. VSMCs are 
vascular cells which slowly divide. Therefore it is suggested the NILV-mediated 
episomal transgene would be diluted slowly, but persist for the duration 
required (George et al., 2006, White et al., 2007).  
Taken together, optimisation of LVs is an area of interest for this study. LVs used 
within this thesis will be optimised in terms of alternative promoters, 
pseudotyping and integration-deficiency for human vascular gene delivery. 
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1.12 Therapeutic genes for the vasculature 
The end point of any vector development and optimisation is to express a gene 
that will exert a therapeutic effect within its aimed target (target validation). 
The complexity of vascular response to injury has given rise to a wide range of 
potential targets for therapeutic intervention in the vasculature. Therapeutic 
strategies aimed to prevent the NIF, include the following associated factors: 
• Reduction in VSMC migration and/or proliferation. 
• Inhibition in the degradation of the ECM (pre-exists) and/or inhibition in the 
up-regulation of newly formed ECM deposits (thus ECM modulation). 
• VSMC apoptosis. 
• Acceleration of re-endothelialisation and improvement of endothelial 
function.  
• Inhibition in vasculature inflammation. 
• Anti-thrombosis 
To date, there are many therapeutic genes that have been/are being 
investigated (involving many different vectors) to prevent the NIF after acute 
vascular injury and to name but a few are listed in Table 1.2. The ideal 
therapeutic gene would target the major contributors to pathogenesis of the NIF 
and mediate an effect by phenotypic modulation of VSMC (migration and/or 
proliferation) and acceleration of re-endothelialisation, therefore possessing a 
key strategy to the regulation of vasculature remodelling and maintenance, and 
inhibition of thrombosis (George et al., 2006, Gaffney et al., 2007). 
One of the major hallmarks in the process of the NIF after acute vascular injury 
is ECM degradation by MMPs, which consequently results in medial VSMC 
migration into the intima. The activity of these proteins is strongly inhibited by 
TIMPs (Baker et al., 2002, Newby, 2007, Raffetto and Khalil, 2008). Studies have 
explored gene transfer of TIMP-1, 2 and 3 mediated by either adenovirus or AAV. 
Over-expression of these TIMPs in preclinical vascular injury models have 
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demonstrated inhibition of medial VSMC migration, which mediated a reduction 
in the NIF (George et al., 1998a, George et al., 1998b, George et al., 2000, Hu 
et al., 2001, Ramirez Correa et al., 2004).  
TIMP-3 is a candidate therapeutic gene that has been extensively studied 
because of its ability to bind to the MMPs, which inhibits ECM degradation, 
blocks VSMC migration and induces VSMC apoptosis mediated by its bystander 
effect. Preclinical studies have demonstrated that the over-expression of TIMP-3 
inhibited vascular remodelling at 28 days post-infection, thus reduced NIF in the 
following acute vascular injury models of disease: ex vivo adenoviral gene 
transfer porcine saphenous vein graft (SVG) model and human SVG organ culture 
model (George et al., 2000); ex vivo non-viral gene transfer mediated by 
microbubble-facilitated ultrasound delivery in a porcine SVG model (Akowuah et 
al., 2005) and in vivo gene-eluting stent-based adenoviral-mediated delivery in a 
porcine vascular injury model (ISR model) (Johnson et al., 2005). 
The tumour suppressor protein 53 (p53) is another candidate therapeutic gene 
because it reduces VSMC migration and it is pro-apoptotic. These characteristics 
are key to the NIF inhibition. It has been shown that adenoviral gene transfer of 
wild-type p53 mediated over-expression, which resulted in inhibition of the NIF 
in an ex vivo organ culture model of a human vein graft and in an in vitro human 
saphenous SMC isolated culture. This effect was induced by modulation of VSMC 
migration and an induction of apoptosis (George et al., 2001). Moreover, a 
further study demonstrated that ex vivo adenoviral-mediated gene transfer of 
p53 prior to grafting an in vivo porcine vein graft model, resulted in an increased 
lumen size and inhibition of the NIF at 28 days post-infection (Wan et al., 2004). 
For Nogo-B, see section 1.12.1.2 for information on its therapeutic potential in 
acute vascular injury, which is an area of interest within this study. However, 
there are still many more potential therapeutic genes, which are key to the NIF 
inhibition. 
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Therapeutic genes 
Anti-VSMC 
migration
Anti-VSMC 
proliferation
ECM 
modulation
Pro-apoptotic
Pro-re-
endothelialisation
Anti-
inflammatory
Bystander 
effect
TIMP-1
TIMP-2
TIMP-3
p53
β-ARKct
Nogo-B ?
p56 and p56/E2F 
35k  
Table 1.2. Therapeutic genes which are key to the NIF inhibition.  
These include the following: tissue inhibitors of matrix metalloproteinases (TIMP)-1(Baker et al., 1998, George et al., 1998b, Ramirez Correa et al., 2004), TIMP-2 
(Baker et al., 1998, George et al., 1998a, Hu et al., 2001), TIMP-3 (Baker et al., 1998, George et al., 2000, Dishart et al., 2003a), tumour suppressor  protein 53 
(p53) (George et al., 2001), carboxyl terminus of the β-adrenergic receptor kinase (β-ARKct) (Iaccarino et al., 1999, Luo et al., 2004), neurite outgrowth inhibitor 
isoform B (Nogo-B)(Acevedo et al., 2004, Kritz et al., 2008), retinoblastoma protein (Rb) also known as tumour suppressor protein 56 (p56) and p56/elongation 2 
transcriptional factor (E2F) (Wills et al., 2001) and broad spectrum CC-chemokine (CK) binding protein 35k also known as  Vaccina virus strain Lister 35KDa protein 
(35k)(Ali et al., 2005). ECM, extracellular matrix; VSMC, vascular smooth muscle cells. 
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1.12.1 Nogo-B 
Nogo-B belongs to a superfamily of transmembrane (TM) proteins associated with 
the endoplasmic reticulum (ER), called the reticulons (RTN). The reticulon 
family is a large (greater than 300 family members) group of evolutionary 
conservative membrane-associated proteins found in many eukaryotes, and 
absent only in archaea and bacteria (Oertle et al., 2003b, Oertle and Schwab, 
2003, Voeltz et al., 2006, Yang and Strittmatter, 2007). 
All RTN proteins are typically between 200-1200 amino-acids in length and 
contain a reticulon homology domain (RHD). This RHD domain is a highly 
conserved region at the carboxyl (C)-terminal domain (approximately 200 amino 
acids in length) and is comprised of a hydrophilic loop (60-70 amino acids long 
and known as the 66-amino-acid loop region) flanked by two hydrophobic regions 
(each 28-36 amino acids in length and membrane embedded known as TMs), 
followed by a short C-terminal hydrophilic stretch (approximately 50 amino acids 
long). Each RTN protein has a specific amino acid (N)-terminal domain (Oertle 
and Schwab, 2003, Voeltz et al., 2006, Yan et al., 2006, Yang and Strittmatter, 
2007, Teng and Tang, 2008).  
There are four independent mammalian RTN genes which encode RTN proteins 1-
4 (RTN1, RTN2, RTN3 and RTN4 also known as Nogo). RTN1-3 were identified 
prior to RTN4/Nogo. Each gene can give rise to a range of different transcripts 
(various isoforms differ greatly in their N-terminal domain, with varying length). 
Each RTN gene and its isoforms have similar but also diverse intracellular and 
extracellular functions and have a ubiquitous expression pattern in different 
tissue (mediated by their divergent N-terminal domain), but all have their close 
association with the ER (mediated through its highly conserved RHD) (Oertle and 
Schwab, 2003, Voeltz et al., 2006, Yan et al., 2006, Yang and Strittmatter, 2007, 
Teng and Tang, 2008). 
The RHD especially the TM domains are important in the RTN protein association 
with/translocation into the ER and ER-associated functions. RTNs are primarily 
localised to the ER (greater than 95%). A small fraction of these RTN proteins 
also associate with other cellular structures within a cell, such as the cell 
membrane. It is possible that RTN proteins have cellular functions in ER 
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morphogenesis (involved in bending and shaping the ER membrane), intracellular 
trafficking (reticulum-Golgi apparatus trafficking), vesicle formation, membrane 
morphogenesis, apoptosis and cell division (Oertle and Schwab, 2003, Voeltz et 
al., 2006, Yan et al., 2006, Yang and Strittmatter, 2007, Teng and Tang, 2008).   
RTN-4/Nogo is encoded by a single gene on human chromosome 2 (2p16). There 
are three major spliced variants/isoforms, known as Nogo-A (RTN-4A), Nogo-B 
(RTN-4B) and Nogo-C (RTN-4C) (Figure 1.14) (Teng and Tang, 2008). The name 
Nogo originates from the longest isoform, Nogo-A; a potent inhibitor of neurite 
outgrowth and axon regeneration after CNS injury, hence the name neurite 
outgrowth inhibitor (Nogo) (Yan et al., 2006, Yang and Strittmatter, 2007, Teng 
and Tang, 2008). All three Nogo isoforms have an N-terminus of varying length 
and (Figure 1.14) various functional roles. Nogo-A and –B have a common N-
terminus for the first 184 amino acids (Oertle and Schwab, 2003, Teng and Tang, 
2008). Nogo-A (longest Nogo isoform, 250 kDa) is highly expressed in the CNS 
(Chen et al., 2000, Huber et al., 2002) and has been extensively studied with its 
myelin-associated neurite outgrowth inhibitory effect (negative regulator in 
regeneration of the adult CNS after injury), associated with neurological 
disorders (Teng and Tang, 2008, Schwab, 2010). Nogo-B (45-55 kDa) is expressed 
ubiquitously, which includes the CNS, peripheral nervous system (PNS), spleen, 
skeletal muscle, testis, lung, intestine, gall bladder, kidney, heart and vessel 
walls (Huber et al., 2002, Acevedo et al., 2004). Nogo-B has gained more 
interest over the recent years because of its diverse biological roles, such as in 
the modulation of vascular maintenance and remodelling (Acevedo et al., 2004, 
Kritz et al., 2008), and its pro-apoptotic function in cancer (Li et al., 2001). 
Nogo-C (shortest Nogo isoform, 25 kDa) is expressed in CNS and skeletal muscle, 
and very little is known about its function (Huber et al., 2002, Teng and Tang, 
2008). All three Nogo spliced variants contain an ER retention sequence at the C-
terminal domain (Dodd et al., 2005).   
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Figure 1.14. The three major spliced isoforms from the Reticulon-4/Nogo gene.  
Three spliced variants are known as Nogo-A (RTN-4A), Nogo-B (RTN-4B) and Nogo-C (RTN-4C). 
The conserved carboxyl (C)-terminus encodes the reticulon-homology domain (RHD). This RHD is 
comprised of a hydrophilic 66-amino acid loop domain (Nogo-66 loop) flanked by two 
hydrophobic regions which forms the transmembrane (TM1 or TM2) domains and this followed by 
a short C-terminal hydrophilic stretch. Each RTN protein has a specific amino acid (N) –terminal 
domain. The Nogo-A specific N-terminal fragment and Nogo-66 loop mediate the inhibition of 
neurite outgrowth. Nogo-A mediates its effect through the engagement of the extracellular 
Nogo-66 loop with the axonal cell-surface Nogo-66 receptor/Nogo receptor. Nogo-B has a 
common N-terminus with Nogo-A for the first 184 amino acids, but does not bear a sequence 
involved with the induction of a strong inhibitory activity of neurite outgrowth. Little is known 
about Nogo-C. All three Nogo isoforms have an N-terminus of varying length, diverse tissue 
expression and various functional roles. Adapted from Oertle and Schwab (2003) (Voeltz et al., 
2006, Yan et al., 2006, Yang and Strittmatter, 2007, Teng and Tang, 2008).  
1.12.1.1 Functional roles of Nogo-B 
Nogo-B [spliced variant of Nogo-A lacking a region involved in strong inhibitory 
activity for neurite out-growth (Oertle et al., 2003a)] has been shown to 
function as a potent pro-apoptotic protein in various cancer cells, whereas 
normal cells are relatively resistant (Li et al., 2001). Nogo-B interacts with anti-
apoptotic members of the B-cell lymphoma-2 (Bcl-2) family [Bcl-2 and B-cell 
lymphoma-extra large (Bcl-xL)]. This is mediated when the over-expression of 
Nogo-B prevents the translocation of Bcl-2 and Bcl-xL to the mitochondria from 
the ER, which reduces their anti-apoptotic effect (Tagami et al., 2000, Watari 
and Yutsudo, 2003). Moreover, the transcription of Nogo-B has been shown to be 
suppressed in certain cancer types (i.e. lung cancer), therefore this protein may 
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also act as a tumour suppressor (Li et al., 2001). The Drs protein (tumour 
suppressor) can interact with Nogo-B, and subsequently induce apoptosis (Tambe 
et al., 2004). In contrast, one study indicated that the stable over-expression of 
Nogo-B in certain types of cancer did not significantly induce a pro-apoptotic 
effect, compared to wild-type control (Oertle et al., 2003c). Nogo-B over-
expression may also have the ability to induce ER-stress mediated apoptosis 
through ER-specific pathways (see section 5.1.1) (Kuang et al., 2006).  
Nogo-B has recently been reported to have more biological roles. Endothelial 
Nogo-B induces adhesion signalling and promotes leukocyte transendothelial 
migration and diapedesis, therefore plays a key part in the acute inflammation 
response (Di Lorenzo et al., 2010). Nogo-B was demonstrated to be expressed 
highly in renal injury from human and murine specimens, and a positive 
regulator of macrophage recruitment to the obstructive kidney in a murine 
model of this disease. Therefore, Nogo-B could potentially be a novel biomarker 
of diverse renal injuries (Marin et al., 2010).  Recently, it was reported that 
Nogo-B displays endogenous expression in the lung epithelium. Data suggested 
that Nogo-B has a major role as a negative regulator of allergic-driven T-
lymphocyte helper 2 (Th2) cells in the asthmatic lung, as supported by the 
genetic gain and loss of function in a murine model (Wright et al., 2010). 
Another study indicated that endogenous levels of Nogo-B are important in the 
airway remodelling in chronic asthma (down-regulated in the airway of chronic 
asthmatic mice), and in the regulation of migration (Nogo-B necessary for 
migration) and contraction (increased contractility after Nogo-B down-
regulation) of airway smooth muscle cells (Xu et al., 2011). Nogo-B has been 
identified as a positive regulator of liver fibrosis and cirrhosis in hepatic injury, 
mediated through the activation of the transforming growth factor-beta (TGF-
β)/Smad2 signalling pathways in myofibroblasts (Zhang et al., 2011).    
The use of Nogo-A/B knockout mice demonstrated the endogenous role of Nogo-
B in inflammatory tissue repair and its essential function in chemotaxis of 
macrophages and associated wound-healing/tissue repair after limb ischaemia. 
Moreover, Nogo-B influenced and regulated the activation of Ras-related C3 
botulinium toxin substrate (Rac), followed by F-actin polymerisation and cell 
migration of monocytes/macrophages (Yu et al., 2009).  A recent study also 
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demonstrated that Nogo-B may influence human monocyte-derived macrophage 
migration via association with cytoskeletal structures and cytoskeletal 
intracellular signalling pathways [actin, Ras homolog gene family, member A 
(RhoA) and Rac] (Schanda et al., 2011).  
Collectively, Nogo-B is an important regulator in wound-healing, tissue repair 
and/or inflammation during renal injury, asthma, hepatic injury and peripheral 
vascular disease/limb ischemia. 
1.12.1.2  Nogo-B has a regulator of vascular remodelling 
Nogo-B has therapeutic potential in the vascular setting (Acevedo et al., 2004, 
Miao et al., 2006, Pan et al., 2007, Paszkowiak et al., 2007, Rodriguez-Feo et 
al., 2007, Kritz et al., 2008, Lee et al., 2009, Yu et al., 2009, Zhao et al., 2010). 
Previous studies have documented high levels of Nogo-B in VECs, VSMCs 
(Acevedo et al., 2004) and monocytes/macrophages (Paszkowiak et al., 2007, 
Rodriguez-Feo et al., 2007, Yu et al., 2009). VSMCs have two variants of Nogo-B: 
Nogo-B1 and Nogo-B2 (Acevedo et al., 2004). Nogo-B protein acts as a positive 
and negative regulator of vascular cells, respectively by mediating the 
chemoattraction of VECs and antagonising migration and proliferation of VSMCs 
in response to PDGF-BB (Figure 1.15) (Acevedo et al., 2004, Kritz et al., 2008). 
Nogo-B protein expression is predominantly found in a reticular pattern [due to 
its ER retention sequence in the C-terminus domain (Raines, 2004a, Dodd et al., 
2005)] with a small fraction (approximately 2% of the total Nogo-B protein per 
vascular cell) localised within the cell membrane of vascular cells (Acevedo et 
al., 2004). Moreover, the N-terminus of Nogo-B has been found to be located 
extracellularly (Acevedo et al., 2004). Nogo-B may have two special topological 
patterns. This is because, the two long TM domains may span the plasma 
membrane once or twice, and thus could locate the Nogo-66 loop either inside 
or outside the vascular cell (Figure 1.15) (Acevedo et al., 2004).  
Endogenous Nogo-B expression is important for vascular maintenance and 
remodelling (Acevedo et al., 2004), as well as cardiac function (Bullard et al., 
2008). Nogo-B expression is down-regulated following acute vascular injury. 
Indeed, mice deficient in Nogo-A/B demonstrated accelerated rates of NIF after 
acute vascular injury, which were attenuated/rescued by adenoviral gene 
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transfer of Nogo-B (Acevedo et al., 2004). Recently, it was shown that the NIF 
was rescued in a porcine vein graft model and a wire injured mouse model 
mediated by adenoviral gene transfer of Nogo-B, and this was associated with a 
reduction in VSMC proliferation (Kritz et al., 2008). In terms of VSMCs, 
mechanistically it is known that the N-terminus of Nogo-B blocks PDGF-BB 
induced VSMC migration in vitro (Acevedo et al., 2004, Kritz et al., 2008). This 
effect may occur through competitive binding antagonism of the PDGF receptor 
(PDGFR) or functional blockade of PDGF signalling downstream of the receptor 
(Acevedo et al., 2004). However, it is unknown if this is the functional domain 
which mediates phenotypic effects of VSMC proliferation. It has been suggested 
that the Nogo-B phenotypic effects on VSMC migration and/or proliferation, 
maybe facilitated through modulation of signal transduction from the cell 
surface and/or it may mediate its effect by ER-specific activities (such as the 
regulation of the structure of th ER network in association with cytoskeletal 
structures, and/or possible ER-stress mediated apoptosis) (see Figure 1.15) 
(Raines, 2004a), all of which will be discussed further in chapter 5. 
Nogo-B expression is down-regulated in human arterial atherosclerotic plaques 
(Rodriguez-Feo et al., 2007, Lee et al., 2009), stenotic lesions (Rodriguez-Feo et 
al., 2007), and lesions of aortic aneurysms (Pan et al., 2007). The reduction of 
Nogo-B protein may contribute to plaque formation, destabilisation and vascular 
abnormalities (Pan et al., 2007, Rodriguez-Feo et al., 2007, Lee et al., 2009). 
Nogo-B has been shown to be reduced in the intima and media, but up-regulated 
in the adventita under conditions of injury-induced NIF and has been regarded as 
a biomarker for injury-induced NIF (Paszkowiak et al., 2007). Shear-stress and 
low-flow induced inward remodelling differs mechanistically, and is distinct from 
injury-induced NIF, and is associated by an endothelium-dependent 
compensatory mechanism and infiltration of inflammatory cells (Tronc et al., 
1996). The injury-induced NIF can only partially account for lumen loss during 
restenosis, and additionally the rearrangement within the vasculature following 
shear-stress and low-flow induced inward remodelling could explain the 
reduction of lumen (Paszkowiak et al., 2007). It has been shown that intimal 
Nogo-B is reduced and no change in medial and adventitial Nogo-B levels during 
inward remodelling. Inward remodelling differs mechanistically from vascular 
injury in terms of Nogo-B expression and therefore Nogo-B is not a 
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marker/mediator of inward remodelling (Paszkowiak et al., 2007). However, 
low-flow induced inward remodelling along with vascular injury-induced NIF 
enhanced NIF associated with reduced Nogo-B expression levels in the intimal 
and medial layers and increased Nogo-B expression in macrophage within the 
adventitial layer. Thus, Nogo-B is a regulator in vascular remodelling and also 
vascular inflammation (Paszkowiak et al., 2007). Nogo-B was demonstrated to 
contribute to vascular apoptosis. High levels of Nogo-B were located in 
macrophage/foam cell-rich areas of human carotid plaques (contribute to lipid-
rich necrotic cores), and therefore may induce VSMC apoptosis (Rodriguez-Feo et 
al., 2007). Additionally, it is also important to consider validating vascular beds 
in terms of cell turnover and macrophage recruitment in the adventitial layer in 
the gene delivery of Nogo-B in ISR and CABG animal models. Mechanistically, 
how Nogo-B inhibits NIF in response to acute vascular injury is unknown, but 
mechanisms will be addressed in chapter 5. 
The lack of Nogo-receptor (Nogo-receptor binds to the Nogo-66 loop) expressed 
in VECs and VSMCs (Acevedo et al., 2004), led to the identification of a Nogo-B 
receptor (Ng-BR), which is highly expressed in blood vessels, VECs and in the 
heart (Miao et al., 2006). This receptor is presumed to be localised at the cell 
surface membrane and the ER (Miao et al., 2006, Harrison et al., 2009). Ng-BR is 
specific for the N-terminus of Nogo-B (Miao et al., 2006). N-terminus of Nogo-B 
promotes the adhesion and chemotaxis of VECs, and negatively regulates PDGF-
BB-induced migration of VSMCs (Figure 1.15) (Acevedo et al., 2004). Ng-BR has 
been described to be essential for Nogo-B- and vascular endothelial growth 
factor (VEGF)- stimulated VECs migration in vascular remodelling and 
angiogenesis, via the activation and phosphorylation of Akt of the 
phosphatidylinositol 3-kinase (PI3K) pathway (Figure 1.15) (Miao et al., 2006, 
Zhao et al., 2010).  
Ng-BR (transmembrane receptor) consists of an intrinsically unstructured 
ectodomain (with no secondary and tertiary structures) and a partially folded 
cytoplasmic domain (with secondary structures and weak tertiary structures). It 
has been suggested that this Ng-BR is very rare (Li and Song, 2007). Plus, the 
intrinsically unstructured protein ectodomain may be favourable and facilitate 
specialised biological functions, such as signal transduction, cytoskeletal 
organisation, protein-DNA recognition, endocytosis and maintenance/production 
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of membrane structures. Thus, this transmembrane receptor may possess a 
disordered function due to its structure (Li and Song, 2007). This receptor has 
been demonstrated to have implications in the regulation of intracellular 
cholesterol trafficking (Harrison et al., 2009) and dolichol biosynthesis (Harrison 
et al., 2011), as well as in vascular remodelling and angiogenesis (Figure 1.15) 
(Miao et al., 2006, Zhao et al., 2010).  
Circulating Nogo-B (secreted Nogo-B) levels are detectable in human plasma, 
however the mechanism of secreting this transmembrane protein is unclear 
(Rodriguez-Feo et al., 2007). As mentioned the soluble N-terminal domain of 
Nogo-B (soluble Nogo-B) promotes vascular cell adhesion and modulates 
migration (Acevedo et al., 2004). Taken together, Nogo-B is presumed to also 
exert its effects on VECs and VSMCs migration through a bystander effect.  
In summary, Nogo-B is a candidate therapeutic gene for the inhibition of the NIF, 
due to its characteristics [positive and negative regulator of VEC migration and 
VSMC migration and proliferation, respectively, and has a possible bystander 
effect (if soluble) (see Table 1.2)] which are key to the regulation of the 
vascular remodelling and maintenance during the acute vascular injury response.  
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Figure 1.15. The involvement of Nogo-B in vascular maintenance and remodelling.  
Nogo-B protein acts as a positive regulator of vascular endothelial cell (VEC) migration and a 
negative regulator of vascular smooth muscle cell (VSMC) migration and proliferation. ER, 
endoplasmic reticulum; NIF, neointima formation; PDGFR, platelet-derived growth factor 
receptor; Ng-BR, Nogo-B receptor. Adapted from Raines (2004a) (Acevedo et al., 2004, Miao et 
al., 2006, Kritz et al., 2008, Yu et al., 2009, Zhao et al., 2010, Schanda et al., 2011).  
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1.13 Ex vivo and in vivo gene delivery for vascular injury 
A number of gene transfer vectors (coupled with a specific therapeutic gene key 
to the NIF) have been explored for local delivery to the vasculature during 
revascularisation (in preclinical vascular injury models such as human, pig, 
rabbit and mouse) mediated through catheters (Luo et al., 2004, Numaguchi et 
al., 2004, Qian et al., 2006, Nakano et al., 2007), direct injection (Ramirez 
Correa et al., 2004, Kritz et al., 2008) or prior to grafting (George et al., 2000, 
Hu et al., 2001, Kritz et al., 2008). Subsequently, these methods have 
demonstrated efficient transduction and effective inhibition of the NIF during 
the acute vascular injury response.   
CABG is particularly well suited to ex vivo gene delivery because of the access of 
vascular tissue before grafting, thus enhancing the safety profile of this 
potentially useful therapy. During a CABG gene therapy procedure, ex vivo 
vascular gene delivery would involve a harvested autologous blood vessel (most 
commonly a saphenous vein) from a patient, which would then be incubated 
with the gene transfer vector of choice (carrying the desired therapeutic gene) 
before grafting. This clinical window would be narrow and between 10-30 
minutes, thus it would be necessary to use an efficient gene delivery vector to 
mediate gene transfer into the vasculature. This genetically engineered vascular 
conduit graft would then be re-introduced into the patient and subsequently 
express the therapeutic transgene (Baker et al., 2006, George et al., 2006). In a 
pig model of vascular bypass grafting surgery, ex vivo delivery of an adenoviral 
vector expressing Nogo-B in an autologous saphenous vein demonstrated 
significant inhibition of the NIF, in comparison to the control adenoviral vector 
treated vein (Kritz et al., 2008). 
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1.14 Aims of Thesis 
The principle aim of this thesis was to assess NILV-mediated gene transfer to 
facilitate over-expression of Nogo-B in VSMCs and assess the phenotypic effects, 
as a potential therapeutic strategy for the prevention of the NIF following acute 
vascular injury. This was achieved through the following assessments: 
• Optimisation of LVs for human vascular cell gene transfer in vitro, in terms of 
alternative promoters, vector pseudotyping and integration-deficiency. 
• Analysis of the effect of Nogo-B over-expression on human primary VSMC 
migration and proliferation, mediated by NILVs or int-LVs in vitro. 
• Analysis of the mechanism of action of Nogo-B on human VSMCs in vitro.  
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2.1 Chemicals 
All Chemicals, unless otherwise stated, were obtained from Sigma-Aldrich 
(Poole, Dorset, UK) and were of the highest grade obtainable. All cell culture 
reagents were obtained from Gibco® (Invitrogen, Paisley, UK) unless otherwise 
stated. Dulbecco’s calcium and magnesium free phosphate buffered saline (PBS) 
(sterile) was obtained from Lonza (Slough, UK). All primers and probes 
(oligonucleotides) were obtained from MWG-Biotech (Ederberg, Germany). 
Nuclease-free water [not diethylpyrocarbonate (DEPC)-treated] was purchased 
from Ambion® (Applied-Biosystems/Ambion, Warrington, UK).  
2.2 Cell culture 
All primary cell isolations and cell cultures were performed in sterile conditions 
using biological safety class II vertical laminar flow cabinets. Cells were grown in 
37ºC incubators maintained at 5 % CO2 and 95 % air. Details of media used for 
growth and maintenance for each established cell line and primary cells are 
shown in Table 2.1. 
2.2.1 Isolation and culture of primary vascular cells 
Freshly obtained saphenous veins from patients that had undergone coronary 
artery bypass grafting (CABG) surgery were stored in sterile saline solution by 
the Glasgow Golden Jubilee National Hospital, until collection. Samples were 
cleaned of excess connective tissue under sterile conditions. The study complies 
with the Declaration of Helsinki and was approved by the West of Scotland 
Research Ethics Committee 1 (Reference number: 06/S0703/110). All 
participants gave written informed consent. 
2.2.1.1 Isolation of vascular endothelial cells from human saphenous 
veins 
Human saphenous vein endothelial cells (HSVECs) were isolated on the day of 
surgery by standard collagenase digestion, based on a modified version of the 
protocol described (Jaffe et al., 1973). In summary, saphenous veins were gently 
perfused with wash media [Dulbecco’s Modified Eagle’s Medium (DMEM) (with 1 
g/L D-glucose, 110 mg/L sodium pyruvate and phenol red and without L-
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glutamine) supplemented with 1 % (v/v) penicillin, 100 µg/ml streptomycin and 
2mM L-glutamine], to flush out remaining blood. Veins were cannulated with a 
sterile small surgical crocodile clip at one end, infused with wash media 
supplemented with 2 mg/ml of type IV collagenase (Sigma-Aldrich and sterile-
filtered) and cannulated on the opposite side. Type IV collagenase was used 
because the endothelial monolayer is seated on a basement membrane 
consisting of collagen type IV, thus allowing detachment (Newby and Zaltsman, 
2000). Vessels were incubated at 37ºC in a sterile petri dish (with a lid) in 5 % 
CO2 for 15 minutes (min). HSVEC suspensions were obtained by flushing the vein 
with wash media and collecting flow-through in a sterile petri dish. Veins were 
refilled with collagenase solution, incubated at 37ºC for a further 10 min, 
flushed through and EC suspension collected and pelleted by centrifugation at 
2,000 x g for 5 min at room temperature (RT). HSVECs were resuspended in 5 ml 
of 20 % complete EC media (Table 2.1), placed in a 25 cm2 tissue culture (T-25) 
flask and incubated at 37ºC in 5 % CO2. After 24 hours (h) incubation culture 
media was removed, HSVECs were washed twice in PBS (to remove remaining 
non-adherent red blood cells and debris) and fresh 20 % complete EC media 
added. Culture media was changed every 3-4 days (d) and these cells were used 
up to passage of 5. In culture, these HSVECs had a cobble like morphology (Jaffe 
et al., 1973). Three individual preparations of HSVECs were used in this thesis. 
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Cell type Description Composition of cell culture media used Detaching reagent
HeLa cells (American Type 
Culture Collection [ATCC]- LGC 
Standards, Middlesex, UK)
Human cervical 
carcinoma cell line.
Minimum Essential Media (MEM) (BioWhittaker, UK) supplemented with 10 % 
(v/v) fetal calf serum (FCS) (FCSPAA Laboratories, Yeovil, UK), 1% (v/v) 
penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 1 mM sodium 
pyruvate (Sigma-Aldrich) (10 % complete MEM).
Trypsin- 
ethylenediamine 
tetra-acetic acid 
(EDTA) 
293 cells (ATCC-LGC 
Standards)
Human Embryonic Kidney 
(HEK) cell line. 
10 % complete MEM. Citric saline
293T cells (ATCC-LGC 
Standards)
HEK transformed cell line 
(contains adenoviral and 
simian virus (SV)-40 DNA 
sequences).
10 % complete MEM. Citric saline
B50 cells (European Collection 
of Cell Cultures [ECACC], 
Health Protection Agency, 
Salisbury, UK)
Rat cortical neuronal cell 
line.
Dulbecco's Modified Eagle Medium (DMEM) 1x (with 1 g/L D-glucose and 110 
mg/L sodium pyruvate and without L-glutamine and phenol red) supplemented 
with 10 % (v/v) FCS, 1 % (v/v) pencillin, 100 µg/ml streptomycin and 2 mM L-
glutamine (10 % complete DMEM).
Trypsin-EDTA
Vascular smooth muscle cells 
(VSMCs) 
Primary vascular smooth 
muscle cells isolated from 
human saphenous vein.
Smooth muscle cell (SMC) growth media 2 (PromoCell, Heidelberg, Germany) 
with the addition of the supplement mix (containing 5 % [v/v] FCS, 0.5 ng/ml 
human epidermal growth factor, 2 ng/ml human basic fibroblast growth factor 
and 5 µg/ml human insulin), plus 10 % (v/v) FCS (for a 15% [v/v] FCS final 
concentration), 1 % (v/v) penicillin,100 µg/ml streptomycin and 2 mM L-
glutamine (15 % complete SMC media).
Trypsin-EDTA
Vascular endothelial cells 
(VECs)
Primary vascular 
endothelial cells isolated 
from human saphenous 
vein.
Large vessel endothelial cell (EC) basal medium (TCS cellworks Ltd, 
Buckingham, UK) supplemented with a large vessel endothelial cell growth 
supplement pack (containing hydrocortisone, human epidermal growth factor, 
human fibroblast growth factor with heparin and an antibiotic supplement 
[containing 25 mg/ml gentamicin and 50 µg/ml amphotericin B]) with the 
addition of 20 % (v/v) FCS, 1 % (v/v) penicillin and 100 µg/ml streptomycin and 
2 mM L-glutamine (20 % complete EC media).
Trypsin-EDTA
 
Table 2.1.  Media used to culture these cells in this study. 
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2.2.1.2 Isolation of vascular smooth muscle cells from human 
saphenous veins  
Following HSVEC isolation, vessels were stored overnight at 4ºC in sterile-filtered 
dissection media [DMEM (with 1 g/L D-glucose, 110 mg/L sodium pyruvate and 
phenol red and without L-glutamine) supplemented with 1 % (v/v) penicillin, 100 
µg/ml streptomycin, 2 mM L-glutamine and 15 mM Hepes buffer]. The following 
day human saphenous vein smooth muscle cells (HSVSMCs) were obtained from 
medial explants extracted from these veins, according to the method described 
(Southgate and Newby, 1990). Briefly, segments of veins were cleaned of fat and 
connective tissue, subsequently cut longitudinally and pinned luminal side up on 
a layer of sylgard [(184 encapsulating resin from BDH, Poole, Dorset, UK) set in a 
glass petri dish]. A rubber policeman was used to remove the endothelial layer, 
if the vein had not undergone HSVEC isolation. The medial layer was scored at 1 
cm intervals with a sterile scalpel, segments of tunica media were then peeled 
off from the adventitial layer with a pair of forceps. Segments were cut into 1 
mm2 size squares using a McIlwain tissue chopper. Segments were washed twice 
in dissection media, followed by a wash in 15 % complete SMC media (Table 2.1) 
and then incubated at 37ºC in 5 % CO2 in minimal media until adhesion to the T-
25 flask (approximately 24 h). Subsequently, explants were cultured in 15 % 
complete SMC media at 37ºC in 5 % CO2. HSVSMCs were seen migrating from 
explants. Culture media was changed every 5-7 d and these cells were used up 
to passage of 8. In culture, these HSV SMCs had a hill and valley morphology 
(Chamley-Campbell et al., 1979). Twenty seven individual preparations of 
HSVSMCs were used in this thesis.  
2.2.1.3 Immunocytochemical characterisation of vascular smooth 
muscle cells 
HSVSMCs were identified by immunocytochemistry staining for smooth muscle 
actin (SM-actin). At passage 1, HSVSMCs were harvested and seeded in 8-well 
culture slides (BD Biosciences, Oxford, UK), and incubated at 37ºC in 5 % CO2. 
Media was removed from HSVSMCs once they had reached 80-90 % confluence, 
washed twice in PBS at RT for 5 min each and fixed in 4 % (w/v) 
paraformaldehyde (PFA) at RT for 10 min. HSVSMCs were washed in PBS three 
times, permeabilised in 0.1 % (v/v) triton x-100 in PBS at RT for 10 min, followed 
by three further PBS washes. HSVSMCs were incubated with 0.3 % H2O2 in PBS at 
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RT for 10 min to block endogenous peroxidases, followed by three PBS washes. 
HSVSMCs were incubated in 10 % rabbit serum and 1 % (w/v) bovine serum 
albumin (BSA) in PBS (blocking solution) at RT for 30 min to block non-specific 
binding of antibodies. HSVSMCs were then incubated with 1.4 µg/ml of 
monoclonal mouse anti-human SM-actin IgG2a (clone 1A4) (Dako, Glostrup, 
Denmark) primary antibody or with appropriate isotype-matched mouse primary 
antibody (Dako) at 4oC for 16-18 h in blocking solution, and then washed once in 
0.1 % (v/v) tween20 in PBS to remove unbound primary antibodies, followed by 
two PBS washes. Next, HSVSMCs were incubated with 2.85 µg/ml of polyclonal 
rabbit anti-mouse IgG biotinylated (conjugated with biotin) (Dako) secondary 
antibody in PBS at RT for 1 h and then washed three times in PBS to remove any 
unbound biotinylated secondary antibodies. For enhanced colour intensity and 
detection of primary/biotinylated antibody complex, HSVSMCs were incubated 
with avidin-biotinylated complex (ABC) associated with horseradish peroxidase 
(HRP) at RT for 30 min [from the Vectastain® ABC elite kit (Vector laboratories, 
Peterborough, UK) and prepared according to the manufacturer’s instructions], 
followed by three washes in PBS to remove any unbound ABC reagent. Avidin 
reacts with biotin on the secondary antibodies, forming a larger complex. 
HSVSMCs were incubated with diaminobenzidine (DAB) solution [consisting of 
DAB (chromogen) and hydrogen peroxide (substrate)] (Vector laboratories) until 
cells developed a brown intensity (approximately 1 min) and placed in deionised 
water to stop the reaction. The HRP enzyme catalyses the substrate/chromogen 
reaction to form a brown colour. HSVSMCs were then counter-stained with Harris 
haematoxylin for nucleus staining for 30 seconds (sec), washed in running water, 
dehydrated in ascending ethanol concentrations (70 %, 95 % and 100 %) and 
incubated twice in Histoclear (each for 7 min), before mounting in DPX. HSVSMCs 
were visualised using bright-field microscopy using Olympus BX40 microscope 
(Olympus®, Essex, UK) at either 100 × or 400 × magnification. Micrographs were 
acquired using Hitachi HV-C20A CCD camera (Hitachi®, Maidenhead, UK) for 
digital imaging with ImagePro (MediaCybernetics®, Bethesda, MD, USA). Nuclei 
appeared blue/purple and areas where the primary antibody had bound 
appeared brown. After immuno-staining, approximately 90 % of these isolated 
and cultured HSVSMCs stained positive for the SM-actin marker (Figure 2.1).    
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Figure 2.1. Immunocytochemistry for smooth muscle (SM)-actin in HSV SMCs. 
Immunocytochemistry was carried out on VSMCs in permeabilised conditions. (A) monoclonal 
mouse anti-human SM-actin IgG2a primary antibody (1.4 µg/ml) was used to detect SM-actin. (B) 
Isotype-matched mouse IgG2a primary antibody was used to indicate no non-specific binding of 
the anti-human SM-actin antibody. A polyclonal rabbit anti-mouse IgG biotinylated (2.85 µg/ml) 
secondary antibody was used, followed by avidin-biotinylated complex associated with 
horseradish peroxidase and diaminobenzidine (DAB) which produced a brown colour for positive 
staining. 100 µm scale bar applicable to both panels (magnification × 100).  
2.2.2 Maintenance of established cell lines and primary cells 
Cells were grown as a monolayer and media was replenished every 3-4 d. Cells 
were routinely passaged at approximately 80 % confluence to prevent loss of 
surface contact and overgrowth. To passage, cells were washed twice in PBS and 
incubated in a minimal volume of trypsin-EDTA or citric-saline (as stated in 
Table 2.1) at 37ºC in 5 % CO2, for approximately 5 min or until the majority of 
cells had detached from the flask. The action of trypsin-EDTA or citric saline was 
blocked by the addition of an equal volume of complete media containing serum 
(rich source of trypsin inhibitors). Cells were pelleted by centrifugation at 480 x 
g for 5 min, supernatant removed and resuspended in fresh complete media for 
passaging or plating.  
For intracellular signal transduction assays the following culture media was also 
used: serum-free media/ 0 % serum complete SMC media [MEM supplemented 
with 1 % (v/v) penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 1 mM 
sodium pyruvate] and 1 % serum complete SMC media [MEM supplemented with 1 
% (v/v) FCS, 1 % (v/v) penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 
1 mM sodium pyruvate]. A 30 min incubation with 50 µM Phorbol 12 myristate 13-
acetate (PMA) (Sigma-Aldrich) in 0 % serum complete SMC media was used as a 
positive control of the activation of ERK 1 & 2 intracellular signal transduction in 
VSMCs.  
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For plating, cells were counted using a haemocytometer (Hausser Scientific, 
Horsham, Pa. USA) for the required cell density. A cover-slip was placed on the 
haemocytometer grid and 10 µl of the cell suspension was applied to the grid 
under the cover-slip. The number of cells per ml was determined by counting 
the number of cells in 4 sets of 16 corner squares, followed by the average 
number of cells in 1 set of 16 corner squares and multiplied by 104. To determine 
the volume of cell suspension required for a specific cell density/well, the 
following equation was used:  
 
 
 
 
 
                   
 
2.2.3 Cryopreservation and recovery of cultured cell lines and 
primary cells 
Cells were harvested as described above (section 2.2.2) and resuspended at a 
density of approximately 1-2 x107 cells/ml for primary cells or 1-2 x106 cells/ml 
for cell lines in cryo-preservation media [complete cell culture media 
supplemented with 10 % (v/v) dimethyl sulphoxide (DMSO) (removed ice crystal 
formation and partially solubilised the cell membrane) and sterile-filtered]. 1 ml 
of the cell suspensions were aliquoted into sterile 2 ml cryo-preservation vials 
and cooled at a constant -1ºC/min at -80oC using isopropanol.  Vials were then 
transferred to liquid nitrogen and stored indefinitely until required. 
For resuscitation, cryo-preserved cells were removed from liquid nitrogen, 
thawed at 37ºC in minimal time required (approximately 1-2 min) and then 
added drop-wise to 10 ml of pre-warmed complete culture media (Table 2.1). 
Cells were then pelleted (section 2.2.2), supernatant discarded (to remove 
DMSO), resuspended in complete culture media and transferred to a T-25 flask. 
Cells were then incubated overnight at 37ºC and the complete culture media 
changed.   
     cell density required 
 
number of cells × 104/ml in cell suspension 
 
 
= ml of cell suspension 
required/ well. 
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2.3  Plasmid DNA 
2.3.1 Transformation of competent bacteria 
All bacterial culturing was performed in sterile conditions using biological safety 
class II vertical laminar flow cabinets. Cells were grown in 37ºC incubators. DNA 
is a hydrophilic molecule and is naturally repelled by the cell membrane. As a 
result, bacteria have to be made ‘competent’ by producing small pores in the 
bacterial cell wall and membrane, by suspending the cells in ice cold 50 mM 
CaCl2 repeatedly.  Competent E.coli cells were used to transform plasmid DNA; 
these were JM109 cells (Promega, Southampton, UK), XL-1 blue cells or XL-10 
gold cells (both from Stratagene-Agilent Technologies, Wokingham, UK) (Table 
2.2). Competent bacterial cells were thawed gently on ice for approximately 5 
min. 50 µl of competent cells were transferred into pre-cooled 1.5 ml micro-
centrifuge tubes and incubated on ice for 10 min with shaking every 2 min. For 
XL-10 gold cells, an additional 2 µl of β-mercaptoethanol was added to increase 
transformation efficiency. To each 50 µl aliquot, 1 µl of unknown concentration 
or approximately 10 ng-50 ng of plasmid DNA was added, mixed and kept on ice 
for 30 min, allowing the plasmid DNA to bind to the cell wall and membrane and 
enter through the small pore. Cells were then subjected to heat shock at 42ºC 
for 40 sec and immediately returned to ice for a further 2 min. Cells were 
removed from the ice and 1 ml of RT SOC (Super Optimal broth with Catabolite 
repression) media (20g/l bactotryptone, 5 g/l yeast extract, 10 mM NaCl, 2.5 mM 
KCl and 20 mM glucose) was added to each aliquot, followed by 1 h incubation at 
37ºC in an orbital shaker at 180 rpm, to allow the expression of the newly 
acquired plasmid DNA. 20 µl or 200 µl of bacterial transformation cultures were 
spread onto Luria-Bertani (LB) agar plates (10 g/l bactotryptone, 5 g/l 
bactoyeast extract, 5 g/l NaCl and 15 g/l agar and pH 7.5) with 100 µg/ml of 
ampicillin [all DNA plasmids used in the study were ampicillin resistant (as 
described in Table 2.2)]. Plates were kept in a 37ºC incubator overnight, to 
allow the growth of antibiotic resistant transformant colonies.  
2.3.2 Glycerol stocks of transformed competent bacteria 
For archiving of plasmid DNA transformant colonies (Table 2.2), glycerol stocks 
were generated. A single colony was picked from a freshly spread/streaked (LB 
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agar plate with ampicillin and amplified in 5 ml of LB broth with 100 µg/ml of 
ampicillin for 8 h (for mid-log phase) at 37ºC with shaking at 180 rpm. Glycerol 
stocks consisted of 30 % (v/v) sterile glycerol and 70 % (v/v) of plasmid DNA 
transformant bacteria in 2 ml sterile cryo-preservation vials. Glycerol stocks 
were mixed thoroughly by vortexing and stored at -80ºC until required for 
streaking on LB agar plate with ampicillin.  
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DNA plasmid name Description of DNA plasmid Plasmid 
specificity 
Reference Antibiotic 
resistance
Competent bacteria used 
in transformation
pHR’SIN-cPPT-SFFV-eGFP-WPRE Lentiviral vector construct with spleen focus 
forming virus  (SFFV) promoter and cDNA 
encoding enhanced green fluorescent protein 
(eGFP)
Lentiviral 
vector 
construct 
plasmid
Demaison et al., 2002 Ampicillin JM109
pHR’SIN-cPPT-UCOE-eGFP-WPRE Lentiviral vector construct with enhancer-less 
ubiquitously acting chromatin opening 
element (UCOE) promoter and cDNA encoding 
eGFP
Lentiviral 
vector 
construct 
plasmid
Zhang,et al., 2007 Ampicillin XL-10 gold
pCMV delta R8.74 Wild-type integrase gene Second-
generation 
packaging 
plasmid
Yanez-Munoz et al., 
2006
Ampicillin JM109
pCMV delta R8.74 D64V Integrase-deficient gene (D64V point 
mutation)
Second-
generation 
packaging 
plasmid
Yanez-Munoz et al., 
2006
Ampicillin JM109
pMD.G2 Vesicular stomatitis virus-glycoprotein 
envelope (VSV-g)
Envelope 
plasmid
Zhang et al., 2007 Ampicillin JM109
pHCMVwhvGP64 Baculovirus gp64 glycoprotein envelope 
(GP64)
Envelope 
plasmid
Sinn et al., 2005 Ampicillin JM109
pEZGP Ebola Zaire glycoprotein envelope Envelope 
plasmid
Sinn et al., 2003 Ampicillin JM109
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DNA plasmid name Description of DNA plasmid Plasmid 
specificity 
Reference Antibiotic 
resistance
Competent bacteria used 
in transformation
pRRV-E2E1 Ross River Virus  glycoprotein envelope (RRV) Envelope 
plasmid
Kang et al., 2002 Ampicillin JM109
pHIT456(MLV-A) Murine Leukaemia Virus-Amphotropic  
glycoprotein envelope (MLV-A)
Envelope 
plasmid
Lodge et al., 1998 Ampicillin JM109
pEcoMLVEnv Murine Leukaemia Virus-Ecotropic  
glycoprotein envelope
Envelope 
plasmid
Koch et al., 2006 Ampicillin JM109
pHNTV-M Hantavirus glycoprotein envelope (HNTV) Envelope 
plasmid
Qian et al., 2006 Ampicillin XL-1 blue
pLP-RVG Rabies glycoprotein envelope Envelope 
plasmid
Rahim et al., 2009 Ampicillin JM109
pHR’SIN-cPPT-SFFV-MCS-WPRE Lentiviral vector construct with SFFV 
promoter and multiple cloning site (MCS)
Lentiviral 
vector 
construct 
plasmid
Ward et al., 2011 Ampicillin JM109
pHR'SIN-cPPT-SFFV-fulllengthNogo-B-
WPRE
Lentiviral vector construct with SFFV 
promoter and cDNA encoding full length Nogo-
B
Lentiviral 
vector 
construct 
plasmid
See Chapter 4 Ampicillin JM109
pHR'SIN-cPPT-SFFV-mutantNogo-B-
WPRE
Lentiviral vector construct with SFFV 
promoter and cDNA encoding mutant Nogo-B
Lentiviral 
vector 
construct 
plasmid
See Chapter 4 Ampicillin JM109
 
Table 2.2. Plasmid DNA used to produce lentiviral vectors.  
SIN, self-inactivating; cPPT, central polypurine tract; WPRE, woodchuck post-transcriptional regulatory element. 
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2.4 Plasmid preparation 
2.4.1 Plasmid DNA isolation and purification from bacterial 
cells  
Plasmid DNA was isolated and purified using either the QIAprep® Miniprep kit or 
the QIAGEN® plasmid purification Maxi kit (Qiagen, Crawley, UK) from bacterial 
cells. 
2.4.1.1  Small scale preparation of plasmid DNA (Miniprep) 
The QIAprep® Miniprep kit was used for fast and cost-effective isolation, and 
purification of approximately 20 µg of plasmid DNA. In this protocol, bacteria 
were lysed under alkaline [sodium hydroxide (NaOH)/ sodium dodecyl sulphate 
(SDS)] conditions, and then applied to the QIAprep spin columns which consisted 
of a silica gel membrane that mediated the binding of DNA in the presence of a 
high-salt buffer, followed by several washes to remove impurities and finally 
pure plasmid DNA was eluted in low-salt buffer.  
This small scale isolation and purification of plasmid DNA was carried out 
according to the manufacturer’s instructions. Briefly, a single colony was picked 
from a freshly spread or streaked LB agar plate with ampicillin, and amplified in 
5 ml of LB broth with ampicillin for 12-16 h (stationary phase) at 37ºC in an 
orbital shaker at 180 rpm. Harvested bacterial cells were centrifuged at 6800 x g 
for 3 min at RT. Pelleted bacterial cells were resuspended in 250 µl of P1 buffer 
[containing Tris-HCl (pH 8.0) and EDTA] with 100 µg/ml of ribonuclease A (RNase 
A) to allow degradation of bacterial RNA. EDTA chelates divalent metals (i.e. 
Mg2+ and Ca2+) and the removal of these cations destabilises the bacterial cell 
wall, which allows P2 buffer to reach the peptidoglycan cell wall for 
degradation. EDTA chelates Mg2+ ions, which are required for function of 
deoxyribonucleases (DNases), and therefore prevents any degradation of plasmid 
DNA during isolation. Tris-HCl provides isotonic conditions to stop the bacterial 
cells bursting open during re-suspension. 250 µl of P2 lysis buffer [containing 
NaOH (alkaline conditions) and SDS] was then added for bacterial cell lysis and 
mixed thoroughly by inverting 4-6 times. NaOH loosens the cell wall. SDS is a 
detergent which disrupts the cell membrane by denaturing cell membrane 
proteins. Subsequently, this results in the release of plasmid DNA and sheared 
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cellular DNA from these cells. NaOH denatures cellular DNA by producing 
linearization and separation of strands. NaOH also denatures RNA, whereas 
plasmid DNA is circular and remains topologically constrained and intact. Taken 
together, the addition of lysis buffer (NaOH/SDS) aids in the denaturing of 
proteins, RNA and cellular DNA and the release of plasmid DNA from bacterial 
cell lysates. Lysis buffer was then neutralised with the addition of 350 µl of N3 
buffer (containing guanidine hydrochloride and acetic acid) and mixed 
immediately by inverting 4-6 times. N3 buffer adjusts the conditions to high-salt 
binding and causes cellular debris, protein, cellular DNA and SDS to precipitate; 
leaving the plasmid DNA in solution. Samples were subjected to centrifugation at 
17900 x g for 10 min at RT, supernatant (containing plasmid DNA, along with 
some RNA and protein contaminants) was then transferred to the QIAprep spin 
column to allow binding of plasmid DNA to the silica gel membrane, followed by 
centrifugation at 17900 x g for 1 min at RT and flow-through was discarded. The 
bound plasmid DNA was washed with 500 µl of buffer PB (containing guanidine 
hydrochloride and isopropanol) to remove endonucleases, RNA and protein, and 
centrifuged at 17900 x g for 1 min at RT and flow-through was discarded. A 
further wash with 750 µl of buffer PE (containing ethanol) was used to remove 
salts, RNA and protein and to ensure DNA-silica membrane bonds remain intact, 
followed by centrifugation at 17900 x g for 1 min at RT and flow-through was 
discarded. Plasmid DNA was subjected to additional centrifugation at 17900 x g 
for 1 min at RT to remove residual wash buffer. Next, plasmid DNA was finally 
eluted after 1 min incubation with 50 µl of nuclease-free water, followed by 
centrifugation at 17900 x g for 1 min at RT.  
2.4.1.2  Large scale preparation of plasmid DNA (maxiprep) 
The QIAGEN® plasmid purification Maxi kit was used for fast isolation and 
purification of approximately 500 µg plasmid DNA (transfection grade/ultrapure 
plasmid DNA). This protocol is based on the same principles of alkaline bacterial 
cell lysis as mentioned in section 2.4.1.1 plasmid DNA miniprep. However, in this 
procedure, bacterial cell lysates were applied into anion-exchange-based 
QIAGEN-tip 500 columns. This anion-exchange chromatography is based on the 
interaction of negatively charged plasmid DNA under appropriate low-salt and pH 
conditions, with a positively charged solid phase of the anion-exchange matrix 
(within the column). RNA, proteins and low molecular weight impurities were 
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removed by a medium salt wash and finally plasmid DNA was eluted under high-
salt conditions (via a high concentration of counter ions i.e. chloride).  
This large scale isolation and purification of plasmid DNA was carried out 
according to manufacturer’s instructions. Briefly, a single colony was picked 
from a freshly streaked LB agar plate with ampicillin, and used to inoculate a 
starter culture of 5 ml of LB broth with ampicillin for 8 h at 37oC in an orbital 
shaker at 180 rpm. This starter culture was then diluted into 500 ml of LB broth 
with ampicillin, for amplification during 12-16 h at 37oC in an orbital shaker at 
180 rpm. Bacterial cells were harvested by centrifugation at 6000 x g for 15 min 
at 4ºC. Bacterial pellet was resuspended in 10 ml P1 buffer with RNase A, and 
then lysed by the addition of 10 ml P2 lysis buffer (NaOH/SDS), mixed thoroughly 
by vigorously inverting 4-6 times and incubated at RT for 5 min. Next, 10 ml of 
chilled buffer P3 was added, mixed immediately and thoroughly by vigorously 
inverting 4-6 times, and incubated on ice for 20 min. Buffer P3 is a 
neutralisation buffer containing acidic potassium acetate. This incubation step 
triggers precipitation of potassium dodecyl sulphate, which traps denatured 
proteins, cellular DNA and cell debris, and leaves plasmid DNA in solution. 
Bacterial cell lysate was then centrifuged at 20000 x g for 30 min at 4ºC and the 
supernatant (containing the plasmid DNA, along with RNA, protein and low 
molecular weight contaminants) was removed. A QIAGEN-tip 500 was 
equilibrated by addition of 10 ml buffer QBT [containing 750 mM NaCl, 50 mM 
MOPS (pH 7.0), 15 % (v/v) isopropanol and 0.15 % (v/v) Triton® X -100] and 
allowed to empty by gravity flow at RT. The supernatant was transferred to 
anion-exchange-based QIAGEN®-tip and allowed to enter the resin by gravity 
flow. This step allows plasmid DNA to selectively bind to the column under low-
salt and pH conditions. The QIAGEN-tip was washed twice with 30 ml of buffer 
QC, a medium-salt wash [containing 1.0 M NaCl, 50 mM MOPS (pH 7.0), 15 % 
(v/v) isopropanol], at RT. QC buffer removes residual RNA, proteins, metabolites 
and other low-molecular weight impurities. The plasmid DNA was then eluted 
from the QIAGEN-tip by addition of 15 ml buffer QF, a high-salt buffer 
[containing 1.25 M NaCl, 50 mM Tris-HCl (pH 8.5), 15 % (v/v) isopropanol], at RT. 
Plasmid DNA was then precipitated by adding 10.5 ml of isopropanol at RT. 
Isopropanol-based DNA precipitation also aides in the concentration and 
desalting of plasmid DNA. Precipitated plasmid DNA was mixed and centrifuged 
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immediately at 15000 x g for 30 min at 4ºC. Supernatant was then removed and 
the pellet washed by an addition of 5 ml of 70 % (v/v) ethanol and centrifuged at 
15000 x g for 10 min at RT. Next, supernatant was removed and the pellet was 
air-dried for 5 min at RT. Plasmid DNA was then re-dissolved in 200 µl of 
nuclease-free water before quantification of yield and measurement of purity by 
NanoDrop™ (section 2.5). Ethanol removes precipitated salts and replaces 
isopropanol because it is more volatile, therefore allows plasmid DNA to re-
dissolve in nuclease-free water easier. 
2.5 Quantification of nucleic acids 
DNA was quantified using NanoDrop™ 1000 Spectrophotometer and ND-1000 
v3.1.0 software (Thermo Scientific, Loughborough, UK). This apparatus detects 
and measures the pulse light produced by a xenon flash lamp that passes through 
the sample, using a linear charged-coupled device (CCD) array. The wavelength 
of maximum absorption of light by RNA and DNA is 260 nm [UltraViolet light (UV) 
spectrophotometry at 260nm=λmax (wavelength of maximum absorption)] due to 
conjugated double bonds present in their constituent bases. The absorption 
properties of nucleic acids are used for detection, quantification and for purity 
measure. The amount of DNA was calculated and based on the modified Beer-
Lambert equation, with ng/µl as units. The equation is as follows: 
c= (A × ε)/b  
c= the nucleic acid concentration in ng/µl 
A=the absorbance in arbitrary units (AU) 
ε= the wavelength-dependent extinction coefficient in ng/µl 
b= the path-length in cm 
The extinction coefficients used for nucleic acids are as the following:  
Doubled-stranded DNA: 50 ng/µl 
Single-stranded DNA: 33 ng/µl 
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RNA: 40 ng/µl 
The purity of the nucleic acid was determined and assessed by calculating 
A260:A280 ratio. A ratio of 1.8-2 was considered pure and a value below 1.6 
indicates protein contamination. 
2.6 Restriction endonuclease digestion 
Restriction endonuclease digestion is a procedure that cuts double stranded DNA 
by the action of type II restriction endonucleases. Restriction endonucleases 
produce either ‘sticky’ ends or ‘blunt’ ends, facilitating the ligation of 
nucleotide sequences with complementary ‘sticky’ ends or ‘blunt’ ends 
respectively, which then generates recombinant plasmid DNA molecules. 
Restriction endonuclease digestions were used for general diagnostics during 
plasmid DNA isolation and purification (section 2.4) or for preparation of plasmid 
DNA for cloning procedures (section 2.8). For general plasmid DNA diagnostic 
digests (Table 2.3 and Figure 2.2), 250-500 ng of plasmid DNA was digested in a 
50 µl single or double restriction endonuclease digestion reaction, containing 10 
U (unit of restriction enzyme activity) (1 µl) of each specific restriction enzyme 
(Promega Southampton, UK) and 5 µl of the appropriate 5 × reaction buffer 
(Table 2.3). The total reaction volume of 50 µl was made up with nuclease-free 
water. For preparing plasmid DNA for lentiviral vector cloning procedures in this 
thesis (section 2.8), 1-10 µg of plasmid DNA was digested in a 50µl restriction 
endonuclease digestion reaction (with BamHI & XhoI). Each restriction 
endonuclease digestion reaction was then mixed gently, centrifuged briefly and 
incubated at 37ºC for 2 h. Completed reactions were analysed via agarose gel 
electrophoresis (section 2.7). 
2.7 Gel electrophoresis 
Gel electrophoresis is used to separate nucleic acids (section 2.7.1) or proteins 
(section 2.13.8.1) using crosslinked polymers within an electrical current. DNA 
molecules and protein are negatively charged. When applying electrical current, 
samples migrate through the gel from the cathode towards the anode, and 
separation is dependent on their molecular size through the crosslinked polymers 
(the pores of the gel). The two main types of gel are agarose and acrylamide. 
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2.7.1 Agarose gel electrophoresis 
Agarose gel electrophoresis is typically used for analysing polymerase chain 
reaction (PCR) fragments or restriction endonuclease digest reactions. Complete 
reaction samples (section 2.6) were electrophoresed through a 1 % (w/v) agarose 
(Invitrogen) gel in 1 x Tris/Borate/EDTA (TBE) [89 mM Tris-base, 89 mM boric 
acid, 2 mM EDTA, pH 8.0, (Fisher Bioreagents, Loughborough, UK)] and ethidium 
bromide (10ng/ml). Samples and DNA size markers [100 base pairs (bp) and/or 1 
kilobase pairs (kbp) DNA ladders, depending on the size of the fragment of 
interest (Promega)] were mixed with 6x blue/orange loading dye for a 1 x final 
concentration [0.4 % orange G, 0.03 % bromophenol blue, 0.03 % xylene cyanol 
FF, 15 % Ficoll® 400, 10 mM Tris-HCl (pH 7.5) and 50 mM EDTA (pH 8.0) 
(Promega)] ready for loading into the gel electrophoresis pre-cast-wells/lanes 
and for tracking migration during electrophoresis (xylene cyanol FF migrates at 
approximately 4 kbp, bromophenol blue at approximately 300 bp and orange G 
at approximately 50 bp). Agarose gels were electrophoresed at a constant 
voltage (V) of 90 to 100 V with a running buffer of 1 x TBE. Plasmid DNA were 
visualised using Molecular Imager® ChemiDoc™ XRS+ Imaging System with Image 
Lab™ software by UV transillumination (Bio-Rad Laboratories, Hemel Hempstead, 
UK). 
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Plasmids DNA Size of plasmid DNA,
base pairs (bp)
Plasmid DNA diagnostic restriction
endonuclease digest (Promega)
Buffer used in
digestion (Promega)
Plasmid DNA
fragments (bp)
Xba I                   Buffer D 1100 & 8600
Nhe I Buffer B 2200 & 7500
pHR’SIN-cPPT-UCOE-eGFP-WPRE 11156 Pvu  II Buffer B 5914, 3064 & 2850
pCMV delta R8.74 11921 Pvu I & Sal I Buffer D 8663 & 3258
pCMV delta R8.74 D64V 11921 Pvu I & Sal I Buffer D 8663 & 3258
pMD.G2 5824 Nde I Buffer D 3651, 1556 & 617
pLP-RVG 5736 Eco RI Buffer H 2927 & 1345
pEcoMLVEnv 9761 Nde I & Pvu I Buffer D 1438 & 8323
Bam HI & Xho I Buffer C 8921 & 10
Sac II Buffer C 8931
Nhe I Buffer B 7246 & 1685
Xba I                   Buffer D 7970 & 961
Bam HI & Xho I Buffer C 8921 & 1163
Sac II Buffer C 8535 & 1549
Nhe I Buffer B 7246 & 2838
Xba I                   Buffer D 9123 & 961
Bam HI & Xho I Buffer C 8921 & 614
Sac II Buffer C 8535 & 1000
Nhe I Buffer B 7246 & 2289
Xba I                   Buffer D 8574 & 961
pHR’SIN-cPPT-SFFV-eGFP-WPRE 9662
pHR'SIN-cPPT-SFFV-mutantNogo-B-WPRE 9535
pHR’SIN-cPPT-SFFV-MCS-WPRE 8931
pHR'SIN-cPPT-SFFV-fulllengthNogo-B-WPRE 10084
 
Table 2.3. Restriction endonucleases used in plasmid DNA diagnostic digestions. 
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Figure 2.2. Plasmid DNA maps including restriction endonuclease recognition sites.  
(A) pHR'SIN-cPPT-SFFV-eGFP-WPRE (lentiviral vector construct) plasmid, (B) pHR'SIN-cPPT-UCOE-
eGFP-WPRE (lentiviral vector construct) plasmid, (C) pCMV delta R8.74/R8.74D64V (second-
generation packaging) plasmid, (D) pMD.G2 [vesicular stomatitis virus-glycoprotein (VSV-g)] 
plasmid, (E) pLP-RVG (rabies glycoprotein) plasmid and (F) pEcoMLVEnv [murine leukaemia virus-
ecotropic (MLV-E) glycoprotein] plasmid. LTR, long terminal repeat; bp, base pairs; cPPT, central 
polypurine tract; WPRE, Woodchuck post-transcriptional regulatory element; SFFV, spleen focus 
forming virus promoter; UCOE, enhancer-less ubiquitously acting chromatin opening element; 
eGFP, enhanced green fluorescent protein; RRE, Rev responsive element; Ψ, packaging 
sequence/signal; HIV-1 3’ del U3 LTR, partial deletion in the U3 region of the 3’ LTR; RVG, rabies 
virus glycoprotein. 
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2.8 Cloning of Nogo-B into the lentiviral vector construct 
plasmid 
Nogo-B was the transgene of interest; cDNA of Nogo-B was cloned into lentiviral 
vector construct/transfer plasmid DNA for the production of lentiviral vectors 
expressing Nogo-B (section 2.9). Full-length Nogo-B-haemaglutinin tagged cDNA 
(insert 1.2 kbp between KpnI and XbaI restriction sites) in a pcDNA3 plasmid 
(full-length Nogo-B) and Nogo-B 1-200 (soluble/mutant Nogo-B) cDNA (insert 603 
bp between HindIII and XhoI restriction sites) in a pSectag2 plasmid with a myc-
6xhistidine tag, were sent concentrated on filter paper [sent from William 
Sessa’s lab, University of Yale, USA (Acevedo et al., 2004)] and reconstituted 
into 50 µl of nuclease-free water. The full-length Nogo-B plasmid and mutant 
(soluble) Nogo-B plasmid (both ampicillin resistant) were transformed into XL-10 
gold and XL-1 blue competent bacterial cells, respectively (section 2.3.1) 
Ampicillin resistant transformant colonies were then amplified, and plasmid DNA 
isolated and purified using QIAprep Miniprep kit (section 2.4.1.1).  
2.8.1 Polymerase Chain Reaction (PCR)  
2.8.1.1 Nogo-B strategy for PCR cloning  
Forward and reverse oligonucleotide primers were designed, each 
complementary to both 3’ prime ends of the double stranded cDNA target 
sequence of either full-length or mutant Nogo-B (as described in Table 2.4 for 
primer design and labelled red), with added restriction enzyme recognition sites 
BamHI and XhoI at 5’ ends of PCR primers (labelled blue) (see Appendix 1 for 
complete cDNA sequences of full-length Nogo-B and mutant Nogo-B). With 
regards to the justification of selected primers for mutant Nogo-B: the forward 
primer was the same design used for full-length Nogo-B, and the reverse primer 
was designed 600 bp downstream from the start codon with an addition of a stop 
codon. Oligonucleotide primers were resuspended in nuclease-free water 
(Ambion-Applied Biosystems, Warrington, UK) to a concentration of 10 pmol/µl. 
For the amplification of plasmid PCR targets, Herculase® II fusion DNA 
polymerase (Stratagene-Agilent Technologies) was used according to the 
manufacturer’s instructions. Herculase® II fusion DNA polymerase was used 
because of its special enzyme formulation and optimised buffer system, which 
ensures high-fidelity PCR (excellent 3’ to 5’ proof-reading exonuclease activity) 
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and successful amplification of difficult GC-rich targets. ArchaeMaxx® 
polymerase enhancing factor was also included, which provides superior yield 
and excellent reliability with shorter cycling times. Briefly, for each 50 µl PCR 
reaction, the following was added: 50 ng of plasmid DNA, 1 µl of Herculase II 
fusion DNA polymerase, 0.5 µl dNTP mix (each dNTP added at 25 mM), 10 µl of 5 
x Herculase II reaction buffer [final concentration of 2 mM Mg2+ (a cofactor for 
this thermostable DNA polymerase, and excessive Mg2+ aids stabilisation of 
double-stranded DNA and inhibits denaturation of DNA products at each cycle)], 
1 µl of each primer (forward and reverse) (Table 2.4) added at 10 pmol/µl (10 
µM) and then made up to 50 µl volume with nuclease-free water.  
Each PCR reaction was completed in a Tetrad high-throughput PCR machine and 
carried out according to the manufacturer’s instructions. Each PCR reaction was 
subjected to 1 cycle of initial denaturation at 95ºC for 1 min and then followed 
by 40 cycles of the following: 30 sec at 95ºC for denaturation, 30 sec at 65ºC for 
primer annealing to the template plasmid DNA and 1.15 min at 74ºC for optimal 
polymerisation (chain extension). Finally, each PCR reaction was subjected to 
ligation at 74ºC for 5 min and 12ºC thereon. PCR products were then isolated 
using 1 % agarose gel electrophoresis (section 2.7.1) for 1.5 h. PCR products at 
approximately 1.2 kbp and 603 bp for full-length Nogo-B and mutant Nogo-B, 
respectively, were visualised alongside a 100 bp and 1 kbp DNA ladder using UV 
transillumination and then excised from the 1 % agarose gel using a clean 
scalpel.  
 
Table 2.4. Primers design for Nogo-B strategy for PCR cloning. 
 
2.8.2 PCR or restriction endonuclease digestion product 
purification from agarose gel 
PCR products or excised DNA fragments following restriction endonuclease 
digestions were subjected to extraction and purification to eliminate excess 
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nucleotides, primers or enzyme reaction reagents. The Wizard® SV Gel and PCR 
Clean-Up System (Promega) was used because of its fast silica membrane-based 
system which is designed to isolate and purify up to 40 µg DNA fragments 
between 100 bp to 10 kbp. This kit was used following the manufacturer’s 
instructions. Briefly, following separation of PCR products or excised DNA 
fragments by agarose gel electrophoresis, each gel portion containing the DNA 
segment of interest at the correct size was cut with a clean scalpel and 
transferred into a clean 1.5 ml micro-centrifuge tube. Next, 10 µl of membrane 
binding solution [containing 4.5 M guanidine isothiocyanate and 0.5 M potassium 
acetate (pH 5.0) (chaotropic salts)] was added per 10 mg of gel slice, vortexed 
and incubated at 65ºC for 10 min until the gel was fully dissolved. The SV mini-
column was inserted into a collection tube. Each dissolved gel mixture was then 
transferred to a SV mini-column, incubated at RT for 1 min to allow binding of 
DNA to the silica-membrane within the column and then subjected to 
centrifugation at 16000 x g for 1 min to discard flow-through containing agarose 
gel contaminants and excess nucleotides, primers and enzyme reaction reagents. 
Each mini-column was washed twice with washing solution [containing 10 mM 
potassium acetate (pH 5.0), 16.7 µM EDTA (pH 8.0) and 80 % ethanol] with 700 µl 
and 500 µl, respectively, and each wash was subjected to centrifugation at 
16000 x g for 1 min to discard flow-through. Ethanolic wash buffer eliminates 
impurities, washes away chaotropic salts from the silica-membrane and ensures 
DNA-silica membrane bonds remain intact. Next, each mini-column was 
centrifuged at 16000 x g for 5 min, flow-through discarded and subjected to 
centrifugation at 16000 x g for 1 min at RT with the micro-centrifuge tube lid 
open to allow evaporation of any residual ethanol. Each mini-column was 
transferred to a clean 1.5 ml micro-centrifuge tube, and DNA bound to the 
silica-membrane of the mini-column was incubated with 50 µl of nuclease-free 
water for 1 min at RT and then centrifuged at 16000 x g for 1 min at RT to elute 
gel-purified DNA. DNA was stored at 4ºC or -20ºC, depending on when required. 
2.8.3 Intermediate plasmid preparation 
The StrataClone™ Blunt PCR Cloning kit was used to clone blunt-ended PCR 
products of either full-length Nogo-B or mutant Nogo-B into an intermediate 
plasmid. This StrataClone™ Blunt PCR Cloning kit provided highly efficient, 5 min 
cloning of blunt-ended PCR products.  
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The StrataClone™ Blunt PCR Cloning kit was used according to manufacturer’s 
instructions. Briefly, each StrataClone™ blunt-ended PCR cloning reaction 
mixture was prepared by combining the following components and in this order 
and mixed gently by repeated pipetting: 3 µl of StrataClone™ Cloning Buffer 
(optimal conditions for DNA topoisomerase I and Cre recombinase to function), 2 
µl of approximately 50 ng of blunt-ended PCR product or StrataClone™ Blunt 
Control Insert, and then 1 µl StrataClone™ Vector Mix. The StrataClone™ Vector 
Mix [StrataClone PCR Cloning Vector pSC-B-amp/kan (ampicillin/kanamycin)] 
contains two blunt-ended DNA arms, each charged with topoisomerase I on one 
end and containing a loxP recognition sequence on the other end (Figure 2.3). 
Blunt-ended PCR products were efficiently ligated between these two 
topoisomerase I-charged vector arms in a 5 min RT reaction, and then placed on 
ice (Figure 2.3).  
This linear molecule was then transformed into StrataClone™ SoloPack 
competent cell line engineered to transiently express Cre recombinase. Cre 
recombinase catalyses the recombination between the two loxP recognition 
sequences on the ends of the linear molecule and creates a circular DNA 
molecule, which is proficient for replication in bacterial cells grown in LB broth 
with ampicillin. StrataClone™ SoloPack competent cells were used according to 
manufacturer’s instructions. Briefly, for each transformation reaction, an aliquot 
of StrataClone™ SoloPack competent cells were thawed on ice for approximately 
5 min and then gently mixed. Per transformation reaction, 1 µl of the completed 
StrataClone™ blunt-ended PCR cloning reaction mixture (of either the blunt-
ended PCR product or StrataClone™ Blunt Control Insert) was added to 
StrataClone™ SoloPack competent cells. StrataClone™ Blunt Control Insert 
transformation reactions were completed to ensure efficiency of DNA 
topoisomerase I and Cre-induced recombination activity and this was performed 
in duplicate. For transformation efficiency of these component bacterial cells, 
extra transformations were performed with or without pUC18 control DNA, in 
duplicate. For the pUC18 transformation control, the provided pUC18 DNA was 
diluted in sterile deionised water (dH2O) at a 1:10 dilution and then 1 µl of 
diluted pUC18 DNA to an aliquot of StrataClone™ SoloPack competent cells. 
Transformation reactions were gently mixed and incubated on ice for 20 min. 
Next, each transformation reaction was heat-shocked at 42ºC for 45 sec, 
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followed by an addition of 250 µl of pre-heated (42ºC) SOC media and then these 
transformation reactions were incubated at 37ºC for 1 h with agitation. For 
blunt-ended PCR product, StrataClone™ Blunt Control Insert or pUC18 control, 5 
µl, 25 µl or 100 µl of each transformation mixture was plated on LB agar plates 
with ampicillin and 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) 
(containing 40 µl of 2 % X-gal on each plate). Plus, 30 µl of pUC18 control (with 
or without plasmid) or 25 µl of the StrataClone™ Blunt Control Insert 
transformation reactions were plated on LB agar-ampicillin plates. All plates 
were then incubated at 37ºC overnight.  
Blue-white screening of blunt-ended PCR product transformation reactions were 
carried out. Positive transformant colonies with the StrataClone blunt-ended 
PCR Cloning Vector pSC-B-amp/kan plasmid appeared white (not blue). This is 
because, the insertion of a blunt-ended PCR product within the lacZ’ gene 
cassette prevents its function, and therefore produces no β-galactosidase for the 
X-gal substrate present on these LB agar-ampicillin plates.  
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Figure 2.3. Overview of the StrataClone™ blunt PCR cloning protocol.  
Amp/kan, ampicillin/kanamycin; lacZ’, lacZ’ gene encoding β-galactosidase; MCS, multiple 
cloning site. Diagram adapted from StrataClone™. 
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2.8.4 DNA sequencing 
Determination of a DNA sequence was completed using the 2’, 3’-
dideoxynucleotide triphosphate (ddNTP) sequencing technique. This procedure is 
based on the use of ddNTPs and each of the four ddNTPs is labelled with a 
specific fluorophore. These ddNTPs have a missing hydroxyl group at the 3’ 
position, making it impossible for another nucleotide to bind. This resulted in a 
series of different size DNA fragments, which are visualised through the last 
nucleotide incorporated as a fluorescent labelled ddNTP. The DNA analyser 
utilised a laser beam focused in a constant position on the capillary 
electrophoresis, to excite the fluorescence caused by the fluorophore labelled 
ddNTP. According to the different wavelength that each fluorophore emitted, 
the analyser then translated the information from these four different 
nucleotides and generated a DNA sequence (Brown, 2010). 
In order to confirm the cDNA of full-length Nogo-B and mutant Nogo-B were 
correct and had the correct orientation in either the StrataClone PCR Cloning 
Vector pSC-B-amp/kan or the lentiviral vector construct plasmid (pHR'SIN-cPPT-
SFFV-fulllengthNogo-B-WPRE or pHR'SIN-cPPT-SFFV-mutantNogo-B-WPRE), DNA 
sequencing was carried out. Plasmid DNA was isolated from amplified single 
colony of competent bacteria (section 2.4) and each insert was sequenced with 
individual reactions for either forward or reverse strand sequencing. For each 
sequencing reaction the following was added per well on a 96-well plate: 200 ng 
of plasmid DNA; 2 µl of each specific forward or reverse primer (at 2 µM) (Table 
2.5 and Table 2.6); 1 µl of v3.1 Ready Reaction Mix (RRM) [consisting of DNA 
polymerase, dNTPs (deoxynucleotide triphosphates) and labelled ddNTPs] and 5 
µl of 5 × v3.1 sequencing buffer [the two latter from the BigDye® Terminator 
v3.1 cycle sequencing kit (Applied Biosystems, MA, USA)], and then each 
reaction was made up to a final volume of 20 µl with nuclease-free water.  
Each forward or reverse sequencing reaction was completed in a Tetrad high-
throughput PCR machine and carried out according to the manufacturer’s 
instructions. Each sequencing reaction was subjected to 96ºC for 45 sec to 
denature, 50ºC or 55ºC for annealing depending on melting temperature (Tm) of 
forward or reverse primer (Table 2.5 and Table 2.6) for 25 sec and 60ºC for 4 
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min to extend the DNA sequenced fragment until the addition of ddNTP 
terminator. 
For each sequence reaction, a sequence clean-up was performed to efficiently 
eliminate sequencing reaction contaminants that reduce signal strength during 
analysis of the DNA sequence. The sequencing reaction was cleaned with 
Agencourt® CleanSEQ® (Beckman Coulter®, Takeley, UK), following the 
manufacturer’s instructions.  Briefly, 10 µl of RT Agencourt® CleanSEQ® 
(contained paramagnetic beads) was added to each sequencing reaction, 
followed by the addition of 62 µl of 85 % ethanol for precipitation of DNA 
sequencing products. Each sequencing reaction was mixed and centrifuged at 
220 x g for 10 sec at RT to allow selective binding of sequencing strands to 
paramagnetic beads. The plate was then placed on a Agencourt® solid phase 
reversible immobilisation (SPRI) magnetic plate for 2 min at RT, to allow 
separation of the sequencing strands from unincorporated dyes, nucleotides, 
salts and other contaminants. With the plate on the magnet, the plate was then 
inverted on tissue paper and the contaminants in the cleared solution were 
discarded. Next, 150 µl of 85 % ethanol wash was added to each well, mixed well 
and incubated at RT on the magnet for another 2 min. The plate was inverted on 
tissue paper and centrifuged to 80 x g for 10 sec at RT, to remove any remaining 
contaminants. The plate was then left to air-dry for 10 min at RT to remove any 
remaining ethanol present. To each sequencing reaction, 40 µl of nuclease-free 
water was added, re-suspended and placed on the magnet for 2 min at RT, to 
allow elution of purified DNA sequencing products from these paramagnetic 
beads. The 20 µl of purified sequencing product was transferred to a bar-coded 
96-well plate and analysed using an ABI PRISM® 3730 DNA analyser using 
Sequencing analysis v5.2 software (Applied Biosystems, MA, USA).  
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Melting 
temperature 
at ºC (Tm) 
Sequencing 
annealing 
temperature 
(ºC)
Forward 5'-GGAAACAGCTATGACCATG-3' 53 50
Reverse 5'-GTAAAACGACGGCCAGTG-3' 54 50
StrataClone PCR Cloning Vector pSC-B-amp/kan with either full
length Nogo-B or mutant Nogo-B cDNA insert
Sequencing primers for M13 binding site
 
Table 2.5. Primers for sequencing in StrataClone PCR Cloning Vector pSC-B-amp/kan (ampicillin/kanamycin) with either full-length Nogo-B or mutant Nogo-B 
cDNA insert. 
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Melting 
temperature 
at ºC (Tm) 
Sequencing 
annealing 
temperature 
(ºC)
Forward 5'-CAATCAGCCTGCTTCTCG-3' 58 55
Reverse 5'-ATGCCTGCAGGTCGACTCTAG-3' 60 55
Forward 5'-GCAGTCTCGCCCTCCAAG-3' 60 55
Reverse 5'-GAGAGCCAAAATCAGTAGTGTCAG-3' 60 55
Forward 5'-CAATCAGCCTGCTTCTCG-3' 58 55
Reverse 5'-ATGCCTGCAGGTCGACTCTAG-3' 60 55
Sequencing primers 
pHR'SIN-cPPT-SFFV-mutantNogo-B-
WPRE
pHR'SIN-cPPT-SFFV-fulllengthNogo-B-
WPRE
 
Table 2.6. Primers for sequencing the lentiviral vector construct plasmid with either the full-length Nogo-B or mutant Nogo-B cDNA insert. 
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2.8.5 Ligation of Nogo-B cDNA into lentiviral vector construct 
plasmid 
2.8.5.1 Dephosphorylation of plasmid DNA ends 
To prevent re-circularisation and re-ligation of the linearised lentiviral vector 
construct plasmid DNA during ligation reaction, it was important to remove the 
5’ phosphate groups. Shrimp Alkaline Phosphatase (SAP) (Promega) was added to 
catalyse the removal of 5’ phosphate groups after the restriction endonuclease 
digestion and prior to ligation reaction, and was carried out according to the 
manufacturer’s instructions. Per de-phosphorylation reaction (using the 
completed 50 µl restriction endonuclease digestion reaction containing the 
lentiviral vector construct plasmid) the following was added: 10 U of SAP per 5 
µg of plasmid DNA backbone, 5 µl of SAP buffer (at a 10 × concentration) and 4 
µl of nuclease-free water. Each reaction was incubated for 1 h at 37ºC, followed 
by heat-inactivation of the SAP for 15 min at 65ºC. Subsequently, the lentiviral 
vector construct backbone was isolated by using 1 % agarose gel electrophoresis 
(see section 2.7.1), excised from the agarose gel using a clean scalpel and then 
subjected to agarose gel extraction and purification (see section 2.8.2).  
2.8.5.2 Ligation of Nogo-B cDNA into digested lentiviral vector 
construct plasmid DNA 
To ligate cDNA of Nogo-B (phosphorylated) and the de-phosphorylated lentiviral 
vector construct plasmid DNA, T4 DNA ligase (isolated from bacteriophage T4) 
(Biolabs) was added and each ligation reaction was carried out according to 
manufacturer’s instructions. T4 DNA ligase catalyses the formation of a 
phosphodiester bond between juxtaposed 5’ phosphate and 3’ hydroxyl termini. 
Ligation reactions were performed at a ratio of 3:1 of insert:vector. To calculate 
how much insert and the vector to add, to get a 3:1 ratio, the following formula 
was used: 
 
     
 
 
 
 
            
 
(ng of vector ) × (kbp size of insert)  
(kbp size of vector)  
 
× (ratio) = ng of insert 
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For example: ng of cDNA of full-length Nogo-B required 
ng of vector = 100 ng 
kbp size of insert = full-length of Nogo-B, 1.2 
kbp size of the vector = 9 
ng of insert = [(100 × 1.2)/9] × 3 = 40 ng of cDNA of full-length Nogo-B required 
Per ligation reaction the following was also added: 1 µl of T4 DNA ligase for 1 U, 
1 µl of T4 ligase buffer (at a 10 × concentration) and then made to a final 
volume of 10 µl with nuclease-free water. Next, ligation reactions were 
incubated at RT for 1 h, before proceeding to transform into competent bacteria 
to select ampicillin resistant transformant colonies with the complete ligated 
plasmid (section 2.3.1).  
2.9 Lentiviral vectors 
All second-generation, self-inactivating (SIN) HIV-1 based lentiviral vectors (LV) 
were produced using a three-plasmid transient transfection system, as previously 
described (Demaison et al., 2002, Buckley et al., 2008). Details of plasmids used 
in generating these LVs, are listed in Table 2.2.  
2.9.1 Lentiviral vector production 
Low passage 293T cells (Table 2.1) were seeded and grown to approximately 70 
% confluence in T-150 flask, and incubated overnight at 37ºC in 5 % CO2. The 
next day the three-plasmid transient transfection was set-up in a flow cabinet 
(with no light on). The following three plasmids were added to 5 ml of Opti-
MEM® I reduced serum media with GlutaMax™ I (plus containing: 2400 mg/l 
sodium bicarbonate, HEPES, sodium pyruvate, hypoxanthine, thymidine, trace 
elements, growth factors and 1.1 mg/l phenol red) (Invitrogen): 50 µg of the SIN 
HIV-1 based lentiviral vector construct/transfer plasmid encoding for the viral 
genome; 17.5 µg of the envelope plasmid and 32.5 µg of the second-generation 
packaging plasmid (see Table 2.2 for plasmid specificity). The three plasmid 
mixture was then filter-sterilised through a 0.22 µm filter. 10 mM stock of 
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branched polyethylenimine (PEI) (Sigma-Aldrich) with an average molecular 
weight of approximately 25000 was prepared. 10 ml of dH2O was added to 10 ml 
of PEI and mixed by vortex. Approximately 10 ml of 12N HCl was added, with 1 
ml at a time and vortexed. This was then topped up to 41.2 ml with dH2O, mixed 
by vortex and stored in 10 µl aliquots at -80ºC until required. 1 µl of 10 mM of 
PEI was added to 5 ml of Opti-MEM® I reduced serum media with GlutaMax™ I 
and filtered through a 0.22 µm filter, for a final concentration of 2 nM of PEI. 
The three plasmid mix and the 2 nM PEI solution was then mixed together at 1:1 
ratio, and incubated for 20 min at RT to allow plasmid DNA and PEI to form 
polyplexes for transfection. These polyplexes facilitate effective DNA binding 
and protection from lysosomes and high endosomolytic competence for 
translocation to the nucleus, hence superior transfection efficacy can be 
achieved. 293T cells were washed with 10 ml of Opti-MEM® I reduced serum 
media with GlutaMax™ I to dilute remaining 10 % complete MEM. Next, 10 ml of 
DNA/PEI polyplexes were added per T-150 flask of 293T cells and were then 
incubated at 37ºC in 5 % CO2 for 4 h. For a control flask, 10 ml of Opti-MEM® I 
reduced serum media with GlutaMax™ I was added alone. After this three-
plasmid transfection of 4 h, transfection media was removed, 25 ml of fresh 10 % 
complete MEM media was then added per flask and incubated at 37ºC in 5 % CO2. 
Supernatant (containing LVs) was collected at 48 h (this time point collection 
was stored at 4ºC until required and media was replenished with 25 ml of fresh 
10 % complete MEM) and 72 h, and then filtered through a 0.22 µm filter to 
remove cellular debris because of its cytotoxic effect when using in in vitro and 
in vivo.   
2.9.2 Concentration of lentiviral vector production 
It was important to concentrate LV preparations and to resuspend in minimal 
volume of Opti-MEM® I reduced serum media with GlutaMax™ I, for the use in in 
vitro experiments. First, 14 ml ultra-clear centrifuge tubes (Beckman Coulter 
Ltd, Buckinghamshire, UK) were sterilised with 70 % (v/v) ethanol, followed by 
rinsing in sterile PBS and then filtered LV vector supernatants were loaded. 
These tubes were loaded into a SW-32.1 Ti rotor bucket (Beckman Coulter), 
placed in the SW32 Ti rotor (Beckman Coulter) and subjected to 
ultracentrifugation at 90353 x g (23000 rpm) for 1 h and 7 min at 4ºC with 
acceleration at maximum and deceleration at 9, using a Optima L-80 XP 
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UltraCentrifuge (Beckman Coulter). Immediately after ultracentrifugation, 
supernatant was decanted from these tubes carefully without disruption to the 
LV pellet and then left for 2 min to sit upside down on fresh tissue paper to 
remove as much supernatant as possible. Next, these tubes were placed upright, 
50 µl of Opti-MEM® I reduced serum media with GlutaMax™ I was added per tube 
and left to incubate on ice for 20 min for the LV pellet to resuspend. After 20 
min on ice, each tube was subjected to pipetting up and down several times to 
resuspend LV vector pellet. Finally, concentrated LVs were then aliquoted at 20 
µl or 50 µl and stored at -80ºC until required.  
2.10 Determining lentiviral vector titres 
Functional titres of concentrated LV vector preparations were determined. 293T 
cells were seeded in a 12-well plate at a density of 5 x 104/well and incubated 
overnight at 37ºC in 5 % CO2. Serial dilutions of concentrated freeze-thawed LV 
vector [functional LV vectors decrease after freeze-thawing (Higashikawa and 
Chang, 2001)] stocks were prepared, ranging from 1 x 102 to 1 x 106 (termed as 
dilution factor) in 10 % complete MEM media (Demaison et al., 2002). Culture 
media was changed for 1 ml of fresh 10 % complete media, followed by an 
addition of either 30 µl or 100 µl of sequential LV vector dilutions and repeated 
in duplicate. The plate was then incubated in a humidified chamber at 37oC in 5 
% CO2. After 3 d post-infection, TaqMan quantitative PCR titres (see section 
2.10.2) were assessed by quantifying pro-viral LV DNA copy numbers. Only 293T 
cells transduced with LV vectors expressing enhanced green fluorescent protein 
(eGFP) were assessed by fluorescence microscopy (see section 2.13.3 and 2.10.1) 
for a visual eGFP titre. 
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2.10.1 Visual eGFP titre 
Expression of eGFP per well was visualised (section 2.13.3) per sequential LV 
dilutions, and percentage of eGFP visualised was recorded (100 × magnification) 
per field of view in triplicate and an average was taken. An infectious unit of LVs 
per ml (iu/ml) was calculated using this equation: 
 
 
      
       
 
 
 
 
 
 
For example: integrating LV expressing eGFP at a dilution factor of 1 × 102 with a 
volume of inoculum at 0.03 ml gave 82.5 % of eGFP expression when transduced 
on 5 × 104 293T cells.  
[(0.825) × (5 × 104)]/0.03 = 1375000    
1375000 × 100 = 1.375 × 108 iu/ml 
All the sequential dilutions were calculated for iu/ml and used to determine an 
average functional LV titre (iu/ml) (Demaison et al., 2002, Sastry et al., 2002). 
2.10.2 Quantitative Real-Time PCR titre 
2.10.2.1 DNA extraction 
Viral and total genomic DNA was isolated from each well of the LV 12-well plate 
titration assay using the QIAamp® DNA Mini Kit (QIAGEN). This was due to its 
rapid purification of high-quality DNA, and complete removal of contaminants 
and inhibitors of PCR.  
QIAamp® DNA Mini Kit was used according to manufacturer’s instructions. 
Briefly, culture media was removed, 293T cells were gently washed with PBS, 
then 200 µl of PBS was added per well and cells were scraped with a rubber 
 
(% of visual expression/100) × (cell density seeded) 
 
volume of inoculum (ml)  
 
 
 
= iu/ml 
× LV dilution factor 
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policeman. Detached cells were transferred into a fresh micro-centrifuge tube 
and resuspended by pipetting up and down gently. Per tube/sample, 20 µl of 
proteinase K (a subtilisin-like endolytic protease) was added prior to 200 µl of 
optimised lysis buffer AL (containing SDS, EDTA and guanidine hydrochloride), 
and then resuspended and mixed by pulse-vortexing for 15 sec. Proteinase K was 
used because Ca2+ is not essential for its function, therefore EDTA and other 
chelating agents do not interfere with its activity and can be used alongside 
proteinase K to inactivate Ca2+-dependent nucleases in DNA preparations. 
Guanidine hydrochloride is a chaotropic salt, which allows adsorption of DNA 
onto the silica-gel membrane of the QIAamp Spin Column [with similar principle 
to plasmid DNA miniprep isolation (section 2.4.1.1)]. Polysaccharides, RNA, 
proteins and PCR inhibitors-divalent cations do not adsorb, and thus are 
removed. Samples were incubated at 56ºC for 10 min for optimal lysis. 200 µl of 
100 % ethanol was added to each sample, mixed by pulse-vortexing for 15 sec, 
briefly centrifuged to remove drops from inside the lid and then the complete 
sample was loaded onto a QIAamp® spin column. Samples were centrifuged at 
6000 x g for 1 min at RT to allow the DNA to be adsorbed onto the silica-gel 
membrane of the spin column and flow-through discarded. Each spin column was 
washed with 500 µl of buffer AW1 (containing guanidine hydrochloride and 
ethanol) and centrifuged at 6000 x g for 1 min at RT, followed by a second wash 
step with 500 µl of buffer AW2 (containing ethanol) and centrifuged at 20000 x g 
for 3 min at RT. To eliminate any chance of possible buffer AW2 carryover and 
remaining contaminants, each spin column was centrifuged at 20000 x g for 1 
min at RT. Finally, each spin column was placed in a clean micro-centrifuge 
tube, 50µl of nuclease-free water was added per sample/spin column, left for 5 
min at RT to allow DNA to de-adsorb from the silica-membrane, and then 
centrifuged at 6000 x g for 1 min at RT to elute DNA from the spin column. The 
quantity of DNA in each sample was quantified by NanoDrop™ (section 2.5), and 
all samples were diluted to 50 ng/µl. 
2.10.2.2 TaqMan Quantitative PCR  
LV vector genomic copy number was quantified in DNA extracted from 293T cells 
3 d post-infection by TaqMan quantitative PCR (qPCR) according to a published 
protocol for late reverse transcriptase amplicon quantification, and standard 
curves were generated using lentiviral vector construct plasmid DNA as 
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described (Butler et al., 2001). Briefly, primers and probe primer: late RT 
forward, MH531 5'-TGTGTGCCCGTCTGTTGTGT-3' (Tm: 59.4ºC), late RT reverse, 
MH532 5'-GAGTCCTGCGTCGAGAGAGC-3' (Tm: 63.5ºC) and late RT fluorescent 
probe 5'-[fluorescein amidite(FAM)]-CAGTGGCGCCCGAACAGGGA-
[teramethylrhodamine(TAMRA)]-3' (Tm: 65.5ºC), were used to detect late reverse 
transcripts (linear double stranded DNA-pre-integration complex) with LTRs at 
both ends.  
For each titre assay, a standard curve of the amplicon being measured was 
created from its construct lentiviral vector plasmid of interest. Serial dilutions of 
plasmid copy numbers were generated and ran in triplicate ranging from 1 x 1012 
to 1 x 100 (dilution factor). Plasmid copy numbers of standards were based upon 
the following equations: 
 
1. To determine molecular weight of plasmid:  
(bp) x (330 Daltons x 2 nt/bp)= Daltons   
Daltons = g/mole 
    
2. Determine weight of one copy of plasmid (molecule):  
        
 
               
      
 
 
 
 
 
3. Determine copy number of plasmid per ml in plasmid stock: 
             
 
 
 
 
 
 
g/mole 
 
Avogadro’s number (molecules/mole) 
 
 
= g/molecule 
 
concentration of plasmid g/ml 
 
    g/molecule 
= copy number of plasmid 
(molecules of plasmid)/ml 
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4. Preparation of top standard: 
    
       
 
 
             
 
 
 
 
 
 
 
 
 
Top standards were aliquoted and stored at -20ºC until required. 
 
For example: pHR’SIN-cPPT-SFFV-eGFP-WPRE plasmid DNA, 9662 bp and plasmid 
stock at a concentration of 909.3 ng/µl. 
1. (9662 x (330 x 2) = 6376920 g/mole. 
2. (6376920 / 6.023 x 1023) = 1.059 x 10-17 g/molecule. 
3. (0.0009093 / 1.059 x 10-17) = 8.59 x 1013 copy number of plasmid/ml. 
4. (8.59 x 1013 / 1 x 1012) = 85.9 initial dilution for 1 x 1012 top standard. 
(1000/85.9) = 11.64 µl of plasmid stock required for 1 ml for 1 x 1012 top 
standard. 
The following was added to each 12.5 µl volume TaqMan qPCR reaction per well 
on a 384-well plate: 6.25 µl of 2 x TaqMan universal master mix [containing 
AmpliTaq Gold® DNA polymerase, dNTPs, passive reference and optimised buffer 
components (Applied Biosystem)], final concentration of each of the forward and 
reverse primer at 300 nM, final concentration of the probe primer at 100nM, 
125ng of DNA (2.5 µl of 50 ng/µl) or 2.5 µl of plasmid DNA standard, and the 
remaining volume was made up with nuclease-free water. Each sample and 
standard was measured in triplicate. A non-template control of 2.5 µl of 
copy number of plasmid/ml  
 
    top standard required  
= initial dilution for top standard 
    1000 
 
initial dilution factor for top standard 
= µl of plasmid stock required 
for 1 ml of top standard 
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nuclease-free water in place of DNA was used to eliminate false positives. The 
384-well plate was then placed in Applied Biosystems 7900HT fast real-time PCR 
system. Each TaqMan qPCR reaction for samples and standards were subjected 
to the following parameters: initial incubations at 50ºC for 2 min and initial 
denaturing at 95ºC for 10 min, followed by 40 cycles of amplification were 
carried out at 15 sec for denaturing at 95ºC and annealing/extending for 1 min 
at 60ºC.    
Each TaqMan qPCR reaction exploits the 5’ nuclease activity of AmpliTaq Gold® 
DNA polymerase, to cleave a probe consisting of an oligonucleotide with a 
reporter dye FAM at the 5’ end and a quencher dye TAMRA at the 3’ end. During 
the reaction, cleavage of the probe separated the FAM and the TAMRA, which 
resulted in an increased fluorescence of the FAM. The amount of late RT 
amplicons during each cycle was detected directly by measuring the increase in 
fluorescence of FAM (with excitation/emission at 540nm/575nm), which was 
quenched by TAMRA and this increase in fluorescence can be measured directly. 
Acquisition of data occurred when PCR amplification was in the exponential 
phase (real-time detection).  
The raw cycle number [cycle-threshold (Ct)] values for standards and samples 
and the values of the dilutions of the standards were exported from the SDS v2.3 
software (Applied Biosystems™) and imported into GraphPad Prism® v4 (La Jolla, 
CA, USA). The standard curve of the amplicon (plasmid) copy numbers was 
sigmoidal (x-axis value was amplicon copy numbers for a given Y-axis value of 
TaqMan Ct value), therefore amplicon copy numbers of each of the standards 
was transformed using x = log (x) in order to form linear regression to 
determine/quantify the late reverse transcriptase amplicons in each of the 
sample diluent of LVs using their Ct values. Amplicon copy numbers determined, 
were then transformed using inverse log (x = 10x) and exported to an Excel 
spread sheet for the final calculations.   
Infectious viral units per ml (iu/ml) of each sample diluent of LVs were based 
upon the following sequential equations: 
1. Total DNA extracted = concentration of DNA (ng/µl) x volume of DNA 
eluted 
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2. Percentage of total cell DNA added to the TaqMan qPCR reaction when 
using 125 ng = (125 ng / total DNA extracted) x100 
3. Cell number used in TaqMan qPCR reaction = 5 x 104 x (Percentage of 
total cell DNA added to the TaqMan qPCR reaction when using 125 ng 
/100) 
4. Amplicon copy number per cell = Amplicon copy number (calculated 
from GraphPad Prism) / cell number used in TaqMan qPCR reaction 
5. Infectious viral units per ml (iu/ml) =  Amplicon copy number per cell x 
((dilution factor) x 1000 / volume (µl) of inoculum)) 
For example: Integrating LV expressing Nogo-B at a dilution factor of 1 x 102 with 
a volume of inoculum at 0.03 ml gave an amplicon copy number of 2.66 x 106 
when transduced with 5 x 104 293T cells. Concentration of DNA extracted was 
491.6 ng/µl in a volume of 50 µl of nuclease-free water. 
1. Total DNA extracted: 491.6 x 50 = 24580 ng 
2. Percentage of total cell DNA added to the TaqMan qPCR reaction when 
using 125ng: (125/24580) x 100 = 0.509 % 
3. Cell number used in TaqMan qPCR reaction: 5 x 104 x (0.509%/100) = 
254.272 
4. Amplicon copy number per cell: 2.66 x 106 / 254.272 = 10461.248 
5. Infectious viral units per ml (iu/ml): 10461.248 x ((100) x 1000/30)) = 
3.487 x 107 iu/ml 
An average of all the sample diluents of LVs was calculated for the functional LV 
titre (iu/ml). 
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2.11  Adenoviral vectors 
High titre preparations of first-generation, replication-defective serotype 5 
adenoviral vectors expressing full-length human Nogo-B-haemaglutinin(HA)-
tagged (Ad-Nogo-B) (Acevedo et al., 2004) were produced by large-scale 
amplification in 293 cells using a plaque pure stock of recombinant Ad-Nogo-B. 
First-generation, replication-defective serotype 5 adenoviral vectors expressing 
eGFP (Ad-eGFP) were obtained from Crucell (Leiden, Netherlands). 
2.11.1 Production of adenoviral vectors expressing Nogo-B 
Low passage 293 cells were seeded and grown to 80 % confluence in 24 T-150 
flasks. 50 µl of plaque pure stock of Ad5-Nogo-B was added into 500 ml of 10 % 
complete MEM media (Table 2.1) and 293 cells were then infected with 21 ml 
per flask. For a control flask of no virus infected 293 cells, 21 ml of 10 % 
complete MEM media alone was added. Media was changed every 3 d until 
cytopathic effect of the vector was initiated. 293 cells were then fed with 10 ml 
of fresh 10% complete MEM media and incubated until all cells were detached 
from the flask. Once detached, media containing cells from each flask were then 
collected immediately to avoid prolonged incubation periods of detached cells, 
which may cause loss of virus titre. Next, the cells were harvested to extract 
adenoviral vectors (this happened on 5th d for this preparation) by centrifugation 
at 850 x g for 10 min at RT (and supernatant was discarded), and resuspended in 
8 ml of PBS between all 24 pellets. An equal volume of Arklone P 
(trichlorotrifluoroethane) (ICI Ltd, Cheshire, UK) was then added to the falcon 
tube, followed by inversion for 10 sec and gentle shaking for 5 sec. This step was 
repeated for 1 min. The solution was subjected to centrifugation at 850 x g for 
15 min at RT to form 3 layers. The upper layer consisted of an aqueous solution, 
containing Ad-Nogo-B, whereas the middle and lower layers contained cellular 
debris and solvent, respectively. The top aqueous layer (pink layer) was 
removed, placed into a fresh falcon tube and stored at -80ºC until purification 
by caesium chloride (CsCl) gradient centrifugation.  
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2.11.2 Adenovirus purification using CsCl density gradient 
purification centrifugation 
A virus extraction with solvents such as Arklone P leaves contaminating cellular 
debris in the preparation, which is cytotoxic when using in vitro and in vivo. For 
this reason a CsCl density gradient was used to separate cellular debris and 
purify virus preparations. This method is also a simple and efficient method to 
concentrate adenoviral vector preparations. First, 14 ml cellulose-nitrate ultra-
clear centrifuge tubes (Beckman Coulter) were sterilised with 70% (v/v) ethanol, 
followed by rinsing in sterile dH2O. In these tubes, a 3 layer gradient was formed 
by pipetting a lower layer of 2 ml of sterile CsCl with a density of 1.45 g/cm3, 
followed by careful layering of 3 ml of sterile CsCl with a density 1.32 g/cm3 and 
finally 2 ml of sterile 40 % (v/v) glycerol. Next, the crude Ad-Nogo-B preparation 
was added drop-wise to the top of the gradient and the remaining space was 
filled with PBS. The tube was loaded into a Sorvall Discovery 90 rotor bucket, 
placed in the rotor (RPS4OT-859) and subjected to ultracentrifugation at 90000 x 
g for 1.5 h at 4ºC with maximum acceleration and zero deceleration, using a 
Optima L-80 XP UltraCentrifuge (Beckman Coulter).  
After ultracentrifugation a discrete white band was formed between the CsCl 
1.45 and the CsCl 1.32, which contained the Ad-Nogo-B. This was removed by 
piercing the tube below the virus band using a 21 gauge needle, and the virus 
was carefully collected into the syringe in the minimum volume (caution was 
taken to prevent disruption of the other bands). To further purify and 
concentrate Ad-Nogo-B preparation, the virus was subjected to dialysis. A sterile 
Slide-A-Lyser Dialysis Cassette (molecular weight cut-off of 10000 
kDa)(PerbioScience UK Ltd, Northumberland, UK) was hydrated for 1 min in 
sterile dialysis solution consisting of 0.01 M Tris pH 8.0 and 0.001 M EDTA (TE 
buffer). The extracted virus was transferred to a dialysis cassette for dialysis. 
The virus was dialysed for approximately 2 h against 2 litres (L) of TE buffer with 
stirring. After 2 h, the TE buffer was changed for 2 L of fresh TE buffer and the 
dialysis repeated overnight with stirring. After the overnight dialysis, the TE 
buffer was changed and supplemented with 10% (v/v) glycerol and dialysis was 
continued for a further 2 h. Finally, the virus was removed from the dialysis 
cassette with a needle and syringe, aliquoted into 50 µl volumes and stored at -
80ºC until required. 
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2.12 Determining adenoviral vector titres 
Adenoviral vector (Ad) titres were determined by using two methods: Micro-BCA 
assay for determining physical virus titres, or by titration of adenoviral vectors 
by end-point dilution assay for determining functional virus titres. 
2.12.1 Micro-BCA assay 
Virus particle titres for Ad-Nogo-B and Ad-eGFP were determined by measuring 
the protein content of the virus stocks, using the micro-bicinchoninic acid (BCA) 
protein assay kit (Pierce, Rockford, IL, USA) according to manufacturer’s 
instruction. Briefly, 8 bovine serum albumin (BSA) standards ranging from 0.5 
µg/ml to 200 µg/ml were prepared in PBS and 150 µl of each was loaded in 
duplicate into wells of a clear 96-well plate, plus 150 µl of PBS in duplicate as 
the blank. Next 1, 3 and 5 µl of virus were added in duplicate and each well was 
made up to a total volume of 150 µl with PBS. Next, 150 µl of BCA working 
reagent was added to all samples and standards and then the plate was 
incubated at 37ºC for 2 h (see section 2.13.5 on the principles of the BCA assay). 
Absorbance (optical density) of each well at 570 nm was measured in a Wallac 
Victor2 plate reader (Wallac, Turku, Finland). To calculate the protein content, 
the blank absorbance was subtracted from the readings of each sample and 
standard. The amount of protein present in each virus was then calculated from 
the linear equation based on the standard curve. The physical virus particle titre 
(vp/ml) was then calculated using the following established formula: 1 µg 
protein = 1 x 109 viral particles (VP)(Von Seggern et al., 1998).  
2.12.2 Titration of adenovirus by end-point dilution assay 
Functional titres of Ad-Nogo-B and Ad-eGFP were quantified by the end-point 
dilution assay, through serial dilutions of adenoviral vectors in 239 cells and 
their ability to form plaques. These functional titres were calculated as plaque-
forming units per ml (pfu/ml). 293 cells were plated in a 96-well plate at 50-60 
% confluence. Serial dilutions of adenoviral vectors were prepared at dilutions 
ranging from 10-2 to 10-12 in 10 % complete MEM media (Table 2.1). Media in each 
well of a row was replaced with 100 µl of sequential adenoviral dilutions (10 
wells per row). An additional row with 100 µl of media alone to each well of 293 
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cells was used as a control (no transduction). The plate was then incubated in a 
humidified chamber at 37oC in 5% CO2 overnight. Next, media in each well was 
changed for 200 µl of fresh media and every 2-3 d thereafter until the 8th d. On 
the 8th d post-transduction, pfu/ml was calculated according to the visible 
cytopathic effect at the two lowest adenoviral dilutions, followed by using these 
sequential equations (Nicklin and Baker, 1999):   
A) The proportionate distance (PD) =   
 
 
 
 
 
 
            
B) And log ID50 (infectivity dose) = 
[Log dilution above 50% + (proportionate distance x dilution factor)] 
For example; for a plate with 9 positive wells at 1-9 dilution and 2 positive wells 
at 1-10 dilution the calculation would be as follows:  
PD= (90%-50%) / (90%-20%) =0.57 
logID50 = -9 + (0.57 x -1) = -9.57 
TCID50 (Tissue Culture Infectivity Dose)  = 1/ 10
-9.57 
TCID50/100µl = 10
9.57 TCID50/1ml = 10
10.57 =3.27 x 1010 TCID50/ml 
1 TCID50 ≈ 0.7 pfu 
Final titre = (3.27 x 1010) x 0.7 = 2.6 x 1010 pfu/ml 
         % positive wells above 50%-50  
   (% positive wells above 50%) - (% positive below 50%) 
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2.13  In vitro infections 
2.13.1 In vitro infections with lentiviral vectors 
Cells were seeded to required density and incubated overnight at 37ºC in 5 % 
CO2. A multiplicity of infection (MOI) per cell of LV was calculated on the basis 
of infective titres (iu/ml) and an accurate cell count prior to infection. LVs were 
diluted in culture media with 8 µg/ml of polybrene to the desired concentrations 
based on MOIs required (Dishart et al., 2003a), unless otherwise stated. Cells 
were transduced with LVs and incubated for 18 h, unless otherwise stated. Next, 
these cells were washed twice in PBS, maintained in fresh culture media and 
incubated at 37ºC in 5 % CO2, until required. 
2.13.2 In vitro infections with adenoviral vectors 
Cells were seeded to required density and incubated overnight at 37ºC in 5 % 
CO2. A MOI per cell of Ad was calculated on the basis of infective titres (pfu/ml) 
and accurate cell count prior to infection. Adenoviral vectors were diluted in 
culture media to the desired concentrations based on MOIs required. Cells were 
transduced with adenoviral vectors and incubated for 18 h. After, 18 h 
transduction, cells were washed twice in PBS, maintained in fresh culture media 
and incubated at 37ºC in 5 % CO2, until required. 
 
The basic MOI calculation used: 
 
 
 
 
   
 
2.13.3 Fluorescence microscopy 
Expression of eGFP was visualised under a Nikon Eclipse TS100 inverted 
microscope (Nikon®, Surrey, UK), with a Nikon mercury burner light source 
attachment for fluorescence imaging. Using 200 ×, 100 × or 40 × magnification 
where stated, micrographs were acquired using QImaging CCD camera 
MOI (per cell) × number of cells/well 
 
    titre  
= µl/well 
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(QImaging®, Surrey, BC, Canada) for digital imaging with Image-Pro software 
(Media Cybernetics, Bethesda, MD, USA). 
Expression of Nogo-B was visualised under an Olympus 1×71 inverted microscope 
(attached with a slide holder) (Olympus®, Southend-on-Sea, Essex, UK), with an 
Olympus Th4-200 mercury burner light source attachment for the fluorescence 
imaging. Using 600 × magnification, micrographs were acquired using the 
Olympus CCD built-in camera for digital imaging with Cell^M imaging software 
(Olympus). 
2.13.4 Protein extraction  
2.13.4.1 Cell lysis 
Cell media was removed, cells were gently washed twice in sterile PBS and cell 
lysates were prepared. Briefly, cells were placed on ice and freshly prepared 
ice-cold cell lysis buffer was added [containing 50 mM Tris-HCl pH 7.4 (at 4oC), 
150mM NaCl, 2 mM EDTA, 2 mM ethylene glycol tetra-acetic acid (EGTA), 0.2 % 
(v/v) Triton X-100 and 0.3 % (v/v) nonylphenoxylpolyethoxylethanol (NP-40)] 
supplemented with 100 mM phenylmethanesulfonyl fluoride (PMSF) (inhibitor of 
serine proteases and cysteine proteases), 1 M NaF (inhibitor of serine 
phosphatases and threonine phosphatases) and 1 x final concentration of 
complete protease inhibitor cocktail (inhibitors for serine proteases, cysteine 
proteases and metallo-proteases) (Roche, Welwyn Garden City, UK). In addition, 
1 x phosphatase inhibitor cocktail 2 (Inhibitors of tyrosine protein phosphatases, 
and acid and alkaline phosphatases) (Sigma-Aldrich) was added to cell lysis 
buffer for phosphorylated-proteins in cell signalling analysis for phosphorylated-
ERK1/2 and phosphorylated-Akt in VSMCs (refer to chapter 5). Cell extracts were 
scraped off, transferred to a micro-centrifuge tube and incubated on ice for 10 
min with agitation every 5 min. Extracts were subjected to centrifugation at 
12000 x g for 1 min at 4oC. Cell lysates were stored at -20oC when not required 
immediately.  
2.13.4.2 Protein isolation from supernatant 
For quantification of secreted Nogo-B, supernatants from VSMCs and HeLa cells 
were collected prior to cell lysis and concentrated using 10k [concentration of 
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protein with a molecular mass greater than 10 kilo Dalton (kDa)] centrifugal 
filter units (Millipore, Livingston, UK) at 4000 x g centrifugation in a swing 
bucket rotor at 25ºC for 20 min, following the manufacturer’s instructions. Each 
concentrated supernatant was transferred from the filter unit into a micro-
centrifuge tube, and stored -20ºC until needed for analysis. 
2.13.5 Determination of protein concentration 
Protein concentration in cell lysates and supernatants were determined using 
the bicinchoninic acid (BCA) protein assay (Fisher Scientific, Loughborough, UK), 
a colourimetric detection and quantification protocol, as per the manufacturer’s 
instructions. Briefly, a standard curve was generated using dilutions of BSA 
prepared in cell lysis buffer as the following: 2000 µg/ml, 1500 µg/ml, 1000 
µg/ml, 750 µg/ml, 500 µg/ml, 250 µg/ml, 125 µg/ml and 25 µg/ml. The BCA 
working reagent was prepared by mixing BCA reagent A with BCA reagent B at a 
ratio of 50:1 (A: B). In a 96-well plate, 25 µl of each standard were added in 
duplicate and each sample added in triplicate. 200 µl of BCA working reagent 
was added to each well (final ratio of 1:8, respectively) and then the plate was 
incubated at 37oC for 30 min. During this incubation, the following reactions 
occur: peptides bonds reduce Cu2+ ions from the cupric sulphate to Cu+ ions (at 
37ºC); next, two molecules of BCA form a complex with Cu+, which forms a 
purple coloured product, and absorbs (optical density) light at 570 nm. Finally 
the amount of Cu2+ ions reduced is proportional to the amount of protein 
present. Following incubation, the plate was analysed and optical density (OD) 
was measured using a Wallac Victor2 plate reader (Wallac, Turku, Finland) at a 
wavelength of 570 nm. To calculate the protein concentration, the blank 
absorbance from 0 µg/ml of BSA (cell lysis buffer alone) was subtracted from the 
readings of each standard and sample. A standard curve was generated, and 
sample protein concentrations were determined from the linear equation based 
on the standard curve. 
2.13.6 Green Fluorescent Protein (GFP) assay 
Briefly, infected cells in a 48-well plate were washed in PBS twice, and then 
lysed in 200 µl cell lysis buffer (section 2.13.4.1). A standard curve was 
generated using dilutions of recombinant eGFP (Clontech, Basingstoke, UK) 
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prepared in cell lysis buffer, as the following: 1 µg/ml, 0.5 µg/ml, 0.25 µg/ml, 
0.1 µg/ml, 0.05 µg/ml and 0.01 µg/ml. In a pre-cooled 96-well plate, 20 µl of 
each standard were transferred in duplicate and each sample transferred in 
triplicate, and subsequently 80 µl of cell lysis buffer was added to each well 
(final ratio of 1:4, respectively). The plate was then analysed immediately on a 
Wallac Victor2 plate reader with emission at 507 nm. Average relative 
fluorescent unit (RFU) readings for standards and samples were calculated. A 
linear standard curve was generated to ensure the assay was functioning. 
Expression of eGFP for all samples were normalised to the total protein amount 
present determined by a BCA assay (section 2.13.5) on these cell lysates, and 
the results were then expressed as RFU/mg protein (Nicklin et al., 2001, Dishart 
et al., 2003a) 
2.13.7 Efficiency and longevity of transgene expression of 
continuous culture 
At appropriate time points post-infection, eGFP expression was monitored by 
fluorescence microscopy (see section 2.13.3) and subsequently cells were 
washed in PBS twice prior to cell lysis (see section 2.13.4.1). Cell lysates were 
scraped, harvested and placed on ice for 10 min, followed by storage at -20ºC 
until required for eGFP quantification (see section 2.13.6). In addition, one 
replicate per condition was reserved prior to cell lysis and used for assessing 
transgene expression longevity. Cells were passaged as described in section 
2.2.2.   
2.13.8 Western blot analysis 
To detect specific proteins and assess levels of protein expression in cell lysates 
and/or supernatants, sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and western immuno-blotting was performed. 
Denaturing (heating at 95ºC) and reducing (use of SDS and β-mercaptoethanol) 
conditions were used for all proteins analysed. 
2.13.8.1 Electrophoresis 
Each SDS-PAGE gel (18 cm × 16 cm) consisted of a reducing 10 % resolving gel 
[consisting of 33.3 % (v/v) N, N’-methylene-bis-acylamide (polyacrylamide 30 %) 
Materials and Methods  143 
    
(Bio-Rad Laboratories), 11.25 mM Tris-HCl pH 8.8, 0.1 % (v/v) SDS, 1 % (v/v) 
ammonium persulphate (APS) and 0.1 % (v/v) N, N,N’, N’-
tetramethylethylenediamine (TEMED)] and reducing 4 % stacking gel [containing 
13.3 % (v/v) polyacrylamide (30 %), 3.75 mM Tris-HCl pH 6.8, 0.1 % (v/v) SDS, 1 % 
(v/v) APS and 0.1 % (v/v) TEMED (the latter two are added for polymerisation to 
occur)]. Protein samples and controls were prepared prior to gel loading, with 6 
x reducing loading buffer for a final concentration of 1 x [consisting of 12 % 
(w/v) SDS, 36 % (v/v) glycerol, 375 mM Tris-HCl pH 6.8, 0.012 % (w/v) 
bromophenol blue and 6 % (v/v) β-mercaptoethanol]. Samples and controls were 
heated at 95oC for 5 min to denature the protein, mildly cooled and loaded into 
the wells within the gel. Amersham full-range rainbow molecular weight marker 
(GE healthcare, Buckingham, UK) at a volume of 40 µl was added to the gel, as a 
marker of protein size. Samples were electrophoresed at 100 V through the 4 % 
stacking gel for approximately 45 min in running buffer (consisting of 25 mM 
Tris, 0.2 M glycine, 1mM SDS), followed by 200 V for electrophoresis through the 
resolving gel for approximately 4 h to achieve separation on the gel.  
Proteins were transferred onto Hybond-P polyvinylidene difluoride (PVDF) 
membrane (GE healthcare), using an electric current to promote protein 
migration from the gel to the membrane (towards the anode) to enable antibody 
binding and detection. Protein transfer was performed overnight at 80 milliAmp 
(mAmp) and 20 V in transfer buffer [consisting of 25 mM Tris, 0.2 M glycine, 20 % 
(v/v) methanol, 0.01 % (v/v) SDS] at 4ºC. To confirm the samples and controls 
had transferred correctly, the membrane was stained with Ponceau S solution 
(Sigma-Aldrich) as per the manufacturer’s instructions for reversible protein 
detection. Briefly, the membrane was immersed in Ponceau S staining solution 
for 5 min to visualise proteins. After staining, the membrane was rinsed with 
distilled water and rapidly immersed in 0.1 M NaOH for protein bands to 
disappear within 10-30 sec. Next, the membrane was rinsed with distilled water 
for 2-3 min; this was then followed by Western immunoblotting.  
2.13.8.2 Western immunoblotting 
After transfer of proteins to the membrane, antibody detection was performed. 
Each membrane blocked in tris-buffered saline tween (TBS-T) buffer [consisting 
of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2.7 mM KCl and 0.1 % (v/v) Tween20] 
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with either 5-10 % (w/v) fat-free milk powder or 5 % (w/v) BSA (see Table 2.7 for 
blocking solution used for each antibody) for 3 h at 4ºC with agitation. After 
blocking, each membrane was incubated with an appropriate concentration of 
primary antibody (Table 2.7) diluted in blocking solution at 4ºC overnight with 
shaking. The membrane was washed by two 5 min washes in blocking solution at 
RT before addition of secondary antibody conjugated with HRP. The secondary 
antibody was diluted in blocking solution (Table 2.7) and incubated with the 
membrane for 1 h at RT with shaking. Following secondary antibody incubation, 
the membrane was washed four times for 15 min in blocking solution and washed 
a further two times in TBS-T alone. Proteins were visualised using Enhanced 
Chemiluminescent (ECL) plus detection system (GE healthcare), as per the 
manufacturer’s instructions. ECL plus is a substrate for HRP on immunoblots and 
the release of luminescence can be exposed to X-ray films.  Briefly, for ECL plus, 
reagent A and B were mixed in a 40:1 ratio and poured onto the membrane. 
After 5 min the excess ECL plus was drained off and the membrane was wrapped 
in saran wrap, and placed in an autoradiography cassette. Kodak general purpose 
medical x-ray films were exposed for various lengths of time, ranging from 1 sec 
to overnight. Films were developed in a Kodak X-Omat 1000 developer.  
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Western blotting Description/Epitope 
recognised
Primary antibody Animal 
raised 
in
Clone 
no.
Source Concentration 
or dilution 
(primary 
antibody)
Blocking soultion Secondary antibody 
[horseradish peroxidase 
(HRP) conjugated 
antibody]
Clone 
no.
Source
Nogo-B (45-50 
kDa)
N-terminus of Nogo-
B
Goat polyclonal 
anti-human Nogo 
IgG
Goat N-18 Santa-Cruz 
Biotechnology®
0.4 µg/ml 10 % (w/v)(non-fat) 
milk in TBS-T
Donkey anti-goat IgG-
HRP
SC-2056 Santa-Cruz 
Biotechnology
GAPDH (36 kDa) Glyceraldehyde 3 
phosphate 
dehydrogenase 
(GAPDH) 
Mouse monoclonal 
IgG1 to GAPDH
Mouse 6C5 Abcam® 0.2 µg/ml 10 % (non-fat) milk 
in TBS-T
Polyclonal rabbit anti-
mouse IgG-HRP
P0260 Dako
p-ERK 1 & 2 (44 
kDa & 42 kDa, 
respectively)
Phosphorylated 
threonine and 
tyrosine residues 
within the regulatory 
site of active MAP 
kinase, ERK 1 & 2 (p-
ERK 1 & 2)
Mouse monoclonal 
IgG1 to p-ERK 1 & 
2
Mouse MAPK-YT Abcam 1 µg/ml 5 % (w/v) BSA in 
TBS-T
Polyclonal rabbit anti-
mouse IgG-HRP
P0260 Dako
ERK1 (44 kDa) ERK1 of MAP kinase Rabbit polyclonal 
IgG to ERK1
Rabbit ab7947 Abcam 0.4 µg/ml 5 % BSA in TBS-T Polyclonal swine anti-
rabbit IgG-HRP
P0217 Dako
p-Akt (Ser473) 
(60 kDa)
Akt phosphorylated 
at serine 473 (p-Akt)
Mouse monoclonal 
IgG2b to p-Akt
Mouse 587F11 Cell Signalling 
Technology®, 
Danvers, MA
1/1000 dilution 5 % (w/v) (non-fat) 
milk in TBS-T
Polyclonal rabbit anti-
mouse IgG-HRP
P0260 Dako
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Western blotting Description/Epitope 
recognised
Primary antibody Animal 
raised 
in
Clone 
no.
Source Concentration 
or dilution 
(primary 
antibody)
Blocking soultion Secondary antibody 
[horseradish peroxidase 
(HRP) conjugated 
antibody]
Clone 
no.
Source
Akt (pan)(60 kDa) Total Akt (pan) Rabbit 
monoclonal IgG to 
Akt (pan)
Rabbit C67E7 Cell Signalling 
Technology
1/1000 dilution 5 % BSA in TBS-T Polyclonal swine anti-
rabbit IgG-HRP
P0217 Dako
GRP78/BiP (75-78 
kDa)
78kDa glucose 
regulated 
protein/Binding 
immunoglobulin 
Protein (GRP78/BiP)
Rabbit polyclonal 
IgG to GRP78 BiP
Rabbit ab21685 Abcam 1 µg/ml 5 % (non-fat) milk in 
TBS-T
Polyclonal swine anti-
rabbit IgG-HRP
P0217 Dako
SM-alpha actin 
(42 kDa) 
Smooth Muscle alpha 
actin (SM-alpha 
actin)
Mouse monoclonal 
IgG2a to SM-alpha 
actin
Mouse 1A4 Abcam 0.4 µg/ml 10 % (non-fat) milk 
in TBS T
Polyclonal rabbit anti-
mouse IgG-HRP
P0260 Dako
 
Table 2.7. Antibodies used for Western immunoblotting.  
TBS-T, tris-buffered saline tween buffer; BSA, bovine serum albumin; ERK, extracellular signal-regulated kinase; MAP Kinase, mitogen-activated protein kinase; 
Akt, PI3 Kinase-Akt. 
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2.13.8.3 Densitometric quantification of protein bands 
To normalise each protein band to a loading control (to ensure that any change 
in protein level was not due to unequal loading), immuno-detected bands on an 
X-ray film were scanned to generate a digital image in Bio-Rad quantity one 1-D 
analysis software (Bio-Rad). The density of each protein band was determined by 
the software, using the global background subtraction method. Demarcated by 
boxes using the volume tool, the density of the bands were measured using the 
analysis for volume report function and expressed in units of optical density per 
mm2 (ODU/mm2). The adjusted density for each protein band was divided by the 
equivalent value obtained for the loading control band to give a final density 
value corrected for loading. 
2.13.9 Immunocytofluorescence 
VSMCs seeded in 4- or 8-well culture chamber slides were washed in PBS at RT 
twice to remove any remaining culture media, and then fixed in 4 % PFA at RT 
for 10 min, followed by three washes in PBS at RT for 5 min each. VSMCs were 
permeabilised for 10 min in 0.1 % (v/v) Triton-X-100 in PBS at RT, followed by 
another three PBS washes, and then blocked using 10 % (v/v) donkey serum 
(Sigma-Aldrich) and 1 % (w/v) BSA in PBS (blocking solution) for 30 min to block 
non-specific binding of antibodies. After blocking, VSMCs were then incubated 
with primary antibodies in blocking solution for 1 h at RT. 2 µg/ml of goat 
polyclonal anti-human Nogo (N-18) IgG (Santa-Cruz Biotechnology, Santa Cruz, 
CA) was used to indicate Nogo-B expression or its isotype-matched goat IgG 
control (Sigma-Aldrich). After incubations, VSMCs were washed three times in 
PBS to remove any unbound primary antibodies, and then incubated with a 
corresponding secondary antibody: 4 µg/ml of Alexa-Fluor®-555 (red) donkey 
anti-goat IgG (Invitrogen) in PBS for 1 h at RT in the dark. Next, VSMCs were 
washed three times in PBS to remove any unbound secondary antibodies, 
mounted on coverslips with Prolong-Gold anti-fade reagent with 4’, 6-diamidino-
2-phenylindole (DAPI) (Invitrogen), and coverslips were sealed with clear nail 
varnish to prevent drying and movement under the microscope. DAPI was used 
for nuclear counter-staining. VSMCs were visualised using either fluorescence 
microscopy (section 2.13.3) or confocal microscopy (section 2.13.10), where 
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stated. The nucleus appeared blue and the areas where the primary antibody for 
Nogo-B had bound appeared red.  
VSMCs were fixed, permeabilised and blocked in blocking solution, as previously 
described. These VSMCs were then ready for double immunostaining. After 
blocking, VSMCs were incubated with the first primary antibody: 10 µg/ml of 
mouse monoclonal anti-human endoplasmic reticulum (ER) protein disulphide 
isomerase (PDI) (clone RL90) IgG2a (Abcam, Cambridge, UK) or isotype-matched 
mouse IgG2a control (Sigma-Aldrich) in blocking solution (10 % donkey serum and 
1 % BSA) in PBS for 1 h at RT. Subsequently, VSMCs were washed in PBS three 
times and then incubated with the first secondary antibody: 4 µg/ml of Alexa-
Fluor®-594 (far red) donkey anti-mouse IgG (Invitrogen) secondary antibody in 
PBS at RT for 1 h in the dark. Next, VSMCs were washed three times in PBS and 
then incubated with the second primary antibody: 2 µg/ml of goat polyclonal 
anti-human Nogo (N-18) IgG or isotype-matched goat IgG control in blocking 
solution for 1 h at RT. After second primary antibody incubation step, VSMCs 
were washed three times in PBS and incubated with the second secondary 
antibody: 4 µg/ml of Alexa-Fluor®-488 (green) donkey anti-goat IgG (Invitrogen) 
secondary antibody in PBS at RT for 1 h in the dark. Subsequently, VSMCs were 
washed three times in PBS and then mounted on coverslips with Prolong-Gold 
anti-fade reagent with DAPI, as previously described. VSMCs were visualised 
using confocal microscopy (section 2.13.10). The nucleus appeared blue, and the 
areas where the primary antibodies for Nogo-B and ER PDI had bound appeared 
green and red, respectively.  
2.13.10 Confocal microscopy 
Immunostaining of Nogo-B and/or ER PDI was/were visualised under a Carl Zeiss 
LSM 510 Meta confocal microscope (Carl Zeiss®, Welwyn Garden City, UK) with a 
LSM 510 laser module (Mbq 52ac) for fluorescence imaging. Using magnification × 
630, micro-photographs were acquired using a built-in CCD camera for digital 
imaging with LSM image software under constant exposure time, gain and offset 
and with approximate optical slice of 1 µM. Channels 420 nm-480 nm band pass 
(BP), 505 nm-530 nm BP and 550 nm-657 nm BP were chosen for imaging DAPI, 
both eGFP and Alexa Fluor®-488 and both Alexa Fluor®-555 and -594, 
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respectively, and used according to the absorption and emission spectra for 
fluorescence.  
2.13.11 Scratch-wound mediated cell migration assay 
VSMC migration was assessed by scratch-wound mediated cell migration assay, 
with reference to a scratch assay protocol written by Liang et al., (2007), with 
modifications. Briefly, VSMCs were seeded at a density of 0.5 x 104 cells per well 
into 8-well culture slides overnight for 50-60 % confluence prior to LV infection. 
After 3 d post-infection when VSMCs had reached 100 % confluence, a scratch 
was created using a p200 pipette tip (for 10 h post-wounding) or p1000 pipette 
tip (for 22 h post-wounding). VSMCs were washed twice in PBS to remove cell 
debris and to smooth the edge of the scratch. VSMCs were maintained in 15 % 
complete SMC media (Table 2.1) and placed in the incubator at 37ºC in 5 % CO2. 
Reference lines close to the edge of the scratch were marked and images of the 
scratch acquired at 0 h and 10 h or 22 h (as stated) using bright-field microscopy 
(Nikon eclipse TS100 inverted microscope). Images were acquired using a 
QImaging CCD camera at magnification × 100 or 40 (as stated). After 10 h or 22 h 
post-wounding, VSMCs were fixed in 4 % PFA, washed three times in PBS at RT 
and absolute migration was measured using ImagePro software. Absolute 
migration measurements involved measuring the furthest distance that these 
VSMCs had migrated from the wound edge. For each condition (repeated in 
triplicate), 10 migration distances of 3 fields of view were measured. 
2.13.12 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) assay 
A 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
used to determine the proliferation/viability status of VSMCs after the over-
expression Nogo-B mediated by LVs 5 d post-infection, and this was carried out 
using a CellTiter 96® Non-radioactive Cell Proliferation Assay (MTT assay) kit 
(Promega). This assay directly measures the reduction of the MTT component 
(tetrazolium) of the dye solution into an insoluble formazan product by the 
mitochondria of proliferating/viable cells present.  
VSMCs were seeded at a density of 0.5 x 104 cells (30 % confluence) per well on a 
48-well plate and incubated at 37ºC in 5 % CO2 overnight. Next, growth-
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arrested/quiescent VSMCs were induced by using serum-free media [MEM 
supplemented with 1 % (v/v) penicillin, 100 µg/ml streptomycin, 2 mM L-
glutamine and 1 mM sodium pyruvate] (Libby and O'Brien, 1983, Fager et al., 
1988) for 48 h prior to LV infection (section 2.13.1) (Kritz et al., 2008). After 4 d 
post-infection, media was removed and 200 µl of fresh 15 % complete VSMC 
media was added to LV treated and untreated VSMCs. These cells were then 
placed in a humidified chamber in the incubator at 37ºC in CO2 overnight.  
The MTT assay kit was used 5 d post-infection, according to the manufacturer’s 
instruction. Briefly, 30 µl of dye solution was added to each well (15:100 ratio of 
dye solution to culture media). Blank controls consisted of 200 µl of 15 % 
complete SMC media, 30 µl of dye solution and no VSMCs; to reduce background 
contributed by non-specific absorbance of chemical interference of compounds 
within the media and/or media supplements. After incubation for 4 h at 37ºC in 
5 % CO2, 200 µl of solubilisation/stop solution was then added to each well to 
solubilise the formazan product and each well was mixed with a fresh p200 tip 
(avoided bubble formation because this can interfere with accurate readings of 
absorbance values). Optical density (OD) was quantified using a Wallac Victor2 
plate reader at a wavelength of 570 nm. The average blank control OD reading 
was subtracted from readings of each sample. OD570nm was directly proportional 
to the number of proliferating/viable VSMCs.   
2.13.13 Caspase-3/7 assay 
A Caspase-Glo®-3/7 assay kit (Promega) was used to determine VSMC apoptosis 
after the over-expression Nogo-B mediated by LVs 5 d post-infection. This assay 
measures the presence of two members of the cysteine aspartic acid-specific 
protease (caspase) family, caspase -3 and -7, which have key effector roles in 
apoptosis. The assay involves two steps for the measurement of caspase-3/7 
activities. Step one involves a luminogenic caspase-3/7 substrate containing the 
tetra-peptide sequence DEVD (Z-DEVD-aminoluciferin), which is selective for 
caspase-3/7 activity and cleaved by caspase-3/7 to release aminoluciferin (a 
substrate for luciferase). Step two involves aminoluciferin cleavage by 
luciferase, which generates a luminescent signal (‘glow-type’ signal).  
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Prior to caspase-3/7 activity assay, VSMCs were seeded at a density of 0.25 x 104 
cells (30 % confluence) per well on a white 96-well plate and incubated at 37ºC 
in 5 % CO2 overnight. Next, VSMC quiescence was induced with serum-free media 
(section 2.13.12) for 48 h prior to LV infection (section 2.13.1) in 15 % complete 
SMC media.  
The caspase-Glo 3/7 assay kit was used according to the manufacturer’s 
instruction. Briefly, lyophilised Caspase-Glo Substrate®-3 and -7 (Z-DEVD-
aminoluciferin) and Caspase-Glo® Buffer (optimised for cell lysis, caspase 
activity and luciferase activity) were mixed to form a Caspase –Glo®-3/7 
Reagent. After 4 d post-infection, media was removed and 100 µl of fresh 15 % 
complete VSMC media was added to LV treated and untreated VSMCs, and these 
cells were then placed in a humidified chamber in the incubator at 37ºC in 5 % 
CO2 overnight. At 5 d post-infection, 100 µl of Caspase –Glo® 3/7 Reagent was 
added per well. A blank reaction was used in this caspase-3/7 assay, namely a 
“no-cell” control consisting of 100 µl of 15 % complete SMC media, 100 µl of 
Caspase –Glo® 3/7 Reagent and no VSMCs; to reduce background luminescence 
associated with cell culture media and supplements, i.e. caspase-3/7 activities 
can be detected in FCS. Next, the plate was covered in aluminium foil to protect 
from light, gently mixed using a plate shaker for 30 sec to aid cell lysis, and then 
incubated at RT. After 3 h incubation, luminescence [in relative luminescence 
units (RLU)] was quantified using a Wallac Victor2 (luminometer function). 
Luminescence measured was directly proportional to the amount of caspase-3/7 
activity present. The “no-cell” control luminescence signal was subtracted from 
luminescence signal produced by LV and Ad infected VSMCs and un-infected 
VSMCs. Caspase-3/7 activities for all samples were normalized to the total 
protein amount present [quantified using the BCA assay on cell lysates from a 
parallel assay (section 2.13.5)] and the results were expressed as RLU/mg 
protein.  
2.14 Statistical analysis 
In vitro experiments were carried out on three independent occasions and 
results shown are representative, unless otherwise stated. Results are expressed 
as the mean ± standard error of the mean (S.E.M) of triplicates, unless otherwise 
stated. Results were tested for, and shown to exhibit, gaussian distribution by 
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applying the Shapiro-Wilk normality test to the data. Subsequently, as stated, 
results were analysed using two-tailed unpaired Student’s t-test, or one-way 
analysis of variance (ANOVA) for Bonferroni’s multiple comparisons (using 
GraphPad Prism). Statistical significance was accepted when p< 0.05. 
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3.1 Introduction 
LVs are highly efficient for vascular cell gene transfer (Dishart et al., 2003a, 
Cefai et al., 2005, Qian et al., 2006, Yang et al., 2010) and have been 
considered useful vectors for delivering therapeutic genes to reduce the NIF 
caused by acute vascular injury in vivo (Qian et al., 2006, Yang et al., 2010). In 
terms of transduction efficiencies for human vascular cells, LVs are similar to 
adenoviral vectors in mediating efficient levels of transgene expression at a 
short exposure time of 30 minutes in vitro (Dishart et al., 2003a, Cefai et al., 
2005), which is necessary in the clinical setting.   
The development of NILVs has greatly increased the therapeutic potential of LVs 
for a range of conditions, owing to the fact that these vectors mediate gene 
transfer with a more favourable safety profile since they minimize the risk of 
insertional  mutagenesis (Nightingale et al., 2006, Philippe et al., 2006, Yanez-
Munoz et al., 2006, Apolonia et al., 2007, Rahim et al., 2009). Many preclinical 
studies have shown NILVs to have important implications for gene transfer in 
dividing cells [Jurkat T lymphocyte cell line, haematopoietic progenitor cells, 
293 T cells and mouse myoblast (C2C12) cell line] by mediating transient 
transgene expression (Nightingale et al., 2006, Philippe et al., 2006, Apolonia et 
al., 2007) and in non-dividing cells (within muscle, the eye and CNS) by providing 
long-term and stable transgene expression (Philippe et al., 2006, Yanez-Munoz 
et al., 2006, Apolonia et al., 2007, Rahim et al., 2009). There are many numbers 
of class I integrase point mutations and the most common mutant residue used 
in most studies up to date is the D64V [part of the catalytic triad and facilitates 
the inactivation of the integrase function, thereby prevents integration (Philpott 
and Thrasher, 2007, Banasik and McCray, 2010)]. Evidently, studies have 
indicated that D64V mutant NILVs [with low residual integration frequency of 
103-fold less than the int-LV (Apolonia et al., 2007)] retain high transduction 
efficiency of their integrating counterparts (Nightingale et al., 2006, Yanez-
Munoz et al., 2006, Apolonia et al., 2007, Rahim et al., 2009). NILVs have yet to 
be explored in vascular gene therapy and have a potential in this clinical setting 
especially in the context of acute vascular injury, providing transgene expression 
can be maintained for an adequate duration required for therapeutic gain. 
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LVs are relatively versatile and thus optimisation can easily be assessed (which 
includes promoter modification/specificity, pseudotyping and/or integration-
proficiency or integration-deficiency). Past studies have indicated LV-mediated 
transgene expression in vascular tissue can be facilitated by various internal 
heterologous promoters and these include the following: viral promoters such as 
CMV and CAG; housekeeping gene promoters for example PGK and EF1α, and 
VEC-specific Tie2 promoter (Dishart et al., 2003a, Cefai et al., 2005, Qian et al., 
2006). The CMV promoter mediated stronger LV-mediated transgene expression 
in VECs and VSMCs, compared to CAG, PGK, EF1α and Tie2 promoters (Dishart et 
al., 2003a, Cefai et al., 2005). The SFFV promoter [enhancer-promoter region of 
the SFFV (U3-LTR) and is a ubiquitous promoter] has the ability to drive a high 
level and long-term LV-mediated transgene expression in human HSC in vivo, 
contrary to the CMV promoter (Demaison et al., 2002). Since this study, this 
particular promoter has been highly regarded for many gene therapy application 
studies involving the eye (Tschernutter et al., 2005, Yanez-Munoz et al., 2006), 
lung (Buckley et al., 2008), muscle (Apolonia et al., 2007), CNS (Rahim et al., 
2009) and haematological disorders (Ward et al., 2011). In relevance to vascular 
gene transfer, LV-mediated transgene expression elicited by the SFFV promoter 
has yet to be evaluated in the vasculature.  
An enhancer element is associated with an internal regulatory element 
(enhancer-promoter element) for up-regulation of transgene expression. This 
enhancer-promoter element has the potential to induce integration-site position 
effects, such as the transactivation of a proto-oncogene (associated with 
integration either near or within this gene), and as a consequence mediates a 
possible risk of insertional oncogenesis (Hacein-Bey-Abina et al., 2003b, Ott et 
al., 2006, Zhang et al., 2007, Hacein-Bey-Abina et al., 2008, Howe et al., 2008, 
Modlich et al., 2009). This has been demonstrated in two clinical studies for X-
linked SCID, where retroviral-mediated gene transfer presented a high risk of 
oncogenesis through insertional activation/insertional mutagenesis in the LMO2 
(LIM-domain only 2) locus in HSCs, which was a consequence of the enhancer 
sequence (Hacein-Bey-Abina et al., 2003b, Hacein-Bey-Abina et al., 2008, Howe 
et al., 2008)  The enhancer-less ubiquitously acting chromatin opening element 
(UCOE) is derived from the human HNRPA2B1-CBX3 house-keeping gene locus 
(Figure 3.1). UCOE, as its name suggests maintains a chromatin-opening 
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function, and is an enhancer-less regulatory element consisting of a methylation-
free CpG island region encompassing two closely spaced dual divergent 
transcribed CBX3 and HNRPA2B1 promoters (Figure 3.1), and therefore is 
resistant to transcriptional silencing (irrespective of tissue type or integration 
site position effects) (Williams et al., 2005, Zhang et al., 2007). Unlike the SFFV 
viral promoter element, UCOE can facilitate highly efficient, consistent, stable 
and long-term LV-mediated transgene expression, as demonstrated in HSCs. 
Moreover, UCOE gave rise to the efficient rescue of the IL-2 receptor gamma 
gene (IL2RG) deficiency in a mouse model of X-linked SCID (Zhang et al., 2007). 
In addition, this UCOE promoter overcomes enhancer-mediated integration-site 
position effects and potentially reduces the risk of insertional mutagenesis, and 
thereby aids in a better safety profile (Zhang et al., 2007). This UCOE regulatory 
element is desirable for many gene therapy applications and has not been tested 
in the vasculature. 
 
Figure 3.1. Illustration of the enhancer-less ubiquitously acting chromatin opening element 
(UCOE).  
This enhancer-less internal regulatory element consists of a methylation-free CpG island region 
associated with two closely spaced dual divergent CBX3 and HNRPA2B1 promoters (derived from 
human HNRPA2B1-CBX3 house keeping gene locus). CBX3, chromobox homolog 3; HNRPA2B1, 
heterogeneous nuclear ribonucleoprotein A2/B1. Adapted from Zhang et al., (2007).  
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As mentioned in section 1.11.2, various viral glycoprotein envelopes have been 
used to pseudotype LVs, as well as the most commonly used VSV-g envelope, and 
these include the following: rabies (Mazarakis et al., 2001, Kato et al., 2007, 
Rahim et al., 2009), RRV (Kang et al., 2002, Jakobsson et al., 2006), EbolaZ 
(Kobinger et al., 2001, Kang et al., 2002, MacKenzie et al., 2002, Sinn et al., 
2003, Sanders, 2004, MacKenzie et al., 2005, Jakobsson et al., 2006), GP64 
(Schauber et al., 2004, Sinn et al., 2005a, Buckley et al., 2008, Rahim et al., 
2009), MLV-A (Hanawa et al., 2002, Watson et al., 2002, Kunicher et al., 2008) 
MLV-E (Koch et al., 2006) and HNTV (Qian et al., 2006). These glycoproteins 
have been explored for their potential usefulness in diverse gene therapy 
applications. All of these pseudotyped LVs mentioned have yet to be explored in 
the context of acute vascular injury, and could provide an additional advantage 
for these vectors in this clinical setting depending on the level and selectivity of 
transgene expression. HNTV pseudotyped LVs have demonstrated their utility in 
vascular gene delivery, especially in acute vascular injury where these vectors 
greatly targeted the site of vascular injury compared to VSV-g pseudotyped LVs 
(Qian et al., 2006).    
The aim of this study was to optimise and assess LV-mediated transgene 
expression in human vascular cells in vitro, in terms of the following: 
• To define transgene expression levels mediated by alternative internal 
heterologous promoters, in particular the SFFV promoter and the UCOE 
promoter in vascular cells. 
• To assess the transduction efficiencies of alternative pseudotyped LVs 
(envelope glycoproteins: rabies, RRV, EbolaZ, GP64, MLV-A, MLV-E and HNTV) 
in vascular cells.  
• To evaluate the potential of NILV-mediated gene transfer (in parallel to their 
integrating counterparts) for efficiency and longevity of eGFP expression in 
vascular cells. 
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3.2 Results 
3.2.1 Promoter alternation for lentiviral-mediated transgene 
expression in human primary vascular cells 
Efficiency and longevity of transgene expression facilitated by LV-mediated gene 
transfer under the control of either the SFFV or UCOE promoter, were evaluated 
in HeLa cells and primary human vascular cells. HeLa cells were tested along 
side vascular cells, because they are a well-established and a permissive cell line 
for LVs. Lentiviral construct plasmids comprising of an eGFP transgene under the 
control of either a SFFV or UCOE promoter (pHR’SIN-cPPT-SFFV-eGFP-WPRE or 
pHR’SIN-cPPT-UCOE-eGFP-WPRE, respectively) (Demaison et al., 2002, Zhang et 
al., 2007), VSV-g envelope (pMD.G2) plasmid (Zhang et al., 2007) and the 
integration-proficient packaging plasmid (pCMV delta R8.74 wild-type integrase) 
(Yanez-Munoz et al., 2006) were obtained from Adrian Thrasher’s lab [University 
College London (UCL), UK] and have been described previously (also see Figure 
2.2, Table 2.2 and Table 2.3 for more details on plasmids). Int-LVs expressing 
eGFP under the control of either the SFFV (int-LV-SFFV) or the UCOE (int-LV-
UCOE) promoter were produced, and visual eGFP titres of 4.29 × 108 iu/ml and 
3.28 × 107 iu/ml, respectively, were used in this part of the LV optimisation 
study.  
Lysates from HeLa cells, VSMCs and VECs infected with either int-LV-SFFV or int-
LV-UCOE or un-infected were assessed for eGFP expression by fluorimetry 
[measured in relative fluorescent units (RFU)]; at various time points of 
continuous culture and then normalised to mg of total protein.  
3.2.1.1 The SFFV promoter compared to the UCOE promoter for 
lentiviral-mediated transgene expression in HeLa cells: 
efficiency and longevity. 
The SFFV promoter compared to the UCOE promoter for LV-mediated transgene 
expression efficiency and longevity in HeLa cells is illustrated in Figure 3.2. 
Results demonstrated that int-LV-UCOE and int-LV-SFFV both mediated efficient 
and sustained transgene expression in HeLa cells, at a MOI of 10 and 50 from 1 w 
to 11 w post-infection (Figure 3.2). Representative fluorescent micrographs of 
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these HeLa cells at 2 w and 4 w post-infection also illustrated these results 
(Figure 3.3). 
At a lower MOI of 10, int-LV-UCOE provided more efficient, stable and consistent 
long-term transgene expression compared to int-LV-SFFV (Figure 3.2). Figure 3.3 
illustrated that int-LV-UCOE at a MOI of 10 4 w post-infection induced more 
efficient eGFP expression compared to int-LV-SFFV. Int-LV-SFFV at a MOI of 50 
mediated a greater increase in eGFP expression, in contrary to int-LV-UCOE at 
all post-infection time points (Figure 3.2). Fluorescent microscopy also 
demonstrated that int-LV-SFFV at MOI of 50 enhanced the expression of eGFP 
greater than int-LV-UCOE in HeLa cells (Figure 3.3). 
Data from this assay indicated that int-LV-SFFV at a MOI of 50 facilitated long-
term transgene expression from 1 w to 11 w post-infection in HeLa cells (Figure 
3.2). Transgene expression mediated by int-LV-SFFV was enhanced at 1 w to 2 w 
post-infection [48.3 ± 3.9 RFU (× 106)/mg protein vs. 66.3 ± 5.9 RFU (× 106)/mg 
protein] (Figure 3.2), however a decreased eGFP expression was observed from 2 
w to 11 w post-infection (Figure 3.2). Notably, results indicated that int-LV-
UCOE at MOI of 50 mediated a relatively stable and consistent transgene 
expression in HeLa cells, from 1 w to 11 w post-infection (Figure 3.2). Overall at 
both MOIs, int-LV-UCOE provided efficient, stable and consistent long-term 
transgene expression, whereas int-LV-SFFV mediated efficient transgene 
expression which was down-regulated overtime in HeLa cells (Figure 3.2).  
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Figure 3.2. Transgene expression efficiency and longevity in HeLa cells mediated by 
lentiviral vectors under the control of the SFFV or UCOE promoter.  
HeLa cells were seeded (cell density of 1 × 104/well on a 48-well plate) and infected with int-LV-
SFFV or UCOE at a MOI of 10 or 50 (in the presence of 8 µg/ml of polybrene for 1 h incubation), 
or un-infected. Efficiency and longevity of eGFP transgene expression were assessed at 1, 2, 3, 
4, 5, 6, 7, 8, 9, 10 and 11 weeks (w) post-infection by analysing eGFP expression in HeLa cell 
lysates by fluorimetry [measured in relative fluorescent units (RFU)], which were then 
normalised to the total mg of protein (measured by a BCA assay with optical density measured at 
570 nm wavelength). Mean value (for technical replicates), repeated in triplicate, and n=1 (cell 
line population used). UCOE, enhancer-less ubiquitously acting chromatin opening element; 
SFFV, spleen focus forming virus; MOI, multiplicity of infection; int-LV, integrating lentiviral 
vector. 
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Figure 3.3. Representative micrographs of the efficiency and longevity of eGFP transgene 
expression in HeLa cells mediated by lentiviral vectors under the control of the SFFV or 
UCOE promoter.  
Fluorescent micrographs of eGFP expression in HeLa cells infected with int-LV-SFFV or int-LV-
UCOE at a MOI of 10 or 50, or un-infected, at 2 and 4 w post-infection. 100 µm scale bar 
applicable to all panels (magnification x 100). Representative of n=1 (cell line population used) 
in triplicate. UCOE, enhancer-less ubiquitously acting chromatin opening element; SFFV, spleen 
focus forming virus; MOI, multiplicity of infection; int-LV, integrating lentiviral vector. 
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3.2.1.2 The SFFV promoter compared to the UCOE promoter for 
lentiviral-mediated transgene expression in VECs: efficiency 
and longevity 
Both int-LV-SFFV and int-LV-UCOE at a MOI of 50 facilitated similar long-term 
efficient transgene expression of eGFP in VECs (Figure 3.4). However, with an 
exception at 4 w post-infection, this time point indicated int-LV-SFFV mediated 
higher eGFP expression in comparison to int-LV-UCOE [16.60 ± 0.69 RFU (× 
105)/mg protein vs. 6.73 ± 0.48 RFU (× 105)/mg protein, respectively] (Figure 
3.4). In terms of longevity, this data indicated that int-LV-SFFV enhanced eGFP 
transgene expression between 1 w to 3 w and 3 w to 4 w post-infection (long-
term) [1 w to 3 w: 5.88 ± 0.65 RFU (× 105)/mg protein vs. 12.07 ± 1.08 RFU (× 
105)/mg protein, respectively, and 3 w to 4 w: 12.07 ± 1.08 RFU (× 105)/ mg 
protein vs. 16.6 ± 0.69 RFU (× 105)/mg protein, respectively] (Figure 3.4). This 
profile was observed until 5 w post-infection, when transgene expression 
decreased from 4 w to 5 w [16.6 ± 0.69 RFU (× 105)/mg protein vs. 4.11 ± 0.32 
RFU (× 105)/mg protein, respectively] (Figure 3.4). In contrast, int-LV-UCOE 
induced stable and consistent eGFP transgene expression from 1 w to 5 w post-
infection (Figure 3.4). Overall, results have a similar profile to data from HeLa 
cells (Figure 3.2). 
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Figure 3.4. Transgene expression efficiency and longevity in VECs mediated by lentiviral 
vectors under the control of the SFFV or UCOE promoter.   
Vascular endothelial cells (VECs) were seeded (cell density of 2 × 104/well on a 48-well plate) 
and infected with int-LV-SFFV or UCOE at a MOI of 25 (in the presence of 8 µg/ml of polybrene 
for 1 h incubation) or un-infected. Efficiency and longevity of eGFP transgene expression were 
assessed at 1, 3, 4 and 5 weeks (w) post-infection by analysing eGFP expression in VEC lysates by 
fluorimetry [measured in relative fluorescent units (RFU)], which were then normalised to the 
total mg of protein (measured by a BCA assay with optical density measured at 570 nm 
wavelength). Mean value (for technical replicates) of patient sample repeated in triplicate and 
n=1 (cell population/number of individual VEC preparations used). UCOE, enhancer-less 
ubiquitously acting chromatin opening element; SFFV, spleen focus forming virus; MOI, 
multiplicity of infection; int-LV, integrating lentiviral vector. 
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3.2.1.3 The SFFV promoter compared to the UCOE promoter for 
lentiviral-mediated transgene expression in VSMCs: efficiency 
and longevity 
Int-LV-SFFV and int-LV-UCOE at both MOIs tested, provided efficient and long-
term transgene expression from 1 w to 8 w post-infection in VSMCs. At a MOI of 
50, int-LV-SFFV mediated higher eGFP expression compared to int-LV-UCOE at 1 
w [11.1 ± 0.8 RFU (× 106)/mg protein vs. 3.6 ± 0.2 RFU (× 106)/mg protein, 
respectively], 4 w [3.7 ± 0.2 RFU (× 106)/mg protein vs. 2.2 ± 0.3 RFU (× 106)/mg 
protein, respectively], 6 w [2.3 ± 0.2 RFU (× 106)/mg protein vs. 0.3 ± 0.1 RFU (× 
106)/mg protein, respectively] and 8 w [0.9 ± 0.08 RFU (× 106)/mg protein vs. 
0.2 ± 0.08 RFU (× 106)/mg protein, respectively] post-infection (Figure 3.5). 
Results from this experiment also demonstrate that transgene expression was 
sustained over-time mediated by int-LV-SFFV and int-LV-UCOE in VSMCs, from 1 
w to 8 w post-infection. Regardless, longevity of transgene expression decreased 
after 1 w to 8 w post-infection with int-LV-SFFV (Figure 3.5), which was similar 
in profile to that observed in HeLa cells (Figure 3.2) and VECs (Figure 3.4). In 
contrast, int-LV-UCOE at a MOI of 50 facilitated an increase in eGFP expression 
from 1 w to 3 w post-infection [3.6 ± 0.2 RFU (× 106)/mg protein vs. 8.8 ± 1.5 
RFU (× 106)/mg protein, respectively], but unfortunately transgene expression 
was greatly down-regulated from 3 w to 4 w post-infection [8.8 ± 1.5 RFU (× 
106)/mg protein vs. 2.2 ± 0.3 RFU (× 106)/mg protein, respectively] (Figure 3.5), 
which was not seen in HeLa cells (Figure 3.2) and VECs (Figure 3.4). Figure 3.6 
illustrated representative fluorescent images of VSMCs at 1 w post-infection, and 
reiterated that int-LV-SFFV and int-LV-UCOE mediated efficient transgene 
expression at MOIs of 10 and 50.  
In summary, results in this section demonstrated that both int-LV-SFFV and int-
LV-UCOE regulate long-term efficient transgene expression in HeLa cells, VECs 
and VSMCs. In addition, int-LV-SFFV mediated greater efficiency of transgene 
expression in all three cell types, compared to int-LV-UCOE. Notably, transgene 
expression facilitated by int-LV-SFFV declined over time in HeLa cells, VECs and 
VSMCs, whereas int-LV-UCOE provided stable and consistent transgene 
expression in HeLa cells and VECs but not in VSMCs. However, difficulties were 
encountered when producing high-titre preparations of int-LV-UCOE (3.28 × 107 
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iu/ml). Collectively and accordingly, the SFFV promoter was used for the 
remaining LV experiments in this thesis. 
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Figure 3.5. Transgene expression efficiency and longevity mediated by SFFV or UCOE 
promoters in VSMCs.   
Vascular smooth muscle cells (VSMCs) were seeded (cell density of 2.5 × 104/well on a 48-well 
plate) and infected with int-LV-SFFV or UCOE (in the presence of 8 µg/ml of polybrene for 1 h 
incubation) at a MOI of 10 or 50, or un-infected. Efficiency and longevity of eGFP transgene 
expression were assessed at 1, 3, 4, 6 and 8 weeks (w) post-infection by analysing eGFP 
expression in VEC lysates by fluorimetry [measured in relative fluorescent units (RFU)], which 
were then normalised to the total mg of protein (measured by a BCA assay with optical density 
measured at 570 nm wavelength). Mean value (for technical replicates) of patient sample 
repeated in triplicate and n=1 (cell population/number of individual VSMC preparations used). 
UCOE, enhancer-less ubiquitously acting chromatin opening element; SFFV, spleen focus forming 
virus; MOI, multiplicity of infection; int-LV, integrating lentiviral vector. 
Optimisation of Lentiviral Vectors for Vascular Cell Gene Transfer 171 
 
    
 
Figure 3.6. Representative micrographs of the efficiency of eGFP transgene expression in 
VSMCs mediated by lentiviral vectors under the control of the SFFV or UCOE promoter. 
Fluorescent images of eGFP expression in VSMCs infected with int-LV-SFFV or int-LV-UCOE at a 
MOI of 10 or 50, or un-infected, at 1 w post-infection. 100 µm scale bar applicable to all panels 
(magnification x 100). Representative of n=1 (cell population/number of individual VSMC 
preparations used) in triplicate. UCOE, enhancer-less ubiquitously acting chromatin opening 
element; SFFV, spleen focus forming virus; MOI, multiplicity of infection; int-LV, integrating 
lentiviral vector; VSMC, vascular smooth muscle cell. 
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3.2.2 Pseudotyping lentiviral vectors 
Next, pseudotyped int-LVs were evaluated for transduction efficiency in vascular 
cells in vitro and these included: rabies, RRV, EbolaZ, GP64, MLV-A, MLV-E and 
HNTV. All envelope plasmids were obtained from Adrian Thrasher’s lab (UCL, 
UK), and have been described elsewhere (Lodge et al., 1998, Demaison et al., 
2002, Kang et al., 2002, Sinn et al., 2003, Sinn et al., 2005a, Koch et al., 2006, 
Qian et al., 2006, Buckley et al., 2008, Rahim et al., 2009). Each pseudotyped-
int-LV-eGFP was generated according to the LV production protocol, as 
described in section 2.9.  
3.2.2.1 Pseudotyped-lentiviral transduction efficiency on rat neuronal 
cells 
Based on previous studies which demonstrated that rabies pseudotyped LVs 
mediated efficient transduction and sustained transgene expression within 
neuronal cells in vivo (Mazarakis et al., 2001, Kato et al., 2007, Rahim et al., 
2009); we evaluated the transduction efficiency of rabies pseudotyped int-LVs in 
comparison to VSV-g pseudotyped int-LVs transduced onto a rat cortical neuronal 
cell line (B50s), as a positive control for gene transfer. For this transduction 
efficiency assessment, rabies and VSV-g pseudotyped int-LV visual titres of 1.08 
× 108 iu/ml and 4.29 × 108 iu/ml were used, respectively. 
B50s were transduced with rabies or VSV-g pseudotyped int-LVs expressing eGFP 
at a MOI of 50, or un-transduced. Next, for transduction efficiency and longevity 
of transgene expression, B50 lysates were assessed for eGFP expression 
(normalised to mg protein) at 3 d, 6 d and 9 d post-transduction of continuous 
culture as described before. Here, results demonstrated that LVs pseudotyped 
with rabies were efficient in transducing B50s (Figure 3.7 and Figure 3.8). 
Notably, results indicated that VSV-g pseudotyped int-LV mediated an increase 
eGFP transgene expression, with a greater efficiency and longevity of eGFP 
expression in B50s at a MOI of 50 in contrast to int-LV pseudotyped with rabies 
(Figure 3.7) at 3 d [10.18 ± 1.15 RFU (x 104)/mg protein vs. 4.09 ± 0.09 RFU (x 
104)/mg protein, respectively], 6 d [9.34 ± 0.58 RFU (x 104)/mg protein vs. 4.33 
± 0.33 RFU (x 104)/mg protein, respectively] and 9 d post-transduction [8.39 ± 
0.61 RFU (x 104)/mg protein vs. 4.50 ± 0.38 RFU (x 104)/mg protein, 
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respectively] (Figure 3.7). Representative fluorescent micrographs also 
illustrated that VSV-g pseudotyped int-LV transduction on B50s at a MOI of 50 
mediated efficient eGFP expression at 9 d post-infection, compared to rabies 
pseudotyped int-LVs (Figure 3.8).   
 
Figure 3.7. Transduction efficiency of pseudotyped int-LVs on B50s.  
B50s (a rat cortical neuronal cell line) were seeded (cell density of 3 × 103/well on a 24-well 
plate) and transduced with either VSV-g (vesicular stomatitis virus- glycoprotein) or rabies 
pseudotyped-int-LV at a multiplicity of infection (MOI) of 50, or un-transduced (in the presence 
of 8 µg/ml of polybrene for an 18 h incubation). Transduction efficiency and longevity of 
transgene expression mediated by each pseudotype int-LV were assessed 3, 6 & 9 days (d) post-
transduction by analysing eGFP expression in VEC lysates by fluorimetry [measured in relative 
fluorescent units (RFU)], which were then normalised to the total mg of protein (measured by a 
BCA assay with optical density measured at 570 nm wavelength). Mean value (for technical 
replicates), repeated in triplicate, and n=1 (cell line population used). Int-LV, integrating 
lentiviral vector. 
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Figure 3.8. Representative micrographs of the transduction efficiency and longevity of 
transgene expression mediated by pseudotyped int-LVs in B50s.  
Fluorescent micrographs of eGFP expression in B50s (a rat cortical neuronal cell line) transduced 
with either VSV-g (vesicular stomatitis virus- glycoprotein) or rabies pseudotyped int-LVs at a 
multiplicity of infection (MOI) of 50, or un-transduced, at 9 days (d) post-transduction. 100 µm 
scale bar applicable to all panels (magnification x 100). Representative of n=1 (cell line 
population used) in triplicate.  Int-LV, integrating lentiviral vector. 
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3.2.2.2 Pseudotyped-lentiviral transduction efficiency on human 
vascular cells 
The transduction efficiency of each pseudotyped int-LV was assessed in primary 
human VECs in vitro. Titres were measured according to their total protein 
contents using the microBCA assay (as previously described in section 2.12.1), 
and protein concentration titres were determined and recorded as described in 
Table 3.1. 
 
Table 3.1. Pseudotyped LV protein concentration titres. 
 
Each pseudotyped int-LV-eGFP was transduced on VECs at 64 µg, 256 µg or 640 
µg of LV protein, or un-transduced, and after 5 days post-transduction lysates 
were assessed for eGFP expression (normalised to mg of protein) to determine 
transduction efficiency. EGFP expression results and fluorescent images (at 4 d 
post-infection) indicated that efficient transduction was achieved by GP64 and 
rabies pseudotyped LVs on VECs (Figure 3.9 and Figure 3.10 A, B & C). Moreover, 
Figure 3.9 and Figure 3.10 B & C also indicate that EbolaZ pseudotyped LVs have 
the ability to transduce VECs. However, RRV, MLV-A, MLV-E and HNTV 
pseudotyped int-LVs did not mediate efficient transduction in VECs (Figure 3.9 
and Figure 3.10), the reason being unclear. It was difficult to produce each 
pseudotyped LV to a high-titre stock, and thereby the evaluation of these 
pseudotyped LVs for their transduction efficiency in VSMCs was suspended in this 
study. VSV-g was deemed a suitable envelope and was used in all future LV 
experiments within the rest of this thesis. 
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Figure 3.9. Transduction efficiency of pseudotyped int-LVs on VECs.  
VECs were seeded (cell density of 3 × 104/well on a 48-well plate) and transduced with a 
pseudotyped-int-LV (in the presence of 8 µg/ml of polybrene for 18 h incubation) at 64 µg, 256 
µg or 640 µg of LV protein contents, or un-transduced. Transduction efficiency of each 
pseudotype int-LV was assessed 5 d post-transduction by analysing eGFP expression in VEC 
lysates by fluorimetry [measured in relative fluorescent units (RFU)], which was then normalised 
to the total mg of protein (measured by a BCA assay with optical density measured at 570 nm 
wavelength). Mean value (for technical replicates) of patient sample repeated in duplicate and 
n=1 (cell population/number of individual VEC preparations used). VEC, vascular endothelial cell; 
Int-LV, integrating lentiviral vector; RRV, Ross River virus; EbolaZ, Ebola Zaire; GP64, baculovirus 
glycoprotein 64; MLV-A, murine leukaemia virus–amphotropic; MLV-E, murine leukaemia virus-
ecotropic; HNTV, Hantaan virus. 
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Figure 3.10. Representative micrographs of the transduction efficiency of pseudotyped int-
LVs on VECs.  
Fluorescent micrographs of eGFP expression in VECs transduced with pseudotyped-int-LVs at (A) 
64 µg (B) 256 µg or (C) 640 µg of LV protein, or un-transduced, at 4 days post-transduction. 100 
µm scale bar applicable to all panels (magnification x 100). Representative of n=1 (cell 
population/number of individual VEC preparations used) in duplicate. VEC, vascular endothelial 
cell; RRV, Ross River virus; EbolaZ, Ebola Zaire; GP64, baculovirus glycoprotein 64; MLV-A, 
murine leukaemia virus-amphotropic; MLV-E, murine leukaemia virus-ecotropic; HNTV, Hantaan 
virus; int-LV, integrating lentiviral vector. 
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3.2.3 Non-integrating lentiviral vectors for gene transfer in 
vascular cells 
Efficiency and longevity of NILV-mediated eGFP expression in vascular cells were 
evaluated in comparison to its integrating counterparts. The integration-
deficient plasmid (pCMV delta R8.74 D64V mutant integrase) was obtained from 
Adrian Thrasher’s lab (UCL, UK) and has been described previously (Yanez-Munoz 
et al., 2006, Apolonia et al., 2007) (also see Figure 2.2, Table 2.2 and Table 2.3 
for more details on plasmids). For the purpose of this part of the optimisation 
study, NILV expressing eGFP (NILV-eGFP) and int-LV expressing eGFP (int-LV-
eGFP) were produced. Visual eGFP titres of 1.58 × 108 iu/ml for NILV-eGFP and 
4.48 × 108 iu/ml for int-LV-eGFP were used to transduce onto VECs at MOIs of 5, 
10 and 50. TaqMan qPCR titres of NILV-eGFP in a range from 3.36 × 107 to 1 × 108 
iu/ml (3 batches) and int-LV-eGFP in a range from 1 × 108 to 1.96 × 109 iu/ml (3 
batches), were used to infect VSMCs at increasing MOIs of 5, 10, 25 and 50. 
Expression of eGFP in lysates of these vascular cells at specific time points of 
continuous culture were quantified for eGFP expression, as described before.  
3.2.3.1 Non-integrating lentiviral-mediated gene delivery in vascular 
endothelial cells  
NILV-eGFP mediated efficient eGFP expression in VECs (Figure 3.11 and Figure 
3.12). However, int-LV-eGFP induced higher eGFP expression in VECs, compared 
to NILV-eGFP at matched MOIs of 5, 10 and 50 at 3 d, 1 w, 2 w, 3 w, 4 w and 5 w 
post-infection (Figure 3.11). For example at a MOI of 50, eGFP expression was 
greater in VECs mediated by int-LVs compared to NILV-eGFP, at post-infection 
time points of 3 d [29.9 ± 5.8 RFU (× 106)/mg protein vs. 6.8 ± 1.7 RFU (× 
106)/mg protein], 1 w [41.1 ± 4.6 RFU (× 106)/mg protein vs. 4.5 ± 0.6 RFU (× 
106)/mg protein, respectively], 2 w [57.3 ± 2.6 RFU (× 106)/mg protein vs. 0.7 ± 
0.1 RFU (× 106)/mg protein, respectively], 3 w [54.5 ± 13.1 RFU (× 106)/mg 
protein vs. 1.1 ± 0.4 RFU (× 106)/mg protein, respectively], 4 w [26.3 ± 1.5 RFU 
(× 106)/mg protein vs. 0.23 ± 0.03 RFU (× 106)/mg protein, respectively] and 5 w 
[13.2 ± 1.1 RFU (× 106)/mg protein vs. 0.11 ± 0.1 RFU (× 106)/mg protein, 
respectively] (Figure 3.11). 
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In terms of longevity, data indicated that int-LV-eGFP gene delivery efficiently 
mediated longevity of transgene expression in VECs at all MOIs from 3 d to 5 w 
post-infection (Figure 3.11). It was observed that int-LV-eGFP at a MOI of 50 
induced long-term transgene expression; however eGFP expression decreased 
from 3 w to 5 w post-infection, with a greater decrease between 3 w to 4 w 
post-infection [54.5 ± 13.1 RFU (× 106)/mg protein vs. 26.3 ± 1.5 RFU (× 106)/mg 
protein, respectively] (Figure 3.11). Importantly, at a MOI of 50, NILV-mediated 
gene transfer induced sustained transgene expression of eGFP in VECs from 3 d 
to 3 w post-infection and notably at 3 d to 1 w post-infection (Figure 3.11). 
However, eGFP expression mediated by NILVs in VECs was greatly down-
regulated from 1 w to 2 w post-infection [4.5 ± 0.6 RFU (× 106)/mg protein vs. 
0.7 ± 0.07 RFU (× 106)/mg protein, respectively] (Figure 3.11). In relation to this 
eGFP transgene expression profile, efficient eGFP expression mediated by NILVs 
was reduced from 3 d to 1 w post-infection at MOIs of 5 [1.37 ± 0.24 RFU (× 
106)/mg protein vs. 0.25 ± 0.054 RFU (× 106)/mg protein, respectively] and 10 
[2.43 ± 0.028 RFU (× 106)/mg protein vs. 0.45 ± 0.036 RFU (× 106)/mg protein, 
respectively] (Figure 3.11). Representative micrographs in Figure 3.12 A, B and C 
illustrated efficient eGFP expression in VECs mediated by NILVs at 3 d, 1 w and 3 
w post-infection at MOIs of 10 and 50 (Figure 3.12). 
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Figure 3.11. Efficiency and longevity of eGFP expression in VECs mediated by NILVs.  
VECs (vascular endothelial cells) were seeded (at a cell density of 2 × 104/well on a 48-well 
plate) and infected with int-LV-eGFP or NILV-eGFP (in the presence of 8 µg/ml of polybrene for 
18 h incubation) at MOIs of 5, 10 or 50 or un-infected. Efficiency and longevity of eGFP transgene 
expression were assessed at 3 days (d), 1, 2, 3, 4 and 5 weeks (w) post-infection by analysing 
eGFP expression in VEC lysates by fluorimetry [measured in relative fluorescent units (RFU)], 
which were then normalised to the total mg of protein (measured by a BCA assay with optical 
density measured at 570 nm wavelength). Mean value (for technical replicates) of patient sample 
repeated in triplicate and n=1 (cell population/number of individual VEC preparations used). 
MOI, multiplicity of infection; LV, lentiviral vectors; int-LV, integrating lentiviral vector; NILV, 
non-integrating lentiviral vector.  
Optimisation of Lentiviral Vectors for Vascular Cell Gene Transfer 186 
 
    
 
Optimisation of Lentiviral Vectors for Vascular Cell Gene Transfer 187 
 
    
 
Optimisation of Lentiviral Vectors for Vascular Cell Gene Transfer 188 
 
    
 
Figure 3.12. Representative micrographs of the efficiency and long-term eGFP transgene 
expression in VECs mediated by NILVs.  
Fluorescent images of eGFP expression in VECs (vascular endothelial cells) infected with int-LV-
eGFP or NILVs-eGFP at MOIs of 10 and 50 or un-infected, at (A) 3 days, (B) 1 week (w) and (C) 3 
w post-infection. 100 µm scale bar applicable to all panels (magnification x 200). Representative 
of n=1 (cell population/number of individual VEC preparations used) in triplicate. VEC, vascular 
endothelial cell; MOI, multiplicity of infection; int-LV, integrating lentiviral vector; NILV, non-
integrating lentiviral vector.  
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3.2.3.2 Non-integrating lentiviral-mediated gene transfer in vascular 
smooth muscle cells 
Data indicated that NILV-mediated gene transfer of eGFP facilitated efficient 
and sustained transgene expression at MOIs of 5, 10, 25 and 50, from 3 d to 14 d 
post-infection in VSMCs (Figure 3.13 and Figure 3.14). However, int-LV-eGFP 
mediated significantly enhanced eGFP transfer compared to NILV-eGFP in VSMCs 
(Figure 3.13). For example at a MOI of 50, eGFP expression was significantly 
induced in VSMCs mediated by int-LVs in contrast to NILV-eGFP, at post-infection 
time points of 3 d [5.60 ± 0.36 RFU (× 106)/mg protein vs. 2.03 ± 0.32 RFU (× 
106)/mg protein, respectively, p < 0.001], 7 d [7.80 ± 1.80 RFU (× 106)/mg 
protein vs. 1.10 ± 0.40 RFU (× 106)/mg protein, respectively, p < 0.01] and 14 d 
[3.0 ± 0.14 RFU (× 106)/mg protein vs. 0.5 ± 0.042 RFU (× 106)/mg protein, 
respectively, p < 0.001] (Figure 3.13). Notably, NILV-eGFP induced efficient 
eGFP expression in VSMCs, in parallel to int-LV-eGFP (Figure 3.13).  
Results demonstrated that int-LV-eGFP gene transfer mediated efficient 
longevity of transgene expression in VSMCs at all MOIs from 3 d to 14 d post-
infection (Figure 3.13). For example, at a MOI of 25 it was observed that int-LV-
eGFP facilitated a significant increase in eGFP expression in VSMCs from 3 d to 7 
d post-infection [3.2 ± 0.17 RFU (× 106)/mg protein vs. 6.6 ± 0.83 RFU (× 106)/mg 
protein, respectively, p < 0.001]; however transgene expression was significantly 
down-regulated from 7 d to 14 d post-infection [6.6 ± 0.83 RFU (× 106)/mg 
protein vs. 2.8 ± 0.07 RFU (× 106)/mg protein, respectively, p < 0.001] (Figure 
3.13). Moreover, at a MOI of 50 it was observed that int-LV-eGFP induced long-
term transgene expression in VSMCs; however eGFP expression was significantly 
down-regulated from 7 d to 14 d post-infection [7.75 ± 1.81 RFU (× 106)/mg 
protein vs. 2.95 ± 0.14 RFU (× 106)/mg protein, respectively, p < 0.05] (Figure 
3.13). Importantly, NILV-mediated gene transfer induced efficient transgene 
expression of eGFP in parallel to int-LV-eGFP, at all MOIs in VSMCs from 3 d to 14 
d post-infection (Figure 3.13). However at each MOI, these transgene expression 
profiles did decrease overtime, which was significantly indicated from 3 d to 7 d 
post-infection at MOIs of 5 [0.51 ± 0.058 RFU (× 106)/mg protein vs. 0.174 ± 
0.006 RFU (× 106)/mg protein, respectively, p < 0.001], 10 [0.87 ± 0.07 RFU (× 
106)/mg protein vs. 0.21 ± 0.07 RFU (× 106)/mg protein, respectively, p < 0.001] 
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and 25 [1.67 ± 0.18 RFU (× 106)/mg protein vs. 0.27 ± 0.03 RFU (× 106)/mg 
protein, respectively, p < 0.001] (Figure 3.13). In addition, NILV-eGFP at a MOI 
of 50 from 3 d to 14 d post-infection mediated a similar down-regulation profile 
for the longevity of transgene expression in VSMCs; nevertheless this was not 
significant (Figure 3.13). Representative fluorescent micrographs at 3 d and 7 d 
post-infection at MOIs of 25 and 50, demonstrated that efficient eGFP expression 
in VSMCs facilitated by NILVs was achievable (Figure 3.14). 
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Figure 3.13. Efficiency and longevity of eGFP expression in VSMCs mediated by NILVs.  
VSMCs (vascular smooth muscle cells) were seeded (at a cell density of 1 × 104/well on a 48-well 
plate) and infected with int-LV-eGFP or NILV-eGFP (in the presence of 8 µg/ml of polybrene for 
18 h incubation) at MOIs of 5, 10, 25 or 50 or un-infected. Efficiency and longevity of eGFP 
transgene expression were assessed at 3 days (d), 7 d and 14 d post-infection by analysing eGFP 
expression in VSMC lysates by fluorimetry [measured in relative fluorescent units (RFU)], which 
were then normalised to the total mg of protein (measured by a BCA assay with optical density 
measured at 570 nm wavelength). Mean value ± S.E.M of patient sample repeated in triplicate. 
Three independent experiments performed [n=3 (representative of each other), cell 
population/number of individual VSMC preparations used]. In terms of efficiency, at each 
matched MOI and time points: ** indicates p < 0.01 (int-LV) vs. NILV and # indicates p < 0.001 
(int-LV) vs. NILV. Statistical analysis was carried out using a two-tailed unpaired Student’s t-test. 
In terms of longevity: * indicates p < 0.05 with int-LV at 3 d to 7 d or 7 d to 14 d post-infection, 
** indicates p < 0.01 with int-LV at 3 d to 7 d or 7 d to 14 d and # indicates p < 0.001 with int-LV 
at 3 d to 7 d or 7 d to 14 d, or NILV at 3 d to 7 d post-infection. Statistical analysis carried out by 
one-way ANOVA for Bonferroni’s post-hoc analysis. MOI, multiplicity of infection; LV, lentiviral 
vectors; int-LV, integrating lentiviral vector; NILV, non-integrating lentiviral vector.  
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Figure 3.14. Representative micrographs of the efficiency and long-term eGFP transgene 
expression in VSMCs mediated by NILVs.  
Fluorescent images of eGFP expression in VSMCs (vascular smooth muscle cells) infected with int-
LV-eGFP or NILVs-eGFP at MOIs of 25 and 50 or un-infected, at 3 days (d) and 7 d post-infection. 
100 µm scale bar applicable to all panels (magnification x 100). Representative of n=3 (cell 
population/number of individual VSMC preparations used) in triplicate. MOI, multiplicity of 
infection; int-LV, integrating lentiviral vector; NILV, non-integrating lentiviral vector. 
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3.3 Discussion 
In this chapter, second generation SIN LVs were optimised for their therapeutic 
potential in the context of vascular gene therapy. 
• In terms of defining an alternative promoter for LV-mediated vascular cell 
transgene expression, it was established that both internal heterologous 
promoters SFFV and UCOE mediated efficient and sustained transgene 
expression in VECs and VSMCs. Importantly, the SFFV promoter was 
significantly more active overtime and enhanced transgene expression in 
VECs and VSMCs compared to UCOE promoter, and therefore was used in 
subsequent experiments.  
• Rabies pseudotyped LVs efficiently transduced and mediated sustained 
transgene expression in rat neuronal cells, similar to VSV-g pseudotyped 
LVs. Interestingly, rabies, GP64 and EbolaZ pseudotyped LVs 
demonstrated their potential utility in VEC transduction through efficient 
transgene expression. However, these pseudotyped LVs were difficult to 
produce at high-titres. 
• NILVs mediated efficient gene transfer and sustained eGFP transgene 
expression in VECs and VSMCs.  
Taken together, selected SFFV-driven VSV-g enveloped NILVs were used for 
analysis. 
In the context of LV-mediated vascular gene transfer, the CMV promoter has 
been defined as the most favourable internal heterologous promoter up to date. 
Importantly, this CMV promoter facilitated sufficient levels of VEGF and TIMP-3 
respectively in VSMC and VECs, which modulated their phenotypic effects in 
vitro (Dishart et al., 2003a, Cefai et al., 2005). It is important to continue to 
define the potential for alternative promoters in LV-mediated transgene 
expression in vascular cells. This is the first study that has explored the 
potential use of the SFFV and the UCOE promoter in LV-mediated vascular gene 
therapy, which successfully induced efficient and long-term transgene 
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expression of eGFP in HeLa cells, VECs and VSMCs. Indeed, the SFFV promoter 
has been indicated in various studies to drive strong and sustained transgene 
expression facilitated by LVs (Demaison et al., 2002, Tschernutter et al., 2005, 
Yanez-Munoz et al., 2006, Apolonia et al., 2007, Buckley et al., 2008, Rahim et 
al., 2009, Ward et al., 2011). In relation to these studies, results from this study 
indicated that the SFFV promoter mediated greater efficiency of transgene 
expression overtime in HeLa cells, VECs and VSMCs, compared to the UCOE 
promoter. In contrast to the SFFV and the CMV promoter, UCOE facilitated 
consistent, stable and reproducible LV-mediated transgene expression in various 
cell lines; for example HeLa cells and more importantly haematopoietic stem 
cells, plus induced a more reliable transgene expression per proviral DNA copy. 
This is due to the fact that the UCOE internal regulatory element is less 
susceptible to insertion-site position effects (Zhang et al., 2007) and is resistant 
to DNA methylation-mediated transcriptional silencing (associated with 
methylation-free CpG islands and the chromatin opening element), unlike the 
SFFV and the CMV promoter which results in variation of transgene expression 
among the targeted cell population (Zhang et al., 2007, Zhang et al., 2010). 
Results from this study indicated that LV-mediated transgene expression in HeLa 
cells, VECs and VSMCs regulated by the SFFV promoter declined over continuous 
long-term culture in vitro possibly due to transcriptional silencing and insertion-
site position effects, whereas the UCOE promoter drove relatively consistent and 
stable long-term transgene expression in HeLa cells and VECs, which correlates 
with previous studies (Zhang et al., 2007). Surprisingly, results from VSMC 
experiments demonstrated that the UCOE promoter was unable to provide stable 
and consistent LV-mediated transgene expression, in contrary to the results 
obtained from HeLa cells and VECs. To further support and clarify results, it is 
important to consider further experiments for example quantifying the variation 
of transgene expression mediated by each promoter among vascular cells, by 
assessing the mean vector copy number per cell and mean percentage of eGFP 
positive cells, to determine the ratio of eGFP expression per copy number as 
described by Zhang et al., (2007). Moreover, it is worth potentially considering 
the assessment of the SFFV promoter versus the UCOE promoter alongside the 
CMV promoter, for completion in these optimisation in vitro studies of LV-
mediated transgene expression in vascular cells. Although, clinical studies now 
prefer the use of mammalian promoters, LV-mediated transgene expression 
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facilitated by the enhancer-less UCOE internal regulatory element would be 
advantageous in vascular cell gene transfer, but unfortunately it was very hard 
to produce high-titres of int-LV-UCOE. With the latter taken into consideration 
as well as int-LV-SFFV facilitating higher efficient long-term transgene compared 
to int-LV-UCOE in VSMCs; the UCOE promoter was not pursued in this study for 
assessing the potential of NILV for vascular gene therapy.  
With regards to pseudotyping LVs for vascular gene transfer, the most commonly 
used envelope is the VSV-g (Dishart et al., 2003a, Cefai et al., 2005). It is 
important to continue to define the potential for alternative pseudotypes in LV-
mediated vascular gene delivery for level and selectivity of transgene expression 
in vascular cells. Here, results interestingly indicated that rabies and GP64 
pseudotyped LVs have the potential to efficiently transduce VECs. In relevance 
to these results, LVs pseudotyped with the GP64 envelope have proven to 
efficiently transduce a variety of cell lines (Schauber et al., 2004) and 
respiratory epithelium (Sinn et al., 2005a, Buckley et al., 2008). Rabies 
pseudotyped LVs have demonstrated their usefulness in gene therapy 
applications involving the CNS (Mazarakis et al., 2001, Kato et al., 2007, Rahim 
et al., 2009), however no up to date publications correlate with results obtained 
in this study, and thus definitively extends the target cell/tissue population of 
rabies pseudotyped LVs. In addition, EbolaZ pseudotyped LVs indicated their 
promising utility in transducing these vascular cells, which correlated with 
previous studies that demonstrated that EbolaZ has the ability to transduce 
myocytes, cardiomyocytes (MacKenzie et al., 2002), muscle (MacKenzie et al., 
2005), skin tissue (Hachiya et al., 2007) and the airway epithelium (Kobinger et 
al., 2001, Sinn et al., 2003). Surprisingly, HNTV pseudotyped LV VEC 
transduction did not occur, which does not correlate with results observed by 
Qian et al., (2006). This may possibly be due to shear difficulty in producing high 
titres of HNTV pseudotyped LVs and this can also be suggested for most 
pseudotyped int-LVs here (Matrai et al., 2010). Unfortunately, difficulty was 
experienced when determining the titres of all these pseudotyped int-LVs using 
the same method (this was to allow direct comparison of each pseudotyped LV), 
such as the eGFP visual titre method and TaqMan PCR titre method, and this was 
suggested to be due to the occurrence of various tropism statuses among all 
pseudotyped LVs with the exception of the VSV-g envelope (Cronin et al., 2005, 
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Kutner et al., 2009). Instead, the microBCA assay was used to determine the 
total protein concentration of each pseudotype int-LV preparation. Furthermore, 
with regards to the latter, protein concentrations of each alternative 
pseudotyped LVs were used in relation to physical titres (however, MOIs could 
not be determined) for transduction efficiencies on VECs. Whereas, 
biological/functional titres were determined for rabies pseudotyped LVs versuses 
VSV-g pseudotyped LVs and MOIs were calculated for transduction efficiencies 
comparison on neuronal cells. Alternatively, the number of vector particles 
present in a LV preparation can be determined irrespective of its pseudotype, 
and these include the assessment of reverse transcriptase activity and enzyme-
linked immunosorbent assay (ELISA) directed against the p24 capsid protein 
content (Kutner et al., 2009). Pseudotyped-LV VEC transduction was explored 
first, due to to abundance of VEC preparations from individual human patient 
saphenous veins. Unfortunately, the evaluation of each pseudotyped LVs (rabies, 
RRV, EbolaZ, GP64, MLV-A, MLV-E and HNTV) for their transduction efficiency in 
vascular cells was not followed through in this thesis, due to the shear effort 
required to produce high-titre preparations of each pseudotyped LV and as a 
consequence the VSV-g envelope was continued. Nevertheless, all pseudotype 
LVs have the potential to be useful in vascular gene therapy and should be 
considered for future LV optimisation studies.   
Preclinical studies have indicated the potential utility of rabies pseudotyped LVs 
for efficient transduction within cells of the CNS (Mazarakis et al., 2001, Kato et 
al., 2007, Rahim et al., 2009). In relation to these investigations, results from 
this in vitro study demonstrated that rabies pseudotyped int-LVs mediated 
efficient transduction and sustained transgene in a rat cortical neuronal cell 
line. However, in comparison to VSV-g pseudotyped int-LVs, these pseudotyped 
LVs were not as efficient for these neuronal cells, which confirms previous in 
vitro results by Mazarakis et al., (2001) and in vivo results (irrespective of the 
retrograde transport) by Wong et al., (2004). Therefore, these results indicate 
that rabies pseudotyped LVs may have the potential for being useful in gene 
therapy for stroke. 
This LV optimisation in vitro study addresses for the first time the potential of 
NILVs for future application in vascular cell gene transfer. Notably, results here 
demonstrated efficient transgene expression in vascular cells can be facilitated 
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by NILVs. However, NILVs did not provide efficient and long-term eGFP 
expression as well as their integrating counterparts in VECs and VSMCs, which 
correlated with previous studies that indicated transient transgene expression 
facilitated by NILV-mediated gene transfer in dividing cells (Nightingale et al., 
2006, Philippe et al., 2006). This was due to these episomal transgenes (1-LTR 
and 2-LTR circles) lacking replication signals, and thus diluting as a consequence 
of cell division (Butler et al., 2002, Pierson et al., 2002, Nightingale et al., 2006, 
Philippe et al., 2006). NILVs would be highly advantageous in vascular gene 
therapy. As mentioned previously, indeed many preclinical acute vascular injury 
models have demonstrated that adenoviral-mediated transient transgene 
expression can provide sufficient therapeutic benefits, which suggests that 
longevity is not necessarily an essential requirement in this clinical niche 
(George et al., 2000, Wan et al., 2004, Johnson et al., 2005, Kritz et al., 2008), 
and therefore NILVs may have the potential to be useful in this clinical setting.  
Previous studies have demonstrated the potential usefulness of LV-mediated 
gene transfer of therapeutic genes such as TIMP-3 (with the inhibition of 
migration and increase in apoptosis of VSMCs), VEGF (with the increase of VEC 
migration and proliferation) and EC-SOD (with the inhibition of the NIF following 
acute vascular injury associated with reduced VSMC proliferation) (Dishart et al., 
2003a, Cefai et al., 2005, Qian et al., 2006). Here in this LV optimisation 
investigation, results indicate that VSV-g pseudotyped NILV under the control of 
SFFV promoter are efficient for vascular cell gene transfer and transgene 
expression; however it is unsure if these vectors have the potential to facilitate 
sufficient levels of a therapeutic transgene to mediate beneficial 
effects/phenotypic modulation of vascular cells, and therefore will require more 
investigation. 
It should be noted that this well-established eGFP reporter gene assay of 
transduced cells (by fluorimetry assessment) (Nicklin et al., 2001, Dishart et al., 
2003a) is not without its limitations and measures the total amount of eGFP 
normalised to total mg of protein present, and thus do not provide information 
in terms of percentage of eGFP positive cells. In addition, a further eGFP 
reporter gene experiment should be considered, such as fluorescence-activated 
cell sorting (FACS) analysis for the percentage of eGFP positive HeLa cells, VECs 
and VSMCs after LV-mediated gene transfer, which has been widely used in 
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various LV studies (Demaison et al., 2002, Cefai et al., 2005, Apolonia et al., 
2007, Zhang et al., 2007). FACS analysis here would confirm all results within 
this LV optimisation chapter, especially for the assessment of the potential of 
NILV gene delivery in vascular cells. 
In this chapter, these VSV-g pseudotyped SFFV-driven LVs facilitated efficient 
gene transfer and transgene expression in VECs and VSMCs, and more broadly 
have the potential to deliver therapeutic genes into the vasculature which are 
key to the inhibition of the NIF. However, for the rest of this study, LV 
transduction on VSMCs will be focused. This is because; vascular injury-induced 
VSMC phenotypic effects (migration and proliferation) are hallmarks in the NIF 
(Westerband et al., 1997, Newby and Zaltsman, 2000, Hilker et al., 2002).  
Taken together, VSV-g pseudotyped NILVs under the control of the SFFV 
promoter mediates efficient transgene expression in primary human VSMCs and 
VECs. In conclusion, these assessments report important implications for the use 
of NILVs in cardiovascular gene therapy and for its use in acute vascular injury.  
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4 In Vitro Assessment of Lentiviral Gene Transfer 
of Nogo-B in Human Vascular Smooth Muscle Cells 
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4.1 Introduction 
4.1.1 Nogo-B, a regulator of vascular remodelling 
An ideal therapeutic gene for the reduction of the NIF, would attenuate 
contributors associated with the acute vascular injury response, such as mediate 
the modulation of VSMC migration and proliferation, and induce the acceleration 
of re-endothelialisation (George et al., 2006, Gaffney et al., 2007). Endogenous 
Nogo-B has been shown to be a regulator in vascular maintenance and 
remodelling (Figure 1.15). A previous study documented high levels of Nogo-B in 
blood vessels from mice, and human VECs and VSMCs, with the latter expressing 
two variants of Nogo-B: Nogo-B1 and Nogo-B2 (Acevedo et al., 2004). Nogo-B has 
a favourable profile for prevention of the NIF, since this protein mediates 
negative regulation of VSMC migration (Acevedo et al., 2004, Kritz et al., 2008) 
and proliferation (Kritz et al., 2008), and positive regulation of VEC migration 
(Acevedo et al., 2004, Miao et al., 2006, Zhao et al., 2010). Nogo-B mediates its 
effect through acting as a chemo-attractant for VECs (Acevedo et al., 2004), 
antagonising of PDGF-BB stimulated VSMC migration (Acevedo et al., 2004, Kritz 
et al., 2008), and negatively regulating VSMC proliferation in response to serum 
and PDGF-BB stimulation (Kritz et al., 2008). Moreover, Nogo-B expression was 
shown to be down-regulated in human arterial atherosclerotic plaques 
(Rodriguez-Feo et al., 2007, Lee et al., 2009), stenotic lesions (Rodriguez-Feo et 
al., 2007), and aneurysm lesions (Pan et al., 2007), and thus this reduction may 
contribute to plaque formation, destabilisation and vascular abnormalities (Pan 
et al., 2007, Rodriguez-Feo et al., 2007, Lee et al., 2009). The function of Nogo-
B has generated a great deal of interest in relation to basic biology and 
therapeutic potential in the vasculature in order to reduce the NIF following 
acute vascular injury. Indeed, mice deficient in Nogo-A/B demonstrated 
accelerated rates of NIF after acute vascular injury, which were 
attenuated/rescued by adenoviral gene transfer of Nogo-B (Acevedo et al., 
2004). It was previously shown that the injury-induced NIF was rescued in a 
porcine vein graft model and a wire injured murine model by adenoviral gene 
transfer of Nogo-B (Figure 4.1), and this was also associated with decreased 
VSMC proliferation (Kritz et al., 2008).  
In Vitro Assessment of Lentiviral Gene Transfer of Nogo-B in Human VSMCs 203 
 
    
 
Figure 4.1. Nogo-B attenuates neointima formation in acute vascular injury. 
Adenoviral-mediated gene delivery of Nogo-B (Ad-Ng-B) reduced neointima formation (NI) in a 
wire-injury induced murine model (scale bar = 100 µm) and a porcine vein graft model (scale bar 
= 500 µm). M, media; A, adventitia (Kritz et al., 2008). 
Nogo-B is primarily located in the ER but with a small fraction (approximately 2% 
of the total Nogo-B protein found in a vascular cell) found within the cell 
membrane of vascular cells, and with the N-terminus in an extracellular 
orientation. The N-terminus domain is the major known functional region of 
Nogo-B in relation to vascular biology. The functional extracellular soluble N-
terminal domain comprises of the first 1-200 amino acids of Nogo-B (soluble 
Nogo-B) and is the important region of Nogo-B for the migration of vascular cells 
(Acevedo et al., 2004). The N-terminus of Nogo-B is essential for stimulating 
chemotaxis and morphogenesis of VECs through its engagement with the Ng-BR 
via Akt signalling (Miao et al., 2006, Zhao et al., 2010). This receptor is 
presumed to be on the cell surface of VECs (Miao et al., 2006). In cell culture 
assays, it has been shown that soluble Nogo-B dose-dependently enhanced VEC 
migration and had a negative effect on VSMC migration (Acevedo et al., 2004, 
Miao et al., 2006). However, it is unclear whether this soluble Nogo-B is the 
functional region that mediates a reduction in VSMC proliferation.  
Results from chapter three indicate that VSV-g-pseudotyped NILVs are able to 
mediate efficient transgene expression under the control of the SFFV promoter 
in human VSMCs. A VSMC has a relatively slow mitotic rate in a disease state 
(Gordon et al., 1990) and even during the acute vascular injury response 
(Westerband et al., 1997, Hilker et al., 2002). Therefore, it is possible that NILV-
mediated episomal transgene would “dilute” slowly out, but persist for a 
duration required in this clinical setting to elicit a beneficial effect. NILV-
mediated gene transfer of Nogo-B provides a great opportunity to explore these 
LVs and their anticipated wait, to assess if these vectors mediate a safe and 
effective delivery strategy of a therapeutic gene key to the inhibition of the NIF. 
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Aim of this chapter 
• To assess int-LV-mediated gene transfer of full-length Nogo-B and 
soluble/mutant Nogo-B for over-expression in primary human VSMCs, and its 
phenotypic effects in vitro.  
• To evaluate NILV gene delivery of full-length Nogo-B for over-expression and 
its phenotypic effect on VSMC migration and proliferation in vitro. 
4.2 Results 
4.2.1 Cloning of cDNA encoding Nogo-B into a lentiviral       
vector construct plasmid 
In order to produce LVs expressing the full-length or mutant (soluble) Nogo-B 
transgene, each cDNA was cloned into a lentiviral construct/transfer plasmid. A 
lentiviral construct plasmid containing a multiple cloning site (MCS) (consisting 
of BamHI, XhoI, KpnI and MIuI) with an internal heterologous SFFV promoter 
(pHR’SIN-cPPT-SFFV-MCS-WPRE), was obtained from Adrian Thrasher’s lab [from 
University College London (UCL), UK]. This construct plasmid has been 
successfully optimised (in terms of biosafety and improved LV performance, see 
section 1.10.2.1 and Figure 4.2) (Demaison et al., 2002) and evaluated in a 
number of publications (Demaison et al., 2002, Zhang et al., 2007, Ward et al., 
2011).  
A strategy for PCR cloning was adopted as described in section 2.8 , due to lack 
of appropriate restriction sites. This was carried out in order to flank cDNA 
inserts with restriction enzyme recognition sites BamHI and XhoI, and therefore 
facilitate insertion (Figure 4.3). Blunt-ended PCR products of full-length or 
mutant Nogo-B were purified and sub-cloned into an intermediate plasmid 
(StrataClone PCR Cloning Vector pSC-B- ampicillin/kanamycin plasmid) (Figure 
4.3). Plasmids were DNA sequenced to confirm cDNAs were correct. The full-
length and the mutant Nogo-B cDNA were excised from their intermediate 
plasmid via BamHI and XhoI digestion, purified and then cloned into the 
corresponding restriction enzyme recognition sites in the LV construct plasmid, 
pHR’SIN-cPPT-SFFV-MCS-WPRE (Figure 4.3). Subsequently, these plasmids 
[pHR’SIN-cPPT-SFFV-fulllengthNogo-B-WPRE and pHR’SIN-cPPT-SFFV-
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mutantNogo-B-WPRE (Figure 4.4)] were confirmed by DNA sequencing (see 
Appendix 2 and Appendix 3) and restriction digests with the following: SacII, 
NheI and XbaI for single digestion reactions, and BamHI and XhoI for a double 
digestion reaction (see method for Table 2.3 for plasmid fragment sizes) (Figure 
4.5). SacII single digests generated the following plasmid DNA fragments: 
linearised the pHR’SIN-cPPT-SFFV-MCS-WPRE (empty) plasmid for a 8931 bp 
band; 8535 bp & 1549 bp fragments were produced from the pHR’SIN-cPPT-SFFV-
fulllengthNogo-B-WPRE (full-length Nogo-B)  plasmid and the pHR’SIN-cPPT-
SFFV-mutantNogo-B-WPRE (mutant Nogo-B) plasmid gave rise to 8535 bp & 1000 
bp fragments (Figure 4.5 A). NheI digests produced the following DNA fragments: 
empty plasmid= 7246 bp & 1685 bp; full-length Nogo-B plasmid = 7246 bp & 2838 
bp and mutant Nogo-B plasmid = 7246 bp & 2289 bp (Figure 4.5 B). XbaI digests 
gave rise to the following DNA fragments: empty plasmid = 7970 bp & 961 bp; 
full-length Nogo-B plasmid = 9123 bp & 961 bp and mutant Nogo-B plasmid = 
8574 bp & 961 bp (Figure 4.5 C). BamHI and XhoI double digests produced the 
following DNA fragments: empty plasmid = 8921 bp & 10 bp (the latter is not 
shown); full-length Nogo-B plasmid = 8921 bp & 1163 bp and mutant Nogo-B 
plasmid = 8921 bp & 614 bp (Figure 4.5 D). A single band of the correct size for 
full-length Nogo-B and mutant Nogo-B with BamHI and XhoI double digests 
confirmed the presence of each cDNA insert (Figure 4.5 D). These completed 
constructs were then used to produce LVs expressing either full-length Nogo-B or 
mutant Nogo-B, and subsequently tested in human VSMCs in vitro.  
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Figure 4.2. Plasmid map of lentiviral vector construct/transfer plasmid consisting of the 
multiple cloning site (MCS).  
Schematic diagram illustrates key elements within the lentiviral construct plasmid, these are as 
follows: HIV-1 5’ long terminal repeat (5’ LTR); HIV-1 3’ partial deletion (del/∆) in unique 3’ 
region (U3) in the LTR; packaging sequence (Ψ); Rev responsive element (RRE); central 
polypurine tract (cPPT); Spleen focus forming virus (SFFV) promoter; multiple cloning site (MCS) 
consists of BamHI, XhoI, KpnI and MluI; Woodchuck post-transcriptional regulatory element 
(WPRE), and ampicillin resistance gene (AmpR).     
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Figure 4.3. Schematic diagram of the cloning of Nogo-B cDNA into the lentiviral vector 
construct plasmid.  
Blunt-ended PCR products (containing BamHI and XhoI sites) were purified and sub-cloned into 
the StrataClone PCR cloning vector pSC-B-ampicillin/kanamycin plasmid (intermediate). Full-
length and mutant Nogo-B cDNA were released from the intermediate plasmid on BamHI and XhoI 
sites and then cloned into the corresponding sites in the lentiviral vector construct plasmid. 
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Figure 4.4. Plasmid maps of complete lentiviral construct/transfer plasmids for full-length 
and mutant Nogo-B.  
(A) Illustrates full-length Nogo-B plasmid (pHR’SIN-cPPT-SFFV-fulllengthNogo-B-WPRE) and (B) 
illustrates mutant Nogo-B plasmid (pHR’SIN-cPPT-SFFV-mutantNogo-B-WPRE). 
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Figure 4.5. Confirmation for the successful cloning of the complete full-length and mutant 
lentiviral construct/transfer plasmids.  
Digestion of 250 ng of each pHR’SIN-cPPT-SFFV-MCS-WPRE (empty) plasmid, pHR’SIN-cPPT-SFFV-
fulllengthNogo-B-WPRE (full-length Nogo-B) plasmid and pHR’SIN-cPPT-SFFV-mutantNogo-B-WPRE 
(mutant Nogo-B) plasmid in 50 µl reactions with 10 U of single digests with (A) SacII, (B) NheI and 
(C) XbaI, and double digests with (D) BamHI and XhoI. Undigested= no presence of restriction 
endonucleases. Kbp, kilo base pairs; bp, base pairs. 
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4.2.2 Effect of integrating lentiviral gene transfer of Nogo-B on 
vascular smooth muscle cells migration and proliferation 
The efficiency of int-LV-mediated gene transfer of Nogo-B was assessed in 
human VSMCs in vitro. SFFV-driven, VSV-g pseudotyped second-generation SIN 
int-LVs expressing either full-length Nogo-B (int-LV-full-length Nogo-B) or mutant 
Nogo-B (int-LV-mutant Nogo-B) were generated. TaqMan qPCR titres of int-LV-
full-length Nogo-B in a range from 1.27 × 107 to 6.58 ×108 iu/ml (5 batches) and 
int-LV-mutant Nogo-B in a range from 7.27 × 108 to 8.01 × 108 iu/ml (2 batches) 
were used to infect VSMCs. 
4.2.2.1 Integrating lentiviral-mediated Nogo-B over-expression  
Western immunoblotting was used to assess the efficiency of int-LV-mediated 
gene delivery of Nogo-B in HeLa cell and human VSMC lysates and post-cell 
membrane supernatants, at 4 days (d) or 5 d post-transduction at MOIs of 25 or 
50, respectively. Detection of Nogo-B protein was assessed using a goat 
polyclonal anti-human Nogo IgG antibody. This antibody recognises the N-
terminus epitope of Nogo-B, which is common in both full-length and mutant 
Nogo-B. Full-length Nogo-B (45-50 kDa) over-expression was detected in HeLa 
cells and VSMCs (in both cell lysates and post-cell membrane supernatants) 
infected with int-LV-full-length Nogo-B, compared to int-LV-eGFP and un-
infected (Figure 4.6 and Figure 4.7). Adenoviral-mediated gene transfer of full-
length Nogo-B (Ad-full-length Nogo-B) at 5 d post-transduction at a MOI of 50, 
was used as a positive control in VSMCs and indicated Nogo-B over-expression 
[compared to the eGFP control (Ad-eGFP) and un-infected] (Figure 4.7). Mutant 
Nogo-B (approximately 27-31 kDa) was identified in cell lysates and supernatants 
of HeLa cells that were transduced with int-LV-mutant Nogo-B, in contrast to 
int-LV-full-length Nogo-B, int-LV-eGFP and un-infected (Figure 4.6). Surprisingly, 
mutant Nogo-B protein (27-31 kDa) was not detected in VSMCs (in both cell 
lysates and supernatants) transduced with int-LV-mutant Nogo-B (Figure 4.7).  
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Figure 4.6. Int-LV-full-length Nogo-B and int-LV-mutant Nogo-B transduction of HeLa cells.  
HeLa cells were seeded (at a cell density of 1.5 × 105/well on a 6-well plate) and transduced with LVs (the presence of 8 µg/ml of polybrene for 18 hours 
incubation) at a MOI of 25. Cell lysates and post-cell supernatants were collected 4 days post-infection and examined for over-expression of Nogo-B protein by 
Western immunoblotting [representative of n=1 (cell line populations used)]. All cell lysates and post-cell membrane supernatants were normalised to 6 µg of 
protein loading (protein concentration determined by BCA assay), and Nogo-B proteins at  45-50 kDa for full-length Nogo-B and 27-31 kDa for mutant Nogo-B were 
detected using a goat polyclonal anti-human Nogo (used to detect the N-terminus region) IgG antibody (0.4 µg/ml). Int-LV, integrating lentiviral vector; kDa, kilo 
Daltons; MOI, multiplicity of infection.  
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Figure 4.7. Int-LV-full-length Nogo-B and int-LV-mutant Nogo-B transduction in VSMCs.  
VSMCs were seeded (at a cell density of 2.5 × 105/well on a 6-well plate) and transduced with 
integrating lentiviral vectors (int-LV) or adenoviral vectors (Ad) (in the presence of 8 µg/ml of 
polybrene or no polybrene, respectively, for 18 hours incubation) at a MOI of 50. Cell lysates and 
post-cell membrane supernatants were collected 5 days post-infection and examined for over-
expression of Nogo-B protein by Western immunoblotting [representative of n=1 (cell 
population/number of individual VSMC preparations used) in duplicate]. All cell lysates and 
supernatants were normalised to 6 µg of protein loading (protein concentration determined by 
BCA assay), and Nogo-B proteins at 45-50 kDa for full-length Nogo-B and 27-31 kDa for mutant 
Nogo-B were detected using a goat polyclonal anti-human Nogo (used to detect the N-terminus 
region) IgG antibody (0.4 µg/ml). VSMC, vascular smooth muscle cell; int-LV, integrating 
lentiviral vector; kDa, kilo Daltons; MOI, multiplicity of infection. 
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Over-expression of full-length or mutant Nogo-B in VSMCs following gene transfer 
mediated by their corresponding int-LVs, were further evaluated by 
immunocytofluorescent staining for Nogo-B. VSMCs were seeded and then 
infected with int-LV-full-length Nogo-B, int-LV-mutant Nogo-B or int-LV-eGFP at 
a MOI of 50, or un-infected. 7 d after transduction VSMCs were assessed for 
Nogo-B with the same goat polyclonal anti-Nogo IgG antibody used to detect 
Nogo-B in Western immunoblotting. A corresponding Alexa-Fluor®-555 donkey 
anti-goat IgG secondary antibody was used and images were taken using 
fluorescence microscopy. Full-length Nogo-B over-expression and mutant Nogo-B 
expression was detected (increased red fluorescence) in VSMCs infected by their 
corresponding int-LVs, in comparison to int-LV-eGFP and endogenous level of 
Nogo-B observed in un-infected VSMCs (Figure 4.8 A). Isotype-matched negative 
controls (goat IgG antibody) were carried out for all LV conditions and un-
infected VSMCs during immunocytofluorescent staining in parallel. No red 
immunocytofluorescence was observed and thus no non-specific binding of the 
anti-Nogo-B antibody occurred (Figure 4.8 B).  
Taken together, the over-expression of full-length Nogo-B mediated by int-LV 
gene delivery was confirmed in HeLa cells and VSMCs. Unfortunately, the 
expression of mutant Nogo-B mediated by int-LV gene transfer could not be 
ascertained due to no presence in cell lysates and supernatants of VSMCs by 
Western immunoblotting; however the presence of this protein was detected in 
VSMCs by immunocytofluorescence, and in cell lysates and supernatants of HeLa 
cells. Consequently, further work determining the effects of int-LV gene transfer 
of mutant Nogo-B on VSMC migration and proliferation was put on hold. For the 
rest of this thesis int-LV-full-length Nogo-B will be referred to as int-LV-Nogo-B. 
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Figure 4.8. Int-LV-full-length Nogo-B and int-LV-mutant Nogo-B infection in VSMCs indicated by immuno-fluorescence.  
Immunocytofluorescent staining was carried out in VSMCs (seeded at a cell density of 2.5 × 104/well on a 4-well chamber slide) transduced with LVs (in presence of 
0.5 µg/ml of polybrene for 18 hours incubation) at a MOI of 50, for 7 days post-infection in permeabilised conditions. (A) A goat polyclonal anti-human Nogo (to the 
N-terminus region) IgG antibody (2 µg/ml) along with its corresponding Alexa-Fluor®-555 (red fluorescence) donkey anti-goat IgG secondary antibody (4 µg/ml) was 
used to detect Nogo-B expression. (B) Immuno-fluorescent staining using an isotype-matched negative control (goat IgG) antibody. 50 µm scale bar applicable to all 
panels (magnification x 600). Representative of n=1 (cell population/number of individual VSMC preparations used) in triplicate. VSMC, vascular smooth muscle 
cell; int-LV, integrating lentiviral vector; MOI, multiplicity of infection. 
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4.2.2.2 Assessment of the effects of int-LV-Nogo-B on VSMC migration 
Kritz et al. (2008) demonstrated adenoviral-mediated over-expression of Nogo-B 
reduced PDGF-BB-induced migration of VSMCs in a chemotaxis assay. A scratch 
wound-mediated cell migration assay was implemented to examine the effect of 
Nogo-B over-expression on VSMC migration, induced by int-LV-mediated gene 
transfer of Nogo-B. VSMCs were seeded and infected with either int-LV-Nogo-B 
or int-LV-eGFP at a MOI of 50, or left un-infected as controls. VSMC migration 
was assessed 3 d post-infection in the presence of 15 % serum. Absolute VSMC 
migration was measured from the wound edge to the final point of VSMC 
migration in µm. VSMCs transduced with int-LV-Nogo-B indicated a significant 
inhibition in VSMC migration at 22 hours (h) post-wounding, compared to both 
int-LV-eGFP and un-infected VSMCs [310.0 ± 25.3 µm vs. 1072.2 ± 54.6 µm (70 % 
significant reduction in VSMC migration) or 1003.3 ± 54.6 µm (69 %), 
respectively, p < 0.001] (Figure 4.9 A). Representative bright-field micrographs 
from this migration assay at 0 h and 22 h after wounding also illustrated that int-
LV-Nogo-B transduction blocked VSMC migration, compared to int-LV-eGFP and 
un-infected VSMCs (Figure 4.9 B).  
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Figure 4.9. Effect of int-LV-Nogo-B on VSMC migration.  
(A) VSMCs were seeded (cell density of 0.5 × 104/well in an 8-well chamber slide) and infected 
with LVs [in the presence of 0.5 µg/ml of polybrene for 18 hours (h) incubation] at a MOI of 50. 
VSMC migration was assessed using a scratch wound-mediated cell migration (using p1000 tip) 
assay 3 days post-infection and absolute migration (from the wound edge to the final point of 
VSMC migration) was measured (µm) at 22 h post-wounding using ImagePro software. For each 
condition (repeated in triplicate) = 10 migration distances of 3 fields of view were measured. 
Mean value ± S.E.M of patient sample repeated in triplicate. Two independent experiments 
performed [n=2 (representative of each other), cell population/number of individual VSMC 
preparations used]. * indicates p < 0.001 vs. int-LV-eGFP vector control or un-infected, by one-
way ANOVA for Bonferroni’s corrections. (B) Representative bright-field micrographs of the 
scratch wound-mediated cell migration assay at 0 hours and 22 hours post-wound. 500 µm scale 
bar applicable to all panels (magnification x 40). Representative of n=2 (cell population/number 
of individual VSMC preparations used) in triplicate. VSMC, vascular smooth muscle cell; int-LV, 
integrating lentiviral vector; MOI, multiplicity of infection. 
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4.2.2.3 Assessment of the effects of int-LV-Nogo-B on VSMC 
proliferation 
A proliferation assay was performed to assess the effect of Nogo-B over-
expression mediated by int-LV-Nogo-B on VSMC proliferation. VSMCs were seeded 
and quiescence-induced in serum-free culture media. After 48 h of quiescence, 
VSMCs were infected with LVs (int-LV-Nogo-B or int-LV-eGFP) at MOIs of 10, 25 
and 50, or un-infected, (all conditions in the presence of 15 % serum). VSMC 
proliferation was quantified using a MTT assay at 5 d post-infection. Results from 
this proliferation assay demonstrated that int-LV-Nogo-B delivery significantly 
blocked VSMC proliferation at MOIs of 25 and 50, compared to int-LV-eGFP 
control vector and un-infected VSMCs [MOI 25: 0.29 ± 0.020 optical density (OD) 
(at 570 nm) vs. 0.46 ± 0.011 OD (37 % significant inhibition in VSMC proliferation) 
or 0.51 ± 0.026 OD (43 %), respectively, p < 0.001. MOI 50: 0.21 ± 0.012 OD vs. 
0.43 ± 0.017 OD (51 %) or 0.51 ± 0.026 OD (59 %), respectively, p < 0.001] (Figure 
4.10). Representative images taken prior to the MTT assay, also illustrated that 
VSMCs infected with int-LV-Nogo-B 5 d post-transduction at MOIs of 25 and 50 
reduced VSMC proliferation, compared to int-LV-eGFP and un-infected VSMCs 
(Figure 4.11).   
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Figure 4.10. Effect of int-LV-Nogo-B on VSMC proliferation.  
VSMCs were seeded (at a cell density of 0.5 × 104/well on a 48-well plate and quiescenced for 48 
hours prior to LV infection) and infected with LVs in 15 % serum (in the presence of 8 µg/ml of 
polybrene for 18 hours incubation) at MOIs of 10, 25 or 50. VSMC proliferation was assessed using 
a 3- (4,5-Dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium bromide (MTT) assay, 5 days post-
transduction and optical density was measured at 570 nm wavelength. Mean value ± S.E.M of 
patient sample repeated in quadruplicate. Three independent experiments performed [n=3 
(representative of each other), cell population/number of individual VSMC preparations used]. * 
indicates p < 0.001 vs. int-LV-eGFP vector control or un-infected, by one-way ANOVA for 
Bonferroni’s post-hoc analysis. VSMC, vascular smooth muscle cell; MOI, multiplicity of infection; 
int-LV, integrating lentiviral vectors.  
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Figure 4.11. Representative images of the effect of int-LV-Nogo-B on VSMC proliferation.  
Bright-field micrographs of the VSMC proliferation assay 5 days post-infection, prior to the addition of the MTT component. 100 µm scale bar applicable to all 
panels (magnification x 100). Representative of n=3 (cell population/number of individual VSMC preparations used) in quadruplicate. VSMC, vascular smooth muscle 
cell; MOI, multiplicity of infection; int-LV, integrating lentiviral vectors.  
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4.2.3 Effect of non-integrating lentiviral gene transfer of Nogo-B 
on vascular smooth muscle cells migration and 
proliferation  
Based on the data with int-LV-Nogo-B, we next evaluated the effects of NILV-
mediated gene transfer of Nogo-B on VSMC migration and proliferation. NILVs 
(D64V mutants) retain transduction efficiency of their integrating counterparts 
with minimal host genome integration in cells of the retina (Yanez-Munoz et al., 
2006), muscle (Apolonia et al., 2007) and CNS (Rahim et al., 2009). SFFV-driven, 
VSV-g pseudotyped second-generation SIN NILVs (D64V mutants) expressing full-
length Nogo-B (NILV-Nogo-B) (Figure 4.12) were generated and TaqMan qPCR 
titres were in a range from 3.54 × 107 to 1.18 × 108 iu/ml (4 batches). 
 
 
Figure 4.12. Production of LVs.  
Schematic diagram illustrates the production of vesicular stomatitis virus glycoprotein (VSV-g) 
pseudotyped NILVs (D64V mutant) expressing full-length Nogo-B (NILV-Nogo-B) under the control 
of the spleen focus forming virus (SFFV) promoter. Int-LV, integrating lentiviral vector; NILV, 
non-integrating lentiviral vector. 
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4.2.3.1 Non-integrating lentiviral-mediated Nogo-B over-expression  
As before (section 4.2.2.1), Western immuno-blotting was used to detect the 
over-expression of Nogo-B in VSMCs following NILVs-mediated gene transfer of 
Nogo-B, and to assess the transduction efficiency of NILV-Nogo-B compared to 
int-LV-Nogo-B in VSMCs. VSMCs were seeded and infected with either NILV-Nogo-
B, NILV-eGFP, int-LV-Nogo-B or int-LV-eGFP at a MOI of 50 or un-infected. Cell 
lysates and supernatants were collected at 5 d post-transduction and assessed by 
Western blot analysis [normalised to 12 µg of protein loading and GAPDH 
(although weak) indicated equal loading for cell lysates]. Cell lysates and 
supernatants demonstrated increased Nogo-B protein (45-50 kDa) expression 
from VSMCs infected with NILV-Nogo-B, compared to NILV-eGFP control vector 
and un-infected (endogenous Nogo-B levels) (Figure 4.13). In addition, 
transduction efficiency of NILV-Nogo-B was illustrated to be lower than int-LV-
Nogo-B in lysates and supernatants of VSMCs (Figure 4.13), however NILV-Nogo-B 
was still efficient in mediating Nogo-B over-expression compared to NILV-eGFP 
vector control.  
As before (section 4.2.2.1), immunocytofluorescence was carried out to further 
illustrate the over-expression of Nogo-B in VSMCs mediated by NILV-Nogo-B. 
VSMCs were seeded and then infected with the following LVs at a MOI of 50: 
NILV-Nogo-B, NILV-eGFP, int-LV-Nogo-B and int-LV-eGFP, and un-infected. After 
5 d post-infection these VSMCs were examined for visual expression of Nogo-B by 
immunocytofluorescence. Nogo-B over-expression (increased red fluorescence) 
was indicated by confocal microscopy in VSMCs infected by NILV-Nogo-B, unlike 
NILV-eGFP and un-infected VSMCs (endogenous level of Nogo-B) (Figure 4.14 A). 
Moreover, it was also demonstrated that NILV-Nogo-B mediated efficient 
transduction and induced Nogo-B over-expression in VSMCs similar to that of int-
LV-Nogo-B (Figure 4.14 A). No red immunocytofluorescent staining was observed 
with either the isotype-matched negative control or the secondary antibody 
alone (PBS used instead of Nogo-B specific antibody), thus no non-specific 
binding of the anti-Nogo-B antibody or the secondary antibody was present 
(Figure 4.14 B).  
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Figure 4.13. Western blot analysis of NILV-Nogo-B transduction in VSMCs. 
VSMCs were seeded (at a cell density of 2.5 × 105/well on a 6-well plate) and transduced with 
LVs (in the presence of 8 µg/ml of polybrene, for 18 hours incubation) at a MOI of 50. Cell lysates 
and post-cell membrane supernatants were collected 5 days post-infection and examined for 
over-expression of Nogo-B protein by Western immunoblotting [representative of n=1 (cell 
population/number of individual VSMC preparations used) in duplicate]. All cell lysates and 
supernatants were normalised to 12 µg of protein loading (protein concentration determined by 
BCA assay) and Nogo-B protein at 45-50 kDa was detected using a goat polyclonal anti-human 
Nogo (used to detect the N-terminus region) IgG antibody (0.4 µg/ml). A mouse monoclonal anti-
human GAPDH antibody (0.2µg/ml) was used to detect GAPDH (36 kDa) in cell lysates for equal 
loading. VSMC, vascular smooth muscle cell; int-LV, integrating lentiviral vector; NILV, non-
integrating lentiviral vector; kDa, kilo Daltons; MOI, multiplicity of infection. 
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Figure 4.14. NILV-Nogo-B transduction in VSMCs indicated by immunocytofluorescence. 
Immunocytofluorescent staining was carried out in VSMCs (seeded at a cell density of 0.5 × 
104/well on an 8-well chamber slide) transduced with LVs (in presence of 0.5 µg/ml of polybrene 
for 18 hours incubation) at a MOI of 50, for 5 days post-infection in permeabilised conditions. (A) 
A goat polyclonal anti-human Nogo (to the N-terminus region) IgG antibody (2 µg/ml) along with 
its corresponding Alexa-Fluor®-555 (red fluorescence) donkey anti-goat IgG secondary (2º) 
antibody (4 µg/ml) was used to detect Nogo-B expression. (B) Immunocytofluorescent staining 
using an isotype-matched negative control (goat IgG) primary antibody or omitting the primary 
antibody [secondary (2O) alone]. 20 µm scale bar applicable to all panels (magnification x 630). 
Representative of n=1 (cell population/number of individual VSMC preparations used) in 
triplicate. VSMC, vascular smooth muscle cell; int-LV, integrating lentiviral vector; NILV, non-
integrating lentiviral vector; MOI, multiplicity of infection. 
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4.2.3.2 Assessment of the effects of NILV-Nogo-B on VSMC migration 
Next to examine was the effect of Nogo-B over-expression on VSMC migration 
induced by NILV-mediated gene transfer of Nogo-B and as before (section 
4.2.2.2) a scratch wound-mediated cell migration assay was carried out. VSMCs 
were seeded and infected with LVs (with either NILV-Nogo-B, NILV-eGFP, int-LV-
Nogo-B or int-LV-eGFP) at MOIs of 25 or 50 or un-infected. VSMC migration was 
examined using this migration assay at 3 days post-transduction, and VSMC 
migration was measured (µm) at 10 h post-wounding (in the presence of 15% 
serum). A significant reduction of VSMC migration was observed after infection 
with NILV-Nogo-B compared to NILV-eGFP and un-infected VSMCs, at 10 h post-
wounding at both MOIs [MOI of 25: 106.24 ± 7.87 µm vs. 174.16 ± 6.49 µm (39 % 
significant reduction in VSMC migration) or 170.15 ± 8.04 µm (38 %), p < 0.001, 
respectively, and MOI of 50: 125.98 ± 8.66 µm vs. 178.9 ± 8.78 µm (30 %) or 
170.15 ± 8.04 µm (26 %), p < 0.001 or p < 0.01, respectively] (Figure 4.15). These 
migration results also reiterated that int-LV-Nogo-B-mediated gene delivery 
reduced VSMC migration unlike its control vector (at both MOIs) or un-infected 
VSMCs [MOI of 25: 101.81 ± 7.93 µm vs. 163.90 ± 6.95 µm (38 % significant 
reduction in VSMC migration) or 170.15 ± 8.04 µm (40 %), p < 0.001, 
respectively, and MOI of 50: 90.88 ± 2.47 µm vs. 149.55 ± 4.2 µm (39 %) or  
170.15 ± 8.04 µm (47 %), p < 0.001, respectively] (Figure 4.15). Moreover, these 
results also demonstrated that NILV-Nogo-B transduction on VSMCs (at both 
MOIs) was as efficient as int-LV-Nogo-B in mediating a reduction in VSMC 
migration (MOI of 25: 106.24 ± 7.87 µm vs. 101.81 ± 7.93 µm, and MOI of 50: 
125.98 ± 8.66 µm vs. 90.88 ± 2.47 µm, respectively) (Figure 4.15).  Micrographs 
of this migration assay also illustrated that NILV-Nogo-B infection in VSMCs 
reduced VSMC migration, compared to NILV-eGFP and no infection (Figure 4.16).  
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Figure 4.15. Effect of NILV-Nogo-B on VSMC migration.  
VSMCs were seeded (cell density of 0.5 × 104/well in an 8-well chamber slide) and infected with 
LVs (in the presence of 0.5 µg/ml of polybrene for an 18 hours incubation) at MOIs of 25 or 50. 
VSMC migration was assessed using a scratch wound-mediated cell migration (using p200 tip) 
assay 3 days post-infection and absolute migration (from the wound edge to the final point of 
VSMC migration) was measured (µm) at 10 hours post-wounding using ImagePro software. For 
each condition (repeated in triplicate) = 10 migration distances of 3 fields of view were 
measured. Mean value ± S.E.M of patient sample repeated in triplicate. Three independent 
experiments performed [n=3 (representative of each other), cell population/number of 
individual VSMC preparations used]. ** indicates p < 0.01 vs. un-infected, # indicates p < 0.001 
vs. their LV-eGFP controls or un-infected at a MOI of 25, # indicates p < 0.001 (int-LV-Nogo-B) vs. 
un-infected or int-LV-eGFP at a MOI of 50 and # indicates p < 0.001 (NILV-Nogo-B) vs. NILV-eGFP 
at a MOI of 50. All statistical analysis was carried out by one-way ANOVA for Bonferroni’s post-
hoc analysis. VSMC, vascular smooth muscle cell; int-LV, integrating lentiviral vector; NILV, non-
integrating lentiviral vector; MOI, multiplicity of infection. 
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Figure 4.16. Representative images of the effect of NILV-Nogo-B on VSMC migration. 
Micrographs of the scratch wound-mediated cell migration assay at 0 (hours) h and 10 h post-
wound. 100 µm scale bar applicable to all panels (magnification x 100). Representative of n=3 
(cell population/number of individual VSMC preparations used) in triplicate. VSMC, vascular 
smooth muscle cell; int-LV, integrating lentiviral vector; NILV, non-integrating lentiviral vector; 
MOI, multiplicity of infection. 
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4.2.3.3 Assessment of the effects of NILV-Nogo-B in VSMC 
proliferation 
Additionally, the effect of NILV-mediated gene delivery of Nogo-B on VSMC 
proliferation was explored. As before (section 4.2.2.3), a MTT assay was carried 
out to assess proliferation status in VSMC infected with either NILV-Nogo-B, 
NILV-eGFP, int-LV-Nogo-B or int-LV-eGFP at MOIs of 10, 25 or 50 or un-infected, 
at 5 d post-transduction. Results from this VSMC proliferation assay 
demonstrated that NILV-Nogo-B gene delivery significantly reduced VSMC 
proliferation at MOIs of 25 and 50, compared to NILV-eGFP control or un-
infected VSMCs [MOI 25: 0.14 ± 0.0084 OD vs. 0.29 ± 0.01 OD (52 % significant 
reduction in VSMC proliferation) or 0.33 ± 0.0038 OD (58 %), respectively, p < 
0.001, and MOI 50: 0.074 ± 0.0011 OD vs. 0.2 ± 0.013 OD (63 %) or 0.35 ± 0.015 
OD (79 %), respectively, p<0.001] (Figure 4.17). Representative images (prior to 
the MTT assay) illustrated this VSMC anti-proliferation effect mediated by NILV-
Nogo-B 5 d post-transduction at a MOI of 50 (Figure 4.18). These proliferation 
results also restated that int-LV-Nogo-B-mediated gene delivery reduced VSMC 
proliferation unlike its control vector (at MOIs of 25 and 50) or un-infected 
VSMCs [MOI 25: 0.24 ± 0.0031 OD vs. 0.32 ± 0.0064 OD (25 % significant reduction 
in VSMC proliferation) or 0.33 ± 0.0038 OD (27 %), respectively, p < 0.001, and 
MOI 50: 0.15 ± 0.0038 OD vs. 0.28 ± 0.0031 OD (46 %) or 0.35 ± 0.015 OD (57 %), 
respectively, p<0.001] (Figure 4.17). In addition, these results also reported that 
NILV-Nogo-B gene delivery (at MOIs of 25 and 50) was at least as good as int-LV-
Nogo-B in mediating a reduction in VSMC proliferation (Figure 4.17).  
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Figure 4.17. Effect of NILV-Nogo-B on VSMC proliferation.  
VSMCs were seeded (at a cell density of 0.5 × 104/well on a 48-well plate and quiescence of 48 
hours in serum-free culture media prior to LV infection) and infected with LVs in 15% serum (in 
the presence of 8 µg/ml of polybrene for 18 hours incubation) at MOIs of 10, 25 or 50. VSMC 
proliferation was assessed using a MTT assay, 5 days post-transduction and optical density was 
measured at 570 nm wavelength. Mean value ± S.E.M of patient sample repeated in 
quadruplicate. Three independent experiments performed [n=3 (representative of each other), 
cell population/number of individual VSMC preparations used]. * indicates p < 0.001 vs. their 
eGFP control vector or un-infected. All statistical analysis was carried out by one-way ANOVA for 
Bonferroni’s post-hoc analysis. VSMC, vascular smooth muscle cell; int-LV, integrating lentiviral 
vector; NILV, non-integrating lentiviral vector; MOI, multiplicity of infection. 
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Figure 4.18. Representative images of the effect of NILV-Nogo-B on VSMC proliferation.  
Bright-field micrographs of the VSMC proliferation assay 5 days post-infection at a MOI 50, prior to the MTT assay. 100 µm scale bar applicable to all panels 
(magnification x 100). Representative of n=3 (cell population/number of individual VSMC preparations used) in quadruplicate. VSMC, vascular smooth muscle cell; 
int-LV, integrating lentiviral vector; NILV, non-integrating lentiviral vector; MOI, multiplicity of infection. 
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4.3 Discussion 
In this chapter, a new gene delivery vector NILV-Nogo-B was constructed and 
evaluated for its potential therapeutic utility in the prevention of the NIF 
following acute vascular injury. Here, successful cloning of Nogo-B cDNA (full-
length and mutant) led to the production of VSV-g pseudotyped second-
generation SIN int-LV-full-length Nogo-B, int-LV-mutant Nogo-B and NILV-Nogo-B, 
with transgene expression under the control of an internal heterologous viral 
promoter SFFV.  
• Once it was established that int-LV-Nogo-B (full-length) gene delivery in 
primary human VSMCs induced efficient Nogo-B up-regulation and 
mediated phenotypic modulation in VSMC migration and proliferation; 
subsequently NILV-Nogo-B-mediated gene transfer was then tested. 
Unfortunately, the expression of mutant (soluble) Nogo-B mediated by 
int-LV-facilitated gene transfer in VSMCs could not be determined 
(however, was ascertained in HeLa cells), and thus the effects of int-LV-
mutant/soluble Nogo-B transduction on VSMC migration and proliferation 
were not pursued. 
• Most importantly, these experiments demonstrated efficient Nogo-B over-
expression in VSMCs transduced with NILV-Nogo-B, and as a consequence 
successfully reduced VSMC migration and proliferation. NILV-Nogo-B-
mediated gene transfer was as efficient as its integrating counterparts by 
mediating inhibition on VSMC migration and proliferation. Interestingly, 
NILV-Nogo-B gene delivery appeared better than int-LV-Nogo-B in 
mediating a reduction on VSMC proliferation.  
Adenoviral vectors are the most widely used and extensively studied viral vector 
gene delivery systems for vascular gene therapy (George et al., 1998a, George et 
al., 1998b, George et al., 2000, George et al., 2001, Acevedo et al., 2004, Kritz 
et al., 2008). Indeed, advances have demonstrated stent-based adenoviral-
delivery of TIMP-3 (Johnson et al., 2005) and endothelial nitric oxide synthase 
(eNOS) (Sharif et al., 2008) reduced ISR in vivo. Adenoviral-Nogo-B gene delivery 
in the vasculature has potential for being a useful therapeutic strategy in 
rescuing injury-induced NIF following revascularisation (Acevedo et al., 2004, 
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Kritz et al., 2008). LVs are an alternative and promising gene delivery vector 
system for the vasculature (Dishart et al., 2003a, Cefai et al., 2005, Qian et al., 
2006, Yang et al., 2010). LVs have the potential to mediate gene transfer of a 
therapeutic gene key to the inhibition of the NIF into the vasculature within a 
short time exposure, which is required in this clinical setting (Dishart et al., 
2003a, Cefai et al., 2005). Firstly, in this study, int-LV-Nogo-B transduction was 
indicated to be an efficient and effective vector system for Nogo-B over-
expression, and its mediated effects on inhibition of VSMC invasion and 
proliferation in a well-established in vitro culture model of VSMCs during 
vascular injury (used over the years in a large number of vasculature 
investigations) (Ross et al., 1977). In relevance to these results, Dishart et al., 
demonstrated that VSV-g pseudotyped int-LV gene delivery of  TIMP-3 (another 
therapeutic gene key to the inhibition of NIF) mediated efficient transduction 
and over-expression in human VSMCs, which phenotypically modified VSMCs in 
vitro (in terms of reduced chemotaxis and induced apoptosis) (Dishart et al., 
2003a). Evidently, LVs are highly efficient in transduction of VSMCs and 
mediated effective delivery of therapeutic genes key to the inhibition of the 
NIF.  
Before this study, previous investigations had used LVs as their gene transfer 
vector of choice for the vasculature (Dishart et al., 2003a, Cefai et al., 2005, 
Qian et al., 2006, Yang et al., 2010), however none had used NILVs. This in vitro 
study addresses the novelty and potential of NILVs for future utility in vascular 
cell gene delivery in preclinical studies. Permanent transgene expression is not 
necessarily required in this clinical niche, because indeed many preclinical acute 
vascular injury models have demonstrated adenoviral-mediated transient 
transgene expression can provide sufficient therapeutic benefits (George et al., 
2000, Wan et al., 2004, Johnson et al., 2005, Kritz et al., 2008). In addition, 
VSMCs have relatively low rates of proliferation in a disease state (Gordon et al., 
1990), and during the acute vascular injury response (Westerband et al., 1997, 
Hilker et al., 2002) with a proliferative index of approximately 1.34 % 
(Westerband et al., 1997). Previous studies have shown NILVs especially the 
D64V mutants to have important aspects relevant for gene transfer into post-
mitotic cells within different organs (eye, muscle and CNS of rodents), by 
retaining transduction efficiency of their wild-type integrase versions with 
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minimal host genome integration in vitro and in vivo (Yanez-Munoz et al., 2006, 
Apolonia et al., 2007, Rahim et al., 2009). In relation to these preclinical 
reports, results from this in vitro study implied efficient gene transfer and 
transgene expression mediated by NILV-Nogo-B in human VSMCs was similar to 
that of int-LV-Nogo-B, and as a consequence was as efficient as its integration-
proficient counterparts in modulating phenotypic effects of VSMCs. Therefore, 
data reported in this study denotes the use of NILVs as an alternative and 
promising gene transfer vector system. It is important to note that even though 
NILV-Nogo-B is as efficient and effective in modulating VSMC phenotypic effects, 
it is therefore essential to analyse the following in subsequent studies: quantify 
the viral copy numbers per cell in contrast to int-LVs and at various matched 
MOIs  by qPCR at a very early time point (Rahim et al., 2009); measure non-
integrated viral DNA [containing a junction of the two deleted U3 region in the 
LTR present in SIN vectors (2d-LTR circles)] copy numbers per total viral DNA 
copy numbers by qPCR (Yanez-Munoz et al., 2006, Apolonia et al., 2007), to 
determine that transgene expression in VSMCs transduced with NILVs originates 
from non-integrated vector templates (transcriptionally proficient episomes) in 
parallel to int-LVs; detect and determine vector-host DNA junctions mediated by 
the NILV DNA (due to genomic integration of episomal LV forms could possibly 
occur through DNA breaks located anywhere in the vector circle) in contrast to 
int-LVs by linear amplification-mediated (LAM)-PCR (Yanez-Munoz et al., 2006), 
and furthermore determine residual integration efficiencies in transduced VSMCs 
with NILVs in contrast to their integrating counterparts (Yanez-Munoz et al., 
2006, Apolonia et al., 2007). In summary, all these experiments mentioned are 
important and should be considered for further experiments involving NILV gene 
transfer and transgene expression of Nogo-B in VSMCs.  
Evidently, the soluble N-terminal domain of Nogo-B (soluble Nogo-B) promotes 
adhesion to VECs and VSMCs, and modulates migration of these vascular cells 
(Acevedo et al., 2004), as previously mentioned. Soluble Nogo-B has a high-
affinity for the Ng-BR, and as consequence promotes soluble Nogo-B–mediated 
chemotaxis and tube formation of VECs in vitro (Miao et al., 2006). Furthermore, 
full-length and soluble Nogo-B (both human) rescued defects in intersomitic 
vessel formation in Nogo-B knock-down zebrafish embryos (Zhao et al., 2010). 
Taken together, these previous reports support the conclusion that soluble Nogo-
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B is the functional domain in VEC migration and VSMC migration. LVs expressing 
mutant (soluble) Nogo-B were generated in this study, and is a novel vector 
which has never been tested for its effects on VSMC proliferation and migration 
in vitro. Unfortunately, this int-LV-mutant Nogo-B was undetermined for its 
mediated expression of mutant (soluble) Nogo-B in VSMC cell lysates and 
supernatants (however was ascertained in HeLa cells), and therefore was put on 
hold for optimisation and evaluation on VSMC proliferation and migration.  
Nogo-B is presumed to also exert its effects on VEC and VSMC migration through 
a bystander effect. However, the mechanism of secreting this transmembrane 
protein is unclear. Secreted Nogo-B (circulating Nogo-B) can be detected in 
human plasma (Rodriguez-Feo et al., 2007). Results from this study also 
indicated that secreted Nogo-B can be detected in the conditioned media of un-
infected human VSMC (45-50 kDa). Interestingly, enhanced secreted Nogo-B was 
found present in the supernatant of VSMCs infected with int-LV-Nogo-B or NILV-
Nogo-B, in contrast to their control eGFP vector and un-infected VSMCs 
(endogenous level). In addition, it is important to assess the effects of secreted 
Nogo-B from its conditioned media on VSMC migration and proliferation in vitro 
and thus further experiments should be considered.  
Here, results from this in vitro study illustrated that int-LV-Nogo-B and NILV-
Nogo-B enhanced Nogo-B expression in VSMC lysates, in contrast to their LV-
eGFP controls and un-infected VSMCs, and in contrast to these supernatants. 
This is plausible since Nogo-B is a reticulon protein with a small fraction found 
within the cell-membrane of VSMCs (Acevedo et al., 2004). These results don’t 
show whether Nogo-B over-expression is co-localised with the ER and/or cell-
membrane, and therefore will require more investigation. 
Nogo-B has a favourable profile in the attenuation of the NIF following stenting 
and vascular bypass grafting. This was determined by adenoviral-mediated over-
expression of Nogo-B, reduced the NIF in two acute vascular injury animal 
models (porcine vein graft model and murine wire-injury model); this notably 
was achieved by a reduction in VSMC invasion and proliferation (Kritz et al., 
2008). In relevance to this, results from this current study further confirmed and 
extended previous in vitro data performed (Kritz et al., 2008). Int-LV-Nogo-B 
and NILV-Nogo-B mediated gene delivery, reduced VSMC proliferation in a similar 
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in vitro proliferation assay (measured using a MTT assay) implemented by Kritz 
et al., (2008). This proliferation assay (48 h of VSMC quiescence prior to LVs 
infections in 15 % serum stimulation) mimics the gene transfer to the 
vasculature. This is because as mentioned previously at the preferred time of 
gene delivery during revascularisation, most VSMCs are quiescent with a 
relatively low rate of proliferation. It should be noted that the MTT assay is not 
without its limitations, and only measures the reduction of tetrazolium 
component (MTT) into an insoluble formazan product by the mitochondria of 
viable cells and not proliferation directly. In addition, further well-established 
proliferation experiments such as bromodeoxyuridine (BrdU) incorporation 
analysis and/or Ki67 detection for quantification of proliferating VSMCs, and 
propidium iodide staining and flow cytometric analysis for quantification of cell-
cycle populations, should be considered to confirm VSMC proliferation results 
observed with NILV-Nogo-B. Determination of int-LV-Nogo-B and NILV-Nogo-B 
mediated effects on the inhibition of VSMC migration was confirmed using a 
scratch-wound cell migration assay, which mimics VSMC migration in vivo 
compared to a chemotaxis assay (Liang et al., 2007), and therefore extends 
previous in vitro VSMC findings of adenoviral-Nogo-B over-expression (Kritz et 
al., 2008). 15 % serum was used to maintain these healthy statuses of LV-
infected VSMCs. However, this scratch-wound cell migration assay does not rule 
out the influence of VSMC proliferation and slightly dilutes these findings. 
Additionally, the optimisation for the minimal percentage of serum used for this 
scratch-wound mediated cell migration assay should have been considered (Liang 
et al., 2007). Furthermore, these migration results could be corrected for 
proliferation subsequently after the scratch-wound migration assay by measuring 
for proliferation using the MTT or BrdU assay, and thus further experiments 
should be considered.  Plus, a chemotaxis assay should be considered to support 
that NILV-Nogo-B-mediated gene transfer reduces VSMC migration.  
It is still unknown on the mechanism of how Nogo-B inhibits VSMC migration and 
proliferation, and therefore will require further investigation. Current results 
and previous data, demonstrate that Nogo-B is a favourable candidate 
therapeutic gene in vascular gene therapy for the prevention of NIF following 
acute vascular injury. This is because of its ability to negatively regulate VSMC 
migration (Acevedo et al., 2004, Kritz et al., 2008) and proliferation (Kritz et 
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al., 2008), and in addition to its function as a positive regulator of VEC migration 
as previously demonstrated (Acevedo et al., 2004, Miao et al., 2006, Zhao et al., 
2010).  
Collectively, these findings report that NILV-Nogo-B retains transduction 
efficiency of its integrating counterparts in human VSMCs. As a direct result, this 
vector efficiently induces Nogo-B over-expression, and is as effective as int-LV-
Nogo-B in modulating phenotypic effects of VSMC migration and proliferation in 
vitro. Thereby, these data support the use of NILV-Nogo-B as a new candidate 
for therapeutic application to acute vascular injury. In conclusion, this study 
addresses the potential of NILVs for future utility in therapeutic gene transfer in 
the vasculature. 
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5.1 Introduction  
Injury-induced NIF was rescued by adenoviral-mediated Nogo-B gene delivery 
(Acevedo et al., 2004, Kritz et al., 2008), an effect mediated by Nogo-B through 
the stimulated migration of VECs (Acevedo et al., 2004), and reduced VSMC 
migration (Acevedo et al., 2004, Kritz et al., 2008) and proliferation (Kritz et 
al., 2008). Nogo-B is essential for stimulating the chemotaxis and morphogenesis 
of VECs through its engagement with the Ng-BR [presumed to be on the cell 
surface of VECs (Miao et al., 2006)] via the Akt signalling pathway (Figure 1.15) 
(Zhao et al., 2010). In terms of VSMCs, it is speculated that the negative 
regulation on VSMC migration in response to PDGF-BB by Nogo-B, possibly occurs 
through the effect of functional repression of PDGF signalling downstream of the 
receptor or by competitive antagonism of the PDGF receptor (PDGFR) tethering 
(Acevedo et al., 2004). It is understood that Nogo-B blocks VSMC proliferation 
(Kritz et al., 2008), however a definitive mechanism is unknown. It has been 
suggested that the phenotypic effect on VSMC proliferation and/or migration by 
Nogo-B could be mediated by ER-specific activities (for example modulation of 
the structure of the ER network in association with cytoskeletal structures 
and/or ER-stress mediated apoptosis) and/or facilitated through the modulation 
of intracellular signal transduction pathways (Figure 1.15) (Raines, 2004a). 
Therefore, it is important to define/validate the mechanism of action of Nogo-B, 
to help understand its ability to restrict the NIF after acute vascular injury and 
for possible future use in the clinical setting of vascular gene therapy. 
5.1.1 Association of Nogo-B with VSMC apoptosis and ER-stress  
Nogo-B (reticulon protein) is primarily found co-localised with the ER [due to its 
ER retention sequence at the C-terminal region (Raines, 2004a, Dodd et al., 
2005)] with a small fraction found within the cell-membrane of vascular cells 
(Acevedo et al., 2004). In chapter 4, it was reported that the over-expression of 
Nogo-B was greatly enhanced in VSMC lysates mediated by int-LVs or NILVs, in 
contrary to supernatants. Nogo-B over-expression co-localised with the ER in 
VSMCs has yet to be explored.  
It has been reported that the over-expression of Nogo-B can act as a pro-
apoptotic protein in various cancer cells (Li et al., 2001, Tambe et al., 2004), 
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without any known apoptosis-related motifs (Li et al., 2001). Nogo-B has the 
ability to interact with anti-apoptotic members of Bcl-2 and Bcl-xL and prevent 
their translocation to the mitochondria from the ER, and thus reducing their 
anti-apoptotic effect (Tagami et al., 2000, Watari and Yutsudo, 2003). 
Interestingly, increased amounts of Nogo-B were found in macrophage/foam 
cell-rich areas of human atherosclerotic plaques (Rodriguez-Feo et al., 2007), 
and enhanced adventitial Nogo-B expression was reported in macrophages and 
VSMCs from a rabbit balloon injury-induced NIF model (Paszkowiak et al., 2007). 
Both studies suggest that Nogo-B may potentially play a role in macrophage and 
VSMC induced apoptosis and/or plaque vulnerability/rupture (Paszkowiak et al., 
2007, Rodriguez-Feo et al., 2007). In chapter 4, the potential of NILV-Nogo-B 
induced over-expression and phenotypic effects on VSMC migration and 
proliferation in vitro was reported. In addition, it is important to assess the 
possible effects of Nogo-B over-expression on VSMC apoptosis mediated by these 
vectors.  
Oertle et al., (2003c) speculated that highly over-expressed Nogo-B induced ER-
stress-mediated apoptosis. In addition, Nogo-B over-expression has been 
demonstrated to induce ER-stress-mediated apoptosis through ER-specific 
pathways in HeLa cells (discussed later in this chapter) (Kuang et al., 2006). The 
ER has essential roles in various cellular processes, for example folding of 
secretory and membrane proteins, calcium homeostasis and lipid biosynthesis 
(Minamino and Kitakaze, 2010, Minamino et al., 2010). A variety of factors such 
as the over-expression of normal and/or incorrectly folded proteins have the 
potential to mediate the accumulation of un-folded/misfolded/abnormal protein 
aggregates, which challenges the function of the ER and this is referred to as ER-
stress (imbalance between the cellular demand for the ER function and ER 
capacity). The accumulation of proteins in the ER membrane increases its 
calcium ion permeability, and thus mediates the disruption of calcium ion 
homeostasis (calcium ion depletion of ER stores) in the ER lumen. As a 
consequence, ER-stress induces the onset of an ER protective mechanism such as 
the unfolded protein response (UPR) to maintain ER homeostasis (Minamino and 
Kitakaze, 2010, Minamino et al., 2010). However, caspase-12 an ER-specific 
caspase (specifically localised on the cytoplasmic side of the ER) is activated by 
prolonged or overwhelming ER-stress and if homeostasis can not be restored. As 
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a consequence, mediates the sequential activation of the caspase (-9, -7, -6 and 
-3) cascade, and thus induces apoptosis (Oertle et al., 2003c, Minamino and 
Kitakaze, 2010, Minamino et al., 2010). In addition, prolonged ER-stress can also 
induce apoptosis via the transcriptional induction of C/EBP homologous protein 
(CHOP) and/or c-JUN NH2-terminal kinase (JNK) signal transduction pathway 
(Myoishi et al., 2007).  
UPR signals transient attenuation of protein translation, degradation of 
abnormal/misfolded proteins, and the induction of resident-ER chaperones and 
protein folding enzymes (i.e. foldase) to augment the ER capacity for protein 
folding, assembly of proteins and degradation. UPR signalling pathway is 
triggered by the activation of three ER transmembrane sensors: the 
transcriptional factor activating transcription factor 6 (ATF6), protein kinase-like 
ER kinase (PERK) and inositol-requiring kinase 1 (IRE1) (located with their N-
terminus domain inside the lumen of the ER and C-terminus domain in the 
cytosol). When the cell is not under stress, all three UPR sensors are maintained 
in an inactive state through the interaction with an ER chaperone protein 
glucose-regulated protein 78 kDa (GRP78) also known as binding immunoglobulin 
protein (BiP). BiP is an ER resident protein and is located inside the lumen of the 
ER. When the UPR occurs, BiP releases these sensors (from their luminal 
domains) to co-ordinately regulate the UPR signalling (activation and 
transduction of unfolded protein signals across the ER membrane to the cytosol 
and the nucleus), involving the up-regulation of transcription of UPR-related 
genes encoding other resident-ER chaperones and protein folding enzymes to 
reduce the accumulation of unfolded proteins. Active ATF6 also up-regulates the 
transcription of BiP. BiP can also associate and form a complex with caspase -7 
and -12. Overall, BiP acts as a key regulator in ER-stress signalling and apoptosis, 
and a monitor of ER-stress (Lee, 2005, Minamino and Kitakaze, 2010, Minamino 
et al., 2010). 
ER-stress and/or UPR have been implicated in patho-physiology of various 
diseases, in particular CVDs (Hotamisligil, 2010, Minamino and Kitakaze, 2010, 
Tabas, 2010). Importantly, the presence of oxidised lipids, inflammation and/or 
metabolic stress in advanced atherosclerotic plaques have been reported to have 
the potential to mediate ER-stress and/or the UPR (Sanson et al., 2009, 
Hotamisligil, 2010, Minamino and Kitakaze, 2010), and as a consequence induce 
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cell death of macrophages and VSMCs, which would contribute to destabilisation 
and rupture of atherosclerotic and stenotic lesions (Hotamisligil, 2010, Minamino 
and Kitakaze, 2010). Indeed, it was reported that there was a strong association 
between ER-stress markers CHOP and BiP, and apoptosis in ruptured 
atherosclerotic plaques in 152 human coronary artery autopsy specimens. This 
suggested that ER-stress is likely to play a role in the progression of plaque 
vulnerability and occurrence of acute complications of coronary atherosclerosis 
in humans (Myoishi et al., 2007). Importantly, Nogo-B over-expression induced 
apoptosis in HeLa cells as a consequence of the ER-stress response as indicated 
in a study by Kuang et al., (2006). Results demonstrated that Nogo-B over-
expression initiated the ER overload response (EOR) (unable to adapt to the 
UPR), and consequently mediated ER-stress (indicated by an increase in BiP) and 
the disorder of ER calcium ion stores which induced ER-specific apoptotic 
pathways [caspase-12 activation and CHOP]. In addition, stable transfectants 
over-expressing Nogo-B were resistant to ER-stress-mediated apoptosis, which 
was a direct result of the protective UPR, and thus allowed cells to adapt and 
cope with large amounts of Nogo-B over-expression (Kuang et al., 2006). Taken 
together, it is important to evaluate the effect of Nogo-B over-expression 
mediated by NILVs and int-LVs on VSMC ER-stress and apoptosis.  
5.1.2 The association of Nogo-B with signal transduction  
VSMC migration and proliferation is a hallmark of NIF associated with acute 
vascular injury. There are many environmental stimuli that are associated with 
the activation of multiple intracellular signal transduction cascades in VSMCs 
(Muto et al., 2007). For example, growth factors such as PDGF-BB, basic 
fibroblast growth factor (bFGF) and epidermal growth factor (EGF) induce 
intracellular signal transduction pathways such as mitogen-activated protein 
kinases (MAPK) and phosphatidylinositol 3-kinase (PI3K)-Akt (Muto et al., 2007, 
Yu et al., 2007, Morello et al., 2009) in VSMCs. These two pathways have 
implications in the vascular response to injury and play important roles in the 
regulation of cell survival, migration, and proliferation and differentiation 
events in vascular cells (Muto et al., 2007, Yu et al., 2007, Morello et al., 2009). 
A receptor tyrosine kinase (RTK) (a membrane associated receptor) such as the 
PDGFR-beta (PDGFR-β) is activated by the binding of its ligand PDGF-BB to its 
extracellular domains, which subsequently induces proliferation, migration and 
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cell survival of VSMCs (Ferns et al., 1990, Ferns et al., 1991, Holycross et al., 
1992, Jawien et al., 1992). Upon activation, PDGFR-β receptors dimerize and are 
stimulated by auto-phosphorylation of several sites on their cytosolic domains, 
which then mediates binding of co-factors and activates signal transduction 
pathways, and subsequently exerts its down-stream effects such as regulation of 
gene expression and the cell-cycle. The PDGFR not only activates MAPK 
pathways but also the PI3K-Akt pathway (Muto et al., 2007). MAPK family 
consists of three sub-families: extracellular signal-regulated kinase (ERK; ERK 1 
& 2), c-Jun N-terminal kinase (JNK) and p38-MAPK (Yu et al., 2007). All three 
MAPK pathways have been demonstrated to participate in PDGF-BB-induced 
VSMC proliferation and migration, using recombinant adenoviral vectors 
containing dominant-negative mutants of ERK 1 & 2, p38-MAPK and JNK (Zhan et 
al., 2003). In addition, it is well-established that ERK 1 & 2 activation is 
important in PDGF-BB-mediated VSMC migration and proliferation (Bornfeldt et 
al., 1997, Graf et al., 1997, Nelson et al., 1998, Muto et al., 2007, Yu et al., 
2007). Evidently, the activation of the PI3K-Akt pathway also plays a pivotal role 
in the regulation of VSMC contractility and induced proliferation (Shigematsu et 
al., 2000, Stabile et al., 2003, Muto et al., 2007, Morello et al., 2009). In terms 
of bone-marrow-derived monocyte/macrophage (BMM) motility and morphology 
in a hindlimb ischaemia murine model, Nogo-B does not mediate any difference 
in the activity of ERK1 & 2, p38-MAPK and PI3K-Akt pathways, as demonstrated 
in BMM in wild-type mice in contrast to Nogo-A/B knockout mice after 
stimulation with colony stimulating factor-1 (CSF-1) (Yu et al., 2009). In 
addition, there are no current reports which have assessed the mechanism of 
action of Nogo-B in VSMCs association with ERK 1 & 2 and PI3K-Akt pathways. 
The aim of this chapter was to assess the effect of Nogo-B over-expression in 
VSMCs in vitro, in terms of the following: 
• Apoptosis (caspase-3/7)  
• Co-location with the ER 
• ER-stress 
• Signal transduction of ERK 1 & 2 and Akt activity 
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5.2 Results 
5.2.1 Assessment of the effects of lentiviral-mediated Nogo-B 
over-expression on VSMC apoptosis 
After 48 h of VSMC quiescence (induced by serum-deprivation), VSMCs were 
infected with either int-LV-Nogo-B, NILV-Nogo-B or their LV-eGFP control at a 
MOI of 50 or un-infected. VSMC apoptosis quantified using a caspase-3/7 activity 
assay measuring luminescence at 5 d post-infection and then normalised to mg 
of total protein. Results demonstrated that int-LV-Nogo-B and NILV-Nogo-B 
mediated Nogo-B over-expression in VSMCs did not significantly induce caspase-
3/7 activation (Figure 5.1). Ad-Nogo-B (as mentioned in chapter 4 as Ad-full-
length-Nogo-B but now referred here as Ad-Nogo-B in this chapter) versus ad-
eGFP (at MOI of 100) or un-infected (no polybrene) were used as a control for 
caspase-3/7 activity; indicated no significant increase in caspase-3/7 activation 
(Figure 5.1).  
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Figure 5.1. Effect of Nogo-B over-expression mediated by LVs on VSMC apoptosis.  
VSMCs were seeded (at a cell density of 0.25 × 104/well on a 96-well plate and quiescence of 48 
h induced by serum-free culture media prior to LV infection) and infected with LVs in 15 % serum 
(in the presence of 8 µg/ml of polybrene for 18 h incubation) at a MOI of 50 or un-infected. 
Additional, VSMCs were infected with Ad-eGFP or Ad-Nogo-B at MOI of 100 in the presence of no 
polybrene for 18 h exposure. VSMC apoptosis was assessed using a caspase-3/7 activity assay 5 d 
post-infection and luminescence was measured in relative luminescence units (RLU) which was 
then normalised to the total mg of protein (measured by a BCA assay with optical density 
measured at 570 nm wavelength). Mean value ± S.E.M of patient sample repeated in triplicate. 
Three independent experiments performed [n=3 (representative of each other), cell 
population/number of individual VSMC preparations used]. No significant difference indicated 
with: int-LV-Nogo-B vs. int-LV-eGFP or un-infected; NILV-Nogo-B vs. NILV-eGFP or un-infected, 
and Ad-Nogo-B vs. Ad-eGFP or un-infected. All statistical analysis was carried out by one-way 
ANOVA for Bonferroni’s post-test. VSMC, vascular smooth muscle cell; MOI, multiplicity of 
infection; Ad, adenoviral vector serotype 5; VSMC, vascular smooth muscle cells; LV, lentiviral 
vectors; int-LV, integrating-LV; NILV, non-integrating-LV.  
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5.2.2 Over-expression of Nogo-B co-localised with the ER 
The over-expression of Nogo-B co-localisation with the ER in VSMCs mediated by 
int-LV-Nogo-B at a MOI of 50 was investigated. Immunocytofluorescent staining 
was performed at 5 d post-infection for the detection of the co-location of ER 
PDI (mouse monoclonal anti-human ER PDI IgG2a antibody) and Nogo-B (goat 
polyclonal anti-human Nogo IgG antibody). A corresponding Alexa-Fluor®-594 
(donkey anti-mouse IgG antibody, for far red fluorescence) or Alexa-Fluor®-488 
(donkey anti-goat IgG secondary antibody, for green fluorescence) secondary 
antibody was used and confocal microscopy was carried out to observe if the 
over-expression of Nogo-B co-localised with the ER PDI by yellow fluorescence 
(green and far red fluorescence merged, respectively). Increased expression 
levels of Nogo-B were observed co-localised with the ER PDI in VSMCs mediated 
by int-LV-Nogo-B compared to endogenous levels of Nogo-B in the un-infected 
VSMCs, as illustrated from fluorescent micrographs in Figure 5.2 A. Isotype-
matched negative controls were carried out in parallel. No far red, green and 
yellow immunocytofluorescent staining was observed with the Isotype-matched 
negative control, thus no non-specific binding of the anti-Nogo-B antibody and 
the anti-ER PDI antibody (Figure 5.2 B). 
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Figure 5.2. Nogo-B over-expression co-localisation with the ER in VSMCs indicated by 
immunocytofluorescence.  
Immunocytofluorescent staining was carried out in VSMCs (seeded at a cell density of 0.5 × 
104/well on an 8-well chamber slide) at 5 d post-infected with int-LV-Nogo-B (in presence of 0.5 
µg/ml of polybrene for 18 h incubation) at a MOI of 50 or un-infected, in permeabilised 
conditions. (A) A mouse monoclonal anti-human ER PDI IgG2a antibody (10 µg/ml) and Alexa-
Fluor®-594 (far red fluorescence) donkey anti-mouse IgG secondary antibody (4 µg/ml) were 
used to detect ER PDI. A goat polyclonal anti-human Nogo IgG antibody (2 µg/ml) and Alexa-
Fluor®-488 (green fluorescence) donkey anti-goat IgG secondary antibody (4 µg/ml) were used to 
detect Nogo-B expression. Nogo-B co-localisation with the ER (merge) in VSMCs was illustrated by 
yellow fluorescence. (B) Immunocytofluorescent staining using isotype-matched negative 
controls (mouse IgG2a and goat IgG) antibodies. Merged fluorescent images illustrated. 20 µm 
scale bar applicable to all panels (magnification x 630). Representative of n=1 (cell 
population/number of individual VSMC preparations used) in triplcate. VSMC, vascular smooth 
muscle cell; int-LV, integrating lentiviral vectors; DAPI, 4’, 6-diamidino-2-phenylindole; ER PDI, 
endoplasmic reticulum protein disulfide isomerase. 
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5.2.3 Assessment of the effects of Nogo-B over-expression on 
BiP 
For the rest of this chapter, Ad-Nogo-B was used because low titre preparations 
of LVs limited their use for assessing the effects of Nogo-B over-expression on 
VSMC ER-stress signalling and ERK 1 & 2 and PI3K-Akt signal transduction by 
Western-immunoblotting. However, for mechanistic studies this is not 
problematic since gene transfer to VSMCs with LV and Ad is very similar (Dishart 
et al., 2003a). The effect of Nogo-B over-expression in VSMCs on BiP expression 
levels was evaluated. VSMCs were seeded and infected Ad-Nogo-B or Ad-eGFP at 
a MOI of 100 or un-infected. VSMC lysates were assessed 5 d post-infection by 
Western immuno-blotting (normalised to 20 µg of protein loading) to detect BiP 
expression at approximately 75-78 kDa. Results indicated that the over-
expression of Nogo-B mediated by Ad-Nogo-B did not induce BiP expression, 
compared to the Ad-eGFP control and un-infected VSMCs (SM α-actin indicated 
protein loading) (Figure 5.3). 
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Figure 5.3. Effect of Nogo-B over-expression on BiP expression levels in VSMCs.  
VSMCs were seeded (at a cell density of 8 × 104/well on a 6-well plate) and infected with Ad-
Nogo-B or Ad-eGFP at a MOI of 100 (18 h exposure time), or un-infected. At 5 d post-infection, 
VSMC lysates [normalised to 20 µg of protein loading (protein concentration determined by BCA 
assay)] were assessed for BiP expression levels (75-78 kDa) by Western immuno-blotting [a rabbit 
polyclonal anti-human BiP IgG antibody (1 µg/ml)]. A mouse monoclonal anti-human SM α-actin 
IgG2a antibody was used to detect SM α-actin (42 kDa) in VSMC lysates for protein loading. BiP 
expression levels in VSMC lysates were normalised to SM α-actin using densitometry. Mean value 
± S.E.M of patient sample repeated in triplicate. Two independent experiments performed [n=2 
(representative of each other), cell population/number of individual VSMC preparations used]. 
No significant difference indicated with Ad-Nogo-B vs. Ad-eGFP or un-infected. All statistical 
analysis was carried out by one-way ANOVA for Bonferroni’s post-hoc analysis. VSMC, vascular 
smooth muscle cell; Ad, adenoviral vector serotype 5; BiP, binding immunoglobulin protein; SM 
α-actin, smooth muscle alpha-actin. 
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5.2.4 Assessment of the effects of Nogo-B over-expression on 
VSMC intracellular signalling mechanism 
The effects of Nogo-B over-expression on VSMC signal transduction involving 
phosphorylation of Akt (p-Akt) and ERK 1 & 2 (p-ERK 1 & 2) were assessed. First, 
the percentage of serum used to cause quiescence in VSMCs which exhibit low 
Akt and ERK 1 & 2 activity was optimised. VSMCs were cultured in 0 %, 1 % or 15 
% serum, and subsequently after 48 h of culture these VSMC lysates were 
collected and assessed by Western immuno-blotting analysis for Akt and ERK 1 & 
2 activity. Results indicated that 1 % serum mediated a low level of p-Akt (60 
kDa) and p-ERK 1 (44 kDa), which was similar to 0 % serum but dissimilar to 15 % 
serum (Figure 5.4). VSMC lysates were normalised to 15 µg of protein loading, 
and Akt (60 kDa) and ERK1 (44 kDa) indicated equal protein loading, 
respectively. Phorbol 12-myristate 13-acetate (PMA) was used as a positive 
control for the activation of ERK 1 & 2 signalling in VSMCs. Second, time points 
of 15 % serum-stimulation which exhibit high Akt and ERK 1 & 2 activity in VSMCs 
were optimised. VSMC quiescence was induced with 1 % serum for 48 h and VSMC 
lysates were collected before serum-stimulation (0 min) and at 5 min, 15 min, 3 
h and 24 h after serum-stimulation, and subsequently assessed by Western 
immuno-blotting analysis. In contrast to un-stimulated VSMCs (0 min), results 
demonstrated that 15 % serum-stimulation at 5 min, 15 min and 3 h greatly up-
regulated p-Akt and p-ERK 1 & 2 levels (44 & 42 kDa, respectively) (Figure 5.5). 
VSMC lysates were normalised to 15 µg of protein, and Akt and GAPDH (36 kDa) 
indicated equal protein loading, respectively. 
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Figure 5.4. Optimisation for the percentage of serum to induce VSMC quiescence with low p-
Akt and p-ERK 1 & 2 activity.  
VSMCs were seeded (at a cell density of 2.5 × 105/well on a 6-well plate), and after 48 h of 
culture in 0 %, 1 % or 15 % serum, VSMC lysates [normalised to 15 µg of protein loading (protein 
concentration determined by BCA assay)] were assessed for (A) p-Akt (60 kDa) and (B) p-ERK 1 & 
2 (44 & 42 kDa) activity by Western immuno-blotting [mouse monoclonal anti-human p-Akt IgG2b 
antibody (1/1000 dilution) and mouse monoclonal anti-human p-ERK 1/2 IgG1 antibody (1 
µg/ml)]. A rabbit monoclonal anti-human Akt IgG antibody (1/1000 dilution) was used to detect 
Akt (60 kDa) and a rabbit polyclonal anti-human ERK 1 IgG antibody (0.4 µg/ml) was to detect 
ERK 1 (44 kDa) in VSMC lysates for protein loading, respectively. Phorbol 12-myristate 13-acetate 
(PMA) at 50 µM in serum-free culture media was used (30 min incubation) as a positive control 
for the activation of p-ERK 1 & 2 signalling in VSMCs. (A) p-Akt activity for each percentage 
serum-stimulation in VSMC lysates was normalised to Akt using densitometry. Mean value ± S.E.M 
(for technical replicates) of patient sample repeated in duplicate and n=1 (cell 
population/number of individual VSMC preparations used). (B) p-ERK 1 & 2 activity for each 
percentage serum-stimulation in VSMC lysates was normalised to ERK 1 using densitometry. Mean 
value ± S.E.M (for technical replicates) of patient sample repeated in duplicate and n=1 (cell 
population/number of individual VSMC preparations used). VSMC, vascular smooth muscle cell; p-
Akt, phosphorylated-Akt; p-ERK 1 & 2, phosphorylated-ERK 1 & 2. 
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Figure 5.5. Optimisation for time points of 15 % serum-stimulation in VSMCs with high p-Akt 
and p-ERK 1 & 2 activity.  
VSMCs were seeded (at a cell density of 2.5 × 105/well on a 6-well plate) and cultured for 48 h in 
1 % serum for VSMC quiescence. VSMC lysates [normalised to 15 µg of protein loading (protein 
concentration determined by BCA assay)] of un-stimulated or 15 % serum-stimulated VSMCs at  5 
min, 15 min, 3 h or 24 h were assessed for (A) p-Akt (60 kDa) and (B) p-ERK 1 & 2 (44 & 42 kDa) 
activity by Western immuno-blotting [mouse monoclonal anti-human p-Akt IgG2b antibody 
(1/1000 dilution) and mouse monoclonal anti-human p-ERK 1/2 IgG1 antibody (1 µg/ml)]. A 
rabbit monoclonal anti-human Akt IgG antibody (1/1000 dilution) was used to detect Akt (60 kDa) 
and a mouse monoclonal anti-human GAPDH IgG1 antibody (0.2 µg/ml) was to detect GAPDH (36 
kDa) in VSMC lysates for protein loading, respectively. Phorbol 12-myristate 13-acetate (PMA) at 
50 µM in serum-free culture media was used (30 min incubation) as a positive control for the 
activation of p-ERK 1 & 2 signalling in VSMCs. (A) p-Akt activity at each time point of serum-
stimulation in VSMC lysates was normalised to Akt using densitometry. Mean value ± S.E.M (for 
technical replicates) of patient sample repeated in duplicate and n=1 (cell population/number of 
individual VSMC preparations used). (B) p-ERK 1 & 2 activity at each time point of serum-
stimulation in  VSMC lysates was normalised to GAPDH using densitometry. Mean value ± S.E.M 
(for technical replicates) of patient sample repeated in duplicate and n=1 (cell 
population/number of individual VSMC preparations used). VSMC, vascular smooth muscle cell; p-
Akt, phosphorylated-Akt; p-ERK 1 & 2, phosphorylated-ERK 1 & 2. 
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As a positive control for adenoviral-mediated gene transfer of Nogo-B, Figure 5.6 
indicated Ad-Nogo-B (3.27 × 1010 pfu/ml) at a MOI 100 mediated over-expression 
of Nogo-B in VSMCs, in contrast to Ad-eGFP control (2.3 × 1010 pfu/ml) and un-
infected VSMCs (Kritz et al., 2008). Third, VSMCs infected with either Ad-Nogo-B 
or Ad-eGFP at a MOI of 100 or un-infected were assessed 5 d post-infection. At 3 
d post-infection VSMC quiescence was induced with 1 % serum for 48 h, and 
subsequently 15 % serum-stimulated for 5 min or 3 h or un-stimulated (0 min). 
VSMC lysates were assessed for Akt and ERK 1 & 2 activity by Western immuno-
blotting. Results indicated that Ad-Nogo-B had no effect on the level of p-Akt in 
VSMCs after serum-stimulation of 5 min and 3 h, compared to Ad-eGFP control 
and un-infected VSMCs (Akt indicated protein loading) (Figure 5.7). With regards 
to the ERK 1 & 2 signal transduction pathway, results demonstrated that Ad-
Nogo-B significantly down-regulated p-ERK 1 & 2 after 3 h of serum-stimulation, 
in contrast to Ad-eGFP control and un-infected VSMCs (1.13 ± 0.030 p-ERK 1 & 
2/SM α-actin ODU/mm2 vs. 1.48 ± 0.013 p-ERK 1 & 2/SM α-actin ODU/mm2 or 
1.53 ± 0.074 p-ERK 1 & 2/SM α-actin ODU/mm2, respectively, p < 0.01) (Figure 
5.8 B). VSMCs lysates were normalised to 20 µg of protein loading, and SM α-
actin (42 kDa) indicated protein loading (Figure 5.8).  
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Figure 5.6. Ad-Nogo-B transduction in VSMCs indicated by immunocytofluorescence. 
Immunocytofluorescent staining was carried out in VSMCs (seeded at a cell density of 0.5 × 
104/well on an 8-well chamber slide) transduced with Ad-eGFP, Ad-Nogo-B or un-infected (18 h 
exposure) at a MOI of 100 for 5 d post-infection in permeabilised conditions. (A) A goat 
polyclonal anti-human Nogo (to the N-terminus region) IgG antibody (2 µg/ml) along with its 
corresponding Alexa-Fluor®-555 (red fluorescence) donkey anti-goat IgG secondary antibody (4 
µg/ml) was used to detect Nogo-B expression. (B) Immunocytofluorescent staining using an 
isotype-matched negative control (goat IgG) primary antibody. 20 µm scale bar (magnification x 
630). Representative of n=1 (cell population/number of individual VSMC preparations used) in 
triplcate. VSMC, vascular smooth muscle cell; Ad, adenoviral vector serotype 5. 
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Figure 5.7. Effect of Nogo-B over-expression on p-Akt activity levels in VSMCs.  
VSMCs were seeded (at a cell density of 8 × 104/well on a 6-well plate) and infected with Ad-
Nogo-B or Ad-eGFP at a multiplicity of infection (MOI) of 100 (18 h exposure time), or un-
infected. At 3 d post-infection, VSMC quiescence was induced using 1 % serum for 48 h. 
Subsequently at 5 d post-infection, VSMC lysates were collected (A) at 0 min (un-stimulated) or 
15 % serum-stimulation at (B) 5 min or (C) 3 h (protein concentration determined by BCA assay), 
and assessed for p-Akt (60 kDa) activity by Western immuno-blotting [mouse monoclonal anti-
human p-Akt IgG2b antibody (1/1000 dilution)]. A rabbit monoclonal anti-human Akt IgG antibody 
(1/1000 dilution) was used to detect Akt (60 kDa) in VSMC lysates for protein loading. Lysates 
from VSMCs serum-stimulated for 5 min from the optimisation experiment were used as a 
positive control (+ ve) for p-Akt Western immuno-blotting [(A) un-stimulated and (B) 5 min 
serum-stimulated VSMC lysates were from the same Western immuno-blot]. At (B) 5 min and (C) 
3 h of serum-stimulation, p-Akt activity levels in VSMC lysates was normalised to Akt using 
densitometry. Mean value ± S.E.M (for technical replicates) of patient sample repeated in 
duplicate and n=1 (cell population/number of individual VSMC preparations used). No significant 
difference with Ad-Nogo-B vs. Ad-eGFP or un-infected at 5 min or 3 h serum-stimultaion. All 
statistical analysis was carried out by one-way ANOVA for Bonferroni’s post-hoc analysis. VSMC, 
vascular smooth muscle cell; Ad, adenoviral vector serotype 5; p-Akt, phosphorylated-Akt. 
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Figure 5.8. Effect of Nogo-B over-expression on p-ERK 1 & 2 activity levels in VSMCs.  
VSMCs were seeded (at a cell density of 8 × 104/well on a 6-well plate) and infected with Ad-
Nogo-B or Ad-eGFP at a multiplicity of infection (MOI) of 100 (18 h exposure time), or un-
infected. At 3 d post-infection, VSMC quiescence was induced with 1 % serum for 48 h. 
Subsequently after 5 d post-infection, VSMCs were (A) un-stimulated at 0 min or (B) 15 % serum-
stimulated at 3 h, and lysates [normalised to 20 µg of protein loading (protein concentration 
determined by BCA assay)] were assessed for p-ERK 1 & 2 (44 & 42 kDa) activity by Western 
immuno-blotting [mouse monoclonal anti-human p-ERK 1 & 2 IgG1 antibody (1 µg/ml)]. A mouse 
monoclonal anti-human SM α-actin IgG2a antibody (0.4 µg/ml) was used to detect SM α-actin (42 
kDa) in VSMC lysates for protein loading. Phorbol 12-myristate 13-acetate (PMA) at 50 µM in 
serum-free culture media was used (30 min incubation) as a positive control for the activation of 
p-ERK 1 & 2 signalling in VSMCs. At (B) 3 h of serum-stimulation, p-ERK 1 & 2 activity levels in 
VSMC lysates was normalised to SM α-actin using densitometry. Mean value ± S.E.M of patient 
sample repeated in triplicate. Two independent experiments performed [n=2 (representative of 
each other), cell population/number of individual VSMC preparations used]. * indicates p < 0.01 
vs. Ad-eGFP or un-infected. All statistical analysis was carried out by one-way ANOVA for 
Bonferroni’s post-hoc analysis. VSMC, vascular smooth muscle cell; Ad, adenoviral vector 
serotype 5; p-ERK 1 & 2, phosphorylated-ERK 1 & 2; SM α-actin, smooth muscle alpha-actin. 
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5.3 Discussion 
In this chapter, the mechanism of action of Nogo-B on VSMCs was explored.  
• It was established that Nogo-B over-expression mediated by int-LVs or 
NILVs did not induce VSMC apoptosis.  
• Over-expression of Nogo-B mediated by int-LV was observed co-localised 
with the ER in VSMCs.  
• In addition, results suggested that Nogo-B over-expression in VSMCs did 
not mediate ER-stress signalling.  
• Interestingly, results demonstrated that Nogo-B over-expression in VSMCs 
did not have an effect on Akt activity; however ERK 1 & 2 activation was 
significantly down-regulated.   
Previously it was reported by Kritz et al., (2008) that the over-expression of 
Nogo-B mediated by adenoviral gene transfer reduced VSMC migration and 
proliferation in vitro, and did not induce VSMC apoptosis assessed by trypan blue 
exclusion assay and caspase-3/7 assay. Moreover, in a porcine vein graft bypass 
grafting model, Ad-Nogo-B rescued the injury-induced NIF associated with a 
reduction in VSMC proliferation, and no effect on VSMC apoptosis which was 
evaluated with terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL) staining (Kritz et al., 2008). In relevance to this, results from a caspase-
3/7 activity assay in this study indicated that Nogo-B over-expression mediated 
by int-LVs and NILVs in VSMCs in vitro did not induce apoptosis in these vascular 
cells. However, it should be noted that this caspase-3/7 assay carried out in this 
study is not without its limitations, and only measures caspase-3/7 activity in 
VSMCs transduced with int-LV-Nogo-B, NILV-Nogo-B or LV-eGFP controls or un-
transduced VSMCs in parallel to Ad-Nogo-B and Ad-eGFP [used as a negative 
control for caspase-3/7 activity mediated by Nogo-B over-expression (Kritz et 
al., 2008)]. Additionally, positive controls for VSMC apoptosis possibly should 
have been considered in this assay, for example the combination of interleukin-1 
beta (IL-1β), tumour necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) 
which are known to induce VSMC apoptosis (Geng et al., 1996). Furthermore, 
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results were deduced using only a caspase-3/7 activity assay, therefore it is 
worth considering further apoptosis assays such as Annexin V and/or TUNEL 
staining to strongly confirm these results observed with int-LV-Nogo-B and NILV-
Nogo-B. Taken together, both studies evidently confirm that regulation of 
apoptosis is not a mechanism for Nogo-B in VSMCs. In correlation to this, 
previous publications have indicated that non-cancerous cells are resistant to 
apoptosis induced by Nogo-B over-expression (Li et al., 2001), and stable over-
expression of Nogo-B in certain types of cancer did not significantly induce a 
pro-apoptotic effect compared to wild-type control (Oertle et al., 2003c).  
Interestingly, results demonstrated that the over-expression of Nogo-B mediated 
by int-LV was observed co-localised with the PDI ER in VSMCs. It is possible that 
Nogo-B exerts its phenotypic effects on VSMCs in association with ER-specific 
pathways, such as the regulation of the structure of the ER network in 
association with cytoskeletal structures (Raines, 2004a), and therefore this 
would need further investigation. It is important to consider completing this in 
vitro study by determining NILV-Nogo-B mediated over-expression co-localisation 
with the ER in VSMCs. In addition, 2 % of the total Nogo-B protein associated 
with vascular cells is found within the cell-membrane (Acevedo et al., 2004). 
Therefore, it is also worth considering assessing int-LV-Nogo-B, NILV-Nogo-B and 
Ad-Nogo-B mediated over-expression and its co-localisation with the cell-
membrane (in parallel to un-infected VSMCs) by immunocytofluorescence, which 
may also help with defining the mechanism of action of Nogo-B with regards to 
phenotypic effects on VSMC proliferation and migration.  
Here, results indicated that the amount of BiP protein did not change after 
Nogo-B over-expression in VSMCs. Therefore, it can be suggested that the over-
expression of Nogo-B does not induce ER-stress in VSMCs, which is an apparent 
contradiction to findings previously reported by Kuang et al., (2006), as 
previously discussed. BiP is a key ER chaperone, regulator in ER-stress/UPR 
signalling and a monitor of cells under ER-stress (Lee, 2005). However, there are 
other markers of ER-stress such as of ATF6, IRE1, PERK and/or CHOP, which 
could have been considered to fully establish that Nogo-B over-expression does 
not induce ER-stress in VSMCs. Additionally, positive controls for ER-stress 
induction could have been considered in this assay, for example tunicamycin and 
staurosporine, which are well-established ER-stress inducers. In addition, it is 
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important to evaluate the effects of Nogo-B over-expression mediated by NILV-
Nogo-B and int-LV-Nogo-B on ER-stress in VSMCs in vitro, and thus further 
experiments should be considered.   
Indeed, Nogo-B over-expression mediated by Ad-Nogo-B inhibited PDGF-BB-
induced VSMC migration (Acevedo et al., 2004, Kritz et al., 2008) and 
proliferation, and blocked serum-stimulated VSMC proliferation (Kritz et al., 
2008). In chapter 4, it was reported that int-LV-Nogo-B and NILV-Nogo-B 
mediated Nogo-B over-expression and reduced serum-stimulated human VSMC 
migration and proliferation in vitro. As mentioned previously, it is speculated 
that Nogo-B’s mechanism of action leading to phenotypic effects on VSMC 
migration and/or proliferation may be governed through intracellular signal 
transduction cascades (Acevedo et al., 2004, Raines, 2004a), such as ERK 1 & 2 
and PI3K-Akt pathways [both cascades are well known signal transduction 
pathways for VSMC migration and proliferation (Bornfeldt et al., 1997, Graf et 
al., 1997, Nelson et al., 1998, Shigematsu et al., 2000, Stabile et al., 2003, Zhan 
et al., 2003, Muto et al., 2007, Yu et al., 2007, Morello et al., 2009)]. In relation 
to this, results in this chapter demonstrated that the over-expression of Nogo-B 
in VSMC reduced the activation of ERK 1 & 2 signalling cascade induced by 
serum-stimulation unlike the PI3K-Akt pathway, and therefore could have 
implications in phenotypic effects on VSMC migration and proliferation. No 
difference in PI3K-Akt activation possibly correlates with the fact that the Ng-BR 
has been described to be necessary for Nogo-B and VEGF induced chemotaxis 
and morphogenesis of VECs, in vascular maintenance and remodelling and 
angiogenesis (Miao et al., 2006, Zhao et al., 2010). This mechanistic effect is 
mediated by the activation of the PI3K pathway, via the phosphorylation of Akt 
(Zhao et al., 2010). Results in this current study, were determined using a well-
established signal transduction activity assay (Nelson et al., 1998, Kaplan-
Albuquerque et al., 2003) followed by Western-immunoblotting. These results 
were determined by Western immunoblotting for p-ERK 1 & 2 normalised to SMα-
actin. This was because, problems were encountered with the total ERK antibody 
used in the optimisation study for the percentage of serum. However, it is 
important to normalise to the total ERK, in order to understand the proportion 
of ERK which is phosphorylated and to verify the total ERK present was equal in 
all VSMC populations, and therefore should be corrected in further work carried 
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out. Additionally, ELISA assays assessing the levels of total and phosphorylated 
ERK 1 & 2 and PI3K-Akt should be considered for confirming these results 
obtained with Ad-Nogo-B. Furthermore for completeness, it is important to 
assess the effects of int-LV-Nogo-B and NILV-Nogo-B on VSMC ERK 1 & 2 and 
PI3K-Akt activation, and therefore will require further investigation.     
Taken together, all results here in this chapter provide the beginning of a long 
investigation into Nogo-B’s mechanism of action on phenotypic effects on VSMC 
migration and proliferation. Indeed, it has been speculated that Nogo-B may 
potentially exert its effect on inhibition of VSMC migration and proliferation by 
competitive antagonism of the PDGFR binding (Acevedo et al., 2004, Kritz et al., 
2008), and thus further experiments such as pull-down assays should be 
considered. VEC function of Nogo-B is mediated via the Ng-BR (Miao et al., 2006, 
Zhao et al., 2010) which is highly expressed in VECs (Miao et al., 2006). The Ng-
BR is presumed to reside at the cell surface of VECs as a receptor for Nogo-B 
(Miao et al., 2006), and evidently is localised with the ER in HeLa cells (Harrison 
et al., 2009). Interestingly, the Ng-BR consists of an intrinsically unstructured 
ectodomain (no secondary and tertiary structures) and a partially folded 
cytoplasmic domain (with secondary structures but no tertiary structures). It has 
been suggested these unusual properties of Ng-BR could be advantageous and 
important for its biological functions, including signal transduction, cytoskeletal 
organisation, ER-specific pathways and maintenance of membrane structure (Li 
and Song, 2007). Nogo-B mediated VSMC phenotypic modulation could 
potentially be facilitated via the Ng-BR; however this is currently unknown and 
will require further investigation.  
The Rho kinase family monomer G proteins, Cdc42 (cell division control protein 
42 homolog), Rac (Ras-related C3 botulinum toxin substrate) and Rho (Ras 
homolog gene family protein) and their activation, play a pivotal role in induced 
cell migration by the control of the intracellular cytoskeletal architecture, such 
as reconstruction of the actin filaments (actin polymerisation) (Muto et al., 
2007). In relation to this, Nogo-B has been reported to co-localise with Rac in 
the ER and plasma membrane of monocytes/macrophages, and is necessary for 
motility. The loss of Nogo-B in macrophages derived from Nogo-A/B knock-out 
mice demonstrated reduced macrophage migration due to impaired Rac 
activation (Yu et al., 2009). Furthermore, another study indicated the 
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association of Nogo-B with cytoskeletal structures in human monocyte-derived 
macrophages. Nogo-B was found co-localised in cell protrusions of migrating 
macrophages as well as with actin/Rho/Rac regions and the tubulin network 
(Schanda et al., 2011). Both studies support that Nogo-B has a possible influence 
on cytoskeletal organisation and regulation in cell migration (Yu et al., 2009, 
Schanda et al., 2011). Therefore, it is possible that the Rho kinase family 
pathway could have implications to Nogo-B’s function in the inhibition of VSMC 
migration, and thus will require additional analysis.   
Collectively, Nogo-B over-expression does not induce VSMC apoptosis and ER-
stress. Moreover, the over-expression of Nogo-B reduces ERK 1 & 2 activation in 
VSMCs, unlike Akt signalling; this may have possible implications in VSMC 
migration and proliferation. Figure 5.9 illustrates the working hypothesis of the 
mechanism of action of Nogo-B on VSMC phenotypic modulation. These results 
provide for the first time, an insight into Nogo-B’s possible mechanisms of action 
leading to phenotypic effects on VSMC migration and proliferation.  
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Figure 5.9. Mechanism of action of Nogo-B on VSMC phenotypic effects. 
This is a schematic diagram illustrating the working hypothesis on Nogo-B’s mechanism of action 
on VSMC phenotypic effects and for future work that could be subsequently 
addressed/investigated (in red). 
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The main focus of this thesis was to construct and assess a suitable candidate 
NILV for potential application to vascular gene therapy in the setting of acute 
vascular injury. Undoubtedly, LVs are highly efficient for vascular cell gene 
transfer (Dishart et al., 2003a, Cefai et al., 2005, Qian et al., 2006, Yang et al., 
2010). A hypothesis for this body of work was to test whether NILVs could have 
the potential to be very useful for vascular gene delivery (George et al., 2006, 
White et al., 2007), due to the reduction of host genome integration (Yanez-
Munoz et al., 2006, Apolonia et al., 2007). For the first time, this thesis reported 
the feasibility of NILVs for use in vascular cell gene transfer studies, especially 
the optimised SFFV-driven VSV-g pseudotyped NILV, which provided efficient 
transgene expression in VECs and VSMCs in vitro. To follow on from this, these 
selected VSV-g pseudotyped NILVs were then used for therapeutic gene transfer 
analysis in VSMCs in vitro. This thesis supports the use of NILV-Nogo-B as a 
candidate for therapeutic application to acute vascular injury. Similar to int-LV-
Nogo-B, NILV-Nogo-B was an efficient vector system for Nogo-B gene transfer to 
VSMCs, which led to phenotypic effects on migration and proliferation in vitro. 
Results in this thesis confirm previous studies (Acevedo et al., 2004, Kritz et al., 
2008), demonstrating that Nogo-B is a favourable candidate therapeutic gene for 
the prevention of NIF associated with acute vascular injury. Therefore, more 
broadly, NILVs have the potential to deliver other therapeutic genes which are 
relevant for the prevention of vascular abnormalities in the context of ISR 
and/or vein graft failure, and for example these include: eNOS (Janssens et al., 
1998, Varenne et al., 1998); inducible nitric oxide synthase (iNOS) (Kibbe et al., 
2001); TIMP-1 (George et al., 1998b, Ramirez Correa et al., 2004); TIMP-2 
(George et al., 1998a, Hu et al., 2001); TIMP-3 (George et al., 2000, Akowuah et 
al., 2005, Johnson et al., 2005) and p53 (George et al., 2001, Wan et al., 2004). 
Clinical and future implications 
This work addressed the potential of this new candidate NILV-Nogo-B for future 
use in vascular cell gene delivery studies, with justification to take forward to in 
vivo models. For example, to assess the potential effectiveness of NILV-Nogo-B 
(in parallel to int-LV-Nogo-B and along with their LV-eGFP controls) mediated 
gene delivery in appropriate preclinical acute vascular injury models, such as a 
human saphenous vein ex vivo organ culture model (George et al., 2000, George 
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et al., 2001), a saphenous vein interposition graft in vivo porcine model (George 
et al., 2000, Kritz et al., 2008) and a porcine in-stent in vivo model.   
Catheter-mediated in vivo gene delivery method has been used in numerous 
investigations, which have reported efficient and effective intravascular 
therapeutic gene transfer in preclinical animal models of PCI, and as a result 
mediated the prevention of the NIF (Luo et al., 2004, Numaguchi et al., 2004, 
Gao et al., 2006, Qian et al., 2006, Nakano et al., 2007). A study by Nakano et 
al., (2007) demonstrated that a percutaneous catheter-based vector delivery 
system of adenoviral-mediated anti-monocyte chemoattractant gene transfer 
attenuated the NIF in a primate ISR model. With regards to a porcine in-stent in 
vivo model, the proposed delivery for NILV-Nogo-B would be to directly deliver 
the vector to the inner vessel/artery wall using a microporous balloon infusion 
catheter during stent intervention (Coats et al., 2008). This infusion catheter-
based gene delivery has previously been used, and successfully delivered 
lentiviral-mediated gene transfer of VEGF to porcine femoral arteries (Gao et 
al., 2006) and EC-SOD to rabbit carotid arteries (Qian et al., 2006) during acute 
vascular injury in vivo.  
First to be addressed would be the assessment of efficiency and longevity of 
eGFP expression mediated by SFFV-driven VSV-g pseudotyped int-LV and NILV in 
a porcine in-stent in vivo model, delivered via this microporous balloon 
catheter-based delivery system (as described above) immediately following 
coronary artery stenting. Each LV-eGFP would be administered at various doses 
(units in iu/ml). In terms of efficiency, vessels would be harvested at an early 
post-infection time point [for example, 7 days (Qian et al., 2006)] and coronary 
artery sections assessed for detection of eGFP co-localised with SM-α actin using 
standard immunohistochemical techniques. This would define the optimised dose 
of LV and also whether NILV mediated efficient gene transfer at this early time 
point. The optimised dose would then be used for a subsequent study to quantify 
longevity. Here, vessels would be harvested at a late time-point post-infection 
[for example 28 days (Johnson et al., 2005, Kritz et al., 2008)] and coronary 
artery sections assessed as previously mentioned. This would confirm the 
longevity of int-LV and define the potential longevity of NILV.  
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Once optimised, next to be investigated would be the effect of over-expression 
of Nogo-B mediated by NILV or int-LV compared to their LV-eGFP controls on the 
status of ISR in this porcine in vivo model. Arteries would be assessed 7 days 
post-infection/stent deployment for the detection of Nogo-B over-expression 
(Johnson et al., 2005, Kritz et al., 2008). For the status of the vascular injury-
induced NIF, vessels would be evaluated at 28 days post-transduction/stenting 
using quantitative morphometry measurements (quantification of neointimal, 
medial, lumen and total vessel areas) in the stented region (Johnson et al., 
2005). These arteries would also be assessed for Nogo-B over-expression, 
proliferation and apoptosis indices and endothelial re-growth over the stented 
area of the vasculature (Kritz et al., 2008). One can speculate that Nogo-B’s 
effect on the inhibition of VSMC proliferation would also assist with the longevity 
of transgene expression mediated by NILVs.  
DESs represent drug reservoirs during PCIs and thus in addition, a stent 
placement is an ideal platform for gene elution for local vector delivery into the 
vasculature. The proof of principle of gene-eluting stents has emerged in 
preclinical studies using non-viral vectors, adenoviral vectors or AAVs. These 
studies have demonstrated successful gene transfer following stent deployment 
(Ye et al., 1998, Klugherz et al., 2000, Klugherz et al., 2002, Takahashi et al., 
2003, Walter et al., 2004, Johnson et al., 2005, Fishbein et al., 2006, Sharif et 
al., 2006, Egashira et al., 2007, Sharif et al., 2008, Brito et al., 2010). 
Furthermore, some of these studies have shown promise in therapeutic gene 
transfer mediated ISR reduction, and these include eNOS (Sharif et al., 2008, 
Brito et al., 2010), VEGF (Walter et al., 2004), TIMP-3 (Johnson et al., 2005) and 
anti-monocyte chemoattractant protein-1 (Egashira et al., 2007). Indeed, gene-
eluting stents have the potential to be very useful in vascular gene therapy, but 
this technology is still in its infancy. Stent-based delivery of Nogo-B mediated by 
NILV or int-LV would be a novel and compelling gene delivery system, and should 
be considered for future utility in a porcine in vivo model. 
The production of int-Nogo-B, NILV-Nogo-B and their LV-eGFP controls would 
need to be scaled-up for use in this porcine in-stent in vivo model. High-titre LV 
production remains an important challenge, particularly in quantities sufficient 
for pre-clinical and clinical studies, plus it is also difficult and expensive (Matrai 
et al., 2010). Attempts have been made to ease the LV production scale-up using 
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stable, inducible packaging or producer cell lines (Klages et al., 2000, Ikeda et 
al., 2003, Ni et al., 2005, Broussau et al., 2008) and alternatively by the 
transient transfection method on an industrial bioreactor scale (Ansorge et al., 
2009); however these LV titres remain relatively low (from a range between 109-
1011 iu/ml) in comparison to other viral vector titres (Matrai et al., 2010). Efforts 
are being made to overcome these shortcomings. A recent publication reported 
an easy and inexpensive method to increase the LV titres (both NILVs and int-
LVs) up to 8-fold, for both research and clinical use. This involves the transient 
transfection method with the addition of 2-4 mM of caffeine, from 17 hours to 
41 hours post-transfection which mediates optimal titres (Ellis et al., 2011). 
High-titre production of NILV-Nogo-B and int-LV-Nogo-B for future use in these 
acute vascular injury preclinical models could be problematic, and therefore it is 
imperative to consider the addition of caffeine during LV production.  
Despite the difficulty in producing high-titre HNTV pseudotyped LVs which was in 
encountered in chapter 3, it would be advantageous to evaluate HNTV 
pseudotyped NILV-Nogo-B for its targeted gene delivery and transgene 
expression in the vasculature (Qian et al., 2006) of these mentioned in vivo and 
ex vivo acute vascular injury models. 
LV-mediated transduction in vascular cells in relation to integration site profiles 
has not been explored. Unfortunately, both retroviral vector and LV mediated 
gene transfer have the potential risk of genotoxicity associated with integration 
and activation of adjacent proto-oncogenes (also known as insertional 
mutagenesis/oncogenesis). Evidently, uncontrolled clonal T-lymphocyte 
proliferation (T-lymphocyte leukaemia) occurred in 2 out of 10 patients after 
gene therapy for X-linked SCID. This was a consequence of retroviral 
(gammaretroviral) vector integration in proximity to the LMO2 (LIM domain-only 
2) proto-oncogene promoter, and thereby led to aberrant transcription and up-
regulation of LMO2 (Hacein-Bey-Abina et al., 2003b). A further 2 patients 
developed adverse events of insertional oncogenesis (T-lymphocyte leukaemia), 
which was reported as a consequence of integration near the LMO2, BMI1 (BMI1 
polycomb ring finger oncogene) and/or CCND2 (G1/S-specific cyclin-D2) proto-
oncogenes in these patients’ blast cells (Hacein-Bey-Abina et al., 2008). In a 
retroviral-mediated gene therapy trial for X-linked chronic granulomatous 
disease in 2 patients (granulocytes colony-stimulating factor mobilised 
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peripheral blood haematopoietic cells), non-malignant amplification of myeloid 
clones facilitated therapeutic efficacy, which was augmented by insertional 
activation of MDS1-EVI1 (myelodysplasia syndrome 1-ecotropic viral integration 
site 1), PRDM16 (PR domain containing 16) and/or SETBP1 (SET binding protein 
1) genes (integration near or within these PR domain-containing zinc-finger 
genes). However, these results do raise concerns that these myeloid clones could 
lead to uncontrolled proliferation, abnormal haematopoiesis and eventually 
leukemogenesis (Ott et al., 2006). Collectively, retroviral-mediated integrative 
gene transfer is semi-random and most harbour common integration sites (CIS) 
(Hacein-Bey-Abina et al., 2003b, Ott et al., 2006, Deichmann et al., 2007, 
Schwarzwaelder et al., 2007, Hacein-Bey-Abina et al., 2008). Clinical success 
occurred in a one patient gene therapy trial for β-thalassaemia by HSC 
transduction with a LV-mediated gene transfer of β-globin. Long-term 
therapeutic benefit derived from a dominant myeloid-biased cell clone, with the 
patient remaining healthy. With similarities to gammaretroviral vectors, 
integration site analysis indicated that LV integration was most commonly 
located within the HMGA2 (high-mobility group AT-hook 2) proto-oncogene 
(accounted for approximately 30 % of all integration sites in erythroid cells and 
thus known as the CIS) and as a consequence induced transcriptional activation 
of this gene. However, this therapeutic efficacy mediated by clonal dominance, 
could have resulted from benign cell expansion caused by dysregulation of the 
HMGA2 gene in stem/progenitor cells (Cavazzana-Calvo et al., 2010). Therefore, 
this suggestion does raise concerns with possible insertional oncogenesis, 
because the HMGA2 gene is linked with abnormal proliferation, malignant 
epithelial tumours and leukaemia (Cleynen and Van de Ven, 2008). Moreover, 
this study raises concerns of LV safety, because the detection of CIS within 
proto-oncogenes is a well-established hallmark of genotoxicity (Cavazzana-Calvo 
et al., 2010). However, a recent study demonstrated that LV-mediated CIS were 
found in specific genomic regions, instead of oncogenic selection (Biffi et al., 
2011). Doubtlessly, it is important to detect and characterise these CIS (the 
integration profile) of int-LV, in parallel to their integration-deficient 
counterparts in vascular cells [NILV D64V mutant has a residual integration 
frequency of approximately 103-fold lower than the integrative wild-type vector 
(Apolonia et al., 2007), and genomic integration of episomal LV form could 
possibly occur through DNA nicks located anywhere in the vector circle (Yanez-
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Munoz et al., 2006)]. Currently, integration site analysis for int-LV-mediated 
gene transfer of eGFP, in parallel to NILV-eGFP in human primary VSMCs is 
underway using highly-sensitive LAM-PCR. This is a nested PCR designed specially 
to amplify integration sites. Amplified integration sites are cloned and 
sequenced, to provide information on the quantity and position on integration in 
the host genome (Schmidt et al., 2007). Additionally, Bartholomae et al., (2011) 
reported that LVs integrate less frequently in actively transcribed genes of post-
mitotic cells, compared to rapidly dividing cells. This could have implications in 
LV-transduced VSMCs, which have low mitotic rates in a disease state (Gordon et 
al., 1990) and even during the acute vascular injury response (Westerband et 
al., 1997, Hilker et al., 2002), and thus possible lesser likelihood of genotoxicity 
(Bartholomae et al., 2011). 
Results obtained in chapter 5, which explored the mechanism of action of Nogo-
B on VSMCs, was just the start of a long investigation. MicroRNAs (MiRs) are 
highly conserved, endogenous, short non-coding RNAs of about 22 nucleotides in 
length. MiRs regulate gene expression at the post-transcriptional level [directly 
regulate about 30 % of encoding genes of the human genome (Lewis et al., 
2005)], generally by either degradation or translational inhibition of their target 
mRNAs through Watson-Crick base pairing between the miR and the seed 
sequence located in the 3’ untranslated region (UTR) of the specific mRNA 
(Small and Olson, 2011). There are certainly numerous miRs that are involved 
and important in phenotypic modulation of VSMCs. Several reports have 
indicated miR-21, 143, 145, 221 and 222 are highly enriched in VSMCs, and 
evidently have critical roles in the regulation of VSMC differentiation, migration, 
proliferation and/or apoptosis in the NIF during the vascular response to injury 
(Ji et al., 2007, Davis et al., 2008, Boettger et al., 2009, Cheng et al., 2009, 
Cordes et al., 2009, Davis et al., 2009, Liu et al., 2009, Xin et al., 2009). MiR 
bioinformatics databases, microrna.org (John et al., 2004, Betel et al., 2010) 
and MicroCosm Targets (Griffiths-Jones et al., 2006, Griffiths-Jones et al., 2008) 
were utilised to identify putative MiR binding sites within the 3’ UTR of Nogo-B. 
In relevance to this, there is presumed to be a seed sequence for miR-21 and 143 
in Nogo-B, and therefore these miRs could have involvement in direct post-
transcriptional regulation of endogenous Nogo-B associated with phenotypic 
modulation of VSMCs. In addition, there are many pathways involved in the 
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regulation of VSMC migration and proliferation, and thus there could be an 
indirect casual effect of Nogo-B with regards to miR-21, 143, 145, 221 and 222 
(Selbach et al., 2008) during phenotypic modulation. Therefore, it would be 
interesting to study if Nogo-B over-expression mediates changes in these MiRs in 
VSMCs and their importance with regards to SM differentiation markers (SM-MHC, 
calponin and SM-α actin). Taken together, experiments investigating the 
association of Nogo-B with these miRs in VSMCs should be considered. 
VSMCs used within this thesis were obtained from patients undergoing bypass 
surgery. Consideration should be given to the fact that LV transduction may 
differ in VSMCs from atherosclerotic plaques (Deng et al., 2006), which is 
important for stent-based delivery, and thus should be considered for 
investigation in vitro and in vivo. Furthermore, LV transduction could vary 
among each VSMC patient preparation depending on drug regime that the 
individual is undertaking and/or the individual’s biological variability. 
Conclusion 
Collectively, this thesis addresses the hypothesis that SFFV-driven VSV-g 
pseudotyped NILVs are efficient in vascular cell gene transfer. Additionally, this 
thesis supports the use of NILV-Nogo-B as a new candidate for therapeutic 
application in the prevention of NIF associated with acute vascular injury 
following revascularisation. In conclusion, this thesis reports important 
implications for the use of NILVs as a potential therapeutic vector for application 
to vascular gene therapy. 
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DNA sequencing results 
 
Complete full-length and mutant Nogo-B cDNA sequences 
 
Complete (full-length) human Nogo-B-haemaglutinin tagged ~ 1.2 kb Nogo-B 
ATGGAAGACCTGGACCAGTCTCCTCTGGTCTCGTCCTCGGACAGCCCACCCCGGCCGCA
GCCCGCGTTCAAGTACCAGTTCGTGAGGGAGCCCGAGGACGAGGAGGAAGAAGAGGAG
GAGGAAGAGGAGGACGAGGACGAAGACCTGGAGGAGCTGGAGGTGCTGGAGAGGAAG
CCCGCCGCCGGGCTGTCCGCGGCCCCAGTGCCCACCGCCCCTGCCGCCGGCGCGCCCCT
GATGGACTTCGGAAATGACTTCGTGCCGCCGGCGCCCCGGGGACCCCTGCCGGCCGCT
CCCCCCGTCGCCCCGGAGCGGCAGCCGTCTTGGGACCCGAGCCCGGTGTCGTCGACCG
TGCCCGCGCCATCCCCGCTGTCTGCTGCCGCAGTCTCGCCCTCCAAGCTCCCTGAGGAC
GACGAGCCTCCGGCCCGGCCTCCCCCTCCTCCCCCGGCCAGCGTGAGCCCCCAGGCAGA
GCCCGTGTGGACCCCGCCAGCCCCGGCTCCCGCCGCGCCCCCCTCCACCCCGGCCGCGC
CCAAGCGCAGGGGCTCCTCGGGCTCAGTGGTTGTTGACCTCCTGTACTGGAGAGACATT
AAGAAGACTGGAGTGGTGTTTGGTGCCAGCCTATTCCTGCTGCTTTCATTGACAGTATT
CAGCATTGTGAGCGTAACAGCCTACATTGCCTTGGCCCTGCTCTCTGTGACCATCAGCTT
TAGGATATACAAGGGTGTGATCCAAGCTATCCAGAAATCAGATGAAGGCCACCCATTCAG
GGCATATCTGGAATCTGAAGTTGCTATATCTGAGGAGTTGGTTCAGAAGTACAGTAATT
CTGCTCTTGGTCATGTGAACTGCACGATAAAGGAACTCAGGCGCCTCTTCTTAGTTGAT
GATTTAGTTGATTCTCTGAAGTTTGCAGTGTTGATGTGGGTATTTACCTATGTTGGTGC
CTTGTTTAATGGTCTGACACTACTGATTTTGGCTCTCATTTCACTCTTCAGTGTTCCTGT
TATTTATGAACGGCATCAGGCACAGATAGATCATTATCTAGGACTTGCAAATAAGAATGT
TAAAGATGCTATGGCTAAAATCCAAGCAAAAATCCCTGGATTGAAGCGCAAAGCTGAAGG
TGGCTACCCATACGACGTCCCAGACTACGCTTGA 
Full-length Nogo-B = 384 amino acids in length 
MEDLDQSPLV SSSDSPPRPQ PAFKYQFVRE PEDEEEEEEE EEEDEDEDLE ELEVLERKPA 
AGLSAAPVPT APAAGAPLMD FGNDFVPPAP RGPLPAAPPV APERQPSWDP SPVSSTVPAP 
SPLSAAAVSP SKLPEDDEPP ARPPPPPPAS VSPQAEPVWT PPAPAPAAPP STPAAPKRRG 
SSGSVVVDLL YWRDIKKTGV VFGASLFLLL SLTVFSIVSV TAYIALALLS VTISFRIYKG 
VIQAIQKSDE GHPFRAYLES EVAISEELVQ KYSNSALGHV NCTIKELRRL FLVDDLVDSL 
KFAVLMWVFT YVGALFNGLT LLILALISLF SVPVIYERHQ AQIDHYLGLA NKNVKDAMAK 
IQAKIPGLKR KAEGGYPYDV PDYA 
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Human mutant (soluble) Nogo-B ~ 600 bp 
ATGGAAGACCTGGACCAGTCTCCTCTGGTCTCGTCCTCGGACAGCCCACCCCGGCCGCA
GCCCGCGTTCAAGTACCAGTTCGTGAGGGAGCCCGAGGACGAGGAGGAAGAAGAGGAG
GAGGAAGAGGAGGACGAGGACGAAGACCTGGAGGAGCTGGAGGTGCTGGAGAGGAAG
CCCGCCGCCGGGCTGTCCGCGGCCCCAGTGCCCACCGCCCCTGCCGCCGGCGCGCCCCT
GATGGACTTCGGAAATGACTTCGTGCCGCCGGCGCCCCGGGGACCCCTGCCGGCCGCT
CCCCCCGTCGCCCCGGAGCGGCAGCCGTCTTGGGACCCGAGCCCGGTGTCGTCGACCG
TGCCCGCGCCATCCCCGCTGTCTGCTGCCGCAGTCTCGCCCTCCAAGCTCCCTGAGGAC
GACGAGCCTCCGGCCCGGCCTCCCCCTCCTCCCCCGGCCAGCGTGAGCCCCCAGGCAGA
GCCCGTGTGGACCCCGCCAGCCCCGGCTCCCGCCGCGCCCCCCTCCACCCCGGCCGCGC
CCAAGCGCAGGGGCTCCTCGGGCTCAGTGGTTGTTGACCTCCTGTACTGGAGAGACATT
AAGAAGACTGGAGTGGTGTGA 
Mutant Nogo-B = 200 amino acids in length 
MEDLDQSPLV SSSDSPPRPQ PAFKYQFVRE PEDEEEEEEE EEEDEDEDLE ELEVLERKPA 
AGLSAAPVPT APAAGAPLMD FGNDFVPPAP RGPLPAAPPV APERQPSWDP SPVSSTVPAP 
SPLSAAAVSP SKLPEDDEPP ARPPPPPPAS VSPQAEPVWT PPAPAPAAPP STPAAPKRRG 
SSGSVVVDLL YWRDIKKTGV V 
Appendix 1. Sequences for full-length Nogo-B and mutant (soluble) Nogo-B. 
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DNA sequencing for full-length Nogo-B in the lentiviral construct 
plasmid 
 
Forward primer 5’-CAATCAGCCTGCTTCTCG-3’ 
CCCACCCCGGCCGCAGCCCGCGTTCAAGTACCAGTTCGTGAGGGAGCCCGAGGACGAG
GAGGAAGAAGAGGAGGAGGAAGAGGAGGACGAGGACGAAGACCTGGAGGAGCTGGAG
GTGCTGGAGAGGAAGCCCGCCGCCGGGCTGTCCGCGGCCCCAGTGCCCACCGCCCCTG
CCGCCGGCGCGCCCCTGATGGACTTCGGAAATGACTTCGTGCCGCCGGCGCCCCGGGG
ACCCCTGCCGGCCGCTCCCCCCGTCGCCCCGGAGCGGCAGCCGTCTTGGGACCCGAGCC
CGGTGTCGTCGACCGTGCCCGCGCCATCCCCGCTGTCTGCTGCCGCAGTCTCGCCCTCC
AAGCTCCCTGAGGACGACGAGCCTCCGGCCCGGCCTCCCCCTCCTCCCCCGGCCAGCGT
GAGCCCCCAGGCAGAGCCCGTGTGGACCCCGCCAGCCCCGGCTCCCGCCGCGCCCCCCT
CCACCCCGGCCGCGCCCAAGCGC 
TCTGTTCGCGCGCTTCTGCTTCCCGAGCTCTATAAAAGAGCTCACAACCCCTCACTCGG
CGCGCCAGTCCTCCGACAGACTGAGTCGCCCGGGGGGGATCCTATGGAAGACCTGGAC
CAGTCTCCTCTGGTCTCGTCCTCGGACAGCCCACCCCGGCCGCAGCCCGCGTTCAAGTA
CCAGTTCGTGAGGGAGCCCGAGGACGAGGAG 
CACAACCCCTCACTCGGCGCGCCAGTCCTCCGACAGACTGAGTCGCCCGGGGGGGATCC
TATGGAAGACCTGGACCAGTCTCCTCTGGTCTCGTCCTCGGACAGCCCACCCCGGCCGC
AGCCCGCGTTCAAGTACCAGTTCGTGAGGGAGCCCGAGGACGAGGAGG 
MEDLDQSPLV SSSDSPPRPQ PAFKYQFVRE PEDEEEEEEE EEEDEDEDLE ELEVLERKPA 
AGLSAAPVPT APAAGAPLMD FGNDFVPPAP RGPLPAAPPV APERQPSWDP SPVSSTVPAP 
SPLSAAAVSP SKLPEDDEPP ARPPPPPPAS VSPQAEPVWT PPAPAPAAPP STPAAPKR 
Reverse primer 5’-GAGAGCCAAAATCAGTAGTGTCAG-3’ 
ACCCACATCAACACTGCAAACTTCAGAGAATCAACTAAATCATCAACTAAGAAGAGGCGC
CTGAGTTCCTTTATCGTGCAGTTCACATGACCAAGAGCAGAATTACTGTACTTCTGAACC
AACTCCTCAGATATAGCAACTTCAGATTCCAGATATGCCCTGAATGGGTGGCCTTCATCT
GATTTCTGGATAGCTTGGATCACACCCTTGTATATCCTAAAGCTGATGGTCACAGAGAGC
AGGGCCAAGGCAATGTAGGCTGTTACGCTCACAATGCTGAATACTGTCAATGAAAGCAG
CAGGAATAGGCTGGCACCAAACACCACTCCAGTCTTCTTAATGTCTCTCCAGTACAGGAG
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GTCAACAACCACTGAGCCCGAGGAGCCCCTGCGCTTGGGCGCGGCCGGGGTGGAGGGG
GGCGCGGCGGGAGCCGGGGCTGGCGGGGTCCACACGGGCTCTGCCTGGGGGCTCACG
CTGGCCGGGGGAGGAGGGGGAGGCCGGGCCGGAGGCTCGTCGTCCTCAGGGAGCTTG
GAGGGCGAGACTGCGGCAGCAGACAGCGGGGATGGCGCGGGCACGGTCGACGACACC
GGGCTCGGGTCCCAAGACGGCTGCCGCTCCGGGGCGACGGGGGGAGCGGCCGGCAGG
GGTCCCCGGGGCGCCGGCGGCACGAAGTCATTTCCGAAGTCCAT 
AGGCCTCTCGAGTTCAAGCGTAGTCTGGGACGTCGTATGGGTAGCCACCTTCAGCTTTG
CGCTTCAATCCAGGGATTTTTGCTTGGATTTTAGCCATAGCATCTTTAACATTCTTATTT
GCAAGTCCTAGATAATGATCTATCTGTGCCTGATGCCGTTCATAAATAACAGGAACACTG
AAGAGTGAAATGAGAGCCAAAATCAGTAGTGTCAGACCATTAAACAAGGCACCAACATAG
GTAAATACCCACATCAACACTGCAAACTTCAGAGAATCAACTAAATCATCAACTAAGAAGA
GGCGCCTGAGTTCCTTTATCGTGCAGTTCACATGACCAAGAGCAGAATTACTGTACTTCT
GAACCAACTCCTCAGATATAGCAACTTCAGATTCCAGATATGCCCTGAATGGGTGGCCTT
CATCTGATTTCTGGATAGCTTGGATCACACCCTTGTATATCCTAAAGCTGATGGTCACAG
AGAGCAGGGCCAAGGCAATGTAGGCTGTTACGCTCACAATGCTGAATACTGTCAATGAA
AGCAGCAGGAATAGGCTGGCACCAAACACCACTCCAGTCTTCTTAATGTCTCTCCAGTAC
AGGAGGTCAACAACCACTGAGCCCGAGGAGCCCCTGCGCTTGGGCGCGGCCGGGGTGG
AGGGGGGCGCGGCGGGAGCC 
GGCCTCTCGAGTTCAAGCGTAGTCTGGGACGTCGTATGGGTAGCCACCTTCAGCTTTGC
GCTTCAATCCAGGGATTTTTGCTTGGATTTTAGCCATAGCATCTTTAACATTCTTATTTG
CAAGTCCTAGATAATGATCTATCTGTGCCTGATGCCGTTCATAAATAACAGGAACACTGA
AGAGTGAAATGAGAGCCAAAATCAGTAGTGTCAGACCATTAAACAAGGCACCAACATAG
GTAAATACCCACATCAACACTGCAAACTTCAGAGAATCAACTAAATCATCAACTAAGAAGA
GGCGCCTGAGTTCCTTTATCGTGCAGTTCACATGACCAAGAGCAGAATTACTGTACTTCT
GAACCAACTCCTCAGATATAGCAACTTCAGATTCCAGATATGCCCTGAATGGGTGGCCTT
CATCTGATTTCTGGATAGCTTGGATCACACCCTTGTATATCCTAAAGCTGATGGTCACAG
AGAGCAGGGCCAAGGCAATGTAGGCTGTTACGCTCACAATGCTGAATACTGTCAATGAA
AGCAGCAGGAATAGGCTGGCACCAAACACCACTCCAGTCTTCTTAATGTCTCTCCAGTAC
AGGAGGTCAACAACCACTGAGCCCGAGGAGCCCCTGCGCTTGGGCGCGGCCGGGGTGG
AGGGG 
VVDLL YWRDIKKTGV VFGASLFLLL SLTVFSIVSV TAYIALALLS VTISFRIYKG 
VIQAIQKSDE GHPFRAYLES EVAISEELVQ KYSNSALGHV NCTIKELRRL FLVDDLVDSL 
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KFAVLMWVFT YVGALFNGLT LLILALISLF SVPVIYERHQ AQIDHYLGLA NKNVKDAMAK 
IQAKIPGLKR KAEGGYPYDV PDYA 
Forward primer 5’-GCAGTCTCGCCCTCCAAG-3’ 
CTCCCCCTCCTCCCCCGGCCAGCGTGAGCCCCCAGGCAGAGCCCGTGTGGACCCCGCCA
GCCCCGGCTCCCGCCGCGCCCCCCTCCACCCCGGCCGCGCCCAAGCGCAGGGGCTCCTC
GGGCTCAGTGGTTGTTGACCTCCTGTACTGGAGAGACATTAAGAAGACTGGAGTGGTGT
TTGGTGCCAGCCTATTCCTGCTGCTTTCATTGACAGTATTCAGCATTGTGAGCGTAACAG
CCTACATTGCCTTGGCCCTGCTCTCTGTGACCATCAGCTTTAGGATATACAAGGGTGTGA
TCCAAGCTATCCAGAAATCAGATGAAGGCCACCCATTCAGGGCATATCTGGAATCTGAAG
TTGCTATATCTGAGGAGTTGGTTCAGAAGTACAGTAATTCTGCTCTTGGTCATGTGAACT
GCACGATAAAGGAACTCAGGCGCCTCTTCTTAGTTGATGATTTAGTTGATTCTCTGAAGT
TTGCAGTGTTGATGTGGGTATTTACCTATG 
GTACTGGAGAGACATTAAGAAGACTGGAGTGGTGTTTGGTGCCAGCCTATTCCTGCTGC
TTTCATTGACAGTATTCAGCATTGTGAGCGTAACAGCCTACATTGCCTTGGCCCTGCTCT
CTGTGACCATCAGCTTTAGGATATACAAGGGTGTGATCCAAGCTATCCAGAAATCAGATG
AAGGCCACCCATTCAGGGCATATCTGGAATCTGAAGTTGCTATATCTGAGGAGTTGGTT
CAGAAGTACAGTAATTCTGCTCTTGGTCATGTGAACTGCACGATAAAGGAACTCAGGCG
CCTCTTCTTAGTTGATGATTTAGTTGATTCTCTGAAGTTTGCAGTGTTGATGTGGGTATT
TACCTATGTTGGTGCCTTGTTTAATGGTCTGACACTACTGATTTTGGCTCTCATTTCACT
CTTCAGTGTTCCTGTTA 
Reverse primer 5’-GAGAGCCAAAATCAGTAGTGTCAG-3’ 
TCAACACTGCAAACTTCAGAGAATCAACTAAATCATCAACTAAGAAGAGGCGCCTGAGTT
CCTTTATCGTGCAGTTCACATGACCAAGAGCAGAATTACTGTACTTCTGAACCAACTCCT
CAGATATAGCAACTTCAGATTCCAGATATGCCCTGAATGGGTGGCCTTCATCTGATTTCT
GGATAGCTTGGATCACACCCTTGTATATCCTAAAGCTGATGGTCACAGAGAGCAGGGCC
AAGGCAATGTAGGCTGTTACGCTCACAATGCTGAATACTGTCAATGAAAGCAGCAGGAA
TAGGCTGGCACCAAACACCACTCCAGTCTTCTTAATGTCTCTCCAGTACAGGAGGTCAAC
AACCACTGAGCCCGAGGAGCCCCTGCGCTTGGGCGCGGCCGGGGTGGAGGGGGGCGC
GGCGGGAGCCGGGGCTGGCGGGGTCCACACGGGCTCTGCCTGGGGGCTCACGCTGGC
CGGGGGAGGAGGGGGAGGCCGGGCCGGAGGCTCGTCGTCCTCAGGGAGCTTGGAGGG
CGAGACTGCGGCAGCAGACAGCGGGGATGGCGCGGGCACGGTCGACGACACCGGGCTC
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GGGTCCCAAGACGGCTGCCGCTCCGGGGCGACGGGGGGAGCGGCCGGCAGGGGTCCC
CGGGGCGCCGGCGGCACGAAGTCATTTCCGAAGTCCATCAGGGGCGCGCCGGCGGCAG
GG 
ACACTGCAAACTTCAGAGAATCAACTAAATCATCAACTAAGAAGAGGCGCCTGAGTTCCT
TTATCGTGCAGTTCACATGACCAAGAGCAGAATTACTGTACTTCTGAACCAACTCCTCAG
ATATAGCAACTTCAGATTCCAGATATGCCCTGAATGGGTGGCCTTCATCTGATTTCTGGA
TAGCTTGGATCACACCCTTGTATATCCTAAAGCTGATGGTCACAGAGAGCAGGGCCAAG
GCAATGTAGGCTGTTACGCTCACAATGCTGAATACTGTCAATGAAAGCAGCAGGAATAG
GCTGGCACCAAACACCACTCCAGTCTTCTTAATGTCTCTCCAGTACAGGAGGTCAACAAC
CACTGAGCCCGAGGAGCCCCTGCGCTTGGGCGCGGCCGGGGTGGAGGGGGGCGCGGC
GGGAGCCGGGGCTGGCGGGGTCCACACGGGCTCTGCCTGGGGGCTCACGCTGGCCGG
GGGAGGAGGGGGAGGCCGGGCCGGAGGCTCGTCGTCCTCAGGGAGCTTGGAGGGCGA
GACTGCGGCAGCAGACAGCGGGGATGGCGCGGGCACGGTCGACGACACCGGGCTCGG
GTCCCAAGACGGCTGC 
Appendix 2. DNA sequencing for the full-length Nogo-B lentiviral construct plasmid.  
DNA sequencing was carried out on pHR’SIN-cPPT-SFFV-fulllengthNogo-B-WPRE plasmid. Italic 
labelling = lentiviral construct sequence, blue and underlined labelling = restriction enzyme 
recognition sites BamHI or XhoI and red labelling = Nogo-B sequence.  
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DNA sequencing for mutant (soluble) Nogo-B in the lentiviral 
construct plasmid 
 
Forward primer 5’-CAATCAGCCTGCTTCTCG-3’ 
TCCTCCGACAGACTGAGTCGCCCGGGGGGGATCCTATGGAAGACCTGGACCAGTCTCCT
CTGGTCTCGTCCTCGGACAGCCCACCCCGGCCGCAGCCCGCGTTCAAGTACCAGTTCGT
GAGGGAGCCCGAGGACGAGGAGGAAGAAGAGGAGGAGGAAGAGGAGGACGAGGACGA
AGACCTGGAGGAGCTGGAGGTGCTGGAGAGGAAGCCCGCCGCCGGGCTGTCCGCGGCC
CCAGTGCCCACCGCCCCTGCCGCCGGCGCGCCCCTGATGGACTTCGGAAATGACTTCGT
GCCGCCGGCGCCCCGGGGACCCCTGCCGGCCGCTCCCCCCGTCGCCCCGGAGCGGCAG
CCGTCTTGGGACCCGAGCCCGGTGTCGTCGACCGTGCCCGCGCCATCCCCGCTGTCTGC
TGCCGCAGTCTCGCCCTCCAAGCTCCCTGAGGACGACGAGCCTCCGGCCCGGCCTCCCC
CTCCTCCCCCGGCCAGCGTGAGCCCCCAGGCAGAGCCCGTGTGGACCCCGCCAGCCCCG
GCTCCCGCCGCGCCCCCCTCCACCCCGGCCGCGCCCAAGCGCAGGGGCTCCTCGGGCTC
AGTGGTTGTTGACCTCCTGTACTGGAGAGACATTAAGAAGACTGGAGTGGTG 
GCGCCAGTCCTCCGACAGACTGAGTCGCCCGGGGGGGATCCTATGGAAGACCTGGACC
AGTCTCCTCTGGTCTCGTCCTCGGACAGCCCACCCCGGCCGCAGCCCGCGTTCAAGTAC
CAGTTCGTGAGGGAGCCCGAGGACGAGGAGGAAGAAGAGGAGGAGGAAGAGGAGGAC
GAGGACGAAGACCTGGAGGAGCTGGAGGTGCTGGAGAGGAAGCCCGCCGCCGGGCTGT
CCGCGGCCCCAGTGCCCACCGCCCCTGCCGCCGGCGCGCCCCTGATGGACTTCGGAAAT
GACTTCGTGCCGCCGGCGCCCCGGGGACCCCTGCCGGCCGCTCCCCCCGTCGCCCCGG
AGCGGCAGCCGTCTTGGGACCCGAGCCCGGTGTCGTCGACCGTGCCCGC 
MEDLDQSPLV SSSDSPPRPQ PAFKYQFVRE PEDEEEEEEE EEEDEDEDLE ELEVLERKPA 
AGLSAAPVPT APAAGAPLMD FGNDFVPPAP RGPLPAAPPV APERQPSWDP SPVSSTVPAP 
SPLSAAAVSP SKLPEDDEPP ARPPPPPPAS VSPQAEPVWT PPAPAPAAPP STPAAPKRRG 
SSGSVVVDLL YWRDIKKTGV V 
Reverse primer 5’-ATGCCTGCAGGTCGACTCTAG-3’ 
GGCCTCTCGAGATCACACCACTCCAGTCTTCTTAATGTCTCTCCAGTACAGGAGGTCAAC
AACCACTGAGCCCGAGGAGCCCCTGCGCTTGGGCGCGGCCGGGGTGGAGGGGGGCGC
GGCGGGAGCCGGGGCTGGCGGGGTCCACACGGGCTCTGCCTGGGGGCTCACGCTGGC
CGGGGGAGGAGGGGGAGGCCGGGCCGGAGGCTCGTCGTCCTCAGGGAGCTTGGAGGG
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CGAGACTGCGGCAGCAGACAGCGGGGATGGCGCGGGCACGGTCGACGACACCGGGCTC
GGGTCCCAAGACGGCTGCCGCTCCGGGGCGACGGGGGGAGCGGCCGGCAGGGGTCCC
CGGGGCGCCGGCGGCACGAAGTCATTTCCGAAGTCCATCAGGGGCGCGCCGGCGGCAG
GGGCGGTGGGCACTGGGGCCGCGGACAGCCCGGCGGCGGGCTTCCTCTCCAGCACCTC
CAGCTCCTCCAGGTCTTCGTCCTCGTCCTCCTCTTCCTCCTCCTCTTCTTCCTCCTCGTCC
TCGGGCTCCCTCACGAACTGGTACTTGAACGCGGGCTGCGGCCGGGGTGGGCTGTCCG
AGGACGAGACCAGAGGAGACTGGTCCAGGTCTTCCATAGGA 
GGCCTCTCGAGATCACACCACTCCAGTCTTCTTAATGTCTCTCCAGTACAGGAGGTCAAC
AACCACTGAGCCCGAGGAGCCCCTGCGCTTGGGCGCGGCCGGGGTGGAGGGGGGCGC
GGCGGGAGCCGGGGCTGGCGGGGTCCACACGGGCTCTGCCTGGGGGCTCACGCTGGC
CGGGGGAGGAGGGGGAGGCCGGGCCGGAGGCTCGTCGTCCTCAGGGAGCTTGGAGGG
CGAGACTGCGGCAGCAGACAGCGGGGATGGCGCGGGCACGGTCGACGACACCGGGCTC
GGGTCCCAAGACGGCTGCCGCTCCGGGGCGACGGGGGGAGCGGCCGGCAGGGGTCCC
CGGGGCGCCGGCGGCACGAAGTCATTTCCGAAGTCCATCAGGGGCGCGCCGGCGGCAG
GGGCGGTGGGCACTGGGGCCGCGGACAGCCCGGCGGCGGGCTTCCTCTCCAGCACCTC
CAGCTCCTCCAGGTCTTCGTCCTCGTCCTCCTCTTCCTCCTCCTCTTCTTCCTCCTCGTCC
TCGGGCTCCCTCACGAACTGGTACTTGAACGCGGGCTGCGGCCGGGGTGGGCTGTCCG
AGGACGAGACCAGAGGAGACTGGTCCAGGTCTTCCATAGGATCCCCCCCGGGCGACTCA
GTCTGTCGGAGGACTGGCGCGCCGAGT 
MEDLDQSPLV SSSDSPPRPQ PAFKYQFVRE PEDEEEEEEE EEEDEDEDLE ELEVLERKPA 
AGLSAAPVPT APAAGAPLMD FGNDFVPPAP RGPLPAAPPV APERQPSWDP SPVSSTVPAP 
SPLSAAAVSP SKLPEDDEPP ARPPPPPPAS VSPQAEPVWT PPAPAPAAPP STPAAPKRRG 
SSGSVVVDLL YWRDIKKTGV V 
Appendix 3. DNA sequencing for the mutant (soluble) Nogo-B lentiviral construct plasmid.  
DNA sequencing was carried out on pHR’SIN-cPPT-SFFV-mutant Nogo-B-WPRE plasmid. Italic 
labelling = lentiviral construct sequence, blue and underlined labelling = restriction enzyme 
recognition sites BamHI or XhoI and red labelling = Nogo-B sequence.   
 
